Movatterモバイル変換


[0]ホーム

URL:


US3850752A - Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically - Google Patents

Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically
Download PDF

Info

Publication number
US3850752A
US3850752AUS00193702AUS19370271AUS3850752AUS 3850752 AUS3850752 AUS 3850752AUS 00193702 AUS00193702 AUS 00193702AUS 19370271 AUS19370271 AUS 19370271AUS 3850752 AUS3850752 AUS 3850752A
Authority
US
United States
Prior art keywords
low molecular
molecular weight
enzyme
organic compound
weight organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00193702A
Inventor
A Schuurs
Weemen B Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzona Inc
Original Assignee
Akzona Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzona IncfiledCriticalAkzona Inc
Application grantedgrantedCritical
Publication of US3850752ApublicationCriticalpatent/US3850752A/en
Anticipated expirationlegal-statusCritical
Expired - Lifetimelegal-statusCriticalCurrent

Links

Images

Classifications

Definitions

Landscapes

Abstract

The invention relates to a process for the demonstration and determination of a low molecular compound, such as a hapten, or a protein or antibody capable of binding this compound specifically, contacting a fluid containing such a compound or protein to be determined with a given quantity of the coupling product of such a low molecular compound and an enzyme, and with a given quantity of the component to be determined, which component is brought in an insoluble form, and determining the enzyme activity of the liquid or solid phase of the resulting reaction mixture.

Description

United States Patent [191 Schuurs et al.
[4 ]*Nov. 26, 1974 1 PROCESS FOR THE DEMONSTRATION AND DETERMINATION OF LOW MOLECULAR COMPOUNDS AND OF PROTEINS CAPABLE OF BINDING THESE COMPOUNDS SPECIFICALLY [75] Inventors: Antonius Hermanus Wilhelmus Maria Schuurs; Bauke Klass Van Weemen, both of Oss, Netherlands [73] Assignee: Akzona Incorporated, Asheville,
[ Notice: The portion of the term of this patent subsequent to Apr. 4, 1989, has been disclaimed.
[22] Filed: Oct. 29, 1971 21 Appl. No.: 193,702
[30] Foreign Application Priority Data Nov. 10, 1970 Netherlands 7016396 [52] US. Cl 195/1035 R, 195/99, 195/63, 424/12 [51] Int. Cl. G01n 31/14, GOln 33/16 8] Field of Search 195/1035 R; 23/253 TP,
[56] References Cited UNITED STATES PATENTS 3,615,222 10/1971 Mead 23/230 B 3,654,090 4/1972 Schuurs et a1. 195/1015 R OTHER PUBLICATIONS Chemical Abstracts 65: ll 124b, (1966). Spector et 11]., 168: 1348. 8. Science," (June 12, 1970).
Primary Examiner-Alvin E. Tanenholtz Attorney, Agent, or Firm-Hugo E. Weisberger [57] ABSTRACT with a given quantity of the component to be deter-- mined, which component is brought in an insoluble form, and determining the enzyme activity of the liquid or solid phase of the resulting reaction mixture.
13 Claims, 6 Drawing Figures PATENT Tia/261974 SHEET 10F 3 O O mu 5 1 N 0.25 0.06 CONCENTRATION ANN-TESTOSTERONE-CELLULOSE (mg/ml) FIG. 2
ng TESTOSTERONE IN THE SAMPLE I PATE NLNNZ SHEET 2M 3 3,850,752
FIG. 3
/o ENZYME ACTIVITY IN SUPERNATANT LIQUID O l Il l l 64 I6 4 l 0.25 0.06 CONCENTRATION ANTI-OESTRADIOL-CELLULOSE (mg/ml) FIG 4 5 lm OESTRADIOL 2 J M Q TESTOSTERONLPROGESTERONE gzo- ANTIOESTRADIOL-CELLULOSE sm /mfl ON. L l l I N O 4 I6 64 256 I024 4096 PATEIIIEDIIUVZBIQYI 3.850.752
suecrsor'a FIG.5
IOO
/o ENZYME ACTIVITY IN SUPERNATANT LIQUID O 8 l I l l I I I6 4 I 0.25 0.06 CONCENTRATION OF ANTPFOLATE-CELLULOSE (mg/ml) FIG, 6
Q g, FOLIC ACID l E 80- E z 5 I GLUTAMIC ACID 40- q I g GLY, ASP, LA I 2I 4 8I6 32 64 I28 CONCENTRATION IN ng/mI PROCESS FOR THE DEMONSTRATION AND DETERMINATION OF LOW MOLECULAR COMPOUNDS AND OF PROTEINS CAPABLE OF BINDING THESE COMPOUNDS SPECIFICALLY For the determination of low molecular substances occurring in low concentrations, such as steroid hormones in body fluids, methods have been developed using proteins capable of binding the substance to be determined specifically. These methods are based on the competition between the substance to be determined in the sample and a known quantity of the same substance which is labelled radioactive, for a limited quantity of specific binding protein. The unknown quantity of bindable substance then determines what portion of the radioactive labelled substance is bound by the specific binding protein.
It is also possible to determine by these methods an unknown quantity of specific binding protein by reacting a sample containing an unknown quantity of specific binding protein with a given quantity of bindable radioactive labelled substance.
in the literature it is common practice to distinguish these determination methods according to the nature of the specific binding protein employed, although the underlying principle of all determinations is identical. Thus, for example, they speak of competitive protein binding assays when they employ receptor or transport proteins occurring in the body, and of radioimmunological determinations when they employ antisubstances.
For both types of determinations radioactive labelled substances are required. The work with these substances requires the presence of precious measuring apparatuses, good laboratory facilities and a highly qualified staff. These high requirements prevent a general application of these determination, especially in smaller laboratories.
A process has now been found for the demonstration and determination of a component of the reaction between a low molecular compound and a protein capable of binding this compound specifically using the binding affinity of such components for each other,
characterized in that the determination is performed with a given quantity of the coupling product of the low molecular compound and an enzyme, and with a given quantity of a component of the said reaction which has been made insoluble, and the enzyme activity of the liquid or the solid phase of the resulting reaction mixture is determined, which activity is a measure for the quantity of the reaction component to be determined.
The method found can often by employed for the determination of haptens, which may be regarded as a special group of low molecular compounds, and their anti-substances. These substances mostly occur in low concentrations. According to the original definition of K. Landsteiner haptens are protein-free substances whose chemical configuration is such that they can react with specific antibodies, but not such that they are capable of causing the formation of anitbodies. In order to be able yet to make antibodies against haptens, the haptens must be coupled to polypeptides before being injected into the test animal. In the determination of a low molecular compound the substance to be determined and its coupling product with an enzyme enter into competition for a given quantity of the insoluble specific binding protein. The more low molecular compound the sample contains, the less opportunity the soluble enzyme conjugate of that compound has to combine with the insoluble specific binding protein and the more of the conjugate will remain in the liquid phase, in which the enzyme activity can be measured in a simple manner.
In the determination of a specific binding protein with the same reagents the soluble protein to be determined and the insoluble protein enter into competition for a given quantity of the conjugate of the corresponding low molecular compound and an enzyme. If the content of specific binding protein of the sample is higher, the insoluble protein will bind less of the enzyme conjugate, and consequently more enzyme remains in the liquid phase.
A specific binding protein having two or more binding possibilities can also be demonstrated and determined according to the invention, i.e. with the enzyme conjugate and. with the low molecular compound in an insoluble form. The liquid phase of the reaction mixture then contains the conjugate bound to the specific binding protein and in the solid phase the complex of enzyme conjugate specific binding protein insoluble low molecular compound. The more of the protein to be determined there is in the sample, the more enzyme activity the liquid phase will possess.
By means of an assay curve for a certain system in which increasing contents of substance to be determined have been set off against the enzyme activity found, preferably in the liquid phase, the quantity of substance to be determined in the sample can be derived from a value of enzyme activity found.
The most important reagents of this detennination method is the coupling product of the low molecular substance and an enzyme, for convenience hereinafter also called enzyme conjugate, which on the one hand can react with the specific binding protein, via the low molecular component and on the other hand possesses enzyme activity. This reagent is prepared by a method described for similar products. The second reagent, the insoluble component in the reaction system, serves to facilitate the separation between various enzymecontaining fractions of the reaction mixture. Addition of this reagent causes the fonnation of a solid phase in addition to a liquid phase. The present determinations can in principle be performed without an insoluble component of the reaction system. In that case the various fractions with enzyme activity will have to be separated by, for example, chromatographic or electrophoretic route or gelfiltration. For practical reasons such a determination is less attractive, however,
The enzyme activity of a fraction of the reaction mixture is demonstrated or measured by incubating that fraction with a substrate and other substances required for processing the relative enzyme: reaction. For preference a reaction is used in which a coloured compound is formed or removed whose absorption can also be measured quantitatively in an easy manner.
Low molecular substances which are eligible for demonstration by the new method and have a molecular weight of up to about 1500 are for example: steroids, vitamin B folinic acid, thyroxine and triiodothyronine, releasing factors, histamine, serotonin and other biogenic amines, digoxine, digitoxin, prostaglandins, adrenalin, nor-adrenalin, vegetable hormones such as auxin, kinetin and gibberellic acid, and antibiotics such as penicillin.
The method of demonstrating specific binding proteins for low molecular substances can be employed for, for example, the determination of antibody against penicillin or for the determination of intrinsic factor.
The preparation of conjugates of enzymes and lowmolecular substances can take place in various manners. Some low molecular substances may already possess groups that can be cross-linked with reactive groups at the surface of the enzyme, while other substances will have to be provided with such groups by organic chemical reactions. It stands to reason that the original binding properties of the low molecular compound and the activity of the enzyme may not change essentially during this process. The groups of the enzyme which are particularly suited for coupling reactions are amino and carboxyl groups. If the modified or unmodified low molecular substance also possesses such groups, the coupling can be performed by, for example, reactions known from the peptide synthesis. Furthermore such substances as glutaraldehyde, difluorodinitrodiphenylsulfon, toluene diisocyanate, diand trichloros-triazine can be employed for the coupling reaction.
Specific examples of the coupling of haptens to proteins are described in, for example, Methods in Immunology and lmmunochemistry, vol. I. The methods described are used for the preparation of conjugates for immunisation but they can also be used for the preparation of conjugates of the low molecular substance and an enzyme which are essential in the invention.
The choice of the enzyme that is to be a component of the conjugate (low molecular substance-enzyme) depends on properties such as the specific activity (a high conversion rate enhances the sensitivity of the test system) and the simplicity of the determination of the enzyme. The determination of an enzyme which catalyses a conversion involving coloured reaction components, is simple. Such colorimetric determinations can be automatized in a simple manner.
According to the invention it is also possible to use enzymes which catalyse conversions involving reaction components that can be determined spectrophotometrically or fluorimetrically. These determinations can also be automatized.
For the preparation of the conjugates enzymes such as catalase, peroxidase, B-glucuronidase, fl-D- glucosidase, B-D-galactosidase, urease, glucoseoxidase and galactose-oxidase are preferred, particularly the group of the oxide reductases.
The insoluble specific binding protein or the insoluble low molecular compound to be used in the present determination can be prepared by a known method, for example, by cross-linking with chloroformic acidethylester, by covalent binding with insoluble carriers such as agarose, cross-linked dextran or filter paper, or by physical coupling to insoluble carriers such as plastic objects.
The form in which the reagents can be used are manifold. The component of the reaction system conjugated with an enzyme can be freeze-dried or dissolved in a buffer. Furthermore a solid carrier, for example, a strip of paper impregnated with the conjugate, can be employed.
The insoluble component can be brought in the form of particles of various sizes, such as grains, platelets and rods, or in the form of a strip of some or other carrier material.
For the performance of the process according to the invention a test pack in preferably employed, chiefly composed of:
a. a given quantity of the coupling product of the low molecular compound and an enzyme;
b. a corresponding quantity of one of the components of the reaction system in an insoluble form;
c. a substrate for the determination of the activity of the enzyme employed.
If required, the test pack can also contain the necessary auxiliaries for making a dilution series of the sample to be examined for a quantitative determination, such as test tubes, pipettes and flasks of diluent. For the determination of a hapten or its antibody the test pack contains at least:
a. a given quantity of the coupling product of this hapten and an enzyme;
b. a corresponding quantity of a component of the reaction system in an insoluble form, haptenantibody;
c. a substrate for the determination of the enzyme activity.
The invention is illustrated further by the following examples, which are not to be construed as limiting.
Example I Determination of testosterone A. Preparation of testosterone-S-HRP One hundred milligrams of testosterone-3-(O-carboxymethyl)-oxim and 0.143 ml of tri-nbutylamine were dissolved in 5 ml of dioxan. The solution was cooled down to 2C and then 0.03 ml of isobutylchlorocarbonate were added. After 30 minutes the solution was added to mg of HRP (horse radish peroxidase) in a mixture of 9 ml of water and 6 ml of dioxan, and adjusted to pH 9 with 0.1 N NaOH. This solution was stirred for 4 hours at 2C and dialysed overnight. The precipitate obtained after the dialysate had been adjusted to pH 4.6 was centrifuged after having been left to stand overnight, suspended in 10 ml of water and dissolved by means of caustic soda solution. The material was precipitated three times with 15 ml of acetone at pH 4.5, dissolved in 15 ml of water which had been adjusted at pH 7.8 with caustic soda solution, dialysed and finally lyophilized.
B. Preparation of testosterone-Zl-BSA This conjugate was prepared in the same manner as the testosterone-B-HRP, but the starting materials were 50 mg of testosterone-3-(O-carboxymethyl)- oxim and mg of BSA (bovine serum albumin).
C. Preparation of antibodies against testosterone-3- BSA Five rabbits were injected intrarnuscularly with increasing dosages of testosterone-3-BSA in complete Freunds adjuvant (0.5, 1 and 2 mg) at intervals of 3 weeks. Two weeks after the last injection the animals were injected intravenously with 2 mg of antigen dissolved in physiological salt. One week after that blood was taken from the animals. The antibodies formed against BSA were removed by treating the serum portionwise with BSA-maminobenzyloxymethyl cellulose, prepared in accordance with Gurvichs method (see D). D. Preparation of anti-testosterone cellulose This substance was prepared in accordance with Gurvichs method as described in Biokhimiya 26, 934 (1961):
1. Preparation of aminocellulose:
Fifty grams of Whatman cellulose, which had been frequently washed and decanted, were suspended in 100 ml of a 0.7 sodium acetate solution containing 2 gm of N(m-nitrobenzoxy methylpyridine. The mixture was dried at 6080C and heated for 40 minutes at 125C. The resulting product was thoroughly washed with distilled water, dried at 80C, washed with benzene and dried again. Fifty grams of the dried product were reduced by suspension in 300 ml of a 15% Na S O solution and stirred for 30 minutes at 5060C. The product was filtered and washed with successively distilled water, 30% acetic acid and again with distilled water.
2. Treatment with ammoniacal copper solution:
Forty millilitres of sulphuric acid, 20 ml of 50% nitric acid and 140 ml of distilled water were heated, while stirring, to 90C, after which 5.9 gm of CuO were added in small portions. The solution was boiled for 2 hours and completed to 500 ml with distilled water. Eighty millilitres of this solution were transferred into an icebath and added to 160 ml of cold 4 N NaOI-I, while stirring. After being stirred for 30 minutes, the precipitate was washed twice with distilled water and dissolved in 80 ml of 25% ammonia. To this solution was gradually added 1 gm of aminocellulose. The mixture was stirred for 1.5 hours, after which 40 ml of boiling water were added, whereupon the solution was quickly cooled down to 0C. The solution was neutralized with 10% sulphuric acid, after whichthe aminocellulose flocculated. It was washed with cold distilled watel.
3. Preparation of 'y-globulin:
To rabbit anti-testosterone serum were added 180 mg of Na SO per ml of serum. The mixture was stirred for 1 hour at room temperature, after which the resulting precipitate was centrifuged, washed twice with an 18% Na SO solution and taken up in so much 0.05 M sodium borate of pH 8.6 that the protein concentration was about 10 mg/ml.
4. Binding 'y-globulin to aminocellulose Aminocellulose (350 mg) was suspended in distilled water (50 ml). The suspension was cooled down to 0C. Ten millilitres of a 36% hydrochloric acid were added and after that dropwise 10 ml of a 10% NaNO solution. The suspension was centrifuged, washed with cold distilled water and then with 0.05 M sodium borate of pH 8.6. The cellulose was suspended in 43 ml of 0.05 M sodium borate of pH 8.6. To this suspension were added 7 ml of the 'y-globulin solution prepared. The mixture was stirred for 26 hours at 4C, centrifuged and washed with 0.02 M phosphate buffer of pH 6.0. From the antiserum of each of the 5 immunized rabbits a cellulose suspension was prepared (A E respectively).
E. Determination of testosterone by means of testosterone-3-HRP and anti-testosterone cellulose The following test system was built up: I Immunoreaction buffer of pH 6.0 and containing 2% sheep serum.
II Enzyme reaction 0.5 ml of the supernatant liquid was incubated at room temperature with 1.5 ml of substrate for 30 minutes. The extinction was measured at 460 nm.
The enzyme substrate contained 10 ,ul of 30% hydrogen peroxide and 20 mg of S-aminosalicylic acid in 150 ml of 0.02 M phosphate buffer of pH 6.2.
FIG. 1 shows the measure in which testosterone3- HRP is bound by the anti-testosteronecellulose preparations made. In this case only buffer was added as a sample in the test system. If cellulose is added instead of anti-testosterone-cellulose, more than of the enzyme activity will remain behind in the supernatant liquid. The preparations B, D and E proved to bind hardly any testosterone-3- HRP, but A and C did.
FIG. 2 shows the results of incubation of a testosterone dilution series with testosterone-3-HRP and four different concentrations ofanti-testosteronecellulose C 1 mg/ml (I), 2 mg/ml (II), 4 mg/ml (III) and 16 mg/ml (IV). It is obvious that with this system a quantity of about 10 ngm of testosterone can be demonstrated.
EXAMPLE III Determination of ,oestradiol A. Oestradiol-l7-succinyl-HRP was prepared by the mixed anhydride method described in example I A, using 50 mg of oestradiol-l7-hemisuccinate and 50 mg of HRP as starting materials.
B. Oestradiol-17-succinyl-BSA was prepared by the mixed anhydride method described in example I A, using mg of oestradiol-l7-hemisuccinate and mg of BSA as starting materials.
C. For the preparation of antibodies against oestradiol-l7-succinyl-BSA five rabbits were immunized in accordance with the scheme described in example I C. The sera were absorbed with BSA- m-amino-benzyloxymethyl-cellulose.
D. Anti-oestradiol-cellulose was prepared in the same manner as the anti-testosterone-cellulose described in example I D. From each of the immunized rabbits a cellulose preparation was made, numbered 16 up to 20 inclusive.
E. The test was performed analogous to that for testosterone as described in example I E.
FIG. 3 and 4 show a few results. FIG. 3 shows that the immunization yielded 3 usable antisera, of which As 17 has the highest titre.
FIG. 4 shows the test system in which anti-oestradiolcellulose 17 is used in a concentration of 8 mg/ml. The system does not discriminate between oestron and 17B-oestradiol. 17a-oestradiol and especially oestriol show a smaller cross-reaction. Testosterone and progesterone influence the system only in very high concentrations.
Example Ill Determination of antibodies against penicillin Penicilloyl-catalase Thirty milligrams of benzyl penicillinic acid were dissolved in ml of 96% ethanol and added dropwise to 200 mg of catalase in 45 ml of 0.1 M phosphate buffer of pH 7.5. The reaction process was continued for 2 hours, the pH being maintained between 7.2 and 8.2 with 0.5 N NaOH. The reaction mixture was dialysed against 6 X 3 l of 0.02 M phosphate buffer of pH 7.0.
In the same manner 250 mg of benzyl penicillinic acid were coupled to 5 gm of m-aminobenzyloxymethyl-cellulose prepared by Gurvichs method. Biokhimiya 26, 934 (1961). The coupling product was not dialysed however, but washed on a glass filter.
It proved to be possible to demonstrate over -sensitiveness to penicillin in humans in the following manner.
0.2 ml of a sample of non-haemolysed serum were mixed with 0.5 ml of a solution of penicilloyl-catalase (1 800). After 30 minutes mg of the penicilloyl-maminobenzyloxymethyl-cellulose were added. The mixture was rotated, for 30 minutes after which the enzyme activity in the supernatant liquid was determined by adding 0.02 ml of it to 2.8 ml of 0.05 M phosphate buffer of pH 6.8, which contained 1.2 a] of 30% H 0 and following the decrease in the extinction at 240 nm. In the serum from patients who were hyper-sensitive to penicillin less enzyme activity was found in the liquid than in checking with rabbit serum. The serum from normal human beings in these tests did not deviate considerably from normal rabbit serum.
Example IV Determination of folic acid A. Preparation of folate-glucose-oxidase Two hundred milligrams of glucose-oxidase (140 lU/mg) were dissolved in 10 ml of PBS (phosphate buffered saline, a phosphate-containing physiological salt solution) of pH 7.0. Thirty milligrams of l-cyclohexyl-3-( 2-morpholino-ethyl carbodiimide (MCDI) were added and then 24 mg of folic acid. The reaction process lasted 2 hours, after which a thorough dialysis was performed against PBS of pH 7.0.
B. Preparation of folate-MBSA (methylated bovine serum albumin) Folate-MBSA was prepared by Ricker and Stollars process described in Biochemistry 6, 2001 (1967). Twenty-five milligrams of MCDI were added to 50 mg of MBSA in 5 ml of water and then mg of folic acid. Two hours later a yellow precipitate had formed. Finally the whole reaction mixture was dialysed against physiological salt for a considerable time.
C. Preparation of antiserum against folate-MBSA On thedays 0, 21 and 42 four rabbits were each injected intramuscularly with 2 mg of folate-MBSA in complete Freunds adjuvant and on day 35 intravenously with 2 mg of folate-MBSA in physiological salt. On day 49 the animals were exsanguinated.
D. Anti-folate cellulose was prepared by the process described in example I D.
E. Test system for folic acid One hundred ul of sample and 700 p.l of anti-folate cellulose suspension were rotated for 3 hours. Two hundred ul of folate-glucose-oxidase (l 1500) were added. The mixture was rotated again for 3 hours and centrifuged, after which the enzyme activity in the supernatant liquid was determined. This was done by mixing 0.5 ml ofit with a solution of 50 mg of glucose, 10 ,ugm of HRP and 1 mg of 5-aminosalicylic acid in 2.5 ml of 0.05N phosphate buffer of pH 6.0 and measuring the extinction after 30 minutes at 460 nm.
FIG. 5 shows the percentage of enzyme bound against the concentration of an anti-folatecellulose.
FIG. 6 shows the sensitivity of the test system in an anti-folate-cellulose concentration of 2 mg/ml and the effect of glycine, asparagine, alanine and glutamic acid.
Example V Determination of digoxin A. Preparation of digoxin-HRP To 22 mg of digoxin, suspended in 1 ml of absolute ethanol, was added dropwise, while stirring, 1 ml of 0.1 M sodium metaperiodate. After 25 minutes 0.3 ml of 0.1 M ethyleneglycol was added. Five minutes later this mixture was added dropwise, while stirring, to asolution 32 mg of horse radish peroxidase (HRP) in 1 ml of distilled water, which had been adjusted to pH 9.5 with a 5% K CO solution. During the reaction the pH was maintained at 9-9.5 with 5% K CO When the pH had become stable 15 mg of NaBH, in 1 ml of distilled water was added. After 3 hours the pH was adjusted to 6.5 with l M formic acid. One hour later 1 M NH OH was added till a pH of 8.5 had been reached. The mixture was dialysed overnight against cold running water. Finally the pH was adjusted at 4.5 with 0.1 N hydrochloric acid. The mixture was left to stand at room temperature for 1 hour and 4 hours at 4C to obtain a precipitate which was centrifuged for 1 hour at 1000 g. The precipitate was dissolved in 5 ml of 0.1 M Nail-[C0 thoroughly dialysed and freeze-dried.
B. Preparation of digoxin-BSA Digoxin bovine serum albumin (BSA) was prepared in the same manner as the above digoxin-HRP, but the starting materials were 436 mg of digoxin and 560 mg of BSA, the quantities of the other reagents having been raised in the same ratio as the digoxin.
C. Preparation of antibodies against digoxin Five rabbits were each injected with 400, 800 and 1600 ugm of digoxin-BSA respectively, at fortnightly intervals. The immunogen was mixed with complete Freunds adjuvant and administered intramuscularly. A fortnight after the last injection the animals were injected intravenously with 800 ugm of digoxin-BSA in physiological salt. Ten days later the animals were bleeded. The serum was adsorbed with BSA-m-aminobenzyloxymethylcellulose. D. Preparation of anti-digoxin-cellulose Anti-digoxin-cellulose was prepared by Gurvichs method as described in example 1 D. E. Determination of digoxin A dilution series was prepared of digoxin in 0.1 M phosphate buffer of pH 7.5 containing 0.9% NaCl, 0.5% Tween-20 and 1.0% of BSA. The dilution series was of from 0.1-100 ngm/ml. One millilitre of a digoxin solution was mixed with 0.1 ml of digoxin-HRP in a suitable dilution, after which 2 mg of antidigoxin-cellulose suspended in 0.4 ml of buffer were added. The mixture was rotated for 6 hours at room temperature, after which it was centrifuged and the enzyme activity in the supernatant liquid determined.
Addition of 0.8 ngm of digoxin proved to cause a measurable increase of enzyme activity in the supernatant liquid. Digitoxin only showed a slight cross-reaction in the system whereas cholesterol, cortisol, oestradiol, testosterone and progesterone did not show any cross-action in the system.
Example VII Determination of transcortine The reagents used for the determination of cortisol, as described in Example IV, were also employed for the determination of transcortine.
Of a dilution series of transcortine of from O 1280 ngm/ml 0.5 ml was incubated for 15 minutes at 4C with 0.2 ml of cortisol-2l-galactose-oxidase in a suit- 10 able dilution. To this dilution series 0.3 ml of transcortine-Sepharose mg/ml) were added and the mixture was rotated for 15 minutes at 4C. The activity in the supernatant liquid was measured as described in example VI. 15 A sample containing 40 ngm/ml of transcortine proved to cause a measurable increase of enzyme activity in the supernatant liquid, whereas in the presence of 320 ngm/ml all the enzyme activity was found in the supernatant liquid.
What is claimed is:
1. Process for the demonstration and determination of a low molecular weight organic compound by means of an antibody against said low molecular weight compound, comprising the steps of:
a. providing a given quantity of the coupling product of said low molecular weight organic compound with an enzyme;
b. providing a corresponding given quantity of an insolubilized antibody against said low molecular weight organic compound;
Example VI Determination of cortisol A. Preparation of cortisol-2l-galactose-oxidase Fifty mg of cortisol-Zl-hemisuccinate and 100 mg of galactose-oxidase were coupled by the mixed anhydride technique as described in example I A. B. Preparation of insoluble transcortine One hundred milligrams of transcortine, purified by DEAE, cellulose, and hydroxyl apatite chromatography respectively, were coupled to 3 gm Sepharose 4 B by the CNBr method, as follows. Three grams of Sepharose 4 B suspension were activated by mixing it with 4 ml of a 2.5% (w/v) CNBr solu tion in distilled water, after which the pH was adjusted between 10 and 11 with 1 N NaOI-l, at which value it was maintained for 6 minutes. The Sepharose was washed with icewaterand with 0.1 M NaHCO Then 100 mg of transcortine in 20 ml of 0.1 M NaHCO were added and the suspension was shakenfor 24 hours at 4C. After being washed with'successively 0.5 M NaI-ICO 0.05 M citrate buffer of pH 1.1 and 0.05 M phosphate buffer of pH 6.0, the Sepharose was kept in the last buffer,
2. The process ofclaim 1 in which said low molecular weight organic compound is a hapten.
3. The process ofclaim 1 in which said enzyme is an oxido-reductase.
4. Process for the demonstration and determination of a low molecular weight organic compound by means of a protein capable of reacting to bind said low molecular weight organic compound specifically, comprising the steps of:
to which 0.1% merthiolate had been added. C. Determination of cortisol Of a cortisol-containing sample (standard, plasma or urine) 0.5 ml were extracted twice with methylene chloride (2 X 3 ml). The combined extraction liquids wereevaporated to dryness. The residue was .a. providing a given quantity of the coupling product taken up in 0.5 ml of physiological salt solution and mixed with 0.2 ml of cortisol-2l-galactose-oxidase s z i :Z ggi wlght orgamc compound m a.smtable concentraum? and 1 b. providing a corresponding given quantity of an incomne'sepharose Suspens lon (5 solubilized specific binding protein having more ture was rotate? for mmutes and cenm' than one valency capable of reacting to bind said fuged, after which the enzyme activity in the superlow molecular weight organic compound specifb natant liquid was determined by adding 0.5 m1 of Cally;
it to m1 of Substrate cotlsistillg 9 mg of c. contacting a sample of a fluid containing the low galactose, zofng S'ammOSahCYhC and 10 molecular weight organic compound to be deterof Permdase 150 ml of 002 M Phosphate mined with said components (a) and (b) to form a buffer of pH 6.0. Thirty minutes later the extinction was measured at 460 nm.
Five ngm/ml of cortisol in the sample caused a measurable increase of the enzyme activity in the supernatant liquid. Corticosterone and progesterone 6 reaction mixture; and
d. determining the enzyme activity of the liquid or the solid phase of the resulting reaction mixture, which activity is a measure of the quantity of low molecular weight organic compound to be deter mined.
5. The process ofclaim 4 in which said enzyme is an oxido-reductase.
6. Process for the demonstration and determination of a specific binding protein having two or more binding sites by means of a low molecular weight organic compound capable of reacting to bind said protein specifically; comprising the steps of:
a. providing a given quantity of the coupling product of said low molecular weight organic compound and an enzyme;
b. providing a corresponding given quantity of an insolubilized specific binding protein having two or more binding sites capable of binding said low molecular weight organic compound;
c. contacting a sample of a fluid containing the protein to be determined with said components (a) and (b) to form a reaction mixture; and
d. determining the enzyme activity of the liquid phase of the resulting reaction mixture, which activity is a measure of the quantity of the specific binding protein to be determined.
7. The process of claim 6 in which said protein is an antibody.
8. A diagnostic pack for the demonstration and determination of a low molecular weight organic compound by means of an antibody against said low molecular weight organic compound, comprising:
a. a given quantity of the coupling product of said low molecular weight organic compound with an enzyme;
b. a corresponding given quantity of an insolubilized antibody against said low molecular weight organic compound; and
c. a substrate for the determination of the enzyme activity of said enzyme.
9. The diagnostic pack ofclaim 8 in which said enzyme is an oxido-reductase.
10. A diagnostic pack for the demonstration and determination of a low molecular weight organic compound by means of a protein capable of reacting to bind said low molecular weight organic compound spe cifically, comprising:
a. a given quantity of the coupling product of said low molecular weight organic compound with an enzyme;
b. a corresponding given quantity of an insolubilized specific binding protein capable of reacting to bind said low molecular weight organic compound specifically; and
c. a substrate for the determination of the enzyme activity of said enzyme.
11. The diagnostic pack of claim 10 in which said enzyme is an oxido-reductase.
12. A diagnostic pack for the demonstration and determination of a hapten by means of an antibody against said hapten, comprising:
a. a given quantity of the coupling product of said hapten with an enzyme;
b. a corresponding given quantity of an insolubilized antibody against said hapten; and
c. a substrate for the determination of the enzyme activity of said enzyme.
13. The diagnostic pack of claim 12 in which said enzyme is an oxido-reductase.
UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION PATENT NO. 3,850,752 A Page: 1 of 2 DATED November 26, 1974 vE 0 (5) Schuurs et a1.
It is certified that error appears in the above-identifiedpatent and that said Letters Patent is hereby corrected as shown below:
On the front page of the patent (disclosing the inventors, assignee, Abstract, References Cited, under [21] Appl No. 193,702" the following heading and contents thereunder:
Related U.S. Application Data p Incolumn 1, beneath the title "PROCESS FOR THE DEMONSTRATION AND DETERMINATION OF LOW MOLECULAR COMPOUNDS AND OF PROTEINS CAPABLE OF BINDING THESE COMPOUNDS SPECIFICALLY" Insert the following paragraph:
This application is a continuation-in-part of Ser. No. 762,120, filed September '24, 1968, issued as U.S. Pat. 3,654,090 on April 4, 1972.
Incolumn 4, line 25, change to In column 5, lines 31 32, place "aminocellulose" in quotation marks. I
In column 5, line 48, place "aminocellulose" in quotation marks.
In column 5, line 49, place "aminocellulose" in quotation marks.
UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION PATENT NO. 3,850,752 Page 2 of 2 DATED November 26, 1974 INVENTQR(S) Schuurs et al.
It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:
In column 7,line 20, change to "z".
Signed and Scaled this Twelfth Day Of Ju1y1983 [SEAL] A nest:
GERALD J. MOSSINGHOFF Arresting Officer Commissioner of Parents and Trademarks

Claims (13)

4. PROCESS FOR THE DEMONSTRATION AND DETERMINATION OF A LOW MOLECULAR WEIGHT ORGANIC COMPOUND BY MEANS OF A PROTEIN CAPABLE OF REACTING TO BIND SAID LOW MOLECULAR WEIGHT ORGANIC COMPOUND SPECIFICALLY, COMPRISING THE STEPS OF: A. PROVIDING A GIVEN QUANTITY OF THE COUPLING PRODUCT OF SAID LOW MOLECULAR WEIGHT ORGANIC COMPOUND WITH AN ENZUME; B. PROVIDING A CORRESPONDING GIVEN QUANTITY OF AN INSOLUBILIZED SPECIFIC BINDING PROTEIN HAVING MORE THAN ONE VALENCY CAPABLE OF REACTING TO BIND SAID LOW MOLECULAR WEIGHT ORGANIC COMPOUND SPECIFICALLY; C. CONTACTING A SAMPLE OF A FLUID CONTAINING THE LOW MOLECULAR WEIGHT ORGANIC COMPOUND TO BE DETERMINED WITH SAID COMPONENTS (A) AND (B) TO FORM A REACTION MIXTURE; AND D. DETERMING THE ENZYME ACTIVITY OF THE LIQUID OR THE SOLID PHASE OF THE RESULTING REACTION MIXTURE, WHICH ACTIVITY IS A MEASURE OF THE QUANTITY OF LOW MOLECULAR WEIGHT ORGANIC COMPOUND TO BE DETERMINED.
6. PROCESS FOR THE DEMONSTRATION AND DETERMINATION OF A SPECIFIC BINDING PROTEIN HAVING TWO OR MORE BINDING SITES BY MEANS OF A LOW MOLECULAR WEIGHT ORGANIC COMPOUND CAPABLE OF REACTING TO BIND SAID PROTEIN SPECIFICALLY; COMPRISING THE STEPS OF: A. PROVIDING A GIVEN QUANTITY OF THE COUPLING PRODUCT OF SAID LOW MOLECULAR WEIGHT ORGANIC COMPOUND AND AN ENZYME; B. PROVIDING A CORRESPONDING GIVEN QUANTITY OF AN INSOLUBILIZED SPECIFIC BINDING PROTEIN HAVING TWO OR MORE BINDING SITES CAPABLE OF BINDING SAID LOW MOLECULAR WEIGHT ORGANIC COMPOUND; C. CONTACTING A SAMPLE OF A FLUID CONTAINING THE PROTEIN TO BE DETERMINED WITH SAID COMPONENTS (A) AND (B) TO FORM A REACTION MIXTURE; AND D. DETERMINING THE ENZYME ACTIVITY OF THE LIQUID PHASE OF THE RESULTING REACTION MIXTURE, WHICH ACTIVITY IS A MEASURE OF THE QUANTITY OF THE SPECIFIC BINDING PROTEIN TO BE DETERMINED.
US00193702A1970-11-101971-10-29Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specificallyExpired - LifetimeUS3850752A (en)

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
NL707016396ANL154598B (en)1970-11-101970-11-10 PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.

Publications (1)

Publication NumberPublication Date
US3850752Atrue US3850752A (en)1974-11-26

Family

ID=19811504

Family Applications (1)

Application NumberTitlePriority DateFiling Date
US00193702AExpired - LifetimeUS3850752A (en)1970-11-101971-10-29Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically

Country Status (16)

CountryLink
US (1)US3850752A (en)
AU (1)AU468060B2 (en)
BE (1)BE775187A (en)
BR (1)BR7107459D0 (en)
CA (1)CA967464A (en)
CH (1)CH617774A5 (en)
DE (1)DE2155658C3 (en)
DK (1)DK140268B (en)
ES (1)ES396741A1 (en)
FI (1)FI54033C (en)
FR (1)FR2113733A5 (en)
GB (1)GB1348935A (en)
IT (1)IT986829B (en)
NL (1)NL154598B (en)
SE (1)SE451162B (en)
ZA (1)ZA717192B (en)

Cited By (1674)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3905871A (en)*1971-05-141975-09-16Syva CoLactam conjugates to enzymes
US3966556A (en)*1972-11-061976-06-29Syva CompanyCompounds for enzyme amplification assay methadone analogs
US3975237A (en)*1972-11-061976-08-17Syva CompanyCompounds for enzyme amplification assay - - ecgonine analogs
US4039385A (en)*1972-05-081977-08-02Syva CompanyCardiac glycoside enzyme conjugates
US4040907A (en)*1974-06-201977-08-09Syva CompanyIodothyronine enzyme conjugates
US4043872A (en)*1975-02-201977-08-23Syva CompanyPolyiodothyronine immunoassay
US4046636A (en)*1974-06-201977-09-06Syva CompanyDiazepam enzyme conjugates
US4061466A (en)*1974-10-161977-12-06Ingvar Gosta Holger SjoholmBiologically active composition and the use thereof
FR2367286A1 (en)*1976-10-071978-05-05Mochida Pharm Co Ltd NEW PROCESS AND REAGENTS FOR IMMUNOCHEMICAL DOSAGE OF PHYSIOLOGICALLY ACTIVE SUBSTANCES
US4096138A (en)*1975-12-081978-06-20Scherr George HImmunological test procedure
US4098876A (en)*1976-10-261978-07-04Corning Glass WorksReverse sandwich immunoassay
DE2805961A1 (en)*1977-04-151978-10-19Syva Co THEOPHYLLINE ANTIGENS AND ANTIBODIES AND THEIR USE FOR THE DETERMINATION OF THEOPHYLLINE
FR2390732A1 (en)*1977-05-121978-12-08Sclavo Inst Sieroterapeut PROCESS FOR DETERMINING THE CONTENTS OF CERTAIN COMPONENTS OF BIOLOGICAL FLUIDS AND MEANS USED
US4134792A (en)*1976-12-061979-01-16Miles Laboratories, Inc.Specific binding assay with an enzyme modulator as a labeling substance
US4166767A (en)*1976-03-251979-09-04Dainippon Pharmaceutical Co., Ltd.Insolubilized antibody
US4191613A (en)*1971-05-141980-03-04Syva CompanyMalate dehydrogenase conjugates for enzyme immunoassays
US4203802A (en)*1971-05-141980-05-20Syva CompanyInhibitable enzyme amplification assay
WO1980002747A1 (en)*1979-05-311980-12-11Rapidex LtdUltrasensitive enzymatic radioimmunoassay method
US4250253A (en)*1977-03-151981-02-10Snamprogetti S.P.A.Composition adapted for the determination of tri-iodo thyronine and diagnosis method employing same
US4269938A (en)*1979-03-081981-05-26Eastman Kodak CompanyAssay of peroxidatively active materials
US4282325A (en)*1971-05-141981-08-04Syva CompanyEnzyme bound corticosteroids
US4299916A (en)*1979-12-261981-11-10Syva CompanyPreferential signal production on a surface in immunoassays
US4323647A (en)*1980-10-151982-04-06University Of MiamiSteric hindrance enzyme immunoassay
USRE31006E (en)*1968-09-241982-08-03Akzona IncorporatedProcess for the demonstration and determination of reaction components having specific binding affinity for each other
US4343896A (en)*1975-02-011982-08-10Akzona IncorporatedMethod and test pack for the demonstration and determination of an antigen or antibody
US4347312A (en)*1980-03-201982-08-31Research Triangle InstituteDetection of antibiotics in milk
US4350761A (en)*1979-05-181982-09-21Yamasu Shoyu Kabushiki KaishaMethod of and reagents for quantitative analysis of cyclic nucleotides
WO1982004323A1 (en)*1981-06-021982-12-09O Neill SeanImmunoprecipitation assay
US4376825A (en)*1979-05-071983-03-15Syva CompanyEnzyme amplification compounds for assays for androgens
US4391904A (en)*1979-12-261983-07-05Syva CompanyTest strip kits in immunoassays and compositions therein
US4419453A (en)*1981-09-281983-12-06The Dow Chemical CompanyImmunological agglutination assays with dyed or colored latex and kits
US4427769A (en)1980-01-171984-01-24Labsystems OyImmunoassay for fecal human hemoglobin
US4443365A (en)*1980-07-011984-04-17Dainippon Pharmaceutical Company LimitedMethod for determination of the valproic acid and reagents therein
US4467030A (en)*1978-06-121984-08-21Boehringer Mannheim GmbhDetermination of the thyroxine-binding index in serum
WO1985000605A1 (en)*1983-07-271985-02-14American Hospital Supply CorporationProcess for selective nitrile reduction
US4506009A (en)*1982-03-301985-03-19University Of CaliforniaHeterogeneous immunoassay method
US4530900A (en)*1982-09-131985-07-23Seragen Diagnostics Inc.Soluble insoluble polymers in enzymeimmunoassay
US4535057A (en)*1982-07-261985-08-13Amf IncorporatedImmunoassay employing monoclonal herpes simplex antibody and biotin-avidin detection system
US4604365A (en)*1981-06-021986-08-05Electro-Nucleonics, Inc.Immunoprecipitation assay
US4713347A (en)*1985-01-141987-12-15Sensor Diagnostics, Inc.Measurement of ligand/anti-ligand interactions using bulk conductance
USRE32696E (en)*1975-09-041988-06-14Akzona IncorporatedEnzymatic immunological method for determination of antigens and antibodies
US4786594A (en)*1986-05-141988-11-22Syntex (U.S.A.) Inc.Enzyme immunoassay
US5047330A (en)*1983-08-171991-09-10Commissariat A L'energie AtomiqueCompound labelled by the acetyl cholinesterase of Electrophorus electricus, its preparation process and its use as a tracer or marker in enzymoimmunological determinations
EP0524502A2 (en)1991-07-221993-01-27Bayer CorporationImmunoassay for free analyte
US5268298A (en)*1991-04-261993-12-07Life Technologies, Inc.System for delivering oxygen to a cell culture medium
US5354692A (en)*1992-09-081994-10-11Pacific Biotech, Inc.Analyte detection device including a hydrophobic barrier for improved fluid flow
US5391483A (en)*1990-07-271995-02-21Eastman Kodak CompanyLigand analogs for immunoassays derived from dicarboxylic acid oxidation products
EP0699754A1 (en)1994-08-121996-03-06Myriad Genetics, Inc.Method for diagnosing a predisposition for breast and ovarian cancer
EP0703296A1 (en)1988-09-291996-03-27Chiron CorporationPolynucleotide determination by strand replacement of a capture probe
EP0705903A1 (en)1994-08-121996-04-10Myriad Genetics, Inc.In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene
US5516639A (en)*1993-07-221996-05-14Mayo Foundation For Medical Education And ResearchAntibodies specific for human prostate glandular kallkrein
US5587294A (en)*1991-07-191996-12-24Assay Research, Inc.Method and kit for measuring endogenous cytokines
US5589344A (en)*1994-06-151996-12-31Johnson & Johnson Clinical Diagnostics, Inc.Test kit and method for competitive specific binding assay
US5605800A (en)*1978-04-131997-02-25Institut PasteurMethod of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method
US5614504A (en)*1990-08-011997-03-25The University Of South FloridaMethod of making inosine monophosphate derivatives and immunopotentiating uses thereof
US5624804A (en)*1991-12-201997-04-29The Rockefeller UniversityImmunochemical detection of In vivo advanced glycosylation end products
US5637467A (en)*1992-10-131997-06-10Behringwerke AgHeterogeneous assay using a pendulous drop
EP0785216A1 (en)1995-12-181997-07-23Myriad Genetics, Inc.Chomosome 13-linked breast cancer susceptibility gene BRCA2
US5652346A (en)*1990-07-271997-07-29Johnson & Johnson Clinical Diagnostics, Inc.Dicarboxylic acid oxidation products
US5684144A (en)*1993-07-281997-11-04University Of North TexasEscherichia coli csrA gene, protein encoded thereby, and methods of use thereof
US5703206A (en)*1981-09-081997-12-30Univ RockefellerMacrophage inflammatory protein 2 (MIP-2)
US5717074A (en)*1988-09-021998-02-10The Rockefeller UniversityMacrophage-derived inflammatory mediator (MIP-2)
US5726023A (en)*1993-03-171998-03-10University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5728807A (en)*1995-05-161998-03-17Ramot-University Authority For Applied Research And Industrial Development, Ltd.Mutated proteins associated with ataxia-telangiectasia
WO1998014593A2 (en)1996-10-011998-04-09Geron CorporationHuman telomerase catalytic subunit
US5777093A (en)*1995-05-161998-07-07Ramot-University Authority For Applied Research & Industrial Development Ltd.cDNAs associated with ataxia-telangiectasia
US5837535A (en)*1994-06-131998-11-17Henry Ford Health SystemNeuronal-neonatal gene: neuronatin
US5840322A (en)*1996-12-191998-11-24Ramot-University Authority For Applied Research & Industrial Devel. Ltd.Anti-oral-microbial adhesion fraction derived from vaccinium
US5843673A (en)*1994-10-251998-12-01Curators Of The University Of MissouriMethod of screening for endometriosis
US5858661A (en)*1995-05-161999-01-12Ramot-University Authority For Applied Research And Industrial DevelopmentAtaxia-telangiectasia gene and its genomic organization
US5869445A (en)*1993-03-171999-02-09University Of WashingtonMethods for eliciting or enhancing reactivity to HER-2/neu protein
US5874423A (en)*1992-09-101999-02-23Yissum Research Development Co. Of The Hebrew University Of JerusalemDigitalis-like compounds
US5876928A (en)*1978-04-131999-03-02Institut PasteurMethod of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method
US5882644A (en)*1996-03-221999-03-16Protein Design Labs, Inc.Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US5939524A (en)*1991-12-091999-08-17The Scripps Research InstitutePlatelet GPIII P1A1 and P1A2 epitopes, their preparation and use
WO1999045124A2 (en)1998-03-041999-09-10Genencor International, Inc.Modified forms of pullulanase
US5965379A (en)*1991-07-191999-10-12Cytimmune Sciences Inc.Method for measuring endogenous cytokines
US6001968A (en)*1994-08-171999-12-14The Rockefeller UniversityOB polypeptides, modified forms and compositions
US6008335A (en)*1994-02-111999-12-28Cedars-Sinai Medical CenterMethods of screening for ulcerative colitis and Crohn's disease
US6013471A (en)*1994-05-102000-01-11Hybritech IncorporatedDNA encoding hK2 variant polypeptides
WO2000015824A1 (en)1998-09-132000-03-23Karolinska Innovations AbTransfer method for specific cellular localisation of nucleic acids
US6048837A (en)*1994-08-172000-04-11The Rockefeller UniversityOB polypeptides as modulators of body weight
US6060260A (en)*1998-02-272000-05-09Dade Behring Inc.Methods for reducing adsorption in an assay
US6093809A (en)*1996-10-012000-07-25University Technology CorporationTelomerase
US6103237A (en)*1993-07-222000-08-15Hybritech IncorporatedStable variant hK2 polypeptide
US6124448A (en)*1994-08-172000-09-26The Rockfeller UniversityNucleic acid primers and probes for the mammalian OB gene
US6124439A (en)*1994-08-172000-09-26The Rockefeller UniversityOB polypeptide antibodies and method of making
US6127338A (en)*1997-04-012000-10-03Calyx Therapeutics, Inc.Orally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes
US6129917A (en)*1996-03-222000-10-10The University Of Georgia Research Foundation, Inc.Immunogenic compositions comprising porphyromonas gingivalis proteins and/or peptides and methods
WO2000073451A1 (en)1999-06-012000-12-07Schering CorporationMammalian receptor proteins; related reagents and methods
US6180411B1 (en)1997-08-012001-01-30The Regents Of The University Of CaliforniaLight-triggered indicators that memorize analyte concentrations
US6187563B1 (en)1998-08-072001-02-13Yale UniversityβIV-spectrin-polypeptides and nucleic acids encoding same
US6207153B1 (en)1996-05-222001-03-27Viventia Biotech, Inc.Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US6228575B1 (en)1996-02-082001-05-08Affymetrix, Inc.Chip-based species identification and phenotypic characterization of microorganisms
US6228638B1 (en)1997-07-112001-05-08University Of North Texas, Health Science Center At Fort WorthEscherichia coli CSRB gene and RNA encoded thereby
US6235486B1 (en)1997-06-202001-05-22Mayo Foundation For Medical Education & ResearchMethod for detection of breast cancer
US6261836B1 (en)1996-10-012001-07-17Geron CorporationTelomerase
WO2001062271A1 (en)2000-02-222001-08-30The Board Of Trustees Of The University Of ArkansasCompositions and methods for the early diagnosis of ovarian cancer
US6284496B1 (en)1997-10-032001-09-04University Of South FloridaDNA vector for determining the presence of out-of-reading-frame mutations
US6294334B1 (en)1996-11-152001-09-25Board Of Regents, The University Of Texas SystemGenetic test for equine severe combined immunodeficiency disease
WO2001075078A1 (en)2000-03-312001-10-11The Scripps Research InstituteHUMAN AMINOACYL-tRNA SYNTHETASE POLYPEPTIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS
US6303344B1 (en)1996-12-182001-10-16Maxygen, Inc.Methods and compositions for polypeptide engineering
US6309853B1 (en)1994-08-172001-10-30The Rockfeller UniversityModulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6312901B2 (en)1996-07-082001-11-06Burstein Technologies, Inc.Spatially addressable, cleavable reflective signal elements, assay device and method
US6331275B1 (en)1996-07-082001-12-18Burstein Technologies, Inc.Spatially addressable, cleavable reflective signal elements, assay device and method
US6342349B1 (en)1996-07-082002-01-29Burstein Technologies, Inc.Optical disk-based assay devices and methods
US6344443B1 (en)1998-07-082002-02-05University Of South FloridaPeptide antagonists of tumor necrosis factor alpha
US6350730B1 (en)1994-08-172002-02-26The Rockefeller UniversityOB polypeptides and modified forms as modulators of body weight
WO2002020569A2 (en)2000-09-082002-03-14Schering CorporationMammalian genes; related reagents and methods
US20020055617A1 (en)*1993-06-182002-05-09Marilyn H. PerrinCloning and recombinant production of cfr receptor(s)
US20020061580A1 (en)*1997-11-202002-05-23Estell David A.Alpha/beta hydrolase-fold enzymes
WO2002044736A2 (en)2000-11-302002-06-06Molecular Skincare LimitedDiagnosis and treatment of epidermal or skin diseases
US6406855B1 (en)1994-02-172002-06-18Maxygen, Inc.Methods and compositions for polypeptide engineering
US6410687B1 (en)1998-04-142002-06-25The Regents Of The University Of CaliforniaPolypeptides for the detection of microtubule depolymerization inhibitors
US20020106661A1 (en)*1996-07-082002-08-08Burstein Laboratories, Inc.Optical disk-based assay devices and methods
US6433155B1 (en)1996-09-242002-08-13Tanox, Inc.Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US20020110860A1 (en)*2000-09-182002-08-15Sierd BronTwin-arginine translocation in Bacillus
US6440682B1 (en)*1999-05-282002-08-27Detroit R&D Inc.Detection of hypertension using immunoreactive metabolic products
US20020127641A1 (en)*1997-09-152002-09-12Estell David A.Proteases from gram-positive organisms
US20020137681A1 (en)*1999-07-062002-09-26Lawrence SteinmanTreatment of demyelinating autoimmune disease with ordered peptides
US6458557B1 (en)1997-11-202002-10-01Genencor International, Inc.Enhancing growth in gram-positive microorganisms using formate supplementation and inactivation of formate-associated transport proteins
US20020154615A1 (en)*2000-01-282002-10-24Martin HansDetection method and device
US6471956B1 (en)1994-08-172002-10-29The Rockefeller UniversityOb polypeptides, modified forms and compositions thereto
US6475789B1 (en)1996-10-012002-11-05University Technology CorporationHuman telomerase catalytic subunit: diagnostic and therapeutic methods
US20020165149A1 (en)*2000-12-082002-11-07Kranz David M.Mutated class II major histocompatibility proteins
US6479263B1 (en)1996-11-142002-11-12Baylor College Of MedicineMethod for detection of micrometastatic prostate cancer
US6482389B1 (en)1997-10-172002-11-19University Of South FloridaMethod to diagnose and monitor cellular immune deficiencies
US20020172980A1 (en)*2000-11-272002-11-21Phan Brigitte ChauMethods for decreasing non-specific binding of beads in dual bead assays including related optical biodiscs and disc drive systems
US20020187467A1 (en)*1998-04-032002-12-12Thomas GingerasMycobacterial rpob sequences
US20020187471A1 (en)*1996-10-012002-12-12Cech Thomas R.Novel telomerase
US6495343B1 (en)1993-06-182002-12-17The Salk Institute For Biological StudiesCloning and recombinant production of CRF receptor(s)
US20020192839A1 (en)*1998-03-302002-12-19Epitope, Inc.Collection device for single step assay of oral fluids
US20030003464A1 (en)*2000-11-272003-01-02Phan Brigitte C.Dual bead assays including optical biodiscs and methods relating thereto
US6506553B1 (en)1995-03-302003-01-14Ortho Diagnostics Systems, Inc.Method for diagnosis of Epstein-Barr virus associated disease
US6506579B1 (en)1997-07-152003-01-14Genencor International, Inc.Increasing production of proteins in gram-positive microorganisms using SecG
US6521421B1 (en)1997-07-162003-02-18Genencor International, Inc.Expression vectors encoding Bacillus subtilis disulfide bond isomerase and methods of secreting proteins in gram-positive microorganisms using the same
US6521440B1 (en)1997-09-152003-02-18Genencor International, Inc.Proteases from gram-positive organisms
US6531277B2 (en)1994-10-252003-03-11The Curators Of The University Of MissouriEndometriosis-specific secretory protein
US20030049254A1 (en)*2001-06-052003-03-13Kaufman Daniel L.Modulating neuronal outgrowth via the major histocompatibility complex Class I (MHC I) molecule
US20030054446A1 (en)*2000-11-292003-03-20Weber Bernard H. F.Novel retina-specific human proteins C7orf9, C12orf7, MPP4 and F379
US20030064058A1 (en)*2001-09-072003-04-03Nadir AskenasyMethods of utilizing bone marrow stem cells for inducing immunological tolerance
US20030064364A1 (en)*1996-01-232003-04-03Lockhart David J.Nucleic acid analysis techniques
US6544792B1 (en)1999-12-212003-04-08Genencor International, Inc.Production of secreted polypeptides
US20030073248A1 (en)*2001-09-282003-04-17J.W. RothBovine pregnancy test
WO2003030835A2 (en)2001-10-122003-04-17Schering CorporationUse of bispecific antibodies to regulate immune responses
US20030078177A1 (en)*1997-12-302003-04-24Estell David A.Proteases from gram positive organisms
US20030082596A1 (en)*2001-08-082003-05-01Michael MittmannMethods of genetic analysis of probes: test3
US20030086914A1 (en)*1999-06-252003-05-08Yissum Research Development Company Of The Hebrew University Of JerusalemMethod and device for inducing biological processes by micro-organs
WO2003043524A2 (en)2001-11-202003-05-30The Curators Of The University Of MissouriCompositions and methods for accurate early pregnancy diagnosis
US20030104491A1 (en)*2000-04-302003-06-05Cabantchik Ioav ZviMolecules and methods using same for measuring non-transferrin bound iron
US20030105770A1 (en)*2001-11-262003-06-05Macleod StewartExtending a directory schema independent of schema modification
US20030104410A1 (en)*2001-03-162003-06-05Affymetrix, Inc.Human microarray
US20030104355A1 (en)*2001-11-022003-06-05Caili WangAdapter-directed display systems
US20030108927A1 (en)*2000-04-032003-06-12Kathryn LeishmanCompositions and methods for the prevention, treatment and detection of tuberculosis and other diseases
US20030114410A1 (en)*2000-08-082003-06-19Technion Research And Development Foundation Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
US20030118593A1 (en)*1997-07-082003-06-26Dan Michael D.Antigen binding fragments, designated 4B5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US6596501B2 (en)1998-02-232003-07-22Fred Hutchinson Cancer Research CenterMethod of diagnosing autoimmune disease
US6599731B1 (en)1997-12-302003-07-29Genencor International, Inc.Proteases from gram positive organisms
US20030152909A1 (en)*1994-11-162003-08-14Mitrani Eduardo N.In vitro micro-organs, and uses related thereto
US20030158133A1 (en)*2001-08-012003-08-21Movsesian Matthew A.Isoform-selective inhibitors and activators of PDE3 cyclic nucleotide phosphodiesterases
US20030157642A1 (en)*1997-07-152003-08-21Caldwell Robert M.Increasing production of proteins in gram-positive microorganisms
US20030158070A1 (en)*1997-07-152003-08-21Estell David A.Proteases from gram-positive organisms
US6610839B1 (en)1997-08-142003-08-26Geron CorporationPromoter for telomerase reverse transcriptase
WO2003072799A2 (en)2002-02-222003-09-04The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human ServicesBrother of the regulator of imprinted sites (boris)
US20030182669A1 (en)*2002-03-192003-09-25Rockman Howard A.Phosphoinositide 3-kinase mediated inhibition of GPCRs
US20030180757A1 (en)*1996-01-232003-09-25Affymetrix, Inc.Nucleic acid labeling compounds
US6630328B2 (en)1909-07-152003-10-07Genencor International, Inc.Increasing production of proteins in gram-positive microorganisms
US20030211556A1 (en)*2002-01-162003-11-13Fatemi S. HosseinMarker for psychiatric conditions
US20030211490A1 (en)*2000-01-242003-11-13Hanan SteinPlants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
US20030220475A1 (en)*2001-04-032003-11-27Fields Howard A.Neutralizing immunogenic hev polypepetides
US20030222908A1 (en)*2002-06-032003-12-04Microsoft CorporationDynamic wizard interface system and method
WO2003101386A2 (en)2002-05-302003-12-11Memorial Sloan-Kettering Cancer CenterKinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis
US20030232979A1 (en)*1998-07-312003-12-18Mcgall GlennNucleic acid labeling compounds
US6673623B1 (en)2000-09-122004-01-06Novocure, Inc.Methods and compositions that control lipid production
US6673914B1 (en)1998-01-222004-01-06John Wayne Cancer InstituteHuman tumor-associated gene
US20040009164A1 (en)*2002-05-012004-01-15Jonathan ReevesPSP94 diagnostic reagents and assays
US20040013665A1 (en)*1993-09-152004-01-22Ortho Diagnostic Systems, Inc.Immunoreactive peptides from Epstein-Barr virus
US20040038237A1 (en)*2001-12-192004-02-26Goldberg Steven L.Pichia pastoris formate dehydrogenase and uses therefor
US6699969B1 (en)1998-04-142004-03-02The Regents Of The University Of CaliforniaAssays for the detection of microtubule depolymerization inhibitors
US20040052928A1 (en)*2002-09-062004-03-18Ehud GazitPeptides and methods using same for diagnosing and treating amyloid-associated diseases
US20040052769A1 (en)*2000-11-302004-03-18Yair ReisnerMethods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease
WO2004037251A1 (en)2002-10-242004-05-06Sterix LimitedInhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2
US20040091946A1 (en)*2000-11-032004-05-13Oakley Robert H.Methods of screening compositions for G protein -coupled receptor desensitization inhibitory activity
US20040101892A1 (en)*1996-01-232004-05-27Affymetrix, Inc.Nucleic acid labeling compounds
US20040121442A1 (en)*2002-05-052004-06-24Ilan ChetFungal chitinase, polynucleotide sequences encoding same, promoters of same, and uses thereof
US20040126868A1 (en)*1997-07-152004-07-01Estell David A.Gram-positive microorganisms with an inactivated cysteine protease-3
US6759243B2 (en)1998-01-202004-07-06Board Of Trustees Of The University Of IllinoisHigh affinity TCR proteins and methods
US20040132109A1 (en)*2001-01-232004-07-08Masato EnariMethod
WO2004060135A2 (en)2003-01-022004-07-22Rappaport Family Institute For Research In The Medical SciencesMethods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients
US20040146949A1 (en)*2002-10-252004-07-29Jun TanMethods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease
US6770622B2 (en)2001-06-082004-08-03Gary A. JarvisN-terminally truncated galectin-3 for use in treating cancer
US6770449B2 (en)1997-06-052004-08-03Duke UniversityMethods of assaying receptor activity and constructs useful in such methods
US6787318B1 (en)1999-06-012004-09-07Roskamp Research Institute, LlcAssay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
US6794179B2 (en)1997-12-302004-09-21Genencor International, Inc.Proteases from gram positive organisms
US20040186280A1 (en)*2002-12-192004-09-23Murdoch UniversityBmpB novel nucleotide and amino acid sequences and diagnostic and therapeutic uses thereof
US20040197334A1 (en)*2003-04-022004-10-07Technion Research & Development Foundation Ltd.Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
US20040209246A1 (en)*2003-04-152004-10-21Agouron Pharmaceuticals, Inc.Dual reporter/dye reduction methodology for evaluating antiviral and cytotoxicity of hepatitis C virus inhibitors
US20040210045A1 (en)*1996-01-232004-10-21Mcgall GlennNucleic acid labeling compounds
US20040214248A1 (en)*2001-04-062004-10-28Roberts David DUse of semenogelin in the diagnosis, prognosis and treatment of cancer
WO2004096157A2 (en)2003-03-072004-11-11New England Medical Center Hospitals, Inc.Treatment of igai deposition diseases
US20040229245A1 (en)*2003-01-062004-11-18Anton BittnerMethods and algorithms for performing quality control during gene expression profiling on DNA microarray technology
US20040242529A1 (en)*1997-04-182004-12-02Geron CorporationVector encoding inactivated telomerase for treating cancer
US20040247613A1 (en)*1997-04-182004-12-09Geron CorporationTreating cancer using a telomerase vaccine
US20040248093A1 (en)*2000-11-272004-12-09Coombs James HowardMagneto-optical bio-discs and systems including related methods
US6833441B2 (en)2001-08-012004-12-21Abmaxis, Inc.Compositions and methods for generating chimeric heteromultimers
US20040259113A1 (en)*1993-07-222004-12-23Mayo Foundation For Medical Education And Research, Hybritech IncorporatedMethod for detection of metastatic prostate cancer
US20050013825A1 (en)*1997-04-182005-01-20Geron CorporationVaccine containing the catalytic subunit of telomerase for treating cancer
US20050022269A1 (en)*2001-07-192005-01-27Joseph HirschbergPolypeptides having carotenoids isomerase catalytic activity, nucleic acids encoding same and uses thereof
US20050020499A1 (en)*2003-05-272005-01-27Bar Ilan UniversityMethods of attenuating cocaine seeking behavior employing glial cell-derived neurotrophic factor (GDNF) and pharmaceutical compositions and articles of manufacture suited for use in practice of the method
US20050032126A1 (en)*2003-03-032005-02-10Coombs James H.Methods and apparatus for use in detection and quantitation of various cell types and use of optical bio-disc for performing same
US20050031618A1 (en)*2001-01-312005-02-10Dror MevorachInduction of tolerance by apoptotic and/or necrotic cells
WO2005016282A2 (en)2003-08-142005-02-24Exelixis, Inc.Prkcs as modifiers of the beta catenin pathway and methods of use
WO2005019409A2 (en)2002-07-152005-03-03Board Of Regents, The University Of Texas SystemCombinatorial protein library screening by periplasmic expression
US20050054097A1 (en)*2002-11-172005-03-10Tony PeledEX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
US20050054103A1 (en)*2003-03-072005-03-10Tony PeledExpansion of renewable stem cell populations using modulators of PI 3-kinase
US20050064479A1 (en)*2003-08-122005-03-24Affymetrix, Inc.Compounds and methods for post incorporation labeling of nucleic acids
US20050064435A1 (en)*2003-09-242005-03-24Xing SuProgrammable molecular barcodes
US6872537B1 (en)1998-04-142005-03-29Regents Of The University Of CaliforniaAssays for the detection of microtubule depolymerization inhibitors
US20050069923A1 (en)*1996-07-082005-03-31Mullis Kary BanksDual bead assays using cleavable spacers and/or ligation to improve specificity and sensitivity including related methods and apparatus
US6875582B1 (en)1999-08-192005-04-05Omniscience Pharmaceuticals, Inc.Methods and targets of antibiotic resistance
WO2005033145A1 (en)2003-10-072005-04-14Yeda Research And Development Co. Ltd.Antibodies to nik, their preparation and use
WO2005033142A2 (en)2003-10-072005-04-14Yeda Research And Development Co. Ltd.Anti-nik antibodies and uses thereof
US20050085432A1 (en)*2001-12-262005-04-21Aviva LapidotMethods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections
US6884590B1 (en)1994-02-112005-04-26Cedars-Sinai Medical CenterMethods of screening for ulcerative colitis and crohn's disease
US20050106623A1 (en)*2000-11-032005-05-19Oakley Robert H.Modified G-protein coupled receptors
US20050113327A1 (en)*1999-08-302005-05-26Levava RoizMethods of and compositions for inhibiting the proliferation of mammalian cells
WO2005051423A2 (en)2003-11-302005-06-09Yeda Research And Development Co. LtdMethods and agents for immune modulation and methods for identifying immune modulators
US20050136431A1 (en)*2000-11-032005-06-23Oakley Robert H.Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity
US20050152912A1 (en)*2003-03-262005-07-14Technion Research & Development Foundation Ltd.Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20050158822A1 (en)*2004-01-202005-07-21Insight Biopharmaceuticals Ltd.High level expression of recombinant human erythropoietin having a modified 5'-UTR
US6924094B1 (en)1996-02-082005-08-02Affymetrix, Inc.Chip-based species identification and phenotypic characterization of microorganisms
US20050176137A1 (en)*1999-02-042005-08-11Technion Research & Development Foundation Ltd.Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
US20050186646A1 (en)*2004-01-262005-08-25Cruz Miguel A.Rapid assay to detect ADAMTS-13 activity
US20050191285A1 (en)*1993-03-172005-09-01University Of WashingtonCompounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US20050202098A1 (en)*2001-01-312005-09-15TolarenDisease therapy using dying or dead cells
US20050214827A1 (en)*1996-07-082005-09-29Burstein Technologies, Inc.Assay device and method
US20050220774A1 (en)*2002-03-182005-10-06Tony PeledMethods of inducing differentiation in ex vivo expanded stem cells
US6958214B2 (en)2000-07-102005-10-25Sequenom, Inc.Polymorphic kinase anchor proteins and nucleic acids encoding the same
US20050249789A1 (en)*1997-11-202005-11-10Estell David AAlpha/beta hydrolase-fold enzymes
US6965020B2 (en)1996-01-232005-11-15Affymetrix, Inc.Nucleic acid labeling compounds
US20050255101A1 (en)*2002-02-132005-11-17Technion Research And Development Foundation Ltd.Antibody having a t-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20050271643A1 (en)*2003-08-142005-12-08Iryna SorokulovaBacterial strains, compositions including same and probiotic use thereof
US20050271655A1 (en)*2002-08-102005-12-08Biogen Idec Ma Inc.Nogo receptor antagonists
WO2005118864A2 (en)2004-05-282005-12-15Agensys, Inc.Antibodies and related molecules that bind to psca proteins
US20050281916A1 (en)*2001-05-182005-12-22Kirsten BojsenMethod of improving dough and bread quality
US20050287604A1 (en)*2002-05-312005-12-29Bohmer Ralph MMaternal antibodies as fetal cell markers to identify and enrich fetal cells from maternal blood
US20050287563A1 (en)*1996-01-232005-12-29Affymetrix, Inc.Nucleic acid labeling compounds
US20060002135A1 (en)*2004-07-012006-01-05Eurodent S.P.A.Dental lamp particularly for medical and dental surgeries
US20060008479A1 (en)*1996-04-012006-01-12University Of WashingtonMethods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
US20060019340A1 (en)*1999-06-082006-01-26David NaorCD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US20060029984A1 (en)*2002-05-012006-02-09Jonathan ReevesPSP94 diagnostic reagents and assays
US6998232B1 (en)1999-09-272006-02-14Quark Biotech, Inc.Methods of diagnosing bladder cancer
US20060035367A1 (en)*1997-12-302006-02-16Estell David AProteases from gram positive organisms
US20060035980A1 (en)*2003-04-182006-02-16Scanlan Thomas SThyronamine derivatives and analogs and methods of use thereof
US20060039897A1 (en)*2002-03-262006-02-23Tamar LotanStinging cells expressing an exogenous polycleotide encoding a therpeutic, diagnostics or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derive therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US20060040307A1 (en)*1997-04-182006-02-23Geron CorporationHuman telomerase catalytic subunit
WO2006024694A2 (en)2004-09-032006-03-09Licentia OyPeptide inhibitors of hk2 and their use
US20060051426A1 (en)*2001-12-052006-03-09Gershon GolombNanoparticles containing polymeric nucleic acid homologs pharmaceutical composition and articles of manufacture containing same and methods of use thereof
WO2006034048A2 (en)2004-09-182006-03-30University Of Maryland, BaltimoreTherapeutic agents targeting the ncca-atp channel and methods of use thereof
US20060073530A1 (en)*2001-08-152006-04-06Olaf SchneewindMethods and compositions involving sortase B
US20060079941A1 (en)*2004-10-122006-04-13Eli OvsyshcherMethods and implantable devices for treating supraventricular arrhythmias
US20060078951A1 (en)*2004-10-082006-04-13Youn Byung SMonoclonal antibody selectively recognizing listeria monocytogenes, hybridoma producing the antibody, test kit comprising the antibody and detection method of listeria monocytogenes using the antibody
US7030228B1 (en)1999-11-152006-04-18Miltenyi Biotec GmbhAntigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
WO2006043178A2 (en)2004-10-182006-04-27Danisco A/SEnzymes
EP1655381A1 (en)2004-11-042006-05-10Affymetrix, Inc. (A US Entity)Nucleic acid labeling methods
US20060099273A1 (en)*2000-09-282006-05-11Nanocyte Inc.Sterile preparations and compositions including stinging capsules and methods of producing and using same
US20060105354A1 (en)*2004-11-182006-05-18Eppendorf Array Technologies S.A.Real-time quantification of multiple targets on a micro-array
US7053188B2 (en)2002-02-222006-05-30Purdue Research FoundationMonoclonal antibodies specific for neoplasia-specific NADH:disulfide reductase
US7053268B1 (en)1999-06-172006-05-30Danisco A/SPromoter
US20060123516A1 (en)*2003-05-222006-06-08Gil RonenMethods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US7060283B1 (en)1992-09-152006-06-13Ortho Diagnostic Systems, Inc.Immunoreactive peptides from Epstein-Barr virus
US20060127366A1 (en)*1999-06-252006-06-15Mitrani Eduardo NMethod and device for inducing biological processes by micro-organs
US20060134538A1 (en)*2004-12-162006-06-22Radu Nora SAromatic chalcogen compounds and their use
US20060134680A1 (en)*2004-12-222006-06-22Alexander KotlyarHomogeneous populations of nucleic acids, methods of synthesyzing same and uses thereof
US20060140934A1 (en)*2004-09-242006-06-29Colin GeggModified Fc molecules
US20060148078A1 (en)*2002-11-292006-07-06Sharon Gerecht-NirMethod of dynamically culturing embryonic stem cells
US20060159769A1 (en)*2000-09-282006-07-20Nanocyte Inc.Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
EP1683874A2 (en)2000-08-292006-07-26YEDA RESEARCH AND DEVELOPMENT Co. LTD.Methods of isolating genes encoding proteins of specific function and of screening for pharmaceutically active agents
US7087395B1 (en)2001-01-162006-08-08Quest Diagnostics Investments IncorporatedVitamin D assay
US20060188944A1 (en)*1997-06-052006-08-24Barak Lawrence SMethods of assaying receptor activity
WO2006090388A2 (en)2005-02-252006-08-31The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani CenterFruit cell culture extract for treating inflammation
US7101839B1 (en)1999-08-302006-09-05Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US20060198817A1 (en)*2002-11-262006-09-07Alverdy John CMaterials and methods for preventing and treating microbe-mediated epithelial disorders
US20060211064A1 (en)*2005-03-182006-09-21Hyesook KimDetection of hypertension using glucuronidated metabolic products
US7115722B1 (en)1997-05-222006-10-03Viventia Biotech, Inc.Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
WO2006107962A2 (en)2005-04-042006-10-12Biogen Idec Ma IncMethods and products for evaluating an immune response to a therapeutic protein
US20060234203A1 (en)*2005-04-192006-10-19Nanocyte Inc.Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
US20060234947A1 (en)*2002-01-312006-10-19Tel Aviv University Future Technology Development L.PPeptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US20060260002A1 (en)*2003-06-192006-11-16Gil RonenNucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US20060257429A1 (en)*2003-10-232006-11-16Dreier Kimberly JVaccine for periodontal disease
US20060263828A1 (en)*2003-01-242006-11-23Sudha ShenoyModified trafficking patterns for arrestin and g-protein-coupled receptors via arrestin-ubiquitin chimera
EP1728875A2 (en)1996-02-082006-12-06Affymetrix, Inc.Chip-based speciation and phenotypic characterization of microorganisms
US20060275267A1 (en)*1998-03-312006-12-07Morin Gregg BNucleic acids encoding inactive variants of human telomerase
US20060281106A1 (en)*1997-10-012006-12-14Andrews William HTelomerase promoter sequences for screening telomerase modulators
WO2006134602A2 (en)2005-06-162006-12-21Ramot At Tel Aviv University Ltd.Isolated cells and populations comprising same for the treatment of cns diseases
US20060292579A1 (en)*1994-10-212006-12-28Affymetrix, Inc.Methods of enzymatic discrimination enhancement and surface bound double-stranded DNA
WO2007001986A2 (en)2005-06-202007-01-04Yuling LuoMethods of detecting nucleic acids in individual cells and of identifying rare cells from large heterogeneous cell populations
US20070026106A1 (en)*2003-01-172007-02-01Kreij Arno DMethod
US20070032421A1 (en)*2003-12-122007-02-08Efrat LevyMethods and compositions relating to cystatin C
US20070037187A1 (en)*2000-03-242007-02-15Isabelle AlexandreIdentification and quantification of a plurality of biological (micro)organisms or their components
WO2007020638A2 (en)2005-08-152007-02-22Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
WO2007023491A2 (en)2005-08-242007-03-01Yeda Research And Development Co. Ltd.Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
WO2007027714A2 (en)2005-08-312007-03-08Schering CorporationEngineered anti-il-23 antibodies
EP1762243A1 (en)1999-03-312007-03-14Oxford Biomedica (UK) LtdFactor for regulation of neurite growth
US20070059717A1 (en)*2005-09-152007-03-15Baylor Research InstituteSystemic lupus erythematosus diagnostic assay
US7192555B2 (en)1998-03-302007-03-20Orasure Technologies, Inc.Device for collection and assay of oral fluids
WO2007031996A1 (en)2005-09-122007-03-22Rappaport Family Institute For Research In The Medical SciencesCompositions and methods for diagnosing and treating an inflammation
US20070065429A1 (en)*2003-04-162007-03-22Biogen Idec Ma Inc.Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques
WO2007034487A1 (en)2005-09-222007-03-29Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer
US20070071751A1 (en)*1996-09-242007-03-29Tanox, Inc.Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US20070087437A1 (en)*2005-10-142007-04-19Jifan HuMethods for rejuvenating cells in vitro and in vivo
US20070099204A1 (en)*2000-03-242007-05-03Isabelle AlexandreIdentification and quantification of a plurality of biological (micro)organisms or their components
WO2007056352A2 (en)2005-11-072007-05-18The Scripps Research InstituteCompositions and methods for controlling tissue factor signaling specificity
US7223902B1 (en)1999-11-192007-05-29Yissum Research Development Company Of The Hebrew University Of JerusalemMethod of producing recombinant Aspergillus niger β-glucosidase and an aroma spreading plant
US20070134814A1 (en)*2005-12-092007-06-14Kajander E OMethods and compositions for the detection of calcifying nano-particles, identification and quantification of associated proteins thereon, and correlation to disease
US20070134658A1 (en)*2003-03-052007-06-14Genetic Technologies Limited, A.C.N. 009 212 328Identification of fetal dna and fetal cell markers in maternal plasma or serum
EP1798287A2 (en)1997-08-012007-06-20Schering CorporationMammalian cell membrane proteins and related reagents
US20070141658A1 (en)*2005-10-272007-06-21The Regents Of The University Of CaliforniaFluorogenic probes for reactive oxygen species
EP1803816A2 (en)1996-12-132007-07-04Schering CorporationMammalian cell surface antigens; related reagents
US20070160546A1 (en)*2000-09-282007-07-12Tamar LotanUse of stinging cells/capsules for the delivery of active agents to keratinous substances
US20070161007A1 (en)*2006-01-112007-07-12Wisconsin Alumni Research FoundationSynthetic cofactor analogs of S-adenosylmethionine as ligatable probes of biological methylation and methods for their use
EP1810978A2 (en)2000-08-082007-07-25St. Jude Children's Research HospitalGroup B streptococcus polypeptides nucleic acids and therapeutic composition and vaccines thereof
US20070178462A1 (en)*2004-02-182007-08-02Uebele Victor NNucleic acid molecules encoding novel murine low-voltage activated calcium channel proteins, designated-alpha1h, encoded proteins and methods of use thereof
US7252950B1 (en)1997-09-042007-08-07The Regents Of The University Of CaliforniaAssays for detecting modulators of cytoskeletal function
US20070184530A1 (en)*2006-02-032007-08-09Fuad FaresLong-acting veterinary polypeptides and methods of producing and administering same
WO2007088051A2 (en)2006-01-312007-08-09Bayer Schering Pharma AktiengesellschaftModulation of mdl-1 activity for treatment of inflammatory disease
US20070190534A1 (en)*2001-06-112007-08-16Genesis Genomics Inc.Mitochondrial sites and genes associated with prostate cancer
WO2007091254A1 (en)2006-02-062007-08-16Rappaport Family Institute For Research In The Medical SciencesMethods and kit for diagnosing t1dm
WO2007092563A2 (en)2006-02-082007-08-16Genzyme CorporationGene therapy for niemann-pick disease type a
US20070196369A1 (en)*2002-02-202007-08-23Hoogenboom Henricus Renerus JMHC-peptide complex binding ligands
US20070202515A1 (en)*2005-10-122007-08-30Pathologica, Llc.Promac signature application
US7270810B2 (en)2000-01-052007-09-18Yeda Research And Development Co. Ltd.Veto cells effective in preventing graft rejection and devoid of graft versus host potential
US20070218511A1 (en)*1998-03-312007-09-20Genzyme CorporationMethods for the diagnosis and treatment of lung cancer
US20070225242A1 (en)*2005-06-212007-09-27The Board Of Trustees Of The Leland Stanford Junior UniversityMethod and composition for treating and preventing tumor metastasis in vivo
US20070232556A1 (en)*2006-03-312007-10-04Montine Thomas JMethods and compositions for the treatment of neurological diseases and disorders
WO2007110869A2 (en)2006-03-282007-10-04Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods and kits for determining predisposition to warfarin resistance
US7291463B2 (en)1996-01-232007-11-06Affymetrix, Inc.Nucleic acid labeling compounds
US20070281883A1 (en)*2006-06-052007-12-06Hanna RosenfeldDevelopment of follicle stimulating hormone agonists and antagonists in fish
WO2008005429A2 (en)2006-07-032008-01-10Charles David AdairComposition for modulating the expression of cell adhesion molecules
WO2008010934A2 (en)2006-07-142008-01-24Chemocentryx, Inc.Triazolyl phenyl benzenesulfonamides
WO2008010228A2 (en)2006-07-202008-01-24Yeda Research And Development Co. Ltd.Photosyntheticorganisms and compositions and methods of generating same
US20080026394A1 (en)*2006-07-112008-01-31Antara Biosciences Inc.Methods of detecting one or more cancer markers
US20080044416A1 (en)*1999-02-092008-02-21Gang AnNovel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer
WO2008026198A2 (en)2006-08-282008-03-06Yeda Research And Development Co. Ltd.Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the cns
EP1897949A2 (en)1998-09-212008-03-12Schering CorporationHuman interleukin-B50. Therapeutic uses
US20080064114A1 (en)*2006-09-072008-03-13Institut PasteurGenomic morse code
EP1903107A1 (en)1999-09-242008-03-26Cybios LLCPluripotent embryonic-like stem cells, compositions, methods and uses thereof
US20080075322A1 (en)*2006-09-132008-03-27Fluidigm CorporationMethods and systems for determining a baseline during image processing
US20080075380A1 (en)*2006-09-132008-03-27Fluidigm CorporationMethods and systems for image processing of microfluidic devices
EP1905832A2 (en)1999-09-092008-04-02Schering CorporationMammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions
US20080082678A1 (en)*2005-01-162008-04-03Zlango Ltd.Communications Network System and Methods for Using Same
EP1908837A2 (en)2000-05-252008-04-09Schering CorporationHuman receptor proteins, related reagents and methods
WO2008041183A2 (en)2006-10-052008-04-10Technion Research & Development Foundation Ltd.Microtubes and methods of producing same
US20080085526A1 (en)*2006-09-082008-04-10United Therapeutics CorporationClinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers
WO2008043566A2 (en)2006-10-112008-04-17Janssen Pharmaceutica N.V.Compositions and methods for treating and diagnosing irritable bowel syndrome
WO2008051761A2 (en)2006-10-262008-05-02Abbott LaboratoriesAssay for cardiac troponin autoantibodies
EP1918377A1 (en)2000-05-102008-05-07Schering CorporationMammalian cytokine receptor subunit proteins, related reagents and methods
US20080131419A1 (en)*2004-09-292008-06-05Yissum Research Development Company Of The Hebrew University Of JerusalemRecombinant Human T2 Rnase and Uses Thereof
WO2008067547A2 (en)2006-11-302008-06-05Research Development FoundationImproved immunoglobulin libraries
US20080129736A1 (en)*2006-11-302008-06-05Fluidigm CorporationMethod and apparatus for biological sample analysis
US20080138346A1 (en)*1994-12-072008-06-12Incyte CorporationAntibodies to a chemokine expressed in inflamed adenoid
WO2008076321A1 (en)2006-12-142008-06-26Schering CorporationEngineered anti-tslp antibody
EP1942114A2 (en)1999-03-112008-07-09Schering CorporationMammalian cytokines; related reagents and methods
EP1947183A1 (en)1996-08-162008-07-23Schering CorporationMammalian cell surface antigens; related reagents
DE212006000071U1 (en)2005-11-182008-07-24Board of Regents, The University of Texas System, Austin Quantification of fusion proteins and their activity as a result of chromosomal translocation
WO2008092164A2 (en)2007-01-262008-07-31University Of Louisville Research Foundation, Inc.Methods of detecting autoantibodies for diagnosing and characterizing disorders
WO2008093341A2 (en)2007-01-312008-08-07Technion Research & Development Foundation Ltd.Electrospun scaffolds and methods of generating and using same
WO2008093342A2 (en)2007-02-012008-08-07Technion Research & Development Foundation Ltd.Albumin fibers and fabrics and methods of generating and using same
US20080199895A1 (en)*2006-10-052008-08-21Yeda Research And Development Co. Ltd.Highly purified and stabilized Na,K-ATPase isoforms and methods of producing same
US20080206188A1 (en)*2004-04-202008-08-28Alverdy John CTherapeutic Delivery System Comprising a High Molecular Weight Peg-Like Compound
EP1964921A2 (en)2000-04-052008-09-03Oscient Pharmaceuticals CorporationThe high bone mass gene of 11q13.3
JP2008203195A (en)*2007-02-222008-09-04Japan Science & Technology Agency BSH immunoassay kit and method for measuring BSH
US20080214407A1 (en)*2006-10-122008-09-04Eppendorf Array Technologies S.A.Method and system for quantification of a target compound obtained from a biological sample upon chips
US20080220498A1 (en)*2007-03-062008-09-11Cervin Marguerite AVariant Buttiauxella sp. phytases having altered properties
US20080219995A1 (en)*2007-02-162008-09-11Konkuk University Industrial Cooperation Corp.Il-32 monoclonal antibodies and uses thereof
WO2008110006A1 (en)2007-03-122008-09-18Miraculins Inc.Biomarkers of prostate cancer and uses thereof
EP1975231A1 (en)2002-01-222008-10-01Corixa CorporationCompositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7432342B2 (en)2002-05-032008-10-07Sequenom, Inc.Kinase anchor protein muteins, peptides thereof and related documents
WO2008120216A1 (en)2007-04-022008-10-09Ramot At Tel Aviv University Ltd.Methods of detecting cancer cells and use of same for diagnosing and monitoring treatment of the disease
WO2008120202A2 (en)2007-03-292008-10-09Technion Research & Development Foundation Ltd.Antibodies, methods and kits for diagnosing and treating melanoma
EP1980573A2 (en)1997-07-092008-10-15Schering CorporationIsolated dendritic cell membrane protein genes
WO2008124670A2 (en)2007-04-062008-10-16Becton, Dickinson And CompanyCompositions and methods for the identification of a carbapenemase gene
EP1983001A2 (en)1998-09-252008-10-22Schering CorporationAntibodies to mammalian Langerhans cell antigen and their uses
US7442781B2 (en)2001-08-162008-10-28Urifer Ltd.Diagnosis, prevention and treatment of cancer
EP1988166A1 (en)1997-05-072008-11-05Schering CorporationHuman Toll-like receptor proteins, related reagents and methods
US20080274905A1 (en)*2005-09-302008-11-06The Trustees Of Columbia University In The City Of New YorkMicrofluidic cells with parallel arrays of individual dna molecules
WO2008132753A2 (en)2007-05-012008-11-06Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods and kits for detecting fetal cells in the maternal blood
EP1990057A1 (en)2001-05-222008-11-12Merck & Co., Inc.Beta-secretase substrates and uses thereof
WO2008137475A2 (en)2007-05-012008-11-13Research Development FoundationImmunoglobulin fc libraries
US20080287667A1 (en)*2001-03-122008-11-20Affymetrix, Inc.Nucleic Acid Labeling Compounds
US20080299084A1 (en)*2004-08-262008-12-04Engeneic Therapy Pty. Ltd.Bacterially derived intact minicells that encompass plasma free functional nucleic acid for in vivo delivery to mammalian cells
US20080305512A1 (en)*2006-10-262008-12-11Mattingly Phillip GAssay for cardiac troponin autoantibodies
US20090005410A1 (en)*2007-06-222009-01-01Chemocentryx, Inc.N-(2-(hetaryl)aryl) arylsulfonamides and n-(2-(hetaryl) hetaryl arylsulfonamides
US20090013087A1 (en)*2005-01-182009-01-08Zlango Ltd.Communications Network System and Methods For Using Same
US20090023594A1 (en)*2006-11-292009-01-22Exiqon A/SReagents for labelling nucleic acids and uses thereof
WO2009010968A2 (en)2007-07-152009-01-22Yitzchak HillmanDisease treatment via antimicrobial peptides or their inhibitors
EP2020239A1 (en)2000-04-182009-02-04Schering CorporationUse of IL-174 agonists for treating infectious diseases
US20090036321A1 (en)*2003-06-032009-02-05Chiron CorporationMethods for predicting the course of a malignant disease
US20090035784A1 (en)*2004-07-302009-02-05Mount Sinai School Of Medicine Of New York UniversityNpc1l1 and npc1l1 inhibitors and methods of use thereof
WO2009021054A2 (en)2007-08-062009-02-12Orion Genomics LlcNovel single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the igf2 gene
US20090042209A1 (en)*2006-09-012009-02-12Nox Technologies, Inc.Neoplasia-Specific tNOX Isoforms and Methods
EP2026070A1 (en)2002-09-092009-02-18Arbor Vita CorporationMethods of diagnosing cervical cancer
EP2028187A1 (en)2000-09-082009-02-25Board Of Regents, The University Of Texas SystemHuman and mouse targeting peptides identified by phage display
US20090053224A1 (en)*2007-08-022009-02-26Arresto BiosciencesLox and loxl2 inhibitors and uses thereof
EP2031070A1 (en)2002-12-042009-03-04Applera CorporationMultiplex amplification of polynucleotides
US20090068669A1 (en)*2007-09-122009-03-12Elias GeorgesSlc9a3r1 directed diagnostics for neoplastic disease
US20090068207A1 (en)*2005-04-152009-03-12Vascular Biogenics Ltd.Compositions Containing Beta 2-Glycoprotein I-Derived Peptides for the Prevention and/or Treatment of Vascular Disease
WO2009032477A2 (en)2007-08-082009-03-12The Board Of Regents Of The University Of Texas SystemVegfr-1/nrp-1 targeting peptides
WO2009034574A2 (en)2007-09-122009-03-19Yeda Research And Development Co. Ltd.Methods of treating tumors in immune-privileged sites
US20090081639A1 (en)*2007-05-312009-03-26Phil HillAssay for sensitivity to chemotherapeutic agents
EP2042869A2 (en)1999-12-062009-04-01Board Of Trustees Of The University Of IllinoisHigh affinity TCR proteins and methods
US20090098249A1 (en)*2007-02-072009-04-16Cervin Marguerite AVariant Buttiauxella sp. Phytases having altered properties
US20090104170A1 (en)*2004-11-022009-04-23Richard William Wyatt ChildsCompositions and methods for treating hyperproliferative disorders
EP2058275A1 (en)2003-01-072009-05-13Ramot at Tel-Aviv University Ltd.Peptide nanostructures encapsulating a foreign material and method of manufacturing same
EP2058333A2 (en)1998-07-232009-05-13Millennium Pharmaceuticals, Inc.Anti-CCR2 antibodies and methods of use therefor
US20090123553A1 (en)*2002-12-092009-05-14Ramot At Tel Aviv University Ltd.Peptide nanostructures and methods of generating and using the same
US20090126042A1 (en)*2004-06-142009-05-14Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US20090136916A1 (en)*2007-08-132009-05-28Trustees Of Tufts CollegeMethods and microarrays for detecting enteric viruses
US7541151B2 (en)1997-06-052009-06-02Duke UniversitySingle-cell biosensor for the measurement of GPCR ligands in a test sample
US20090143243A1 (en)*2007-08-122009-06-04Gunning Kerry BMicroarray system with improved sequence specificity
US20090143321A1 (en)*2005-07-072009-06-04Avraham HochbergNucleic acid agents for downregulating h19 and methods of using same
EP2070944A1 (en)2001-10-112009-06-17Amgen Inc.Specific binding agents of human angiopoietin-2
EP2071021A2 (en)2007-12-122009-06-17University of South FloridaBone marrow-derived neuronal cells
US20090156471A1 (en)*2004-07-152009-06-18Ramot At Tel Aviv University Ltd.Use of anti-amyloid agents for treating and typing pathogen infections
US20090170072A1 (en)*1999-03-292009-07-02Orasure Technologies, Inc.Device for collection and assay of oral fluids
EP2077277A1 (en)2002-02-012009-07-08Schering CorporationUse of mammalian cytokine; related reagents
WO2009083958A2 (en)2007-12-272009-07-09Evogene Ltd.Isolated polypeptides, polynucleotides useful for modifying water user efficiency, fertilizer use efficiency, biotic/abiotic stress tolerance, yield and biomass in plants
WO2009082817A1 (en)2007-12-272009-07-09Protiva Biotherapeutics, Inc.Silencing of polo-like kinase expression using interfering rna
EP2080766A1 (en)2001-06-062009-07-22Bristol-Myers Squibb CompanyB7-related nucleic acids and polypeptides useful for immunomodulation
WO2009094551A1 (en)2008-01-252009-07-30Amgen Inc.Ferroportin antibodies and methods of use
US20090208533A1 (en)*2004-08-112009-08-20University Of Georgia Research Foundation, Inc.Neisseria meningitidis serogroup a capsular polysaccharide acetyltransferase, methods and compositions
WO2009104174A2 (en)2008-02-212009-08-27Technion Research & Development Foundation Ltd .A method of attaching a cell-of-interest to a microtube
US20090221015A1 (en)*2006-05-092009-09-03Spinale Francis GDetecting Diastolic Heart Failure by Protease and Protease Inhibitor Plasma Profiling
WO2009105833A1 (en)2008-02-282009-09-03Murdoch UniversityNovel sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof
US20090226387A1 (en)*2005-12-232009-09-10Partnership & Corp. Technology TransferSynthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of cellular relaxation
EP2100959A2 (en)1997-07-252009-09-16Schering CorporationMammalian cytokine: interleukin-B30 and related reagents
US20090233986A1 (en)*2004-07-272009-09-17Mount Sinai School Of MedicineMethods and compositions for using sax2
US20090233295A1 (en)*2008-01-292009-09-17Elias GeorgesTrim59 directed diagnostics for neoplastic disease
US20090233946A1 (en)*2007-07-122009-09-17Antoni KrasinskiFused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treatment of inflammation
US20090246800A1 (en)*2006-10-262009-10-01Abbott LaboratoriesImmunoassay of analytes in samples containing endogenous anti-analyte antibodies
WO2009117773A1 (en)2008-03-272009-10-01Murdoch UniversityNovel sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof
EP2107125A1 (en)2008-03-312009-10-07Eppendorf Array Technologies SA (EAT)Real-time PCR of targets on a micro-array
US20090253170A1 (en)*2003-06-192009-10-08Evogene Ltd.Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US7605149B1 (en)1998-07-132009-10-20University Of South FloridaModulation of the phospholipase A2 pathway as a therapeutic
WO2009129319A2 (en)2008-04-152009-10-22Protiva Biotherapeutics, Inc.Silencing of csn5 gene expression using interfering rna
WO2009127060A1 (en)2008-04-152009-10-22Protiva Biotherapeutics, Inc.Novel lipid formulations for nucleic acid delivery
US20090269780A1 (en)*2008-04-232009-10-29Luminex CorporationMethod for Creating a Standard for Multiple Analytes Found in a Starting Material of Biological Origin
WO2009132124A2 (en)2008-04-242009-10-29The Trustees Of Columbia University In The City Of New YorkGeometric patterns and lipid bilayers for dna molecule organization and uses thereof
EP2116618A1 (en)2008-05-092009-11-11Agency for Science, Technology And ResearchDiagnosis and treatment of Kawasaki disease
EP2119771A2 (en)2003-12-242009-11-18Danisco A/SProteins
WO2009139822A1 (en)2008-05-012009-11-19Amgen Inc.Anti-hepcidin antibodies and methods of use
US20090293146A1 (en)*2006-12-202009-11-26Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US7625707B2 (en)2003-10-022009-12-01Ramot At Tel Aviv University Ltd.Antibacterial agents and methods of identifying and utilizing same
EP2128270A1 (en)2003-08-082009-12-02Genenews Inc.Osteoarthritis biomarkers and uses thereof
EP2131198A2 (en)2001-09-202009-12-09Board of Regents, The University of Texas SystemMeasuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
US20090311695A1 (en)*2008-03-122009-12-17Talat NasimMethod
EP2135611A1 (en)2001-03-012009-12-23Hollis-Eden Pharmaceuticals Inc.Pregn-5-en-20-yne-3,7,17-triol derivatives for use in therapy
EP2135619A1 (en)2003-12-102009-12-23Millennium Pharmaceuticals, Inc.Humanized anti-CCR2 antibodies and methods of use therefor
EP2138510A1 (en)1999-07-302009-12-30Schering CorporationMethods of generating antibodies against cytokines
US20090324612A1 (en)*2001-06-052009-12-31Kaufman Daniel LModulating neuronal outgrowth via the major histocompatibility complex class i (mhc i) molecule
US20100004162A1 (en)*1998-09-182010-01-07Nathaniel HeintzLynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses thereof
US20100015156A1 (en)*2007-03-062010-01-21Cedars-Sinai Medical CenterDiagnosis of inflammatory bowel disease in children
US20100015651A1 (en)*2006-07-112010-01-21Musc Foundation For Research DevelopmentPredicting Heart Failure Following Myocardial Infarction by Protease and Protease Inhibitor Profiling
US7655225B2 (en)2002-01-252010-02-02Gamida Cell, Ltd.Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
WO2010016806A1 (en)2008-08-082010-02-11Agency For Science, Technology And Research (A*Star)Vhz for diagnosis and treatment of cancers
WO2010017544A2 (en)2008-08-082010-02-11Genisphere, Inc.Long-acting dna dendrimers and methods thereof
US7668658B2 (en)1999-10-132010-02-23Sequenom, Inc.Methods for generating databases and databases for identifying polymorphic genetic markers
US20100047230A1 (en)*2005-02-212010-02-25Hellenic Pasteur InstituteAnti her2/neu antibody
US20100055033A1 (en)*2006-04-072010-03-04The Government Of The United States Of America As Represented By The SecretaryAntibody compositions and methods for treatment of neoplastic disease
US20100062501A1 (en)*2003-12-242010-03-11Paul WassellMethod
US20100062947A1 (en)*2007-01-112010-03-11Erasmus University Medical CenterCircular chromosome conformation capture (4c)
WO2010031006A1 (en)2008-09-122010-03-18Cryopraxis Criobiologia Ltda.Ischemic tissue cell therapy
WO2010029545A2 (en)2008-09-112010-03-18Ben Gurion University Of The Negev Research And Development AuthorityCompositions and methods for treating s. pneumoniae infection
US20100068135A1 (en)*2005-08-082010-03-18Onconon, LlcAntibody compositions, methods for treating neoplastic disease and methods for regulating fertility
US7687057B2 (en)1998-01-092010-03-30Yissum Research Development Company Of The Hebrew University Of JerusalemIn vitro micro-organs, and uses related thereto
US20100081177A1 (en)*2008-09-052010-04-01TransAlgae LtdDecreasing RUBISCO content of algae and cyanobacteria cultivated in high carbon dioxide
WO2010035261A2 (en)2008-09-292010-04-01Ben Gurion University Of The Negev Research And Development AuthorityAmyloid beta-peptides and methods of use thereof
EP2172478A2 (en)1997-02-072010-04-07THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICESActivity-dependent neurotrophic factor III (ADNF III)
EP2174668A2 (en)2004-11-142010-04-14Vascular Biogenics Ltd.Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20100092386A1 (en)*2007-04-232010-04-15David SegevSystem for delivering therapeutic agents into living cells and cells nuclei
WO2010040277A1 (en)2008-10-092010-04-15The University Of Hong KongCadherin-17 as diagnostic marker and therapeutic target for liver cancer
EP2177503A1 (en)2004-02-202010-04-21UCL Business PLCModulators of cannabinoid receptors
US20100105759A1 (en)*2007-01-162010-04-29Abraham HochbergH19 silencing nucleic acid agents for treating rheumatoid arthritis
US20100105608A1 (en)*2002-01-312010-04-29Tel Aviv University Future Technology Development L.P.Peptides and methods using same for diagnosis and treatment of amyloid-associated disease
US20100105071A1 (en)*2007-02-282010-04-29Children's Medical Center CorporationMethods for predicting the onset of menarche
EP2182052A1 (en)2002-10-072010-05-05Technion Research and Development Foundation, Ltd.Human foreskin cells suitable for culturing stem cells
WO2010049897A2 (en)2008-10-302010-05-06Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficieny
WO2010054328A2 (en)2008-11-072010-05-14Research Development FoundationCompositions and methods for the inhibition of cripto/grp78 complex formation and signaling
EP2186530A1 (en)2000-11-172010-05-19Vascular Biogenics Ltd.Promoters exhibiting endothelial cell specificity and methods of using same
WO2010055525A1 (en)2008-11-172010-05-20Technion Research & Development Foundation Ltd.Method for predicting a patient's responsiveness to anti-folate therapy
US20100129346A1 (en)*2006-08-222010-05-27G2 Inflammation Pty Ltd.Anti-C5aR Antibodies With Improved Properties
WO2010058396A1 (en)2008-11-192010-05-27Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.A cd44vra antibody and diagnostic and therapeutic methods using same
WO2010061383A1 (en)2008-11-262010-06-03Biodalia Microbiological Technologies Ltd.A method of in-situ enrichment of foods with fructan
WO2010064247A1 (en)2008-12-032010-06-10Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods and kits for determining predisposition to cancer
WO2010065437A1 (en)2008-12-032010-06-10Research Development FoundationModulation of olfml-3 mediated angiogenesis
WO2010064231A1 (en)2008-12-022010-06-10Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods of analyzing a-i rna editing and nucleic acid constructs capable of same
WO2010066252A1 (en)2008-12-092010-06-17Dako Denmark A/SMethod for evaluating pre-treatment
WO2010068757A1 (en)2008-12-122010-06-17The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesCompositions and methods useful for detecting and treating diseases associated with 16p chromosomal disruptions
WO2010071610A1 (en)2008-12-192010-06-24Agency For Science, Technology And Research (A*Star)Severe chikungunya biomarkers
EP2202240A1 (en)2000-08-182010-06-30Sterix LimitedCompound
WO2010076642A1 (en)2008-12-292010-07-08Tel Hashomer Medical Research, Infrastructure And Services LtdPeptides and compositions for prevention of cell adhesion and methods of using same
WO2010076794A1 (en)2008-12-312010-07-08Technion Research & Development Foundation Ltd.Method of denitrifying brine and systems capable of same
WO2010076788A2 (en)2008-12-292010-07-08Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
WO2010076756A2 (en)2008-12-292010-07-08Evogene Ltd.Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance, biomass and/or yield in plants expressing same
EP2208797A2 (en)2004-03-012010-07-21Applied Biosystems, LLCMethods, compositions and kits for use in polynucleotide amplification
US20100184065A1 (en)*2007-07-102010-07-22University Of South FloridaMethod of Predicting Non-Response to First Line Chemotherapy
EP2210899A1 (en)2004-11-112010-07-28Danisco A/Spntr transcription factor
US20100190662A1 (en)*2007-01-262010-07-29Rebecca SutphenMethods and materials for detection, diagnosis and management of ovarian cancer
WO2010086856A2 (en)2009-02-012010-08-05Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of generating tissue using devitalized, acellular scaffold matrices derived from micro-organs
WO2010086867A2 (en)2009-02-022010-08-05Ramot At Tel Aviv University Ltd.Peptides, pharmaceutical compositions comprising same and uses thereof
US20100196403A1 (en)*2007-01-292010-08-05Jacob HochmanAntibody conjugates for circumventing multi-drug resistance
US20100196419A1 (en)*2007-05-022010-08-05Compans Richard WEnhancement of glycoprotein incorporation into virus-like particles
EP2216033A2 (en)2003-03-062010-08-11Yeda Research and Development Co. Ltd.Methods of treating disease by transplantation of allogeneic or xenogeneic organs or tissues
WO2010089707A1 (en)2009-02-042010-08-12Yeda Research And Development Co. Ltd.Methods and kits for determining sensitivity or resistance of prostate cancer to radiation therapy
WO2010093450A2 (en)2009-02-112010-08-19Ludwing Institute For Cancer Research Ltd.Pten phosphorylation-driven resistance to cancer treatment and altered patient prognosis
WO2010093820A2 (en)2009-02-112010-08-19Orion Genomics LlcCombinations of polymorphisms for determining allele-specific expression of igf2
WO2010096434A2 (en)2009-02-182010-08-26Ludwig Institute For Cancer ResearchSpecific binding proteins and uses thereof
US20100215803A1 (en)*2007-08-172010-08-26Niels Erik LarsenProcess
WO2010096658A1 (en)2009-02-192010-08-26The Cleveland Clinic FoundationCorin as a marker for heart failure
EP2224008A2 (en)2005-05-122010-09-01Murdoch UniversityGenes and proteins of brachyspira hyodysenteriae and use of same for diagnosis and therapy
WO2010097794A1 (en)2009-02-262010-09-02Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods of reprogramming renal cells
US20100221233A1 (en)*2003-12-152010-09-02University Of South FloridaCompositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers
US20100221272A1 (en)*2007-06-282010-09-02University Of SaskatchewanImmunomodulatory compositions and methods for treating disease with modified host defense peptides
WO2010100595A2 (en)2009-03-022010-09-10Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
WO2010103517A1 (en)2009-03-122010-09-16Rappaport Family Institute For Research In The Medical SciencesSoluble compositions for the treatment of cxcr3-ligand associated diseases
US20100240101A1 (en)*2009-03-192010-09-23Massachusetts Institute Of TechnologyParallel Proximity Ligation Event Analysis
US20100240065A1 (en)*2009-03-182010-09-23Boehringer Ingelheim International GmbhProlyl Hydroxylase Compositions and Methods of Use Thereof
WO2010113146A1 (en)2009-04-012010-10-07The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical CenterA method of regulating proliferation and differentiation of keratinocyes
US20100255004A1 (en)*2007-04-132010-10-07Dana Farber Cancer InstituteReceptor tyrosine kinase profiling
WO2010113096A1 (en)2009-03-302010-10-07Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods of predicting clinical course and treating multiple sclerosis
WO2010115261A1 (en)2009-03-272010-10-14Genesis Genomics Inc.Aberrant mitochondrial dna, associated fusion transcripts and translation products and hybridization probes therefor
WO2010116375A1 (en)2009-04-082010-10-14Yeda Research And Development Co. Ltd.Isolated peptides for regulating apoptosis
EP2246444A1 (en)2004-09-142010-11-03The Regents of the University of Colorado, A Body CorporateMethod for treatment with bucindolol based on genetic targeting
WO2010126670A2 (en)2009-03-272010-11-04Gojo Industries, Inc.Compositions and methods for screening and using compounds antagonizing spore-surface interactions
US20100291602A1 (en)*2009-05-142010-11-18University Of OxfordClinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers
WO2010134035A1 (en)2009-05-192010-11-25Danisco A/SUse
EP2256203A1 (en)2003-11-212010-12-01Schering CorporationIL-23 and its receptor; related reagents and methods
WO2010137020A1 (en)2009-05-282010-12-02Yeda Research And Development Co. Ltd.Methods of treating inflammation
WO2010137021A2 (en)2009-05-272010-12-02Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of generating connective tissue
WO2010137017A2 (en)2009-05-272010-12-02Yeda Research And Development Co. Ltd.Proteasome inhibitors and uses thereof
WO2010137013A1 (en)2009-05-272010-12-02Ramot At Tel Aviv University Ltd.Crystallized photosystem i units from the pea plant and their use in solid state devices
EP2258726A1 (en)1995-06-142010-12-08The Regents of the University of CaliforniaHigh affinity human antibodies to c-erbB-2
WO2010141421A1 (en)2009-06-022010-12-09The Board Of Regents Of The University Of Texas SystemIdentification of small molecules recognized by antibodies in subjects with neurodegenerative diseases
EP2261256A2 (en)1999-11-242010-12-15Schering CorporationMethods of inhibiting metastasis
US7855075B2 (en)1998-02-172010-12-21Gamida Cell Ltd.Methods of controlling proliferation and differentiation of stem and progenitor cells
EP2266405A2 (en)2004-03-122010-12-29Danisco A/SFungal lipolytic enzymes
EP2267107A2 (en)2004-07-162010-12-29Danisco A/SLipolytic Enzyme. Uses Thereof In The Food Industry
WO2010150259A1 (en)2009-06-242010-12-29Fund For Medical Research Development Of Infrastructure And Health Services -Rambam Medical CenterMethods and kits for isolating placental derived microparticles and use of same for diagnosis of fetal disorders
WO2010150213A1 (en)2009-06-252010-12-29Danisco A/SProtein
EP2266624A2 (en)2002-07-152010-12-29Board of Regents, The University of Texas SystemDuramycin peptide binding to anionic phospholipids and aminophospholipids conjugates and their use in treating viral infections
WO2011002834A2 (en)2009-07-012011-01-06American Type Culture CollectionCompositions and methods for diagnosis and treatment of type 1 diabetes
WO2011000107A1 (en)2009-07-012011-01-06Protiva Biotherapeutics, Inc.Novel lipid formulations for delivery of therapeutic agents to solid tumors
EP2272869A2 (en)2001-10-112011-01-12Amgen Inc.Angiopoietin-2 specific binding agents
WO2011004361A2 (en)2009-07-092011-01-13Prolor Biotech Inc.Long-acting coagulation factors and methods of producing same
US20110009861A1 (en)*2007-01-042011-01-13Music Foundation For Research DevelopmentPredicting atrial fibrillation recurrence by protease and protease inhibitor profiling
WO2011004379A1 (en)2009-07-102011-01-13Tel Hashomer Medical Research Infrastructure And Services Ltd.Compositions and methods for treating cancer
EP2275445A2 (en)2004-03-122011-01-19Vasgene Therapeutics, Inc.Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
EP2278015A1 (en)2003-01-172011-01-26Danisco A/SMethod of producing a carbohydrate ester
WO2011010309A1 (en)2009-07-212011-01-27Tel Hashomer Medical Research Infrastructure And Services Ltd.A method of diagnosing cancer
US20110020357A1 (en)*2008-04-092011-01-27Technion Research & Development Foundation Ltd.Anti human immunodeficiency antibodies and uses thereof
WO2011011447A1 (en)2009-07-202011-01-27Protiva Biotherapeutics, Inc.Compositions and methods for silencing ebola virus gene expression
EP2280285A1 (en)2003-09-152011-02-02Oklahoma Medical Research FoundationMethod of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases
EP2279726A2 (en)2005-05-262011-02-02Biorest Ltd.Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
WO2011013130A2 (en)2009-07-312011-02-03Ramot At Tel-Aviv University Ltd.Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
EP2281841A2 (en)2004-12-032011-02-09Schering CorporationBiomarkers for pre-selection of patients for anti-IGF1R therapy
US20110033473A1 (en)*2008-04-092011-02-10Yoram ReiterAnti influenza antibodies and uses thereof
WO2011019423A2 (en)2009-05-202011-02-17Schering CorporationModulation of pilr receptors to treat microbial infections
WO2011021171A1 (en)2009-08-212011-02-24Beeologics, LlcPreventing and curing beneficial insect diseases via plant transcribed molecules
WO2011021194A2 (en)2009-08-172011-02-24Technion Research & Development Foundation Ltd.Pericyte progenitor cells and methods of generating and using same
EP2289567A2 (en)2003-12-222011-03-02Regentis Biomaterials Ltd.Matrix comprising naturally-occurring crosslinked protein backbone
US20110052501A1 (en)*2008-01-312011-03-03Liat DassaPolypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
WO2011024172A2 (en)2009-08-272011-03-03Technion Research & Development Foundation Ltd.Liposomal compositions and uses of same
EP2292661A2 (en)2003-11-102011-03-09Schering CorporationInterleukin-10 antibodies
EP2292760A2 (en)2000-11-102011-03-09Schering CorporationMammalian cytokines, receptors, related reagents and methods
EP2295980A1 (en)2002-10-302011-03-16Yissum Research Development Company, of The Hebrew University of JerusalemMolecules and methods using same for measuring non-transferrin bound iron
EP2295978A2 (en)1998-03-202011-03-16The Curators Of The University Of MissouriEarly pregnancy diagnosis using PAGs(Pregnancy-associated Glycoproteins)
WO2011030329A1 (en)2009-09-102011-03-17Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of treating tumors
WO2011030332A2 (en)2009-09-082011-03-17Yeda Research And Development Co. Ltd.Methods for hematopoietic precursor mobilization
WO2011030336A1 (en)2009-09-082011-03-17Ramot At Tel-Aviv University Ltd.Methods of diagnosing amyotrophic lateral sclerosis (als)
US20110065649A1 (en)*2006-04-272011-03-17Centre National De La Recherche Scientifique (Cnrs)Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation
EP2298316A1 (en)2002-08-282011-03-23Harbor BioSciences, Inc.Therapeutic treatment methods
WO2011034950A1 (en)2009-09-162011-03-24Vaxart, Inc.Immunization strategy to prevent h1n1 infection
WO2011033511A1 (en)2009-09-172011-03-24Ramot At Tel-Aviv University Ltd.Peptides for the treatment of oxidative stress related disorders
WO2011033506A2 (en)2009-09-172011-03-24Yeda Research And Development Co. Ltd.Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
EP2302072A1 (en)2004-11-182011-03-30Eppendorf Array Technologies S.A.Real time-PCR of targets on a micro-array
WO2011038403A1 (en)2009-09-282011-03-31Yuling LuoMethods of detecting nucleic acid sequences with high specificity
WO2011038160A2 (en)2009-09-232011-03-31Protiva Biotherapeutics, Inc.Compositions and methods for silencing genes expressed in cancer
EP2305794A1 (en)2002-01-242011-04-06Gamida Cell Ltd.Expansion of renewable stem cell populations
WO2011041319A2 (en)2009-09-292011-04-07Ludwig Institute For Cancer ResearchSpecific binding proteins and uses thereof
WO2011040973A2 (en)2009-10-022011-04-07Ludwig Institute For Cancer Research Ltd.Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
US20110081706A1 (en)*2009-10-022011-04-07TransAlgae LtdMethod and system for efficient harvesting of microalgae and cyanobacteria
WO2011040972A1 (en)2009-10-022011-04-07Ludwig Institute For Cancer Research Ltd.Anti-fibroblast activation protein antibodies and methods and uses thereof
EP2308994A1 (en)2001-03-232011-04-13Yeda Research And Development Co., Ltd.Methods for determining a risk to develop cancer
WO2011044553A1 (en)2009-10-112011-04-14Biogen Idec Ma Inc.Anti-vla-4 related assays
WO2011044186A1 (en)2009-10-062011-04-14The Board Of Trustees Of The University Of IllinoisHuman single-chain t cell receptors
WO2011046570A1 (en)2009-10-162011-04-21The University Of Medicine And Dentistry Of New JerseyMethod for treating chronic nerve tissue injury using a cell therapy strategy
WO2011045796A1 (en)2009-10-142011-04-21Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Compositions for controlling varroa mites in bees
US20110091454A1 (en)*2004-01-272011-04-21Alex DiberMethods and systems for annotating biomolecular sequences
WO2011048600A1 (en)2009-10-212011-04-28Danziger Innovations Ltd.Generating genotypic variations in plant genomes by gamete infection
EP2316950A1 (en)2000-03-272011-05-04Technion Research and Development Foundation, Ltd.Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same
EP2316441A1 (en)2005-02-172011-05-04Hadasit Medical Research Services And DevelopmentBisphosphonates for treating endometriosis
EP2319857A2 (en)2003-03-042011-05-11Yeda Research And Development Co., Ltd.Pon polypeptides, polynucleotides encoding same and compositions and methods utilizing same
EP2319941A2 (en)2005-10-212011-05-11GeneNews Inc.Method and apparatus for correlating levels of biomarker products with disease
WO2011056688A2 (en)2009-10-272011-05-12Caris Life Sciences, Inc.Molecular profiling for personalized medicine
WO2011055366A1 (en)2009-11-082011-05-12Medical Research & Development Fund For Health Services Bnai Zion Medical Center, The State Of IsraelMo-1 conditional knock-out non-human animal and uses thereof
WO2011058555A1 (en)2009-11-122011-05-19Yeda Research And Development Co. Ltd.A method of editing dna in a cell and constructs capable of same
US20110117560A1 (en)*2009-11-172011-05-19Musc Foundation For Research DevelopmentASSESSING LEFT VENTRICULAR REMODELING VIA TEMPORAL DETECTION AND MEASUREMENT OF microRNA IN BODY FLUIDS
WO2011058557A1 (en)2009-11-122011-05-19Ramot At Tel-Aviv University Ltd.Compositions comprising pedf and uses of same in the treatment and prevention of ovary-related syndromes
WO2011061657A1 (en)2009-11-172011-05-26Danisco A/SMethod
WO2011061736A1 (en)2009-11-172011-05-26Protalix Ltd.Alkaline alpha galactosidase for the treatment of fabry disease
US20110130306A1 (en)*2008-06-102011-06-02The Regents Of The University Of CaliforniaPro-fluorescent probes
US20110129818A1 (en)*2009-12-022011-06-02Abbott LaboratoriesASSAY FOR CARDIAC TROPONIN-T (cTnT)
US20110129854A1 (en)*2009-12-022011-06-02Abbott LaboratoriesAssay for diagnosis of cardiac myocyte damage
WO2011064773A1 (en)2009-11-242011-06-03Collplant Ltd.Method of generating collagen fibers
WO2011064669A2 (en)2009-11-302011-06-03Pluristem Ltd.Adherent cells from placenta and use of same in disease treatment
US7955814B2 (en)2003-01-172011-06-07Danisco A/SMethod
EP2330132A1 (en)2003-04-042011-06-08Yeda Research and Development Co. Ltd.Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
WO2011068676A1 (en)2009-12-032011-06-09Abbott LaboratoriesPeptide reagents and method for inhibiting autoantibody antigen binding
WO2011067745A2 (en)2009-12-062011-06-09Rosetta Green Ltd.Compositions and methods for enhancing plants resistance to abiotic stress
US20110136103A1 (en)*2009-12-032011-06-09Abbott LaboratoriesAutoantibody enhanced immunoassays and kits
US7960150B2 (en)2007-01-252011-06-14Danisco A/SProduction of a lipid acyltransferase from transformed Bacillus licheniformis cells
WO2011072091A1 (en)2009-12-092011-06-16Quark Pharmaceuticals, Inc.Methods and compositions for treating diseases, disorders or injury of the cns
EP2336321A1 (en)1999-05-132011-06-22Medical Research CouncilOx2 receptor homolog
EP2335728A1 (en)2001-05-112011-06-22Ludwig Institute for Cancer Research Ltd.Specific binding proteins and uses thereof
US20110150874A1 (en)*2006-05-192011-06-23Teva Pharmaceutical Industries Ltd.Fusion proteins, uses thereof and processes for producing same
US20110147993A1 (en)*2008-04-102011-06-23Objet Geometries Ltd.System and method for three dimensional model printing
EP2339032A1 (en)2005-04-182011-06-29Mitomics Inc.Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
EP2338896A2 (en)2002-12-122011-06-29R.B.T. (Rakuto Bio Technologies) Ltd.Use of lignin peroxidase in skin and hair lightening
EP2338913A1 (en)1995-12-182011-06-29The University of Utah Research FoundationChromosome 13-linked breast cancer susceptibility gene
WO2011076881A1 (en)2009-12-222011-06-30Arabian Gulf UniversityMutant ldl receptor gene
US7972638B2 (en)1998-07-212011-07-05Danisco A/SFoodstuff
EP2341346A2 (en)2000-10-182011-07-06The Regents of the University of CaliforniaMethods of high-throughput screening for internalizing antibodies and metal-chelating liposomes
EP2341144A1 (en)1999-01-112011-07-06Schering CorporationInterleukin-17 related mammalian cytokines. Polynucleotides encoding them. Uses
WO2011080740A1 (en)2009-12-292011-07-07Gamida-Cell Ltd.Methods for enhancing natural killer cell proliferation and activity
WO2011080674A2 (en)2009-12-282011-07-07Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
US20110171346A1 (en)*2008-04-182011-07-14Spaangner Christiansen LivProcess
WO2011084882A2 (en)2010-01-052011-07-14Contrafect CorporationMethods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria
WO2011084357A1 (en)2009-12-172011-07-14Schering CorporationModulation of pilr to treat immune disorders
US20110172113A1 (en)*2008-03-282011-07-14Mitomics Inc.Aberrant mitochondrial dna, associated fusion transcripts and hybridization probes therefor
WO2011086509A1 (en)2010-01-122011-07-21Vascular Biogenics Ltd.Methods of producing adenovirus vectors and viral preparations generated thereby
US20110184747A1 (en)*2006-08-092011-07-28Carmen BozicMethod for distribution of a drug
US20110190477A1 (en)*2008-02-202011-08-04Peter WhitfeldHumanized Anti-C5aR Antibodies
WO2011094669A1 (en)2010-01-292011-08-04Advanced Cell Diagnostics, Inc.Methods of in situ detection of nucleic acids
US20110189677A1 (en)*2010-02-032011-08-04Massachusetts Institute Of TechnologyMethods For Preparing Sequencing Libraries
WO2011092700A1 (en)2010-01-272011-08-04Yeda Research And Development Co. Ltd.Antibodies that inhibit metalloproteins
WO2011097627A1 (en)2010-02-082011-08-11Agensys, Inc.Antibody drug conjugates (adc) that bind to 161p2f10b proteins
US20110201559A1 (en)*2008-05-222011-08-18Centre National De La Recherche Scientifique (Cnrs)New Optically Pure Compounds for Improved Therapeutic Efficiency
WO2011099006A2 (en)2010-02-112011-08-18Yeda Research And Development Co. Ltd.Enzymatic systems for carbon fixation and methods of generating same
EP2359853A1 (en)2000-08-082011-08-24Technion Research and Development Foundation, Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis
EP2359832A2 (en)2004-09-182011-08-24University of Maryland, BaltimoreTherapeutic agents targeting the NCCA-ATP channel and methods of use thereof
US20110207664A1 (en)*2000-02-252011-08-25Vegenics Pty LimitedMaterials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and Proteins
US8008453B2 (en)2005-08-122011-08-30Amgen Inc.Modified Fc molecules
US8007847B2 (en)2004-01-132011-08-30Eytan BidermanFeeding formula appliance
WO2011104708A2 (en)2010-02-242011-09-01Ben Gurion University Of The Negev Research And Development AuthorityMethods for inhibiting necrosis
WO2011107939A1 (en)2010-03-012011-09-09Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of predicting efficacy of an anti-vegfa treatment for solid tumors
WO2011107994A1 (en)2010-03-042011-09-09Yeda Research And Development Co. Ltd.Methods of measuring protein stability
EP2365087A2 (en)2003-05-222011-09-14Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
EP2364994A1 (en)1994-01-052011-09-14Schering CorporationPurfied primate CTLA-8 antigens and related reagents
WO2011111034A1 (en)2010-03-082011-09-15Yeda Research And Development Co. Ltd.Recombinant protein production in heterologous systems
WO2011111050A2 (en)2010-03-112011-09-15Jacob EdreiMethods of generating hydrogen
EP2366775A1 (en)2006-03-232011-09-21Pluristem Ltd.Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
WO2011114251A1 (en)2010-03-182011-09-22Danisco A/SFoodstuff
US8030044B2 (en)2003-12-242011-10-04Danisco A/SLipid acyltransferases
EP2371955A1 (en)2002-09-262011-10-05K.U. Leuven Research & DevelopmentIntegrase cofactor
EP2371861A1 (en)2002-01-252011-10-05G2 Therapies LimitedMonoclonal antibodies against extracellular loops of C5aR
US8034553B2 (en)2004-06-242011-10-11Kimberly-Clark Worldwide, Inc.Biomarkers for wound healing
WO2011125015A2 (en)2010-04-052011-10-13Bar-Ilan UniversityProtease-activatable pore-forming polypeptides
WO2011127150A2 (en)2010-04-062011-10-13Massachusetts Institute Of TechnologyGene-expression profiling with reduced numbers of transcript measurements
WO2011128897A1 (en)2010-04-122011-10-20Technion Research & Development Foundation Ltd.Populations of pancreatic progenitor cells and methods of isolating and using same
WO2011132182A1 (en)2010-04-182011-10-27Yeda Research And Development Co. Ltd.MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES
WO2011135527A2 (en)2010-04-282011-11-03Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
EP2385124A2 (en)1999-05-142011-11-09Arbor Vita CorporationPeptides or peptide analogues for modulating the binding of a PDZ protein and a PL protein
WO2011138776A2 (en)2010-05-062011-11-10Hervana Ltd.Biologic female contraceptives
WO2011140234A1 (en)2010-05-072011-11-10Abbott LaboratoriesMethods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor
WO2011138778A2 (en)2010-05-042011-11-10Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of identifying inhibitors of polypeptides-of-interest
WO2011138785A2 (en)2010-05-052011-11-10Rappaport Family Institute For Research In The Medical SciencesUse of ccl1 in therapy
WO2011141914A1 (en)2010-05-132011-11-17Tel Hashomer Medical Research Infrastructure And Services Ltd.Isolated populations of adult renal cells and methods of isolating and using same
WO2011146479A1 (en)2010-05-182011-11-24The Texas A&M University SystemMethod and composition for the diagnosis and monitoring of inflammatory diseases
EP2390312A1 (en)2005-11-292011-11-30Gamida Cell Ltd.Methods of improving stem cell homing and engraftment
WO2011151833A1 (en)2010-06-032011-12-08Ramot At Tel-Aviv University Ltd.Methods of treating diabetes and compositions capable of same
EP2395012A2 (en)2005-11-022011-12-14Protiva Biotherapeutics Inc.Modified siRNA molecules and uses thereof
EP2395025A1 (en)2007-02-282011-12-14Schering CorporationEngineered Anti-IL-23R Antibodies
WO2011154940A1 (en)2010-06-072011-12-15Osnat Ashur-FabianMethods and kits for diagnosing conditions related to hypoxia
US8080417B2 (en)2004-09-162011-12-20Gamida-Cell Ltd.Methods of ex vivo hematopoietic stem cell expansion by co-culture with mesenchymal cells
WO2011158242A2 (en)2010-06-162011-12-22Futuragene Israel Ltd.Pest -resistant plants containing a combination of a spider toxin and a chitinase
WO2011158243A2 (en)2010-06-162011-12-22Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of diagnosing and treating cancer
EP2400030A1 (en)2004-05-182011-12-28The Board Of Trustees Of The University Of the Leland Stanford Junior UniversityDetection of protein translocation by beta-galactosidase reporter fragment complementation
US8088160B2 (en)2000-07-202012-01-03Multi-Gene Vascular Systems Ltd. (“MGVS”)Drug-eluting intravascular prostheses and methods of use
EP2402752A2 (en)2006-10-272012-01-04Janssen Pharmaceutica, N.V.A method for pharmacologically profiling compounds
WO2012004759A2 (en)2010-07-082012-01-12Danisco A/SMethod
WO2012006056A2 (en)2010-06-292012-01-12Oregon Health & Science UniversityCcr6 as a biomarker of alzheimer's disease
EP2407242A1 (en)2010-07-132012-01-18Dublin City UniversityDirect clone analysis and selection technology
WO2012009627A2 (en)2010-07-162012-01-19Vanderbilt UniversityLow resource processor using surface tension valves for extracting, concentrating and detecting molecular species
WO2012007951A1 (en)2010-07-152012-01-19Technion Research & Development Foundation Ltd.Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
WO2012007950A2 (en)2010-07-152012-01-19Technion Research & Development Foundation Ltd.Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides
WO2012007919A2 (en)2010-07-152012-01-19Technion Research & Development Foundation Ltd.Nucleic acid construct for increasing abiotic stress tolerance in plants
WO2012007945A2 (en)2010-07-122012-01-19The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani CenterIsolated polynucleotides and methods and plants using same for regulating plant acidity
USRE43135E1 (en)2001-05-182012-01-24Danisco A/SMethod of improving dough and bread quality
WO2012012748A2 (en)2010-07-232012-01-26Luminex CorporationCo-coupling to control reactivity of reagents in immunoassays
WO2012011113A2 (en)2010-07-222012-01-26Shai YarkoniRegulatory immune cells with enhanced targeted cell death effect
WO2012014207A2 (en)2010-07-272012-02-02Technion Research & Development Foundation Ltd.Method for generating induced pluripotent stem cells from keratinocytes derived from plucked hair follicles
WO2012014208A2 (en)2010-07-272012-02-02Yeda Research And Development Co. Ltd.Methods and systems for assessing clonality of cell cultures
WO2012014205A1 (en)2010-07-272012-02-02Technion Research & Development Foundation Ltd.Isolated mesenchymal progenitor cells and extracellular matrix produced thereby
WO2012017439A2 (en)2010-08-042012-02-09Ramot At Tel-Aviv University Ltd.Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
WO2012018476A1 (en)2010-07-262012-02-09Abbott LaboratoriesAntibodies relating to pivka-ii and uses thereof
US8114619B2 (en)2006-03-212012-02-14The Johns Hopkins UniversityMethods for diagnosis and optimizing treatment of multiple sclerosis
EP2423333A1 (en)2006-08-252012-02-29Oncotherapy Science, Inc.Prognostic markers and therapeutic targets for lung cancer
WO2012025925A1 (en)2010-08-242012-03-01Rappaport Family Institute For Research In The Medical SciencesMethods of improving transplantation using sdf-1alpha
WO2012025914A1 (en)2010-08-222012-03-01Ramot At Tel-Aviv University Ltd.Induced pluripotent stem cells derived from human pancreatic beta cells
EP2426199A2 (en)2006-10-202012-03-07Danisco US Inc.Polyol oxidases
EP2426144A1 (en)2007-02-232012-03-07Schering CorporationEngineered anti-IL-23p19 antibodies
EP2426145A1 (en)2007-02-232012-03-07Schering CorporationEngineered anti-IL-23p19 antibodies
EP2425850A2 (en)2005-06-152012-03-07The Regents of The University of CaliforniaBispecific single chain FV antibody molecules and methods of use thereof
EP2425841A1 (en)2000-11-242012-03-07Vascular Biogenics Ltd.Methods Employing and Compositions Containing Defined Oxidized Phospholipids for Prevention and Treatment of Atherosclerosis
WO2012032520A1 (en)2010-09-072012-03-15Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Readthrough acetylcholinesterase (ache-r) for treating or preventing parkinson's disease
WO2012032525A2 (en)2010-09-082012-03-15Yeda Research And Development Co. Ltd.An immunosuppressive drug combination for a stable and long term engraftment
WO2012032519A2 (en)2010-09-072012-03-15Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of diagnosing parkinson's disease
WO2012032521A2 (en)2010-09-072012-03-15Technion Research & Development Foundation Ltd.Novel methods and culture media for culturing pluripotent stem cells
WO2012032526A2 (en)2010-09-082012-03-15Yeda Research And Development Co. Ltd.Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment
WO2012032510A1 (en)2010-09-072012-03-15Yeda Research And Development Co. Ltd.Primers for amplifying dna and methods of selecting same
WO2012035539A1 (en)2010-09-152012-03-22Ramot At Tel-Aviv University Ltd.Methods of expanding and redifferentiating islet beta cells
US8143045B2 (en)2004-10-042012-03-27Danisco A/SMutant Citrobacter freundii phytase polypeptide
WO2012040168A2 (en)2010-09-202012-03-29Advanced Cell Diagnostics, Inc.Biomarkers for differentiating melanoma from benign nevus in the skin
WO2012038956A1 (en)2010-09-202012-03-29Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of treating neurodegenerative diseases
WO2012047724A1 (en)2010-09-292012-04-12Agensys, Inc.Antibody drug conjugates (adc) that bind to 191p4d12 proteins
EP2441520A1 (en)2010-10-122012-04-18Eppendorf AGReal-time amplification and micro-array based detection of nucleic acid targets in a flow chip assay
EP2441840A1 (en)2005-07-182012-04-18Protalix Ltd.Mucosal or enteral administration of biologically active macromolecules
EP2444099A1 (en)2005-03-312012-04-25Agensys, Inc.Antibodies and related molecules that bind to 161P2F10B proteins
WO2012052872A2 (en)2010-10-172012-04-26Yeda Research And Development Co. Ltd.Methods and compositions for the treatment of insulin-associated medical conditions
WO2012052878A1 (en)2010-10-192012-04-26Vascular Biogenics Ltd.Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells
WO2012054795A1 (en)2010-10-212012-04-26Advanced Cell Diagnostics, Inc.An ultra sensitive method for in situ detection of nucleic acids
WO2012056452A2 (en)2010-10-272012-05-03Nanocyte (Israel) Ltd.Pharmaceutical compositions and delivery devices comprising stinging cells or capsules
WO2012056455A1 (en)2010-10-282012-05-03Yeda Research And Development Co. Ltd.Methods of generating antibodies to metalloenzymes
EP2450456A2 (en)2006-11-022012-05-09Yale UniversityAssessment of oocyte competence
WO2012059925A2 (en)2010-11-042012-05-10Ben-Gurion University Of The Negev Research And Development AuthorityAcyl-coa: diacylglycerol acyltransferase 1-like gene (ptdgat1) and uses thereof
WO2012059922A2 (en)2010-11-032012-05-10Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Transgenic plants with improved saccharification yields and methods of generating same
WO2012066495A2 (en)2010-11-172012-05-24Ben Gurion University Of The Negev Research And Development AuthorityT-cell therapy to neurodegenerative diseases
EP2457999A2 (en)2002-12-162012-05-30Technion Research & Development Foundation Ltd.Culture medium for pluropotent stem cells
WO2012073238A1 (en)2010-12-022012-06-07Technion Research & Development Foundation Ltd.Methods of generating corneal cells and cell populations comprising same
EP2463382A1 (en)2010-12-072012-06-13Enterologics, Inc.Method for identifying E. Coli M-17
WO2012081029A1 (en)2010-12-152012-06-21Kadimastem Ltd.Insulin producing cells derived from pluripotent stem cells
WO2012090205A2 (en)2010-12-282012-07-05Kamedis Ltd.Plant extracts for the treatment and prevention of infections
WO2012099896A2 (en)2011-01-172012-07-26Life Technologies CorporationWorkflow for detection of ligands using nucleic acids
WO2012098537A1 (en)2011-01-202012-07-26Protalix Ltd.Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
WO2012103414A2 (en)2011-01-282012-08-02Advanced Cell Diagnostics, Inc.Rnascope® hpv assay for determining hpv status in head and neck cancers and cervical lesions
US8236493B2 (en)1994-10-212012-08-07Affymetrix, Inc.Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA
WO2012104851A1 (en)2011-01-312012-08-09Yeda Research And Development Co. Ltd.Methods of diagnosing disease using overlap extension pcr
EP2487182A2 (en)2005-07-072012-08-15FULCRUM SP Ltd.SP1 polypeptides, modified SP1 polypeptides and uses thereof
WO2012109133A1 (en)2011-02-072012-08-16Research Development FoundationEngineered immunoglobulin fc polypeptides
US8252588B2 (en)2003-04-082012-08-28Yeda Research And Development Co. Ltd.Stem cells having increased sensitivity to SDF-1 and methods of generating and using same
WO2012114339A1 (en)2011-02-232012-08-30Rappaport Family Institute For Research In The Medical SciencesHigh affinity molecules capable of binding a type a plexin receptor and uses of same
WO2012117373A1 (en)2011-03-032012-09-07Ramot At Tel-Aviv University Ltd.Genetically modified muscle cells which express neurotrophic factors
WO2012117406A2 (en)2011-03-022012-09-07Futuragene Israel Ltd.Bacterial resistant transgenic plants
WO2012120500A2 (en)2011-03-062012-09-13Merck Serono S.A.Low fucose cell lines and uses thereof
WO2012120377A2 (en)2011-03-082012-09-13King Abdullah University Of Science And TechnologyMolecular biomarker set for early detection of ovarian cancer
WO2012120518A1 (en)2011-03-082012-09-13Ramot At Tel-Aviv University Ltd.Compositions and methods for diagnosing and treating phenylketonuria (pku)
EP2500428A2 (en)2007-07-112012-09-19Yeda Research and Development Co. Ltd.Nucleic acid construct systems capable of diagnosing or treating a cell state
WO2012125582A1 (en)2011-03-112012-09-20Board Of Regents Of The University Of NebraskaBiomarker for coronary artery disease
WO2012123949A1 (en)2011-03-172012-09-20Ramot At Tel-Aviv University Ltd.Bi- and monospecific, asymmetric antibodies and methods of generating the same
WO2012123938A1 (en)2011-03-172012-09-20Tel Hashomer Medical Research Infrastructure And Services Ltd.Quinolone analogs for treating autoimmune diseases
WO2012127320A1 (en)2011-03-222012-09-27Pluristem Ltd.Methods for treating radiation or chemical injury
WO2012129378A1 (en)2011-03-222012-09-27Keutgen Xavier MDistinguishing benign and malignant indeterminate thyroid lesions
WO2012127475A1 (en)2011-03-242012-09-27Neurim Pharmaceuticals (1991) Ltd.Neuroprotective peptides
WO2012131680A2 (en)2011-03-282012-10-04Yeda Research And Development Co. Ltd.Compositions and methods for treating inflammation
WO2012135360A1 (en)2011-04-012012-10-04Ludwig Institute For Cancer Research Ltd.Binding proteins specific for egfr expressed on tumor and uses thereof
WO2012131594A1 (en)2011-03-282012-10-04Novartis AgMarkers associated with cyclin-dependent kinase inhibitors
WO2012137202A1 (en)2011-04-052012-10-11Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Composition comprising an iron indicator attached to a microparticle and uses of same for quantifying non-transferrin bound iron (ntbi) and cellular labile iron (lci)
WO2012137207A1 (en)2011-04-062012-10-11Ramot At Tel-Aviv University Ltd.Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same
WO2012138941A1 (en)2011-04-052012-10-11Longevity Biotech, Inc.Compositions comprising glucagon analogs and methods of making and using the same
WO2012137147A1 (en)2011-04-082012-10-11Danisco Us, Inc.Compositions
EP2511708A1 (en)2007-10-052012-10-17Affymetrix, Inc.Highly multiplexed particle-based assays
WO2012140519A2 (en)2011-04-152012-10-18Pluristem Ltd.Methods and systems for harvesting cells
EP2514763A1 (en)2004-02-202012-10-24The Ludwig Institute for Cancer ResearchEgf receptor epitope peptides and uses thereof
EP2520669A2 (en)2005-02-072012-11-07GeneNews Inc.Mild osteoathritis biomarkers and uses thereof
WO2012150600A2 (en)2011-05-042012-11-08Ramot At Tel-Aviv University Ltd.Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease
WO2012150959A1 (en)2011-05-042012-11-08Abbott LaboratoriesMethods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor
WO2012153336A2 (en)2011-05-122012-11-15Rakuto Bio Technologies Ltd.Methods and device for lightening skin complexion
WO2012153333A1 (en)2011-05-092012-11-15Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Regeneration and repair of mesenchymal tissue using amelogenin
WO2012156976A1 (en)2011-05-162012-11-22Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of producing artemisinin in non-host plants and vectors for use in same
EP2526952A1 (en)2003-07-152012-11-28Bar-Ilan UniversityMethods and pharmaceutical compositions for healing wounds
EP2526968A2 (en)2006-01-272012-11-28Biogen Idec MA Inc.Nogo receptor antagonists
EP2527441A2 (en)2007-07-152012-11-28Technion Research & Development FoundationCompositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis
WO2012162179A1 (en)2011-05-202012-11-29Oligomerix, Inc.Tau protease compositions and methods of use
WO2012160526A2 (en)2011-05-232012-11-29Ofir MenasheFormulations of microorganism comprising particles and uses of same
US8323636B2 (en)2006-02-032012-12-04Prolor Biotech Ltd.Long-acting interferons and derivatives thereof and methods thereof
EP2529754A1 (en)2007-05-032012-12-05Agency For Science, Technology And Research (A*star)Antibodies binding to an intracellular PRL-1 or PRL-3 polypeptide
WO2012164380A2 (en)2011-05-312012-12-06Hutchison Biofilm Medical Solutions LimitedDispersion and detachment of cell aggregates
WO2012164565A1 (en)2011-06-012012-12-06Yeda Research And Development Co. Ltd.Compositions and methods for downregulating prokaryotic genes
EP2532746A2 (en)2007-03-302012-12-12EnGeneIC Molecular Delivery Pty Ltd.Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells
WO2012172555A1 (en)2011-06-142012-12-20Yeda Research And Development Co. Ltd.Combination therapy to prevent dcis formation and progression to breast cancer
WO2012176203A1 (en)2011-06-232012-12-27Kaiima Bio Agritech Ltd.Common wheat, plants or parts thereof having partially or fully multiplied genome, hybrids and products thereof and methods of generating and using same
US8352031B2 (en)2004-03-102013-01-08Impulse Dynamics NvProtein activity modification
EP2546359A1 (en)2005-12-082013-01-16Novartis AGEffects of inhibitors of FGFR3 on gene transcription
WO2013010170A1 (en)2011-07-142013-01-17Lovell Mark AProcess for detection of alzheimer's disease from a serum sample
WO2013011507A1 (en)2011-07-202013-01-24Kaiima Bio Agritech Ltd.Maize plants having a partially or fully multiplied genome and uses thereof
WO2013012924A2 (en)2011-07-182013-01-24President And Fellows Of Harvard CollegeEngineered microbe-targeting molecules and uses thereof
EP2550982A1 (en)2011-07-272013-01-30Technion Research & Development Foundation Ltd.Devices for surgical applications
WO2013018098A2 (en)2011-08-022013-02-07Prolor Biotech Ltd.Long-acting growth hormone and methods of producing same
WO2013018060A2 (en)2011-08-042013-02-07Yeda Research And Development Co. Ltd.Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
US8375327B2 (en)2005-01-162013-02-12Zlango Ltd.Iconic communication
WO2013021389A2 (en)2011-08-092013-02-14Yeda Research And Development Co.Ltd.Downregulation of mir-7 for promotion of beta cell differentiation and insulin production
WO2013022599A1 (en)2011-08-052013-02-14Research Development FoundationImproved methods and compositions for modulation of olfml3 mediated angiogenesis
WO2013024481A1 (en)2011-08-142013-02-21Kaiima Bio Agritech Ltd.Durum wheat plants having a partially or fully multiplied genome and uses thereof
WO2013025834A2 (en)2011-08-152013-02-21The University Of ChicagoCompositions and methods related to antibodies to staphylococcal protein a
EP2561889A2 (en)2002-08-012013-02-27Yeda Research and Development Co. Ltd.Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
US8388954B2 (en)2003-04-092013-03-05Laboratoire Francais Du Fractionnement Et Des BiotechnologiesStabilising formulation for immunoglobulin G compositions in liquid form and in lyophilised form
WO2013035099A1 (en)2011-09-082013-03-14Yeda Research And Development Co. Ltd.Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
WO2013035070A1 (en)2011-09-072013-03-14Yeda Research And Development Co. Ltd.Olfactory signature and odorant mixture having the same
WO2013035071A1 (en)2011-09-082013-03-14Yeda Research And Development Co. Ltd.Novel risk biomarkers for lung cancer
US8415318B2 (en)2001-10-192013-04-09Vascular Biogenics Ltd.Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
WO2013052643A1 (en)2011-10-052013-04-11The Rockefeller UniversityDimeric bacteriophage lysins
EP2581445A1 (en)2007-08-152013-04-17Yeda Research And Development Co. Ltd.Regulators of MMP-9 and uses thereof
WO2013054331A1 (en)2011-10-112013-04-18Tel Hashomer Medical Research Infrastructure And Services Ltd.Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
US8426166B2 (en)2006-02-032013-04-23Prolor Biotech Inc.Long-acting polypeptides and methods of producing same
WO2013056377A1 (en)2011-10-212013-04-25Augurex Life Sciences CorporationAntigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis
WO2013061328A2 (en)2011-10-272013-05-02Yeda Research And Development Co. Ltd.Method of treating cancer
WO2013067076A2 (en)2011-11-032013-05-10Quark Pharmaceuticals, Inc.Methods and compositions for neuroprotection
WO2013064163A1 (en)2011-11-012013-05-10Academisch Medisch CentrumMethylation markers for colorectal cancer
EP2591789A2 (en)2007-09-192013-05-15Pluristem Ltd.Adherent cells from adipose or placenta tissues and use thereof in therapy
WO2013070821A1 (en)2011-11-082013-05-16Quark Pharmaceuticals, Inc.Methods and compositions for treating diseases, disorders or injury of the nervous system
US8445637B2 (en)2008-12-052013-05-21Abraxis Bioscience, LlcSPARC binding peptides and uses thereof
WO2013076730A1 (en)2011-11-272013-05-30Yeda Research And Development Co. Ltd.Methods of regulating angiogenesis and compositions capable of same
WO2013076729A1 (en)2011-11-232013-05-30Danziger Dan Flower FarmOtomeria plants
EP2599790A1 (en)2007-11-262013-06-05Yissum Research Development Company of The Hebrew University of JerusalemCompositions comprising fibrous polypeptides and polysachharides
WO2013084190A1 (en)2011-12-082013-06-13Yeda Research And Development Co. Ltd.Mammalian fetal pulmonary cells and therapeutic use of same
WO2013093921A1 (en)2011-12-202013-06-27Collplant Ltd.Collagen coated synthetic polymer fibers
WO2013093920A2 (en)2011-12-222013-06-27Yeda Research And Development Co. Ltd.A combination therapy for a stable and long term engraftment
WO2013098820A1 (en)2011-12-282013-07-04Kaiima Bio Agritech Ltd.Cultivated sorghum plant having a partially or fully multiplied genome and uses of same
WO2013098813A1 (en)2012-01-012013-07-04Qbi Enterprises Ltd.Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
WO2013101758A1 (en)2011-12-292013-07-04Baylor Research InstituteBiomarkers for kawasaki disease
US8486640B2 (en)2007-03-212013-07-16Cedars-Sinai Medical CenterIleal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
US8486693B2 (en)2006-05-232013-07-16Bellicum Pharmaceuticals, Inc.Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
EP2620493A1 (en)2008-05-282013-07-31Ramot at Tel Aviv University Ltd.Mesenchymal stem cells for the treatment of CNS diseases
WO2013114374A1 (en)2012-02-012013-08-08Protalix Ltd.Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
WO2013114363A2 (en)2012-01-302013-08-08Yeda Research And Development Co.Ltd.Antimicrobial agents
US8513488B2 (en)2007-04-092013-08-20Evogene Ltd.Polynucleotides, polypeptides and methods for increasing oil content, growth rate and biomass of plants
US8512990B2 (en)2009-08-212013-08-20Gilead Biologics, Inc.Catalytic domains from lysyl oxidase and LOXL2
WO2013121426A1 (en)2012-02-132013-08-22Gamida-Cell Ltd.Culturing of mesenchymal stem cells
WO2013121405A1 (en)2012-02-192013-08-22Protalix Ltd.Oral unit dosage forms and uses of same for the treatment of gaucher disease
WO2013121416A1 (en)2012-02-142013-08-22Prolor Biotech Inc.Long-acting coagulation factors and methods of producing same
WO2013124817A2 (en)2012-02-222013-08-29Brainstem Biotec Ltd.MicroRNAS FOR THE GENERATION OF ASTROCYTES
WO2013126803A1 (en)2012-02-242013-08-29Protiva Biotherapeutics Inc.Trialkyl cationic lipids and methods of use thereof
WO2013124816A2 (en)2012-02-222013-08-29Brainstem Biotec Ltd.Generation of neural stem cells and motor neurons
EP2633854A1 (en)2008-12-052013-09-04Yeda Research And Development Co. Ltd.miRNA-9 or miRNA-9* for use in treating MND
WO2013130811A1 (en)2012-02-292013-09-06Chemocentryx, Inc.Pyrazol-1-yl benzene sulfonamides as ccr9 antagonists
WO2013128454A1 (en)2012-03-012013-09-06The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani CenterMale sterile garlic plants, hybrid offspring of same and methods of generating and using same
EP2636743A1 (en)2006-04-212013-09-11Intervet International B.V.Pestivirus species
WO2013132495A1 (en)2012-03-072013-09-12Yeda Research And Development Co. Ltd.Compositions for inhibition of quiescin sulfhydryl oxidase (qsox1) and uses of same
WO2013136335A1 (en)2012-03-152013-09-19Yeda Research And Development Co. Ltd.Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
EP2641606A1 (en)2008-05-272013-09-25Pluristem Ltd.Methods of treating inflammatory colon diseases
WO2013140389A1 (en)2012-03-222013-09-26Ramot At Tel-Aviv University Ltd.Plif multimeric peptides and uses thereof
WO2013149219A2 (en)2012-03-302013-10-03Sorrento Therapeutics Inc.Fully human antibodies that bind to vegfr2
WO2013152295A1 (en)2012-04-052013-10-10Advanced Cell Diagnostics, Inc.Detection of immunoglobulin light chain restrication by rna in situ hybridization
WO2013153553A2 (en)2012-04-132013-10-17Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Compositions for controlling varroa mites in bees
US8569025B2 (en)2009-06-292013-10-29The University Of British ColumbiaTerpene synthases from santalum
WO2013160895A1 (en)2012-04-242013-10-31Biokine Therapeutics Ltd.Peptides and use thereof in the treatment of large cell lung cancer
WO2013163035A1 (en)2012-04-232013-10-31Uhl Ii, LlcDevices and methods for detecting analyte in bodily fluid
WO2013162751A1 (en)2012-04-262013-10-31University Of ChicagoCompositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
WO2013170168A1 (en)2012-05-102013-11-14Bioatla LlcMulti-specific monoclonal antibodies
WO2013168164A1 (en)2012-05-092013-11-14Yeda Research And Development Co. Ltd.Variants of tace pro-domain as tnf-a inhibitor and their medical use
WO2013175480A1 (en)2012-05-242013-11-28A.B. Seeds Ltd.Compositions and methods for silencing gene expression
WO2013174003A1 (en)2012-05-242013-11-28Mountgate Group LimitedCompositions and methods related to prevention and treatment of rabies infection
WO2013181530A1 (en)2012-06-012013-12-05Icahn School Of Medicine At Mount SinaiCeramide levels in the treatment and prevention of infections
WO2013183048A1 (en)2012-06-032013-12-12Ben-Gurion University Of The Negev Research And Development AuthorityFunctionalized titanium binding peptides and implants coated with same
WO2013183052A1 (en)2012-06-042013-12-12Prolor Biotech Inc.Pegylated oxm variants
EP2674440A2 (en)2005-12-162013-12-18IBC Pharmaceuticals, Inc.Multivalent immunoglobulin-based bioactive assemblies
US8613926B2 (en)2011-06-062013-12-24Novo Nordisk A/SAnti-C5a receptor antibodies
WO2013192594A2 (en)2012-06-212013-12-27Sorrento Therapeutics Inc.Antigen binding proteins that bind c-met
WO2013192596A2 (en)2012-06-222013-12-27Sorrento Therapeutics Inc.Antigen binding proteins that bind ccr2
WO2013192616A1 (en)2012-06-222013-12-27Htg Molecular Diagnostics, Inc.Molecular malignancy in melanocytic lesions
US8617551B2 (en)1995-02-172013-12-31Incyte CorporationMethods of diagnosing pancreatic inflammation by using chemokine PANEC-1 antibodies
EP2679599A1 (en)2008-02-202014-01-01Amgen Inc.Antibodies directed to Angiopoietin-1 and Angiopoietin-2 and use thereof
WO2014006621A1 (en)2012-07-032014-01-09Nanospun Technologies Ltd.Methods and devices for adsorption and biodegradation of petroleum
US8629250B2 (en)2007-02-022014-01-14Amgen Inc.Hepcidin, hepcidin antagonists and methods of use
WO2014011398A1 (en)2012-07-092014-01-16Novartis AgBiomarkers associated with cdk inhibitors
WO2014011881A2 (en)2012-07-112014-01-16Imstem Biotechnology, Inc.Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
WO2014014788A2 (en)2012-07-182014-01-23President And Fellows Of Harvard CollegeModification of surfaces for simulataneous repellency and targeted binding of desired moieties
WO2014018375A1 (en)2012-07-232014-01-30Xenon Pharmaceuticals Inc.Cyp8b1 and uses thereof in therapeutic and diagnostic methods
WO2014020502A2 (en)2012-07-312014-02-06Novartis AgMarkers associated with human double minute 2 inhibitors
WO2014020599A1 (en)2012-07-292014-02-06Yeda Research And Development Co. Ltd.Use of the reductive glycine pathway for generating formatotrophic and autotrophic microorganisms
WO2014020608A1 (en)2012-07-312014-02-06Yeda Research And Development Co. Ltd.Methods of diagnosing and treating motor neuron diseases
WO2014024183A1 (en)2012-08-062014-02-13Brainstorm Cell Therapeutics Ltd.Methods of generating mesenchymal stem cells which secrete neurotrophic factors
US8658128B2 (en)2011-02-032014-02-25Pop Test Cortisol LlcSystem and method for diagnosis and treatment
WO2014033723A1 (en)2012-09-032014-03-06A.B. Seeds Ltd.Method of improving abiotic stress tolerance of plants and plants generated thereby
WO2014042763A1 (en)2011-09-162014-03-20Steve GoodisonBladder cancer detection composition kit, and associated methods
WO2014041544A1 (en)2012-09-122014-03-20Ramot At Tel-Aviv University Ltd.Immunoparticles and methods of generating and using same
US8680062B2 (en)2004-07-062014-03-25Deliversir Ltd.System for delivering therapeutic agents into living cells and cells nuclei
US8680246B2 (en)2010-02-042014-03-25Gilead Biologics, Inc.Antibodies that bind to lysyl oxidase-like 2 (LOXL2)
US8686227B2 (en)2007-07-242014-04-01Evogene Ltd.Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same
EP2712620A1 (en)2008-02-072014-04-02Cornell UniversityMethods for Preventing or Treating Insulin Resistance
EP2716654A1 (en)2005-10-242014-04-09Evogene Ltd.Isolated polypeptides, polynucleotides encoding same, transgenic plants expressing same and methods of using same
WO2014057490A1 (en)2012-10-092014-04-17Ramot At Tel-Aviv University Ltd.Methods and kits for predicting prognosis of cancer using soluble mortalin in blood
WO2014059442A2 (en)2012-10-122014-04-17Arizona Board Agents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State UniversityAntibody based reagents that specifically recognize toxic oligomeric forms of tau
WO2014058915A2 (en)2012-10-082014-04-17St. Jude Children's Research HospitalTherapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
WO2014062635A1 (en)2012-10-192014-04-24Novartis AgMarkers for acute lymphoblastic leukemia
WO2014063097A1 (en)2012-10-192014-04-24Danisco Us Inc.Stabilization of biomimetic membranes
WO2014064682A1 (en)2012-10-242014-05-01Yeda Research And Development Co. Ltd.Combinations of epidermal growth factor receptor targeting antibodies for treating cancer
WO2014066590A1 (en)2012-10-242014-05-01Research Development FoundationJam-c antibodies and methods for treatment of cancer
US8715665B2 (en)2007-04-132014-05-06The General Hospital CorporationMethods for treating cancer resistant to ErbB therapeutics
WO2014068553A1 (en)2012-10-292014-05-08Yeda Research And Development Co. Ltd.Aptamers, multimeric aptamers and uses thereof
WO2014083567A2 (en)2012-11-292014-06-05Yeda Research And Development Co. Ltd.Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitors
US8759292B2 (en)2006-02-032014-06-24Prolor Biotech, LlcLong-acting coagulation factors and methods of producing same
US8775526B2 (en)2006-01-162014-07-08Zlango Ltd.Iconic communication
WO2014106837A2 (en)2013-01-012014-07-10A. B. Seeds Ltd.ISOLATED dsRNA MOLECULES AND METHODS OF USING SAME FOR SILENCING TARGET MOLECULES OF INTEREST
WO2014108850A2 (en)2013-01-092014-07-17Yeda Research And Development Co. Ltd.High throughput transcriptome analysis
WO2014108854A1 (en)2013-01-092014-07-17Fusimab Ltd.Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
WO2014111936A1 (en)2013-01-172014-07-24Novellusdx Ltd.Methods and systems for identifying patient specific driver mutations
US8791232B2 (en)2008-04-302014-07-29Dupont Nutrition Biosciences ApsProteins
WO2014118785A1 (en)2013-02-042014-08-07Ramot At Tel-Aviv University Ltd.Generation of cytotoxic tumor specific cell lines and uses thereof
WO2014121077A2 (en)2013-02-012014-08-07The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesMETHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs)
US8828386B2 (en)2002-07-252014-09-09Glenveigh Pharmaceuticals, LlcMethod for extending pregnancy by reducing intraventricular hemorrhaging in patients exhibiting at least one symptom of preeclampsia and eclampsia
EP2774987A1 (en)2006-08-172014-09-10Affymetrix, Inc.Nucleic acid quantitation from tissue slides
WO2014136113A1 (en)2013-03-062014-09-12Protalix Ltd.Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same
WO2014136117A1 (en)2013-03-062014-09-12Protalix Ltd.USE OF PLANT CELLS EXPRESSING A TNFalpha POLYPEPTIDE INHIBITOR IN THERAPY
WO2014145718A2 (en)2013-03-152014-09-18Longevity Biotech, Inc.Peptides comprising non-natural amino acids and methods of making and using the same
WO2014144170A1 (en)2013-03-152014-09-18The Cleveland Clinic FoundationIn-vitro method for monoclonal antibody production using non-human act1 -deficient mice
WO2014141038A2 (en)2013-03-112014-09-18Irm LlcMarkers associated with wnt inhibitors
EP2781223A1 (en)2007-10-192014-09-24Rappaport Family Institute for Research in the Medical SciencesCompositions comprising semaphorins for the treatment of angiogenesis related diseases
WO2014151683A1 (en)2013-03-152014-09-25Bayer Healthcare LlcGla domains as targeting agents
WO2014147622A1 (en)2013-03-212014-09-25Collplant Ltd.Compositions comprising collagen and prp for tissue regeneration
WO2014153056A2 (en)2013-03-142014-09-25Parkash GillCancer treatment using antibodies that bing cell surface grp78
US8847008B2 (en)2008-05-222014-09-30Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant utility
US8846393B2 (en)2005-11-292014-09-30Gamida-Cell Ltd.Methods of improving stem cell homing and engraftment
WO2014159239A2 (en)2013-03-142014-10-02Novartis AgAntibodies against notch 3
WO2014159242A1 (en)2013-03-142014-10-02Novartis AgNotch 3 mutants and uses thereof
WO2014155376A1 (en)2013-03-242014-10-02Biokine Therapeutics Ltd.Methods of treating myeloid leukemia
US8859467B2 (en)2009-07-172014-10-14Bioatla, LlcSimultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
EP2789626A2 (en)2008-09-242014-10-15Tel Hashomer Medical Research Infrastructure and Services Ltd.Peptides and compositions for prevention of cell adhesion and methods of using same
US8865158B2 (en)2012-05-222014-10-21Ramot At Tel-Aviv University Ltd.Bacteriophages for reducing toxicity of bacteria
WO2014176047A1 (en)2013-04-252014-10-30Novartis AgMarkers for ezh2 inhibitors
WO2014174511A1 (en)2013-04-212014-10-30Yeda Research And Development Co. Ltd.Agents for downregulation of the activity and/or amount of bcl-xl and/or bcl-w
WO2014174470A1 (en)2013-04-232014-10-30Yeda Research And Development Co. Ltd.Isolated naive pluripotent stem cells and methods of generating same
WO2014174520A1 (en)2013-04-252014-10-30Yeda Research And Development Co. Ltd.Use of inhibitory peptides for the treatment of inflammatory diseases
WO2014190040A1 (en)2013-05-212014-11-27President And Fellows Of Harvard CollegeEngineered heme-binding compositions and uses thereof
WO2014188423A1 (en)2013-05-212014-11-27Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Treatment of mast cell related pathologies
EP2808344A1 (en)2010-06-012014-12-03Monash UniversityAntibodies directed to the receptor tyrosine kinase c-Met
WO2014191995A2 (en)2013-05-272014-12-04Rakuto Bio Technologies Ltd.Enzymatic system-containing cosmetic compositions
WO2014200767A1 (en)2013-06-122014-12-18The General Hospital CorporationMethods, kits, and systems for multiplexed detection of target molecules and uses thereof
WO2014204814A1 (en)2013-06-182014-12-24Dnatrix, Inc.Treatment of brain cancer with oncolytic adenovirus
EP2816117A2 (en)2004-09-292014-12-24Collplant Ltd.Collagen producing plants and methods of generating and using same
WO2014210540A1 (en)2013-06-282014-12-31Baylor Research InstituteDendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
WO2014207744A1 (en)2013-06-242014-12-31Ramot At Tel-Aviv University Ltd.Omentum based scaffold and delivery system
US8940519B2 (en)2009-04-242015-01-27Dupont Nutrition Biosciences ApsMethod of producing a lipolytic enzyme
US8946155B2 (en)2006-02-032015-02-03Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
WO2015015489A1 (en)2013-07-302015-02-05Biolinerx Ltd.Antibody for treating diabetes and autoimmune diseases
WO2015017552A1 (en)2013-08-012015-02-05Agensys, Inc.Antibody drug conjugates (adc) that bind to cd37 proteins
EP2839839A1 (en)2007-02-282015-02-25Yeda Research And Development Company LimitedNuclear targeting sequences
US8975016B2 (en)2009-04-162015-03-10Diagnostic Hybrids, Inc.Methods for direct fluorescent antibody virus detection in liquids
WO2015033337A1 (en)2013-09-032015-03-12Technion Research & Development Foundation Limited.A flap for de-novo tissue regeneration
WO2015033343A1 (en)2013-09-032015-03-12Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Compositions and methods for expressing recombinant polypeptides
WO2015033344A1 (en)2013-09-052015-03-12Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs)
WO2015037009A1 (en)2013-09-162015-03-19Plexicure Ltd.Isolated proteins capable of binding plexin-a4 and methods of producing and using same
WO2015040609A1 (en)2013-09-172015-03-26Yeda Research And Development Co. Ltd.Erk-derived peptides and uses thereof
WO2015049677A1 (en)2013-10-012015-04-09Kadimastem Ltd.Directed differentiation of astrocytes from human pluripotent stem cells for use in drug screening and the treatment of amyotrophic lateral sclerosis (als)
US9018445B2 (en)2008-08-182015-04-28Evogene Ltd.Use of CAD genes to increase nitrogen use efficiency and low nitrogen tolerance to a plant
WO2015059695A1 (en)2013-10-212015-04-30Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
WO2015059690A1 (en)2013-10-242015-04-30Yeda Research And Development Co. Ltd.Polynucleotides encoding brex system polypeptides and methods of using s ame
WO2015063768A1 (en)2013-10-312015-05-07Biokine Therapeutics Ltd.Methods of treating acute myeloid leukemia with a flt3 mutation
WO2015070009A2 (en)2013-11-082015-05-14The Board Of Regents Of The University Of Texas SystemVh4 antibodies against gray matter neuron and astrocyte
US9035039B2 (en)2011-12-222015-05-19Protiva Biotherapeutics, Inc.Compositions and methods for silencing SMAD4
US9040667B2 (en)2009-05-012015-05-26Dako Denmark A/SAntibody cocktail
WO2015077473A1 (en)2013-11-202015-05-28University Of Iowa Research FoundationMethods and compositions for treating amyloid deposits
WO2015077607A1 (en)2013-11-222015-05-28The Board Of Trustees Of The University Of IllinoisEngineered high-affinity human t cell receptors
WO2015079413A2 (en)2013-11-282015-06-04Yeda Research And Development Co. Ltd.Synaptojanin-2 inhibitors and uses thereof
WO2015079411A1 (en)2013-11-282015-06-04Tel Hashomer Medical Research Infrastructure And Services Ltd.Rna polymerase i inhibitors and uses thereof
US9057092B2 (en)2006-03-062015-06-16Zetiq Technologies Ltd.Methods and compositions for identifying a cell phenotype
WO2015087327A1 (en)2013-12-102015-06-18Yeda Research And Development Co. Ltd.Use of enzymes which catalyze pyruvate synthesis from formate and acetyl-coa and bacteria expressing same
WO2015094527A1 (en)2013-12-192015-06-25Danisco Us Inc.Use of hydrophobins to increase gas transferin aerobic fermentation processes
EP2889041A1 (en)2005-07-262015-07-01Rutgers, The State University of New JerseyKit of reagents for tuberculosis assay
WO2015105888A1 (en)2014-01-072015-07-16Bioatla, LlcProteins targeting orthologs
US9096645B2 (en)2010-11-152015-08-04Ramot At Tel-Aviv University Ltd.Dipeptide analogs for treating conditions associated with amyloid fibril formation
US9096865B2 (en)2009-06-102015-08-04Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance
WO2015114633A1 (en)2014-01-302015-08-06Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd.Actin binding peptides and compositions comprising same for inhibiting angiogenes is and treating medical conditions associated with same
WO2015116753A1 (en)2014-01-292015-08-06Dana-Farber Cancer Institute, Inc.Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)
WO2015114638A2 (en)2014-02-032015-08-06Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of eliminating stem cells
WO2015118537A2 (en)2014-02-052015-08-13Yeda Research And Development Co. Ltd.Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
WO2015118538A1 (en)2014-02-062015-08-13Yeda Research And Development Co. Ltd.Anti cd84 antibodies, compositions comprising same and uses thereof
WO2015120273A1 (en)2014-02-072015-08-13The General Hospital CorporationDifferential diagnosis of hepatic neoplasms
WO2015118547A1 (en)2014-02-102015-08-13Protalix Ltd.Method of maintaining disease stability in a subject having gaucher's disease
US9107935B2 (en)2009-01-062015-08-18Gilead Biologics, Inc.Chemotherapeutic methods and compositions
WO2015121859A1 (en)2014-02-112015-08-20Brainstorm Cell Therapeutics Ltd.Method of qualifying cells
WO2015123565A1 (en)2014-02-142015-08-20The General Hospital CorporationMethods for diagnosing igg4-related disease
US9121022B2 (en)2010-03-082015-09-01Monsanto Technology LlcMethod for controlling herbicide-resistant plants
WO2015131099A1 (en)2014-02-282015-09-03The General Hospital CorporationDiagnosis of multiple myeloma and lymphoma
US9125931B2 (en)2010-04-062015-09-08Massachusetts Institute Of TechnologyPost-transcriptional regulation of RNA-related processes using encoded protein-binding RNA aptamers
WO2015132784A1 (en)2014-03-032015-09-11Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method and device for detection of pseudomonas aeruginosa
EP2923709A1 (en)2014-03-282015-09-30Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Multi-component-multistage malaria vaccine
US9150644B2 (en)2011-04-122015-10-06The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesHuman monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US9156865B2 (en)2007-04-232015-10-13Deliversir LtdSystem for delivering therapeutic agents into living cells and cells nuclei
EP2933265A2 (en)2005-06-032015-10-21Amicus Therapeutics, Inc.Pharmacological chaperones for treating obesity
WO2015159292A2 (en)2014-04-142015-10-22Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.A method and kit for determining the tissue or cell origin of dna
WO2015159295A1 (en)2014-04-172015-10-22Yeda Research And Development Co. Ltd.Methods and kits for analyzing dna binding moieties attached to dna
EP2936976A1 (en)2008-04-212015-10-28Danziger Innovations Ltd.Plant viral expression vectors and use of same for generating genotypic variations in plant genomes
US9175266B2 (en)2012-07-232015-11-03Gamida Cell Ltd.Enhancement of natural killer (NK) cell proliferation and activity
WO2015166492A2 (en)2014-04-282015-11-05Yeda Research And Development Co. Ltd.Microbiome response to agents
US9182403B2 (en)2009-05-192015-11-10Zetiq Technologies Ltd.Kits for and methods of differential staining of cervical cancer cells and/or tissues
EP2942627A1 (en)2014-05-052015-11-11MicroBPlex, Inc.Media elaborated with newly synthesized antibodies (mensa) from recently proliferated antibody secreting cells (asc) and uses thereof
WO2015170323A2 (en)2014-05-042015-11-12Forrest Innovations Ltd.Compositions and methods of using same for reducing resistance to mosquito larvicides
WO2015171938A1 (en)2014-05-082015-11-12Novodiax, Inc.Direct immunohistochemistry assay
EP2944649A1 (en)2008-01-102015-11-18Research Development FoundationVaccines and diagnostics for the ehrlichioses
WO2015179435A1 (en)2014-05-192015-11-26Bayer Healthcare LlcOptimized humanized monoclonal antibodies against activated protein c and uses thereof
WO2015177800A2 (en)2014-05-222015-11-26Yeda Research And Development Co. Ltd.Recombinant microorganisms capable of carbon fixation
WO2015186129A1 (en)2014-06-022015-12-10Technion Research & Development Foundation Limited.Compositions and methods of selectively inhibiting irp1 and treating inflammation
WO2015186128A1 (en)2014-06-022015-12-10Kadimastem Ltd.Methods of inducing myelination and maturation of oligodendrocytes
US9212258B2 (en)2011-02-232015-12-15The Board Of Trustees Of The University Of IllinoisAmphiphilic dendron-coils, micelles thereof and uses
WO2015198320A1 (en)2014-06-242015-12-30Insight Biopharmaceuticals Ltd.Methods of purifying antibodies
WO2015198334A2 (en)2014-06-252015-12-30Tel Hashomer Medical Research Infrastructure And Services Ltd.Identification of cancer stem cells and use of same for diagnosis and treatment
WO2016005985A2 (en)2014-07-092016-01-14Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method for reprogramming cells
US9238843B2 (en)2010-12-272016-01-19Eli Lilly And CompanyCompositions and methods for identifying and differentiating viral components of multivalent shipping fever vaccines
WO2016009436A1 (en)2014-07-152016-01-21Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Isolated polypeptides of cd44 and uses thereof
US9249407B2 (en)2006-02-032016-02-02Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
WO2016016894A1 (en)2014-07-302016-02-04Yeda Research And Development Co. Ltd.Media for culturing pluripotent stem cells
US9261462B2 (en)2011-12-122016-02-16Step Ahead Innovations, Inc.Monitoring of photo-aging of light-based chemical indicators using illumination-brightness differential scheme
US9260517B2 (en)2009-11-172016-02-16Musc Foundation For Research DevelopmentHuman monoclonal antibodies to human nucleolin
WO2016024278A1 (en)2014-08-142016-02-18Memed Diagnostics Ltd.Computational analysis of biological data using manifold and a hyperplane
US9273349B2 (en)2013-03-142016-03-01Affymetrix, Inc.Detection of nucleic acids
EP2990421A1 (en)2009-04-302016-03-02Tel HaShomer Medical Research Infrastructure and Services Ltd.Anti ceacam1 antibodies and methods of using same
WO2016030899A1 (en)2014-08-282016-03-03Yeda Research And Development Co. Ltd.Methods of treating amyotrophic lateral scleroses
EP2992895A1 (en)2014-09-082016-03-09Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Three-component-multistage malaria vaccine
WO2016038616A1 (en)2014-09-142016-03-17Yeda Research And Development Co. Ltd.Nmda receptor antagonists for treating gaucher disease
WO2016038617A1 (en)2014-09-112016-03-17The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Methods of producing mogrosides and compositions comprising same and uses thereof
WO2016038550A1 (en)2014-09-112016-03-17Novartis AgInhibition of prmt5 to treat mtap-deficiency-related diseases
WO2016038609A1 (en)2014-09-082016-03-17Yeda Research And Development Co. Ltd.Anti-her3 antibodies and uses of same
WO2016038610A1 (en)2014-09-082016-03-17Yeda Research And Development Co. Ltd.Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
WO2016042561A2 (en)2014-09-212016-03-24Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Downregulating mir-132 for the treatment of lipid related disorders
WO2016044234A1 (en)2014-09-162016-03-24Eric TsaoAnti-egfr antibody and uses of same
EP3006039A1 (en)2004-03-022016-04-13Acceleron Pharma Inc.Alk7 polypeptides for use in promoting fat loss
WO2016057424A1 (en)2014-10-062016-04-14Chemocentryx, Inc.Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies
US9316641B2 (en)2010-01-112016-04-19Biogen Ma Inc.Assay for JC virus antibodies
WO2016061111A1 (en)2014-10-132016-04-21Life Technologies CorporationMethods, kits & compositions for determining gene copy numbers
WO2016065238A1 (en)2014-10-242016-04-28Danisco Us Inc.Method for producing alcohol by use of a tripeptidyl peptidase
WO2016062857A1 (en)2014-10-242016-04-28Dupont Nutrition Biosciences ApsUse of proline tolerant tripeptidyl peptidases in feed additive compositions
WO2016064887A1 (en)2014-10-202016-04-28Gen-Probe IncorporatedRed blood cell lysis solution
EP3018139A2 (en)2007-08-032016-05-11Boehringer Ingelheim Vetmedica GmbHGenes and proteins of brachyspira hyodysenteriae and uses thereof
EP3020410A1 (en)2008-04-182016-05-18Collplant Ltd.Methods of generating and using procollagen
WO2016075697A1 (en)2014-11-132016-05-19Enzootic Holdings Ltd.Functional sex-reversal of decapod crustacean females
EP3023438A1 (en)2009-09-032016-05-25Merck Sharp & Dohme Corp.Anti-gitr antibodies
WO2016079736A2 (en)2014-11-172016-05-26Yeda Research And Development Co. Ltd.Methods of treating diseases related to mitochondrial function
WO2016079739A2 (en)2014-11-202016-05-26Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Compositions and methods for producing polypeptides with a modified glycosylation pattern in plant cells
WO2016079731A2 (en)2014-11-172016-05-26Yeda Research And Development Co. Ltd.Method of analyzing microbiome
EP3026057A2 (en)2009-03-092016-06-01Ramot at Tel Aviv University Ltd.Compositions for prevention and treatment of neurodegenerative diseases
WO2016084084A1 (en)2014-11-272016-06-02Danziger Innovations Ltd.Nucleic acid constructs for genome editing
WO2016084088A1 (en)2014-11-262016-06-02Ramot At Tel-Aviv University Ltd.Targeted elimination of bacterial genes
WO2016089883A1 (en)2014-12-012016-06-09Novartis AgCompositions and methods for diagnosis and treatment of prostate cancer
WO2016092554A1 (en)2014-12-112016-06-16Memed Diagnostics Ltd.Marker combinations for diagnosing infections and methods of use thereof
WO2016092555A2 (en)2014-12-112016-06-16Yeda Research And Development Co. Ltd.Isolated phosphotriesterase polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
WO2016103269A1 (en)2014-12-232016-06-30Ramot At Tel-Aviv University Ltd.Populations of neural progenitor cells and methods of producing and using same
WO2016108219A1 (en)2014-12-302016-07-07Cell Cure Neurosciences Ltd.Methods of treating retinal diseases
WO2016108239A1 (en)2014-12-302016-07-07Cell Cure Neurosciences Ltd.Rpe cell populations and methods of generating same
WO2016108244A1 (en)2015-01-042016-07-07Protalix Ltd.Modified dnase and uses thereof
WO2016108240A1 (en)2014-12-302016-07-07Cell Cure Neurosciences Ltd.Assessing retinal pigment epithelial cell populations
US9395369B2 (en)2012-10-192016-07-19Regents Of The University Of MinnesotaGuinea pig cytomegalovirus (CIDMTR strain)
WO2016116935A1 (en)2015-01-212016-07-28Yeda Research And Development Co. Ltd.Use of rasa2 as a prognostic and therapeutic marker for melanoma
US9411930B2 (en)2013-02-012016-08-09The Regents Of The University Of CaliforniaMethods for genome assembly and haplotype phasing
US9416363B2 (en)2011-09-132016-08-16Monsanto Technology LlcMethods and compositions for weed control
WO2016130898A2 (en)2015-02-132016-08-18Sorrento Therapeutics, Inc.Antibody therapeutics that bind ctla4
WO2016130516A1 (en)2015-02-092016-08-18Research Development FoundationEngineered immunoglobulin fc polypeptides displaying improved complement activation
US9422558B2 (en)2011-09-132016-08-23Monsanto Technology LlcMethods and compositions for weed control
US9422557B2 (en)2011-09-132016-08-23Monsanto Technology LlcMethods and compositions for weed control
WO2016135732A1 (en)2015-02-262016-09-01Yeda Research And Development Co. Ltd.Method of promoting hair growth
WO2016138312A2 (en)2015-02-252016-09-01Vanderbilt UniversityAntibody-mediated neutralization of marburg virus
US9434985B2 (en)2008-09-252016-09-06University Of MassachusettsMethods of identifying interactions between genomic loci
WO2016142948A1 (en)2015-03-112016-09-15Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Decoy oligonucleotides for the treatment of diseases
WO2016145409A1 (en)2015-03-112016-09-15The Broad Institute, Inc.Genotype and phenotype coupling
WO2016145099A1 (en)2015-03-092016-09-15Agensys, Inc.Antibody drug conjugates (adc) that bind to flt3 proteins
US9447467B2 (en)2009-04-212016-09-20Genetic Technologies LimitedMethods for obtaining fetal genetic material
US9447454B2 (en)2003-10-232016-09-20The Rockefeller UniversityMethod of purifying RNA binding protein-RNA complexes
WO2016147194A1 (en)2015-03-192016-09-22Yeda Research And Development Co. Ltd.Anti amphiregulin antibodies, compositions comprising same and uses thereof
US9458444B2 (en)2006-02-032016-10-04Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
US9458438B2 (en)2010-04-122016-10-04Ben Gurion University Of The Negev Research And Development AuthoritySulfotransferase of a red microalga and uses thereof
WO2016160618A2 (en)2015-03-272016-10-06University Of Southern CaliforniaCar t-cell therapy directed to lhr for the treatment of solid tumors
WO2016157190A1 (en)2015-03-312016-10-06Yeda Research And Development Co. Ltd.Glutamate oxaloacetate transaminase 1 (got1), preparations and methods of generating same and uses thereof
WO2016157192A1 (en)2015-04-012016-10-06The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Erodium crassifolium l'her plant extracts and uses thereof
WO2016162870A1 (en)2015-04-072016-10-13Ilana NathanCompositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto
US9476884B2 (en)2013-10-042016-10-25University Of MassachusettsHybridization- independent labeling of repetitive DNA sequence in human chromosomes
WO2016174673A1 (en)2015-04-292016-11-03The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Anti-phytopathogenic compositions
WO2016174652A1 (en)2015-04-302016-11-03Technion Research & Development Foundation LimitedChimeric antigen receptors and methods of their use
WO2016174674A1 (en)2015-04-272016-11-03The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterEgr1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions
US9487559B2 (en)2010-10-042016-11-08Elro Pharma SarlCompositions comprising multivalent synthetic ligands of surface nucleolin and glycosaminoglycans
EP3091026A1 (en)2015-05-082016-11-09Centrillion Technology Holdings CorporationDisulfide-linked reversible terminators
WO2016178207A1 (en)2015-05-042016-11-10Ramot At Tel-Aviv University Ltd.Methods and kits for fragmenting dna
WO2016181393A1 (en)2015-05-112016-11-17Yeda Research And Development Co. Ltd.Citrin inhibitors for the treatment of cancer
WO2016187356A1 (en)2015-05-182016-11-24Agensys, Inc.Antibodies that bind to axl proteins
WO2016185469A1 (en)2015-05-212016-11-24Yeda Research And Development Co. Ltd.Bacterial populations for promoting health
WO2016185471A1 (en)2015-05-172016-11-24The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterCompositions and methods for treating cancer
WO2016185457A1 (en)2015-05-192016-11-24Yeda Research And Development Co. Ltd.Methods of promoting lymphangiogenesis
WO2016187354A1 (en)2015-05-182016-11-24Agensys, Inc.Antibodies that bind to axl proteins
WO2016185481A2 (en)2015-05-202016-11-24Yeda Research And Development Co. Ltd.Method of targeting senescent cells
WO2016193969A2 (en)2015-05-292016-12-08Opko Biologics Ltd.Pegylated oxyntomodulin variants
WO2016197064A1 (en)2015-06-042016-12-08Epstein Alan LLym-1 and lym-2 targeted car cell immunotherapy
EP3103451A1 (en)2007-01-122016-12-14University of Maryland, BaltimoreTargetting ncca-atp channel for organ protection following ischemic episode
WO2016199141A2 (en)2015-06-082016-12-15Adicet Bio Inc.Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
US9522945B2 (en)2012-04-192016-12-20Opko Biologics Ltd.Long-acting oxyntomodulin variants and methods of producing same
WO2016203477A1 (en)2015-06-182016-12-22Yeda Research And Development Co. Ltd.Conditioning protocols and use of same for tissue regeneration
WO2016203482A2 (en)2015-06-192016-12-22Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
WO2016203476A1 (en)2015-06-182016-12-22Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods and compositions for diagnosing and treating urothelial cancer
US9528998B2 (en)2010-04-162016-12-27Abbott LaboratoriesMethods and reagents for diagnosing rheumatoid arthrtis
WO2016210395A1 (en)2015-06-262016-12-29Dupont Nutrition Biosciences ApsAminopeptidases for protein hydrlyzates
US9540642B2 (en)2013-11-042017-01-10The United States Of America, As Represented By The Secretary Of AgricultureCompositions and methods for controlling arthropod parasite and pest infestations
EP3115451A1 (en)2008-09-022017-01-11Pluristem Ltd.Adherent cells from placenta tissue and use thereof in therapy
WO2017009852A1 (en)2015-07-162017-01-19Yeda Research And Development Co. Ltd.Use of anti third party central memory t cells
WO2017011329A1 (en)2015-07-102017-01-19West Virginia UniversityMarkers of stroke and stroke severity
WO2017009842A2 (en)2015-07-162017-01-19Biokine Therapeutics Ltd.Compositions and methods for treating cancer
US9551006B2 (en)2010-12-222017-01-24Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for improving plant properties
WO2017013661A1 (en)2015-07-222017-01-26Phytopharma International Ltd.Bee-ingestible compositions, methods of using same for producing honey and honey produced thereby
US9556210B2 (en)2007-04-232017-01-31Sabag-Rfa Ltd.System for delivering therapeutic agents into living cells and cells nuclei
WO2017017686A1 (en)2015-07-292017-02-02Hadasit Medical Research Services And Development Ltd.Large scale production of retinal pigment epithelial cells
WO2017021963A1 (en)2015-08-032017-02-09Biokine Therapeutics Ltd.Cxcr4 binding agents for treatment of diseases
WO2017023929A1 (en)2015-08-042017-02-09Cd Diagnostics, Inc.Methods for detecting adverse local tissue reaction (altr) necrosis
WO2017024114A1 (en)2015-08-062017-02-09President And Fellows Of Harvard CollegeImproved microbe-binding molecules and uses thereof
WO2017021972A1 (en)2015-08-052017-02-09Cell Cure Neurosciences Ltd.Preparation of photoreceptors for the treatment of retinal diseases
WO2017021973A1 (en)2015-08-052017-02-09Cell Cure Neurosciences Ltd.Preparation of retinal pigment epithelium cells
WO2017021961A1 (en)2015-08-042017-02-09Yeda Research And Development Co. Ltd.Methods of screening for riboswitches and attenuators
US9567569B2 (en)2012-07-232017-02-14Gamida Cell Ltd.Methods of culturing and expanding mesenchymal stem cells
WO2017025963A1 (en)2015-08-102017-02-16The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterMethods and pharmaceutical compositions for improving wound healing using cd24
WO2017025967A1 (en)2015-08-132017-02-16Forrest Innovations Ltd.Formulations and compositions for delivery of nucleic acids to plant cells
US9580752B2 (en)2008-12-242017-02-28Cedars-Sinai Medical CenterMethods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
WO2017033188A1 (en)2015-08-242017-03-02Yeda Research And Development Co. Ltd.Algal oil and biofuel and methods of producing same
WO2017033152A1 (en)2015-08-252017-03-02Prothena Biosciences LimitedMethods for detecting phosphorylated alpha-synuclein
WO2017040380A2 (en)2015-08-282017-03-09Research Development FoundationEngineered antibody fc variants
WO2017040813A2 (en)2015-09-022017-03-09University Of MassachusettsDetection of gene loci with crispr arrayed repeats and/or polychromatic single guide ribonucleic acids
WO2017044419A1 (en)2015-09-082017-03-16University Of MassachusettsDnase h activity of neisseria meningitidis cas9
WO2017042814A1 (en)2015-09-102017-03-16Yeda Research And Development Co. Ltd.Use of perforin positive immature dendritic cells in disease treatment
US9611315B2 (en)2003-12-232017-04-04Arbor Vita CorporationAntibodies for oncogenic strains of HPV and methods of their use
WO2017059108A1 (en)2015-09-292017-04-06Htg Molecular Diagnostics, Inc.Methods for subtyping diffuse b-cell lymphoma (dlbcl)
WO2017062953A1 (en)2015-10-102017-04-13Intrexon CorporationImproved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
EP3159405A1 (en)2010-01-052017-04-26Vascular Biogenics Ltd.Methods for use of a specific anti-angiogenic adenoviral agent
WO2017072763A1 (en)2015-10-262017-05-04Cell Cure Neurosciences Ltd.Preparation of retinal pigment epithelium cells
WO2017072757A1 (en)2015-10-252017-05-04Yeda Research And Development Co. Ltd.Antibodies targeting quiescin sulfhydryl oxidase (qsox1) and uses of same
WO2017072773A1 (en)2015-10-272017-05-04Ilana NathanCompositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
WO2017072772A1 (en)2015-10-292017-05-04Yeda Research And Development Co. Ltd.A method of inducing cardiomyocytes proliferation and treating heart diseases
WO2017077539A1 (en)2015-11-032017-05-11Ariel-University Research And Development Company Ltd.Compositions for regeneration and repair of neural tissue
WO2017081689A1 (en)2015-11-112017-05-18Ramot At Tel-Aviv University Ltd.Methods of detecting 5-hydroxymethylcytosine and diagnosing of cancer
WO2017083296A1 (en)2015-11-092017-05-18The Children's Hospital Of PhiladelphiaGlypican 2 as a cancer marker and therapeutic target
US9663778B2 (en)2009-07-092017-05-30OPKO Biologies Ltd.Long-acting coagulation factors and methods of producing same
EP3176183A1 (en)2015-12-022017-06-07Yeda Research and Development Co. LtdCompositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
WO2017096304A1 (en)2015-12-042017-06-08Board Of Regents, The University Of Texas SystemSlc45a2 peptides for immunotherapy
WO2017094001A1 (en)2015-11-302017-06-08Kadimastem LtdMethods for differentiating and purifying pancreatic endocrine cells
WO2017112492A2 (en)2015-12-222017-06-29The Regents Of The University Of Colorado, A Body CorporateProtecting rnas from degradation using engineered viral rnas
WO2017109679A1 (en)2015-12-212017-06-29Novartis AgCompositions and methods for decreasing tau expression
WO2017118985A1 (en)2016-01-062017-07-13Yeda Research And Development Co. Ltd.Compositions and methods for treating malignant, autoimmune and inflammatory diseases
WO2017122203A1 (en)2016-01-112017-07-20Technion Research & Development Foundation LimitedMethods of determining prognosis of sepsis and treating same
US9715573B2 (en)2015-02-172017-07-25Dovetail Genomics, LlcNucleic acid sequence assembly
WO2017125931A1 (en)2016-01-212017-07-27The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Parthenocarpic plants and methods of producing same
WO2017132562A1 (en)2016-01-292017-08-03Heyue ZhouAntigen binding proteins that bind pd-l1
WO2017130205A1 (en)2016-01-312017-08-03Hadasit Medical Research Services And Development Ltd.Autosomal-identical pluripotent stem cell populations having non-identical sex chromosomal composition and uses thereof
US9726581B2 (en)2011-12-222017-08-08Realbio Technologies Ltd.Sequential lateral flow capillary device for analyte determination
WO2017134671A1 (en)2016-02-042017-08-10Yeda Research And Development Co. Ltd.Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53
US9733242B2 (en)2012-10-072017-08-15Sevident, Inc.Devices for capturing analyte
WO2017138007A1 (en)2016-02-142017-08-17Yeda Research And Development Co. Ltd. At The Weizmann Institute Of ScienceMicrobiome-based diagnosis, prediction and treatment of relapsing obesity
WO2017138008A2 (en)2016-02-142017-08-17Yeda Research And Development Co. Ltd.Methods of modulating protein exocytosis and uses of same in therapy
US9739773B1 (en)2010-08-132017-08-22David Gordon BermudesCompositions and methods for determining successful immunization by one or more vaccines
WO2017141253A1 (en)2016-02-162017-08-24Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Non-protein phenylalanine analogues for inhibiting cyanobacteria and plant growth
WO2017147186A1 (en)2016-02-222017-08-31Ursure, Inc.System and method for detecting therapeutic agents to monitor adherence to a treatment regimen
WO2017147060A1 (en)2016-02-252017-08-31Dupont Nutrition Biosciences ApsMethod for producing a protein hydrolysate employing an aspergillus fumigatus tripeptidyl peptidase
WO2017145162A1 (en)2016-02-232017-08-31Chaya BrodieGeneration of cancer stem cells and use thereof
WO2017149547A1 (en)2016-03-032017-09-08Memed Diagnostics Ltd.Analyzing rna for diagnosing infection type
WO2017153982A1 (en)2016-03-062017-09-14Yeda Research And Development Co. Ltd.Method for modulating myelination
WO2017158610A1 (en)2016-03-172017-09-21Yeda Research And Development Co. Ltd.Methods of isolating barrel-like proteases and identifying peptides processed thereby
WO2017165438A1 (en)2016-03-252017-09-28Muralidhar Reddy MoolaCombinatorial synthesis and biomarker development
US9777288B2 (en)2013-07-192017-10-03Monsanto Technology LlcCompositions and methods for controlling leptinotarsa
WO2017173091A1 (en)2016-03-302017-10-05Musc Foundation For Research DevelopmentMethods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
WO2017172518A1 (en)2016-03-292017-10-05Stcube, Inc.Dual function antibodies specific to glycosylated pd-l1 and methods of use thereof
US9784686B2 (en)2013-06-192017-10-10Step Ahead Innovations, Inc.Aquatic environment water parameter testing systems and methods
WO2017175228A1 (en)2016-04-062017-10-12Technion Research & Development Foundation LimitedInfiltrating immune cell proportions predict anti-tnf response in colon biopsies
US9796762B2 (en)2013-04-102017-10-244D Pharma Research LimitedPolypeptide and immune modulation
WO2017189746A1 (en)2016-04-272017-11-02Gen-Probe IncorporatedBlood cell lysis reagent
US9808534B2 (en)2012-11-202017-11-07Opko Biologics Ltd.Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
WO2017194589A1 (en)2016-05-102017-11-16Vib VzwInhibition of tau-mediated early synaptic dysfunction
US9822134B2 (en)2012-10-222017-11-21Sabag-Rfa Ltd.System for delivering therapeutic agents into living cells and cells nuclei
WO2017201064A1 (en)2016-05-162017-11-23President And Fellows Of Harvard CollegeAqueous biomolecule coupling on co2-plasma-activated surfaces
US9828417B2 (en)2006-02-032017-11-28Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
WO2017203532A1 (en)2016-05-252017-11-30Yeda Research And Development Co. Ltd. At The Weizmann Institute Of ScienceAgents for use treating drug resistant tumors and triple negative breast cancer
WO2017203520A1 (en)2016-05-222017-11-30Yeda Research And Development Co. Ltd.Methods of using pulmonary cells for transplantation and induction of tolerance
EP3252155A1 (en)2011-04-212017-12-06The Rockefeller UniversityStreptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
WO2017208247A1 (en)2016-06-022017-12-07Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Assay for the removal of methyl-cytosine residues from dna
US9840715B1 (en)2011-09-132017-12-12Monsanto Technology LlcMethods and compositions for delaying senescence and improving disease tolerance and yield in plants
WO2017212494A1 (en)2016-06-092017-12-14Opko Biologics Ltd.Long-acting oxyntomodulin formulation and methods of producing and administering same
WO2017214068A1 (en)2016-06-052017-12-14Berg LlcSystems and methods for patient stratification and identification of potential biomarkers
WO2017212476A1 (en)2016-06-052017-12-14Tel Hashomer Medical Research Infrastructure And Services Ltd.Novel molecules for the treatment of inflammation
US9850496B2 (en)2013-07-192017-12-26Monsanto Technology LlcCompositions and methods for controlling Leptinotarsa
WO2017221225A1 (en)2016-06-192017-12-28Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Screening for chemotherapy resistance in human haploid cells
EP3263127A1 (en)2011-05-232018-01-03Yeda Research and Development Co. LtdUse of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
WO2018002924A1 (en)2016-06-272018-01-04Yeda Research And Development Co. Ltd.Veto cells generated from memory t cells
WO2018001932A1 (en)2016-06-302018-01-04Koninklijke Philips N.V.Device, system and method for detecting an analyte in a body fluid sample containing a plurality of cells
WO2018011796A1 (en)2016-07-102018-01-18Memed Diagnostics Ltd.Early diagnosis of infections
WO2018011806A1 (en)2016-07-112018-01-18Yeda Research And Development Co. Ltd.Combination therapy to increase endogenous nitric oxide (no) synthesis
WO2018011799A1 (en)2016-07-112018-01-18Opko Biologics Ltd.Long-acting coagulation factor vii and methods of producing same
WO2018011795A1 (en)2016-07-102018-01-18Memed Diagnostics Ltd.Protein signatures for distinguishing between bacterial and viral infections
WO2018011805A2 (en)2016-07-112018-01-18Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Systems and methods for growing cells in vitro
WO2018011804A1 (en)2016-07-112018-01-18Bonus Therapeutics Ltd.Cell compositions for tissue regeneration
WO2018015881A1 (en)2016-07-182018-01-25Ramot At Tel-Aviv University Ltd.Modular platform for targeted therapeutics
WO2018017673A1 (en)2016-07-202018-01-25Stcube, Inc.Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
WO2018015296A1 (en)2016-07-202018-01-25Vib VzwTherapeutic agents for neurological and psychiatric disorders
WO2018020489A1 (en)2016-07-242018-02-01Yeda Research And Development Co. Ltd.Methods and kits for analyzing dna binding moieties attached to dna
US9884901B2 (en)2006-02-032018-02-06Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
WO2018029693A1 (en)2016-08-102018-02-15Ramot At Tel-Aviv University Ltd.Analysis of methylation status and copy number
WO2018029682A1 (en)2016-08-082018-02-15Ramot At Tel-Aviv University Ltd.Bacterial systems for analyzing ubiquitylated polypeptides
WO2018029690A1 (en)2016-08-102018-02-15Memed Diagnostics Ltd.System and method for analysis of biological data
WO2018033929A1 (en)2016-08-182018-02-22Yeda Research And Development Co. Ltd.Diagnostic and therapeutic uses of exosomes
WO2018033911A1 (en)2016-08-142018-02-22Ramot At Tel-Aviv University Ltd.Mesenchymal cell-derived exosomes to treat neurological disorders
WO2018037416A1 (en)2016-08-252018-03-01Yeda Research And Development Co. Ltd.Methods and compositions for treating autoimmune diseases
US9910040B2 (en)2012-07-092018-03-06Sevident, Inc.Molecular nets comprising capture agents and linking agents
EP3293269A1 (en)2007-08-032018-03-14MUSC Foundation For Research DevelopmentHuman monoclonal antibodies and methods for producing the same
WO2018047154A1 (en)2016-09-072018-03-15Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Anti-nkp46 antibodies and therapeutic use of same
US9920326B1 (en)2011-09-142018-03-20Monsanto Technology LlcMethods and compositions for increasing invertase activity in plants
WO2018051347A1 (en)2016-09-142018-03-22Yeda Research And Development Co. Ltd.Crisp-seq, an integrated method for massively parallel single cell rna-seq and crispr pooled screens
US9925143B2 (en)2012-04-182018-03-27Ramot At Tel-Aviv University Ltd.Lipidated glycosaminoglycan particles for the delivery of nucleic acids
EP3301446A1 (en)2009-02-112018-04-04Caris MPI, Inc.Molecular profiling of tumors
WO2018060998A1 (en)2016-09-292018-04-05Memed Diagnostics Ltd.Methods of prognosis and treatment
US9938316B2 (en)2013-08-292018-04-10Yeda Research And Development Co. Ltd.Selective inhibitors of α2 isoform of Na,K-ATPase and use thereof for reduction of intra-ocular pressure and as cardiotonic agents
US9937211B2 (en)2011-10-072018-04-104D Pharma Research LimitedComposition of Roseburia hominis
WO2018069885A1 (en)2016-10-132018-04-19Technion Research & Development Foundation LimitedUse of caspase-3 inhibitors and caspase-3 activators in the manufacture of medicament for treating cancer and wound healing
US9952211B2 (en)2008-06-292018-04-24Realbio Technologies Ltd.Liquid-transfer device particularly useful as a capturing device in a biological assay process
WO2018073823A2 (en)2016-10-182018-04-26Yeda Research And Development Co. Ltd.Treatment of a circadian rhythm disorder
EP3318273A1 (en)2011-04-012018-05-09ImmunoGen, Inc.Methods for increasing efficacy of folr1 cancer therapy
WO2018085679A1 (en)2016-11-042018-05-11Stave James WDirect detection of microorganisms in patient samples by immunoassay
WO2018085400A1 (en)2016-11-022018-05-11Vanderbilt UniversityHuman zika virus antibodies and methods of use therefor
WO2018087759A1 (en)2016-11-102018-05-17Yeda Research And Development Co. Ltd.Phosphotriesterases for treating or preventing organophosphate exposure associated damage
WO2018089231A1 (en)2016-11-092018-05-17Qiagen Sciences LlcPhotoprotective mixtures as imaging reagents in sequencing-by-synthesis
WO2018096547A1 (en)2016-11-282018-05-31Yeda Research And Development Co. Ltd.Isolated polynucleotides and polypeptides and methods of using same for expressing an expression product of interest
EP3329905A1 (en)2016-12-052018-06-06Nuritas LimitedTopical cosmetic compositions comprising an oligopeptide against anti-aging of the skin
EP3329930A1 (en)2016-12-052018-06-06Nuritas LimitedPharmaceuctical compositions
WO2018100574A1 (en)2016-11-302018-06-07Yeda Research And Development Co. Ltd.Methods of treating liver toxicity and disorders
WO2018100431A1 (en)2016-11-292018-06-07Genomic VisionMethod for designing a set of polynucleotide sequences for analysis of specific events in a genetic region of interest
WO2018100511A1 (en)2016-12-012018-06-07Ramot At Tel-Aviv University Ltd.Combined treatment for nerve injuries
WO2018104346A1 (en)2016-12-052018-06-14Nuritas LimitedCompositions comprising peptide wkdeagkplvk
US10000767B2 (en)2013-01-282018-06-19Monsanto Technology LlcMethods and compositions for plant pest control
EP3348575A1 (en)2011-08-162018-07-18Emory UniversityJaml specific binding agents, antibodies, and uses related thereto
WO2018134824A1 (en)2017-01-182018-07-26Yeda Research And Development Co. Ltd.Genetically modified veto cells and use of same in immunotherapy
US10036011B2 (en)2016-02-112018-07-31Qiagen Waltham, Inc.Scavenger compounds for improved sequencing-by-synthesis
EP3354723A1 (en)2005-08-292018-08-01Technion Research & Development Foundation Ltd.Media for culturing stem cells
WO2018138668A1 (en)2017-01-252018-08-02Mor Research Applications Ltd.Methods of diagnosing malignant diseases
WO2018140606A1 (en)2017-01-262018-08-02Oklahoma Medical Research FoundationBiomarkers for systemic lupus erythematosus disease activity, and intensity and flare
WO2018144425A1 (en)2017-01-312018-08-09Vanderbilt UniversityGeneration of human allergen-and helminth-specific ige monoclonal antibodies for diagnostic and therapeutic use
WO2018142416A1 (en)2017-02-062018-08-09Yeda Research And Development Co. Ltd.Isolated cells genetically modified to express a disarm system having an anti-phage activity and methods of producing same
US10047399B2 (en)2013-01-072018-08-14The Cleveland Clinic FoundationABCA1 downregulation in prostate cancer
WO2018146162A1 (en)2017-02-072018-08-16Academisch Medisch CentrumMolecular biomarker for prognosis of sepsis patients
EP3366762A1 (en)2007-05-072018-08-29Protalix Ltd.Large scale disposable bioreactor
WO2018158775A1 (en)2017-03-022018-09-07Yeda Research And Development Co. Ltd.Methods of culturing t cells and uses of same
WO2018163051A1 (en)2017-03-062018-09-13Novartis AgMethods of treatment of cancer with reduced ubb expression
US10077451B2 (en)2012-10-182018-09-18Monsanto Technology LlcMethods and compositions for plant pest control
WO2018170494A1 (en)2017-03-162018-09-20Bio Time, Inc.Methods for measuring therapeutic effects of retinal disease therapies
WO2018167778A1 (en)2017-03-122018-09-20Yeda Research And Development Co. Ltd.Methods of diagnosing and prognosing cancer
WO2018167780A1 (en)2017-03-122018-09-20Yeda Research And Development Co. Ltd.Methods of prognosing and treating cancer
US10089437B2 (en)2013-02-012018-10-02The Regents Of The University Of CaliforniaMethods for genome assembly and haplotype phasing
WO2018185760A1 (en)2017-04-052018-10-11Yeda Research And Development Co. Ltd.Ex-vivo culture system and methods of using same
US10107826B2 (en)2011-05-202018-10-23Abbott Japan Co. Ltd.Immunoassay methods and reagents for decreasing nonspecific binding
US10119976B2 (en)2013-05-282018-11-06Biogen Ma Inc.Method of assessing risk of PML
US10125373B2 (en)2013-01-222018-11-13Arizona Board Of Regents On Behalf Of Arizona State UniversityGeminiviral vector for expression of rituximab
WO2018207184A2 (en)2017-05-102018-11-15Ariel Scientific Innovations Ltd.Methods of purifying antibodies
WO2018207178A1 (en)2017-05-072018-11-15Yeda Research And Development Co. Ltd.Methods of treating psychiatric stress disorders
EP3404116A1 (en)2013-03-152018-11-21The University of ChicagoMethods and compositions related to t-cell activity
WO2018216006A1 (en)2017-05-212018-11-29The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterCombination of markers for diagnosing cancer
WO2018216011A1 (en)2017-05-232018-11-29Technion Research & Development Foundation LimitedAgents which inhibit gads dimerization and methods of use thereof
WO2018220581A1 (en)2017-05-312018-12-06Tropic Biosciences UK LimitedCompositions and methods for increasing shelf-life of banana
WO2018222689A1 (en)2017-05-312018-12-06Stcube & Co., Inc.Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
WO2018220582A1 (en)2017-05-312018-12-06Tropic Biosciences UK LimitedMethods of selecting cells comprising genome editing events
WO2018222685A1 (en)2017-05-312018-12-06Stcube & Co., Inc.Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
WO2018220579A1 (en)2017-05-312018-12-06Tropic Biosciences UK LimitedCompositions and methods for increasing extractability of solids from coffee beans
WO2018226671A1 (en)2017-06-062018-12-13Stcube & Co., Inc.Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
WO2018229764A1 (en)2017-06-132018-12-20Yeda Research And Development Co. Ltd.Treatment of advanced or progressive multiple sclerosis
EP3418397A1 (en)2012-01-242018-12-26CD Diagnostics, Inc.System for detecting infection in synovial fluid
US10166295B2 (en)2011-06-022019-01-01Opko Biologics Ltd.Pegylated OXM variants
US10172916B2 (en)2013-11-152019-01-08The Board Of Trustees Of The Leland Stanford Junior UniversityMethods of treating heart failure with agonists of hypocretin receptor 2
WO2019012543A1 (en)2017-07-132019-01-17Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Dna targets as tissue-specific methylation markers
WO2019012542A1 (en)2017-07-132019-01-17Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Detecting tissue-specific dna
WO2019012544A1 (en)2017-07-132019-01-17Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Dual-probe digital droplet pcr strategy for specific detection of tissue-specific circulating dna molecules
US10184131B2 (en)2012-02-062019-01-22A.B. Seeds Ltd.Isolated polynucleotides expressing or modulating microRNAs or targets of same, transgenic plants comprising same and uses thereof
WO2019016772A2 (en)2017-07-212019-01-24Novartis AgCompositions and methods to treat cancer
EP3435087A1 (en)2010-07-162019-01-30Bioatla LLCNovel methods of protein evolution
WO2019021284A1 (en)2017-07-242019-01-31Yeda Research And Development Co. Ltd.Combination therapy for the treatment of cancer
WO2019035128A1 (en)2017-08-142019-02-21Yeda Research And Development Co. Ltd.Immunotherapy against transferrin receptor 1 (tfr1)-tropic arenaviruses
WO2019038771A1 (en)2017-08-232019-02-28Technion Research & Development Foundation LimitedCompositions and methods for improving alcohol tolerance in yeast
WO2019038761A1 (en)2017-08-212019-02-28Savicell Diagnostic Ltd.Methods of diagnosing and treating lung cancer
US10221228B2 (en)2006-02-032019-03-05Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
WO2019042153A1 (en)2017-09-012019-03-07四川科伦博泰生物医药股份有限公司 Recombinant bispecific antibody
WO2019050997A1 (en)2017-09-052019-03-14GLAdiator Biosciences, Inc.Delivery of payloads to stem cells
WO2019058376A1 (en)2017-09-192019-03-28The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Genome-edited birds
WO2019067543A1 (en)2017-09-262019-04-04The Regents Of The University Of CaliforniaCompositions and methods for treating cancer
WO2019071054A1 (en)2017-10-042019-04-11The Broad Institute, Inc.Methods and compositions for altering function and structure of chromatin loops and/or domains
EP3472193A1 (en)2016-06-202019-04-24The Board of Trustees of the Leland Stanford Junior UniversityCircular rnas and their use in immunomodulation
WO2019094595A2 (en)2017-11-092019-05-16Pinteon Therapeutics Inc.Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
EP3485910A2 (en)2014-08-222019-05-22Sorrento Therapeutics, Inc.Antigen binding proteins that bind cxcr3
WO2019097514A1 (en)2017-11-142019-05-23Yeda Research And Development Co. Ltd.Hematopoietic stem cells with improved properties
US10308987B2 (en)2005-04-182019-06-04Mdna Life Sciences Inc.3.4 kb mitochondrial DNA deletion for use in the detection of cancer
WO2019106680A1 (en)2017-12-032019-06-06Yeda Research And Development Co. Ltd.Treatment of an ischemic heart disease
WO2019106667A1 (en)2017-11-292019-06-06Weedout Ltd.Compositions, kits and methods for controlling weed of the amaranthus genus
WO2019106671A1 (en)2017-11-292019-06-06Ramot At Tel-Aviv University Ltd.Methods of preventing or treating neurogenic shock
US10316083B2 (en)2013-07-192019-06-11Cedars-Sinai Medical CenterSignature of TL1A (TNFSF15) signaling pathway
EP3494996A1 (en)2012-08-232019-06-12Agensys, Inc.Antibody drug conjugates (adc) that bind to 158p1d7 proteins
WO2019109864A1 (en)2017-12-042019-06-13厦门万泰凯瑞生物技术有限公司Kit and method for quantitative detecting hbsag
US10322151B2 (en)2015-06-152019-06-184D Pharma Research LimitedCompositions comprising bacterial strains
WO2019118721A2 (en)2017-12-152019-06-20Syngenta Participations AgNon-antibody ligands for detecting target proteins
WO2019116376A1 (en)2017-12-172019-06-20Yeda Research And Development Co. Ltd.Cop9 signalosome (csn) complex modulators and uses thereof
US10335783B2 (en)2005-01-312019-07-02Realbio Technologies, Ltd.Multistep reaction lateral flow capillary device
US10334848B2 (en)2014-01-152019-07-02Monsanto Technology LlcMethods and compositions for weed control using EPSPS polynucleotides
US10337050B2 (en)2016-02-112019-07-02Qiagen Sciences, LlcPolyphenolic additives in sequencing by synthesis
EP3503729A1 (en)2016-08-282019-07-03The State of Isreal, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO)Method of controlling fungal infections in plants
WO2019130313A1 (en)2017-12-282019-07-04Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method to reproduce circadian rhythms on a microfluidic chip
US10351615B2 (en)2006-02-032019-07-16Opko Biologics Ltd.Methods of treatment with long-acting growth hormone
WO2019145964A1 (en)2018-01-292019-08-01Yeda Research And Development Co. Ltd.Combination of a mek inhibitor and a cdk4/6 inhibitor for the treatment of sarcoma
WO2019150373A1 (en)2018-01-312019-08-08Yeda Research And Development Co. Ltd.Endoplasmic reticulum targeting signal
US10378012B2 (en)2014-07-292019-08-13Monsanto Technology LlcCompositions and methods for controlling insect pests
WO2019155041A1 (en)2018-02-122019-08-15Vib VzwGβγ COMPLEX ANTIBODIES AND USES THEREOF
WO2019155465A1 (en)2018-02-082019-08-15Yeda Research And Development Co. Ltd.Methods of identifying and using agents for treating diseases associated with intestinal barrier dysfunction
WO2019156758A2 (en)2018-01-052019-08-15Vanderbilt UniversityAntibody-mediated neutralization of chikungunya virus
WO2019155459A1 (en)2018-02-082019-08-15Yeda Research And Development Co. Ltd.Inhibitors of the 20s proteasome
US10391128B2 (en)2015-11-232019-08-274D Pharma Research LimitedCompositions comprising bacterial strains
US10393739B2 (en)2013-10-032019-08-27Oklahoma Medical Research FoundationBiomarkers for systemic lupus erythematosus disease activity, and intensity and flare
US10391130B2 (en)2015-06-152019-08-274D Pharma Research LimitedCompositions comprising bacterial strains
WO2019165217A1 (en)2018-02-222019-08-29The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesCd153 and/or cd30 in infection
WO2019169212A1 (en)2018-03-022019-09-06Five Prime Therapeutics, Inc.B7-h4 antibodies and methods of use thereof
WO2019167047A1 (en)2018-02-282019-09-06The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterMethods of diagnosing and treating bladder cancer
WO2019175869A1 (en)2018-03-122019-09-19Yeda Research And Development Co. LtdTreatment of a heart disease
WO2019182867A1 (en)2018-03-232019-09-26Board Of Regents, The University Of Texas SystemDual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
WO2019182896A1 (en)2018-03-232019-09-26Board Of Regents, The University Of Texas SystemDual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
EP3546474A2 (en)2013-12-182019-10-02President and Fellows of Harvard CollegeCrp capture/detection of gram positive bacteria
WO2019186569A1 (en)2018-03-292019-10-03Yeda Research And Development Co. Ltd.Use of electric field gradients to control gene expression
WO2019186570A1 (en)2018-03-292019-10-03Yeda Research And Development Co. Ltd.Methods of disrupting a biofilm and/or preventing formation of same
US10435701B2 (en)2013-03-142019-10-08Monsanto Technology LlcMethods and compositions for plant pest control
EP3553086A1 (en)2012-05-312019-10-16Sorrento Therapeutics Inc.Antigen binding proteins that bind pd-l1
WO2019199643A1 (en)2018-04-092019-10-17Bio-Techne CorporationMethods to further enhance signal amplification for the in situ detection of nucleic acids
US10456444B2 (en)2014-12-232019-10-294D Pharma Research LimitedPirin polypeptide and immune modulation
US10457934B2 (en)2015-10-192019-10-29Dovetail Genomics, LlcMethods for genome assembly, haplotype phasing, and target independent nucleic acid detection
US10457954B2 (en)2010-08-302019-10-29Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance
WO2019206095A1 (en)2018-04-242019-10-31安源医药科技(上海)有限公司Antibody against tim-3 and application thereof
WO2019213276A1 (en)2018-05-022019-11-07Novartis AgRegulators of human pluripotent stem cells and uses thereof
WO2019211750A1 (en)2018-05-012019-11-07Tropic Biosciences UK LimitedCompositions and methods for reducing caffeine content in coffee beans
US10471108B2 (en)2015-11-202019-11-124D Pharma Research LimitedCompositions comprising bacterial strains
WO2019220441A1 (en)2018-05-152019-11-21Hadasit Medical Research Services And Development Ltd.Compositions and methods for treating cancer resistant to an anti-cancer agent
WO2019220437A1 (en)2018-05-152019-11-21Yeda Research And Development Co. Ltd.Vaccination with cancer neoantigens
WO2019222618A1 (en)2018-05-172019-11-21The Trustees Of Columbia University In The City Of New YorkMethods for treating, preventing and detecting the prognosis of colorectal cancer
US10485830B2 (en)2016-12-122019-11-264D Pharma PlcCompositions comprising bacterial strains
US10493112B2 (en)2015-06-152019-12-034D Pharma Research LimitedCompositions comprising bacterial strains
EP3575311A1 (en)2012-03-202019-12-04Biogen MA Inc.Jcv neutralizing antibodies
EP3575792A1 (en)2011-05-312019-12-04Biogen MA Inc.Method of assessing risk of pml
WO2019229745A1 (en)2018-05-272019-12-05Biolinerx Ltd.Agi-134 combined with a checkpoint inhibitor for the treatment of solid tumors
US10500237B2 (en)2015-06-152019-12-104D Pharma Research LimitedCompositions comprising bacterial strains
WO2019234754A1 (en)2018-06-072019-12-12The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Nucleic acid constructs and methods of using same
WO2019234750A1 (en)2018-06-072019-12-12The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Methods of regenerating and transforming cannabis
WO2019238962A1 (en)2018-06-142019-12-19University College Cork - National University Of Ireland, CorkPeptide for disease treatment
WO2019244107A1 (en)2018-06-212019-12-26Daiichi Sankyo Company, LimitedCompositions including cd3 antigen binding fragments and uses thereof
WO2020003311A1 (en)2018-06-252020-01-02Yeda Research And Development Co. Ltd.Systems and methods for increasing efficiency of genome editing
US10526641B2 (en)2014-08-012020-01-07Dovetail Genomics, LlcTagging nucleic acids for sequence assembly
WO2020008412A1 (en)2018-07-042020-01-09Ukko Inc.Methods of de-epitoping wheat proteins and use of same for the treatment of celiac disease
WO2020012478A2 (en)2018-07-112020-01-16Immunity Pharma Ltd.Peptide compounds and therapeutic uses of same
WO2020012467A2 (en)2018-07-082020-01-16Yeda Research And Development Co. Ltd.Person-specific assessment of probiotics responsiveness
WO2020012486A1 (en)2018-07-112020-01-16Kahr Medical Ltd.SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
US10543171B2 (en)2013-02-222020-01-28The Board Of Trustees Of The University Of IllinoisDermal drug delivery using amphiphilic dendron-coil micelles
US10550196B2 (en)2014-04-272020-02-04Famewave Ltd.Humanized antibodies against CEACAM1
US10550439B2 (en)2014-07-212020-02-04Novellusdx Ltd.Methods for determining drug response of patient specific mutations
WO2020026241A1 (en)2018-07-312020-02-06Collplant Ltd.Tobacco transgenic event and methods for detection and use thereof
US10557138B2 (en)2013-12-102020-02-11Beeologics, Inc.Compositions and methods for virus control in Varroa mite and bees
US10561706B2 (en)2015-12-282020-02-18B. G. Negev Technologies And ApplicationsIsolated polypeptide and compositions comprising same
WO2020035863A1 (en)2018-08-142020-02-20Yeda Research And Development Co. Ltd.Chimeric quiescin sulfhydryl oxidase (qsox1) antibodies and uses of same
US10568328B2 (en)2013-03-152020-02-25Monsanto Technology LlcMethods and compositions for weed control
WO2020039440A1 (en)2018-08-242020-02-27Yeda Research And Development Co. Ltd.Methods of modulating m2 macrophage polarization and use of same in therapy
US10577412B2 (en)2015-04-122020-03-03Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V.Anti-plasmodium parasite antibodies
US10583084B2 (en)2014-06-262020-03-10Ramot At Tel-Aviv University Ltd.Liposomal formulations for delivery of nucleic acids
US10583158B2 (en)2016-03-042020-03-104D Pharma PlcCompositions comprising bacterial strains
WO2020056077A1 (en)2018-09-132020-03-19The Board Of Regents Of The University Of Texas SystemNovel lilrb4 antibodies and uses thereof
WO2020058979A2 (en)2018-09-202020-03-26Yeda Research And Development Co. Ltd.Methods of treating amyotrophic lateral sclerosis
WO2020069424A1 (en)2018-09-282020-04-02Centrillion Technologies, Inc.Disulfide-linked reversible terminators
WO2020065647A1 (en)2018-09-252020-04-02Biolinerx Ltd.Methods of selecting treatment for cxcr4-associated cancer
US10612019B2 (en)2013-03-132020-04-07Monsanto Technology LlcMethods and compositions for weed control
US10610548B2 (en)2016-07-132020-04-074D Pharma PlcCompositions comprising bacterial strains
US10609930B2 (en)2013-03-132020-04-07Monsanto Technology LlcMethods and compositions for weed control
US10610550B2 (en)2015-11-202020-04-074D Pharma Research LimitedCompositions comprising bacterial strains
EP3633025A1 (en)2009-11-122020-04-08Technion Research & Development Foundation Ltd.Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
EP3636664A1 (en)2012-07-272020-04-15The Board of Trustees of the University of IllinoisEngineering t-cell receptors
WO2020081568A1 (en)2018-10-152020-04-23University Of MassachusettsProgrammable dna base editing by nme2cas9-deaminase fusion proteins
WO2020081204A1 (en)2018-10-182020-04-23Oklahoma Medical Research FoundationBiomarkers for a systemic lupus erythematosus (sle) disease activity immune index that characterizes disease activity
US10633442B2 (en)2013-08-212020-04-28Board Of Regents Of The University Of Texas SystemAntibodies to connexin 43 (Cx43) hemichannels and methods of use thereof to inhibit Cx43 hemichannel opening
US10633449B2 (en)2013-03-272020-04-28Cedars-Sinai Medical CenterTreatment and reversal of fibrosis and inflammation by inhibition of the TL1A-DR3 signaling pathway
WO2020082209A1 (en)2018-10-222020-04-30上海吉倍生物技术有限公司Anti-cldn128.2 antibody and uses thereof
WO2020083979A1 (en)2018-10-232020-04-30Glycardial Diagnostics, S.L.Antibodies specific for glycosylated apoj and uses thereof
US10640762B2 (en)2007-07-262020-05-05The Regents Of The University Of CaliforniaMethods for enhancing bacterial cell display of proteins and peptides
WO2020089892A1 (en)2018-10-282020-05-07Yeda Research And Development Co. Ltd.Prevention of age related clonal hematopoiesis and diseases associated therewith
US10655136B2 (en)2015-06-032020-05-19Monsanto Technology LlcMethods and compositions for introducing nucleic acids into plants
WO2020105050A2 (en)2018-11-212020-05-28Yeda Research And Development Co. Ltd.Method of treating cancer and compositions for same
WO2020103691A1 (en)2018-11-202020-05-28厦门万泰凯瑞生物技术有限公司Specific antibody for amh, and uses thereof
US10668094B2 (en)2015-07-192020-06-02Yeda Research And Development Co. Ltd.Selective inhibitors of Alpha2-containing isoforms of Na,K-ATPase and use thereof for reduction of intraocular pressure
WO2020113084A1 (en)2018-11-282020-06-04Oregon Health & Science UniversityTherapeutic factor xii antibody
WO2020113237A1 (en)2018-11-302020-06-04Caris Mpi, Inc.Next-generation molecular profiling
US10683505B2 (en)2013-01-012020-06-16Monsanto Technology LlcMethods of introducing dsRNA to plant seeds for modulating gene expression
WO2020135201A1 (en)2018-12-282020-07-02四川科伦博泰生物医药股份有限公司Antibody and use thereof
DE112018005145T5 (en)2017-09-152020-07-23The Regents Of The University Of California INHIBITION OF AMINOACYLASE 3 (AA3) IN TREATMENT OF CANCER
WO2020152686A1 (en)2019-01-232020-07-30Yeda Research And Development Co. Ltd.Culture media for pluripotent stem cells
US10736926B2 (en)2015-06-152020-08-114D Pharma Research LimitedCompositions comprising bacterial strains
WO2020161724A1 (en)2019-02-102020-08-13Yeda Research And Development Co. Ltd.Anti-matrix metalloproteinase 7 (mmp-7) inhibitory antibody and uses thereof
US10744166B2 (en)2015-11-232020-08-184D Pharma Research LimitedCompositions comprising bacterial strains
EP3694872A1 (en)2017-10-122020-08-19Board Of Regents, The University Of Texas SystemT cell receptors for immunotherapy
WO2020165907A1 (en)2019-02-142020-08-20Yeda Research And Development Co. Ltd.Spt5 inhibitors and uses thereof
WO2020168162A1 (en)2019-02-152020-08-20Bio-Techne CorporationMethods for multiplex detection of nucleic acids by in situ hybridization
WO2020170240A1 (en)2019-02-212020-08-27Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method for reduction drug-induced nephrotoxicity
WO2020170239A1 (en)2019-02-212020-08-27Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of generating organoids for high throughput screening of drugs
US10758540B2 (en)2017-10-112020-09-01Chemocentryx, Inc.Treatment of focal segmental glomerulosclerosis with CCR2 antagonists
US10760088B2 (en)2011-05-032020-09-01Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
US10760086B2 (en)2011-09-132020-09-01Monsanto Technology LlcMethods and compositions for weed control
US10765706B2 (en)2015-09-032020-09-08University Of South FloridaMethod of stem cell delivery into the brain during chronic disease using blood brain barrier permeabilizers
US10768185B2 (en)2017-07-202020-09-08Trustees Of Boston UniversityTenofovir detection assay
WO2020178822A1 (en)2019-03-052020-09-10The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Genome-edited birds
WO2020183416A1 (en)2019-03-142020-09-17Tropic Biosciences UK LimitedPRODUCTION OF dsRNA IN PLANT CELLS FOR PEST PROTECTION VIA GENE SILENCING
WO2020183419A1 (en)2019-03-142020-09-17Tropic Biosciences UK LimitedIntroducing silencing activity to dysfunctional rna molecules and modifying their specificity against a gene of interest
WO2020185312A2 (en)2019-01-252020-09-17President And Fellows Of Harvard CollegeCompositions and method for synthesizing nucleic acids
WO2020183414A2 (en)2019-03-142020-09-17Tropic Biosciences UK LimitedModifying the specificity of non-coding rna molecules for silencing genes in eukaryotic cells
WO2020185763A1 (en)2019-03-112020-09-17Memorial Sloan Kettering Cancer CenterCd22 antibodies and methods of using the same
WO2020188572A1 (en)2019-03-192020-09-24Yeda Research And Development Co. Ltd.Bistable type ii opsins and uses thereof
WO2020194317A1 (en)2019-03-282020-10-01Yeda Research And Development Co. Ltd.Method of treating lipid-related disorders
US10792360B1 (en)2019-11-212020-10-06Chemocentryx, Inc.Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
WO2020202142A2 (en)2019-03-312020-10-08Yeda Research And Development Co. Ltd.Anti-viral and anti-tumoral compounds
US10806146B2 (en)2011-09-132020-10-20Monsanto Technology LlcMethods and compositions for weed control
US10808249B2 (en)2011-09-132020-10-20Monsanto Technology LlcMethods and compositions for weed control
WO2020211674A1 (en)2019-04-162020-10-22四川科伦博泰生物医药股份有限公司Anti-fxi/fxia antibody and use thereof
WO2020222241A1 (en)2019-05-022020-11-05Yeda Research And Development Co. Ltd.Compositions comprising the propeptide of lysyl oxidase and uses thereof
WO2020223576A1 (en)2019-04-302020-11-05Chondrial Therapeutics, Inc.Frataxin-sensitive markers for determining effectiveness of frataxin replacement therapy
US10829828B2 (en)2011-09-132020-11-10Monsanto Technology LlcMethods and compositions for weed control
WO2020230133A1 (en)2019-05-132020-11-19Yeda Research And Development Co. Ltd.Cell-free mirna biomarkers for prognosis and diagnosis of neurodegenerative diseases
IT201900007222A1 (en)2019-05-242020-11-24Univ Degli Studi Di Torino COMPOSITION OF LIPOSOMES AND METHOD OF DOSAGE BASED ON THE USE OF THE SAME
WO2020234888A1 (en)2019-05-222020-11-26Hadasit Medical Research Services And Development Ltd.Methods of culturing human pluripotent cells
WO2020234875A2 (en)2019-05-192020-11-26Yeda Research And Development Co. Ltd.Identification of recurrent mutated neopeptides
WO2020237491A1 (en)2019-05-282020-12-03Shanghaitech UniversityComposition and methods to treat ectodermal dysplasia 2, clouston type
WO2020250232A1 (en)2019-06-122020-12-17Hadasit Medical Research Services And Development Ltd.Methods of generating oligodendrocytes
EP3754027A1 (en)2014-12-012020-12-23The Broad Institute, Inc.Methods for altering or modulating spatial proximity between nucleic acids inside of a cell
WO2020255124A1 (en)2019-06-162020-12-24Yeda Research And Development Co. Ltd.Method for stabilizing intracellular rna
US10877045B2 (en)2015-07-212020-12-29Saint Louis UniversityCompositions and methods for diagnosing and treating endometriosis-related infertility
WO2020264185A1 (en)2019-06-272020-12-30Dovetail Genomics, LlcMethods and compositions for proximity ligation
WO2020261281A1 (en)2019-06-272020-12-30Ramot At Tel-Aviv University Ltd.Semaphorin 3a antibodies and uses thereof
US10883103B2 (en)2015-06-022021-01-05Monsanto Technology LlcCompositions and methods for delivery of a polynucleotide into a plant
WO2021001784A1 (en)2019-07-042021-01-07Ukko Inc.De-epitoped alpha gliadin and use of same for the management of celiac disease and gluten sensitivity
US10889637B2 (en)2016-02-262021-01-12The Board Of Regents Of The University Of Texas SystemMethods of treating an osteolytic tumor and spinal cord injury by administering connexin (Cx) 43 hemichannel-binding antibodies
WO2021005599A1 (en)2019-07-112021-01-14Kahr Medical Ltd.Heterodimers and methods of use thereof
WO2021009740A1 (en)2019-07-162021-01-21Ramot At Tel-Aviv University Ltd.Compositions and methods for the treatment of tuberculosis
WO2021009763A1 (en)2019-07-162021-01-21Yeda Research And Development Co. Ltd.Methods of treating pain
WO2021016062A1 (en)2019-07-192021-01-28The Children's Hospital Of PhiladelphiaChimeric antigen receptors containing glypican 2 binding domains
US10906987B2 (en)2016-03-012021-02-02Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Antibodies specific to human poliovirus receptor (PVR)
WO2021019536A1 (en)2019-07-302021-02-04The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Methods of controlling cannabinoid synthesis in plants or cells and plants and cells produced thereby
WO2021019526A1 (en)2019-07-292021-02-04Yeda Research And Development Co. Ltd.Methods of treating and diagnosing lung cancer
WO2021021605A1 (en)2019-07-262021-02-04Vanderbilt UniversityHuman monoclonal antibodies to enterovirus d68
WO2021028909A1 (en)2019-08-122021-02-18Yeda Research And Development Co. Ltd.Dna repair blood test for predicting response of lung cancer patients to immunotherapy
EP3783012A1 (en)2019-08-202021-02-24Nuritas LimitedAn antimicrobial peptide
WO2021032650A1 (en)2019-08-202021-02-25Nuritas LimitedPeptides for treating muscle atrophy
WO2021033176A1 (en)2019-08-222021-02-25Ariel Scientific Innovations Ltd.Scaled-up methods for purifying antibodies
WO2021038569A1 (en)2019-08-272021-03-04Yeda Research And Development Co. Ltd.Treatment of bacterial vaginosis
US10947579B2 (en)2016-05-132021-03-16Dovetail Genomics, LlcRecovering long-range linkage information from preserved samples
WO2021048852A1 (en)2019-09-112021-03-18Yeda Research And Development Co. Ltd.Methods of treating breast cancer
US10954313B2 (en)2016-01-282021-03-23Sp Nano Ltd.Composition comprising SP1 and carbon based nanoparticles and uses thereof
WO2021055489A1 (en)2019-09-162021-03-25Grohar Patrick JCompositions and methods for the treatment of swi-snf mutant tumors
WO2021051390A1 (en)2019-09-202021-03-25上海吉倍生物技术有限公司Bcma-targeted antibody and chimeric antigen receptor
US10964443B2 (en)2016-01-282021-03-30Sp Nano Ltd.Conductive yarn
WO2021062323A1 (en)2019-09-262021-04-01Stcube & Co.Antibodies specific to glycosylated ctla-4 and methods of use thereof
WO2021059269A1 (en)2019-09-252021-04-01Yeda Research And Development Co. Ltd.Assembly of protein complexes on a chip
US10968449B2 (en)2015-01-222021-04-06Monsanto Technology LlcCompositions and methods for controlling Leptinotarsa
WO2021063201A1 (en)2019-09-302021-04-08四川科伦博泰生物医药股份有限公司Anti-pd-1 antibody and use thereof
US10973809B2 (en)2016-11-232021-04-13Chemocentryx, Inc.Method of treating focal segmental glomerulosclerosis
US10975417B2 (en)2016-02-232021-04-13Dovetail Genomics, LlcGeneration of phased read-sets for genome assembly and haplotype phasing
WO2021072277A1 (en)2019-10-092021-04-15Stcube & Co.Antibodies specific to glycosylated lag3 and methods of use thereof
US10988764B2 (en)2014-06-232021-04-27Monsanto Technology LlcCompositions and methods for regulating gene expression via RNA interference
US10987387B2 (en)2017-05-242021-04-274D Pharma Research LimitedCompositions comprising bacterial strain
WO2021078912A1 (en)2019-10-222021-04-29Nuritas LimitedTreatment of non-alcoholic fatty liver disease
WO2021084540A1 (en)2019-10-302021-05-06Yeda Research And Development Co. Ltd.Inhibitors of mmej pathway for prevention and treatment of pre-myeloid and myeloid malignancies
WO2021084526A1 (en)2019-10-312021-05-06Yeda Research And Development Co. Ltd.Engineered autotrophic bacteria for co2 conversion to organic materials
US11001872B2 (en)2015-09-222021-05-11Shawn ClarkDesigning customized protein-specific buffer system
US11007233B2 (en)2017-06-142021-05-184D Pharma Research LimitedCompositions comprising a bacterial strain of the genus Megasphera and uses thereof
WO2021095031A2 (en)2019-11-112021-05-20Ibi-Ag Innovative Bio Insecticides Ltd.Insect control nanobodies and uses thereof
US11013773B2 (en)2011-07-142021-05-254D Pharma Research LimitedLactic acid bacterial strains
US11015229B2 (en)2014-07-212021-05-25Novellusdx Ltd.Methods and systems for determining oncogenic index of patient specific mutations
WO2021100034A1 (en)2019-11-192021-05-27Protalix Ltd.Removal of constructs from transformed cells
WO2021100041A1 (en)2019-11-202021-05-27Yeda Research And Development Co. Ltd.Treating alzheimer's disease
WO2021119402A1 (en)2019-12-122021-06-17President And Fellows Of Harvard CollegeCompositions and methods for light-directed biomolecular barcoding
WO2021115240A1 (en)2019-12-132021-06-17四川科伦博泰生物医药股份有限公司Anti-tslp antibody and uses thereof
WO2021126435A1 (en)2019-12-202021-06-24Novarock Biotherapeutics, Ltd.Anti-interleukin-23 p19 antibodies and methods of use thereof
EP3842452A1 (en)2019-12-262021-06-30Universitat Autònoma de BarcelonaScaffold proteins and therapeutic nanoconjugates based on nidogen
WO2021130753A1 (en)2019-12-222021-07-01Yeda Research And Development Co. Ltd.Diagnosis of frontotemporal dementia
WO2021130752A1 (en)2019-12-222021-07-01Yeda Research And Development Co. Ltd.Systems and methods for identifying cells that have undergone genome editing
WO2021136082A1 (en)2020-01-022021-07-08厦门大学Polypeptide encoded by bnlf2b gene in eb virus and detection use thereof
WO2021137222A1 (en)2019-12-312021-07-08Ichilov Tech Ltd.Methods of treating atopic dermatitis
WO2021137231A1 (en)2019-12-312021-07-08Kahr Medical Ltd.Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same
WO2021137230A1 (en)2019-12-312021-07-08Kahr Medical Ltd.Methods of culturing t cells and uses of same
WO2021144798A1 (en)2020-01-152021-07-22Immunity Pharma Ltd.Peptide compounds and methods of treating diseases using same
WO2021149053A1 (en)2020-01-222021-07-29Yeda Research And Development Co. Ltd.Multispecific antibodies for use in treating diseases
US11078528B2 (en)2015-10-122021-08-03Advanced Cell Diagnostics, Inc.In situ detection of nucleotide variants in high noise samples, and compositions and methods related thereto
WO2021152584A1 (en)2020-01-282021-08-05Ariel Scientific Innovations Ltd.Methods of analyzing cell membranes
WO2021152590A1 (en)2020-01-302021-08-05Yeda Research And Development Co. Ltd.Articles of manufacture comprising anti pd-l1 antibodies and their use in therapy
WO2021151180A2 (en)2020-01-312021-08-05Fundação Oswaldo CruzAntibody, related use, pharmaceutical composition including method for diagnosing fungal infections, fungal infection diagnosis kit and method for treating fungal infections
WO2021152586A1 (en)2020-01-302021-08-05Yeda Research And Development Co. Ltd.Methods of analyzing microbiome, immunoglobulin profile and physiological state
WO2021152592A1 (en)2020-01-302021-08-05Yeda Research And Development Co. Ltd.Methods of treating cancer
WO2021152587A1 (en)2020-01-302021-08-05Yeda Research And Development Co. Ltd.Treating acute liver disease with tlr-mik inhibitors
EP3862014A1 (en)2020-02-072021-08-11Nuritas LimitedTreatment of panx1 associated diseases
WO2021156490A2 (en)2020-02-062021-08-12Vib VzwCorona virus binders
WO2021156878A2 (en)2020-02-092021-08-12Nlc Pharma LtdRapid detection test for sars-cov-2
US11091770B2 (en)2014-04-012021-08-17Monsanto Technology LlcCompositions and methods for controlling insect pests
WO2021161310A1 (en)2020-02-102021-08-19Yeda Research And Development Co. Ltd.Method for analyzing cell clusters
WO2021163265A1 (en)2020-02-112021-08-19Vanderbilt UniversityHuman monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov- 2)
WO2021167908A1 (en)2020-02-172021-08-26Board Of Regents, The University Of Texas SystemMethods for expansion of tumor infiltrating lymphocytes and use thereof
WO2021170540A1 (en)2020-02-252021-09-02Vib VzwLeucine-rich repeat kinase 2 allosteric modulators
WO2021173674A1 (en)2020-02-262021-09-02A2 Biotherapeutics, Inc.Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
US11123378B2 (en)2017-05-222021-09-214D Pharma Research LimitedCompositions comprising bacterial strains
US11123379B2 (en)2017-06-142021-09-214D Pharma Research LimitedCompositions comprising bacterial strains
WO2021186431A1 (en)2020-03-162021-09-23Yeda Research And Development Co. Ltd.Peptide analogs and use of same in treating diseases, disorders or conditions associated with a mutant p53 protein
WO2021188389A2 (en)2020-03-172021-09-23Genevant Sciences GmbhCationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
WO2021195418A1 (en)2020-03-262021-09-30Vanderbilt UniversityHuman monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
WO2021195385A1 (en)2020-03-262021-09-30Vanderbilt UniversityHUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
WO2021199047A1 (en)2020-03-312021-10-07Biomuse Ltd.Bacteria for the prevention and treatment of smoke-induced lung damage
WO2021199039A1 (en)2020-03-292021-10-07Yeda Research And Development Co. Ltd.Variants of beta-glucocerebrosidase for use in treating gaucher disease
WO2021205444A1 (en)2020-04-062021-10-14Yeda Research And Development Co. Ltd.Methods of diagnosing cancer and predicting responsiveness to therapy
WO2021205459A1 (en)2020-04-072021-10-14Ramot At Tel-Aviv University Ltd.Cannabidiol-containing compositions and uses thereof
EP3895697A1 (en)2020-04-162021-10-20Ichilov Tech Ltd.Cell-derived particles presenting heterologous cd24 and use thereof in therapy
WO2021209995A1 (en)2020-04-132021-10-21Exoprother Medical Ltd.Cell-derived vesicles comprising wild-type p53 protein for antiviral therapy
US11156613B2 (en)2006-02-092021-10-26University Of South FloridaDetection of cancer by elevated levels of bcl-2
GB202112866D0 (en)2021-09-092021-10-27Tropic Biosciences Uk LtdResistance to fusarium wilt in a banana
GB202112865D0 (en)2021-09-092021-10-27Tropic Biosciences Uk LtdResistance to black sigatoka disease in banana
WO2021216728A1 (en)2020-04-222021-10-28President And Fellows Of Harvard CollegeIsothermal methods, compositions, kits, and systems for detecting nucleic acids
US11175584B2 (en)2015-03-312021-11-16Arizona Board Of Regents On Behalf Of Arizona State UniversityMethods for detecting traumatic brain injury
EP3909983A1 (en)2015-12-022021-11-17STCube & Co. Inc.Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
WO2021228141A1 (en)2020-05-152021-11-18四川科伦博泰生物医药股份有限公司Antibody drug conjugate, preparation method therefor and use thereof
WO2021229577A1 (en)2020-05-122021-11-18Collplant Ltd.Collagen as a delivery tool for metal-based anti-viral agents
WO2021234698A1 (en)2020-05-202021-11-25Yeda Research And Development Co. Ltd.Indexing spatial information for a single-cell downstream applications
US11186872B2 (en)2016-03-172021-11-30Cedars-Sinai Medical CenterMethods of diagnosing inflammatory bowel disease through RNASET2
WO2021247908A1 (en)2020-06-032021-12-09Bionecure Therapeutics, Inc.Trophoblast cell-surface antigen-2 (trop-2) antibodies
US11197915B2 (en)2013-10-212021-12-14Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
EP3925980A1 (en)2013-08-302021-12-22ImmunoGen, Inc.Antibodies and assays for detection of folate receptor 1
WO2021260675A1 (en)2020-06-242021-12-30Yeda Research And Development Co. Ltd.Agents for sensitizing solid tumors to treatment
US11214800B2 (en)2015-08-182022-01-04The Broad Institute, Inc.Methods and compositions for altering function and structure of chromatin loops and/or domains
US11224620B2 (en)2016-07-132022-01-184D Pharma PlcCompositions comprising bacterial strains
EP3939999A1 (en)2020-07-142022-01-19Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO)Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof
US11236393B2 (en)2008-11-262022-02-01Cedars-Sinai Medical CenterMethods of determining responsiveness to anti-TNFα therapy in inflammatory bowel disease
WO2022034588A1 (en)2020-08-102022-02-17Yeda Research And Development Co. Ltd.Compositions for diagnosis and treatment of coronavirus infections
WO2022034575A1 (en)2020-08-092022-02-17Yeda Research And Development Co. Ltd.Mage-a1 specific t cell receptor and uses thereof
US11253590B2 (en)2015-12-022022-02-22Stsciences, Inc.Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
WO2022040455A1 (en)2020-08-212022-02-24Advanced Cell Diagnostics, Inc.Compositions and methods for determining t cell clonality
WO2022038536A1 (en)2020-08-182022-02-24International Rice Research InstituteMethods of increasing outcrossing rates in gramineae
EP3961214A1 (en)2010-12-312022-03-02BioAtla, Inc.Comprehensive monoclonal antibody generation
WO2022047359A1 (en)2020-08-312022-03-03Berg LlcProtein biomarkers for pancreatic cancer
US11270782B2 (en)2014-11-192022-03-08Koninklijke Philips N.V.Diagnostic method employing HNL
US11267885B2 (en)2017-01-262022-03-08Zlip Holding LimitedCD47 antigen binding unit and uses thereof
WO2022051591A2 (en)2020-09-042022-03-10Novarock Biotherapeutics, Ltd.Nectin-4 antibodies and uses thereof
WO2022059015A1 (en)2020-09-212022-03-24Yeda Research And Development Co. Ltd.Method for modulating weight
US11287423B2 (en)2010-01-112022-03-29Biogen Ma Inc.Assay for JC virus antibodies
WO2022064494A2 (en)2020-09-232022-03-31Yeda Research And Development Co. Ltd.Methods and compositions for treating coronaviral infections
US11292845B2 (en)2006-02-282022-04-05Biogen Ma Inc.Methods of treating inflammatory and autoimmune diseases with natalizumab
WO2022070194A1 (en)2020-10-012022-04-07Yeda Research And Development Co. Ltd.Method of diagnosing breast cancer
WO2022074656A1 (en)2020-10-072022-04-14Protalix Ltd.Long-acting dnase
WO2022074646A1 (en)2020-10-052022-04-14Protalix Ltd.Dicer-like knock-out plant cells
US11306144B2 (en)2017-08-252022-04-19Five Prime Therapeutics, Inc.B7-H4 antibodies and methods of use thereof
WO2022079719A1 (en)2020-10-152022-04-21Yeda Research And Development Co. Ltd.Method of treating myeloid malignancies
EP3992210A1 (en)2014-01-132022-05-04Baylor Research InstituteNovel vaccines against hpv and hpv-related diseases
WO2022091100A1 (en)2020-10-292022-05-05Yeda Research And Development Co. Ltd.Polynucleotides for rna editing and methods of using same
WO2022097157A2 (en)2020-11-092022-05-121E Therapeutics, Ltd.Catalytic sequence based methods of treating or preventing bacterial infections
US11333670B2 (en)2006-03-032022-05-17Biogen Ma Inc.Methods of treating inflammatory and autoimmune diseases with natalizumab
WO2022108897A1 (en)2020-11-202022-05-27Vanderbilt UniversityUse of microvirin in the identification of mycobacterium tuberculosis mannose-capped lipoarabinomannan
WO2022115498A1 (en)2020-11-262022-06-02Ukko Inc.Modified high molecular weight glutenin subunit and uses thereof
WO2022120378A1 (en)2020-12-042022-06-09University Of Tennessee Research FoundationMethod for diagnosing amyloid diseases
WO2022130384A1 (en)2020-12-172022-06-23Yeda Research And Development Co. Ltd.Controlling ubiquitination of mlkl for treatment of disease
WO2022133344A1 (en)2020-12-182022-06-23Genevant Sciences GmbhPeg lipids and lipid nanoparticles
WO2022144883A2 (en)2020-12-282022-07-071E Therapeutics, Ltd.P21 mrna targeting dnazymes
WO2022143743A1 (en)2020-12-312022-07-07和铂医药(苏州)有限公司Human lifr antigen binding protein, preparation method therefor, and application thereof
WO2022144882A2 (en)2020-12-282022-07-071E Therapeutics, Ltd.P21 mrna target areas for silencing
WO2022149142A2 (en)2021-01-102022-07-14Supermeat The Essence Of Meat Ltd.Pluripotent stem cell aggregates and microtissues obtained therefrom for the cultured meat industry
WO2022153286A1 (en)2021-01-142022-07-21Yeda Research And Development Co. Ltd.Methods of producing vitamin d
WO2022157774A1 (en)2021-01-212022-07-28Yeda Research And Development Co. Ltd.Antibodies, peptides and combinations of same for the treatment or prevention of coronavirus infection
WO2022159984A1 (en)2021-01-222022-07-28Bionecure Therapeutics, Inc.Anti-her-2/trop-2 constructs and uses thereof
WO2022162192A2 (en)2021-01-292022-08-04Thelper AsTherapeutic and diagnostic agents and uses thereof
WO2022170971A1 (en)2021-02-092022-08-18苏州宜联生物医药有限公司Bioactive substance conjugate, preparation method therefor and use thereof
WO2022175532A1 (en)2021-02-192022-08-25Vib VzwCation-independent mannose-6-phosphate receptor binders
WO2022175952A1 (en)2021-02-182022-08-25Yeda Research And Development Co. Ltd.Method of generating vaccines
WO2022175951A1 (en)2021-02-182022-08-25Yeda Research And Development Co. Ltd.Genetically modified bacteria for generating vaccines
US11427647B2 (en)2014-04-272022-08-30Famewave Ltd.Polynucleotides encoding humanized antibodies against CEACAM1
US11433163B2 (en)2014-04-102022-09-06Bonus Therapeutics Ltd.Bone repair compositions
WO2022183502A1 (en)2021-03-052022-09-09上海吉倍生物技术有限公司Anti-cldn6 antibody and use thereof
WO2022188652A1 (en)2021-03-092022-09-15四川科伦博泰生物医药股份有限公司Ror1 binding protein and use thereof
WO2022192134A1 (en)2021-03-082022-09-15Immunogen, Inc.Methods for increasing efficacy of immunoconjugates targeting adam9 for the treatment of cancer
EP4059507A1 (en)2015-12-162022-09-21Ramot at Tel-Aviv University Ltd.Particles comprising decellularized omentum
WO2022195589A2 (en)2021-03-162022-09-22Yeda Research And Development Co. Ltd.Methods and devices for ex-utero mouse embryonic development
WO2022208369A1 (en)2021-03-302022-10-06Biomx Ltd.Pseudomonas bacteriophage and uses thereof
WO2022216846A1 (en)2021-04-062022-10-13Berg LlcProtein markers for estrogen receptor (er)-positive-like and estrogen receptor (er)-negative-like breast cancer
WO2022216798A1 (en)2021-04-062022-10-13Berg LlcProtein markers for the prognosis of breast cancer progression
WO2022215080A1 (en)2021-04-082022-10-13Yeda Research And Development Co. Ltd.A combined use of ketamine and retigabine (ezogabine) for the treatment of psychiatric disorders
WO2022216841A1 (en)2021-04-062022-10-13Berg LlcProtein markers for estrogen receptor (er)-positive luminal a(la)-like and luminal b1 (lb1)-like breast cancer
WO2022219168A1 (en)2021-04-142022-10-20University College Cork - National University Of Ireland, CorkPsg1 for use in the treatment of osteoarthritis
WO2022219008A1 (en)2021-04-142022-10-20University College Cork - National University Of Ireland, CorkTreatment of cerebrovascular events and neurological disorders
WO2022224137A1 (en)2021-04-192022-10-27Temple Therapeutics BVMethods for detecting or treating endometrial and ovarian hyperproliferative disorders
WO2022238947A1 (en)2021-05-122022-11-17Biomx Ltd.Staphylococcus bacteriophage and uses thereof
WO2022254430A1 (en)2021-05-302022-12-08Yeda Research And Development Co. Ltd.Anti-microbial peptide (amp) signatures for diagnostics, stratification, and treatment of microbiome-associated disease
WO2022259242A1 (en)2021-06-062022-12-15Yeda Research And Development Co. Ltd.Combined treatment for cancer
NL2028466B1 (en)2021-06-162022-12-21Sakata Holland B VMethods of sorting matthiola seeds
WO2022264132A1 (en)2021-06-132022-12-22Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method for reprogramming human cells
WO2022264076A1 (en)2021-06-162022-12-22Seedx Technologies Inc.Methods of sorting matthiola seeds
WO2023275255A1 (en)2021-07-022023-01-05Tropic Biosciences UK LimitedDelay or prevention of browning in banana fruit
EP4116327A1 (en)2017-10-112023-01-11Board Of Regents, The University Of Texas SystemHuman pd-l1 antibodies and methods of use therefor
US11555199B2 (en)2017-09-192023-01-17Tropic Biosciences UK LimitedModifying the specificity of plant non-coding RNA molecules for silencing gene expression
WO2023288046A1 (en)2021-07-152023-01-19President And Fellows Of Harvard CollegeCompositions and methods relating to cells with adhered particles
WO2023002492A1 (en)2021-07-222023-01-26Yeda Research And Development Co. Ltd.Codon optimization of nucleic acids
WO2023003809A1 (en)2021-07-182023-01-26Gamida-Cell Ltd.Therapeutic nk cell populations
US11571433B2 (en)2018-02-232023-02-07Carmel Haifa University Economic Corporation Ltd.Methods for treating memory impairment and cognitive dysfunction
EP4130028A1 (en)2021-08-032023-02-08Rhazes Therapeutics LtdEngineered tcr complex and methods of using same
WO2023012798A2 (en)2021-08-022023-02-09Yeda Research And Development Co. Ltd.Antibodies for the treatment of cancer
WO2023012584A2 (en)2021-08-032023-02-09Genicity LimitedEngineered tcr complex and methods of using same
WO2023018621A1 (en)2021-08-102023-02-16Gamida-Cell Ltd.Engineered nk cells, methods of their production and uses thereof
WO2023016828A2 (en)2021-07-302023-02-16Vib VzwCation-independent mannose-6-phosphate receptor binders for targeted protein degradation
WO2023042202A1 (en)2021-09-142023-03-23Yeda Research And Development Co. Ltd.Multispecific antibodies for use in treating diseases
WO2023081070A1 (en)2021-11-022023-05-11University Of MassachusettsNme2Cas9 INLAID DOMAIN FUSION PROTEINS
US11648260B2 (en)2018-03-292023-05-16Technion Research And Development Foundation LimittedVesicles comprising a PTEN inhibitor and uses of same
EP4180058A1 (en)2015-04-082023-05-17Sorrento Therapeutics, Inc.Antibody therapeutics that bind cd38
WO2023089377A2 (en)2021-11-192023-05-25Mirobio LimitedEngineered pd-1 antibodies and uses thereof
WO2023105526A1 (en)2021-12-082023-06-15Yeda Research And Development Co. Ltd.Multipotent lung progenitor cells for lung regeneration
EP4218771A1 (en)2015-03-272023-08-02Yeda Research and Development Co. LtdMethods of treating motor neuron diseases
WO2023144392A1 (en)2022-01-282023-08-03Thelper AsTherapeutic and diagnostic agents and uses thereof
WO2023143263A1 (en)2022-01-252023-08-03苏州宜联生物医药有限公司Antibody against her3, conjugate and use thereof
WO2023144798A1 (en)2022-01-312023-08-03Genevant Sciences GmbhIonizable cationic lipids for lipid nanoparticles
US11723933B2 (en)2014-12-232023-08-15Cj Bioscience, Inc.Composition of bacteroides thetaiotaomicron for immune modulation
EP4225364A1 (en)2020-10-092023-08-16Board of Regents, The University of Texas SystemPrefusion-stabilized hmpv f proteins
EP4238988A1 (en)2022-03-012023-09-06Consejo Superior De Investigaciones CientíficasAntibodies against sars-cov-2 and uses thereof
EP4242329A2 (en)2014-12-082023-09-13Berg LLCUse of markers including filamin a in the diagnosis and treatment of prostate cancer
WO2023174029A1 (en)2022-03-162023-09-21沈阳三生制药有限责任公司Prlr antigen-binding protein, preparation method therefor and use thereof
WO2023187407A1 (en)2022-04-012023-10-05Bradcode LimitedHuman monoclonal antibodies binding to sars-cov-2 and methods of use thereof
WO2023192976A1 (en)2022-04-012023-10-05Board Of Regents, The University Of Texas SystemDual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
WO2023196937A1 (en)2022-04-062023-10-12Larimar Therapeutics, Inc.Frataxin-sensitive markers for monitoring frataxin replacement therapy
WO2023196866A1 (en)2022-04-062023-10-12Mirobio LimitedEngineered cd200r antibodies and uses thereof
WO2023209708A1 (en)2022-04-252023-11-02Yeda Research And Development Co. Ltd.Compositions for altering cyclic adp-ribose secondary messenger signalling
US11807857B2 (en)2014-06-252023-11-07Monsanto Technology LlcMethods and compositions for delivering nucleic acids to plant cells and regulating gene expression
US11807896B2 (en)2015-03-262023-11-07Dovetail Genomics, LlcPhysical linkage preservation in DNA storage
US11842805B2 (en)2019-12-022023-12-12Caris Mpi, Inc.Pan-cancer platinum response predictor
WO2023240201A1 (en)2022-06-082023-12-14Larimar Therapeutics, Inc.Frataxin-sensitive markers for monitoring progression and treatment of leigh syndrome
WO2023239710A1 (en)2022-06-082023-12-14Onkure, Inc.Benzopyrimidin-4(3h)-ones as pi3k inhibitors
WO2023239940A1 (en)2022-06-102023-12-14Research Development FoundationEngineered fcriib selective igg1 fc variants and uses thereof
WO2023246701A1 (en)2022-06-202023-12-28四川汇宇制药股份有限公司Antibody and use thereof
WO2024012523A1 (en)2022-07-142024-01-18苏州宜联生物医药有限公司Antibody-drug conjugate, and preparation method therefor and use thereof
US11883391B2 (en)2020-03-312024-01-30Chemocentryx, Inc.Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-IL-23 blocking antibodies
WO2024028794A1 (en)2022-08-022024-02-08Temple Therapeutics BVMethods for treating endometrial and ovarian hyperproliferative disorders
EP4322837A1 (en)2021-04-162024-02-21Advanced Cell Diagnostics, Inc.Materials and methods related to image processing
WO2024038160A1 (en)2022-08-182024-02-22Vib VzwMeans and methods to modulate neuron excitability
WO2024040020A1 (en)2022-08-152024-02-22Absci CorporationQuantitative affinity activity specific cell enrichment
WO2024054469A1 (en)2022-09-082024-03-14Onkure, Inc.Isoquinolones as pi3k inhibitors
WO2024064002A1 (en)2022-09-202024-03-28Onkure, Inc.Hdac inhibitor oki-179 for the treatment of cancers resulting from a mapk pathway mutation
WO2024064024A1 (en)2022-09-192024-03-28Onkure, Inc.((4-oxo-3,4-dihydroquinazolin-8-yl)methyl)amine derivatives as p13k inhibitors for the treatment of cancer
WO2024068744A1 (en)2022-09-272024-04-04Vib VzwAntivirals against human parainfluenza virus
WO2024081345A1 (en)2022-10-142024-04-18Onkure, Inc.Benzopyrimidin-4(3h)-ones as pi3k inhibitors
WO2024078729A1 (en)2022-10-142024-04-18University College Cork - National University Of Ireland, CorkPlacenta expressed proteins for use in the treatment of tendon injury
WO2024102466A2 (en)2022-11-112024-05-16Igan BiosciencesIga protease polypeptide agents
WO2024124041A1 (en)2022-12-072024-06-13Advanced Cell Diagnostics, Inc.Multiplexed detection of nucleic acid targets
US12048720B2 (en)2017-06-142024-07-30Cj Bioscience, Inc.Compositions comprising bacterial strains
WO2024178172A1 (en)2023-02-232024-08-29University Of RochesterAgents and methods for making closed-end dna thread molecules
US12077569B2 (en)2020-06-222024-09-03Ramot At Tel-Aviv University Ltd.Multi subunit protein modules, cells expressing same and uses thereof
US12098381B2 (en)2013-12-172024-09-24University Of MassachusettsCompositions and methods for differential Cas9 gene labeling and/or editing
WO2024213640A1 (en)2023-04-112024-10-17Sterling Ip Pte. Ltd.Inhibition of: stroma/cancer cell cross-talk &/or stroma generated resistance to treatment
US12140592B2 (en)2017-06-162024-11-12Oklahoma Medical Research FoundationBiomarkers for assessing risk of transitioning to systemic lupus erythematosus classification and disease pathogenesis
EP4461356A2 (en)2017-10-242024-11-13Elani, DaliaMethods of treating an ischemic disease
WO2024258743A1 (en)2023-06-132024-12-19Adcentrx Therapeutics, Inc.Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
US12174187B2 (en)2017-05-102024-12-24Rowan UniversityMethods for detecting multiple sclerosis (MS) diagnostic autoantibodies
WO2024261344A1 (en)2023-06-232024-12-26Vib VzwNovel binders targeting the multi-drug resistant pathogen acinetobacter baumannii
EP4484956A2 (en)2020-01-292025-01-01MeMed Diagnostics Ltd.Methods of diagnosing and classifying viral infections
US12195531B2 (en)2013-03-212025-01-14Code Biotherapeutics, Inc.Cellular delivery of DNA intercalating agents
US12203113B2 (en)2009-07-092025-01-21Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
WO2025038395A1 (en)2023-08-112025-02-20Onkure, Inc.Benzopyridinones and benzopyrimidinones as pi3k inhibitors
EP4521115A2 (en)2020-06-102025-03-12Ramot at Tel-Aviv University Ltd.Methods of detecting methylated cpg
WO2025054524A1 (en)2023-09-072025-03-13University Of Tennessee Research FoundationMethod for diagnosing amyloid diseases
WO2025052278A1 (en)2023-09-052025-03-13Genevant Sciences GmbhPyrrolidine based cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
US12281328B2 (en)2017-02-082025-04-22Hadasit Medical Research Services And Development Ltd.Photoreceptor cells for the treatment of retinal diseases
WO2025125577A1 (en)2023-12-142025-06-19Vib VzwAntibodies against influenza b virus
US12338435B2 (en)2016-02-192025-06-24Code Biotherapeutics, Inc.Nucleic acid carriers and therapeutic methods of use
WO2025133951A1 (en)2023-12-212025-06-26Genevant Sciences GmbhIonizable lipids suitable for lipid nanoparticles
US12343723B2 (en)2021-12-072025-07-01Insilixa, Inc.Methods and compositions for surface functionalization of optical semiconductor-integrated biochips
WO2025150045A1 (en)2024-01-122025-07-17Gabriel NussbaumBacterial targets, therapeutics, compositions, kits and methods of use in treating and/or preventing cancer
WO2025155991A2 (en)2024-01-192025-07-24Bpgbio, Inc.Predictive biomarkers for response to coenzyme q10 treatment in pancreatic cancer
US12378592B2 (en)2018-01-312025-08-05Dovetail Genomics, Llc.Sample prep for DNA linkage recovery
EP4610372A2 (en)2018-01-292025-09-03Lavie Bio Ltd.Plant microbial preparations, compositions and formulations comprising same and uses thereof
US12428637B2 (en)2017-08-082025-09-30Technology Innovation Momentum Fund (Israel) Limited PartnershipChloramphenicol resistant split protein and uses thereof
EP4623930A2 (en)2020-12-032025-10-01The Board Of Regents Of The University Of Texas SystemMethods for identifying lilrb-blocking antibodies
WO2025202871A1 (en)2024-03-272025-10-02Pfizer Inc.Methods for identifying biomarkers of treatment response and use thereof with a cdk4 inhibitor
WO2025207755A1 (en)2024-03-292025-10-02Onkure, Inc.Quinolizinones as pi3k inhibitors
US12435145B2 (en)2018-02-212025-10-07Five Prime Therapeutics, Inc.B7-H4 antibody formulations
US12441776B2 (en)2019-11-272025-10-14Eirgen Pharma Ltd.Oxyntomodulin peptide analog formulations

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
NL171930C (en)*1972-05-111983-06-01Akzo Nv METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING.
US3790447A (en)*1972-07-051974-02-05Abbott LabStreptococci diagnostic method
JPS5341420A (en)*1976-09-291978-04-14Mochida Pharm Co LtdImmunochemically measuring methoa of hapten
IL51667A (en)*1977-03-161979-10-31Miles Yeda LtdImmunoassay for the determination of a hapten
ZA841924B (en)*1983-07-251984-10-31Becton Dickinson CoChromogenic tracers for use in an assay
DE3433652A1 (en)*1984-09-131986-03-20Boehringer Mannheim Gmbh, 6800 Mannheim IMMUNCHEMICAL MEASUREMENT METHOD FOR HAPTENES AND PROTEINS

Citations (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3615222A (en)*1968-09-041971-10-26New England Nuclear CorpMethod and apparatus for measuring the amount of a component in a biological fluid
US3654090A (en)*1968-09-241972-04-04OrganonMethod for the determination of antigens and antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3615222A (en)*1968-09-041971-10-26New England Nuclear CorpMethod and apparatus for measuring the amount of a component in a biological fluid
US3654090A (en)*1968-09-241972-04-04OrganonMethod for the determination of antigens and antibodies
US3654090B1 (en)*1968-09-241982-07-20

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts 65: 11124b, (1966).*
Spector et al., 168: 1348, 8, Science, (June 12, 1970).*

Cited By (2625)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US6630328B2 (en)1909-07-152003-10-07Genencor International, Inc.Increasing production of proteins in gram-positive microorganisms
USRE31006E (en)*1968-09-241982-08-03Akzona IncorporatedProcess for the demonstration and determination of reaction components having specific binding affinity for each other
US4203802A (en)*1971-05-141980-05-20Syva CompanyInhibitable enzyme amplification assay
US4282325A (en)*1971-05-141981-08-04Syva CompanyEnzyme bound corticosteroids
US4191613A (en)*1971-05-141980-03-04Syva CompanyMalate dehydrogenase conjugates for enzyme immunoassays
US3905871A (en)*1971-05-141975-09-16Syva CoLactam conjugates to enzymes
US4039385A (en)*1972-05-081977-08-02Syva CompanyCardiac glycoside enzyme conjugates
US3966556A (en)*1972-11-061976-06-29Syva CompanyCompounds for enzyme amplification assay methadone analogs
US3975237A (en)*1972-11-061976-08-17Syva CompanyCompounds for enzyme amplification assay - - ecgonine analogs
US4046636A (en)*1974-06-201977-09-06Syva CompanyDiazepam enzyme conjugates
US4040907A (en)*1974-06-201977-08-09Syva CompanyIodothyronine enzyme conjugates
US4061466A (en)*1974-10-161977-12-06Ingvar Gosta Holger SjoholmBiologically active composition and the use thereof
US4343896A (en)*1975-02-011982-08-10Akzona IncorporatedMethod and test pack for the demonstration and determination of an antigen or antibody
US4043872A (en)*1975-02-201977-08-23Syva CompanyPolyiodothyronine immunoassay
USRE32696E (en)*1975-09-041988-06-14Akzona IncorporatedEnzymatic immunological method for determination of antigens and antibodies
US4096138A (en)*1975-12-081978-06-20Scherr George HImmunological test procedure
US4166767A (en)*1976-03-251979-09-04Dainippon Pharmaceutical Co., Ltd.Insolubilized antibody
US4248965A (en)*1976-10-071981-02-03Mochida Seiyaku Kabushiki KaishaImmunochemical process of measuring physiologically active substances
FR2367286A1 (en)*1976-10-071978-05-05Mochida Pharm Co Ltd NEW PROCESS AND REAGENTS FOR IMMUNOCHEMICAL DOSAGE OF PHYSIOLOGICALLY ACTIVE SUBSTANCES
US4098876A (en)*1976-10-261978-07-04Corning Glass WorksReverse sandwich immunoassay
US4134792A (en)*1976-12-061979-01-16Miles Laboratories, Inc.Specific binding assay with an enzyme modulator as a labeling substance
US4250253A (en)*1977-03-151981-02-10Snamprogetti S.P.A.Composition adapted for the determination of tri-iodo thyronine and diagnosis method employing same
DE2805961A1 (en)*1977-04-151978-10-19Syva Co THEOPHYLLINE ANTIGENS AND ANTIBODIES AND THEIR USE FOR THE DETERMINATION OF THEOPHYLLINE
FR2390732A1 (en)*1977-05-121978-12-08Sclavo Inst Sieroterapeut PROCESS FOR DETERMINING THE CONTENTS OF CERTAIN COMPONENTS OF BIOLOGICAL FLUIDS AND MEANS USED
US5605800A (en)*1978-04-131997-02-25Institut PasteurMethod of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method
US5955262A (en)*1978-04-131999-09-21Institut PasteurMethod of detecting and characterizing a nucleic acid or reactant for the application of this method
US5876928A (en)*1978-04-131999-03-02Institut PasteurMethod of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method
US4467030A (en)*1978-06-121984-08-21Boehringer Mannheim GmbhDetermination of the thyroxine-binding index in serum
US4269938A (en)*1979-03-081981-05-26Eastman Kodak CompanyAssay of peroxidatively active materials
US4376825A (en)*1979-05-071983-03-15Syva CompanyEnzyme amplification compounds for assays for androgens
US4350761A (en)*1979-05-181982-09-21Yamasu Shoyu Kabushiki KaishaMethod of and reagents for quantitative analysis of cyclic nucleotides
WO1980002747A1 (en)*1979-05-311980-12-11Rapidex LtdUltrasensitive enzymatic radioimmunoassay method
US4289748A (en)*1979-05-311981-09-15United States Of AmericaUltrasensitive enzymatic radioimmunoassay method
US4391904A (en)*1979-12-261983-07-05Syva CompanyTest strip kits in immunoassays and compositions therein
US4299916A (en)*1979-12-261981-11-10Syva CompanyPreferential signal production on a surface in immunoassays
US4427769A (en)1980-01-171984-01-24Labsystems OyImmunoassay for fecal human hemoglobin
US4347312A (en)*1980-03-201982-08-31Research Triangle InstituteDetection of antibiotics in milk
US4443365A (en)*1980-07-011984-04-17Dainippon Pharmaceutical Company LimitedMethod for determination of the valproic acid and reagents therein
US4323647A (en)*1980-10-151982-04-06University Of MiamiSteric hindrance enzyme immunoassay
WO1982004323A1 (en)*1981-06-021982-12-09O Neill SeanImmunoprecipitation assay
US4604365A (en)*1981-06-021986-08-05Electro-Nucleonics, Inc.Immunoprecipitation assay
US5703206A (en)*1981-09-081997-12-30Univ RockefellerMacrophage inflammatory protein 2 (MIP-2)
US4419453A (en)*1981-09-281983-12-06The Dow Chemical CompanyImmunological agglutination assays with dyed or colored latex and kits
US4506009A (en)*1982-03-301985-03-19University Of CaliforniaHeterogeneous immunoassay method
US4535057A (en)*1982-07-261985-08-13Amf IncorporatedImmunoassay employing monoclonal herpes simplex antibody and biotin-avidin detection system
US4530900A (en)*1982-09-131985-07-23Seragen Diagnostics Inc.Soluble insoluble polymers in enzymeimmunoassay
WO1985000605A1 (en)*1983-07-271985-02-14American Hospital Supply CorporationProcess for selective nitrile reduction
US5047330A (en)*1983-08-171991-09-10Commissariat A L'energie AtomiqueCompound labelled by the acetyl cholinesterase of Electrophorus electricus, its preparation process and its use as a tracer or marker in enzymoimmunological determinations
US4713347A (en)*1985-01-141987-12-15Sensor Diagnostics, Inc.Measurement of ligand/anti-ligand interactions using bulk conductance
US4786594A (en)*1986-05-141988-11-22Syntex (U.S.A.) Inc.Enzyme immunoassay
US5717074A (en)*1988-09-021998-02-10The Rockefeller UniversityMacrophage-derived inflammatory mediator (MIP-2)
US6103234A (en)*1988-09-022000-08-15The Rockefeller UniversityComposition comprising an antibody to macrophage-derived inflammatory mediator (MIP-2)
EP0703296A1 (en)1988-09-291996-03-27Chiron CorporationPolynucleotide determination by strand replacement of a capture probe
US5391483A (en)*1990-07-271995-02-21Eastman Kodak CompanyLigand analogs for immunoassays derived from dicarboxylic acid oxidation products
US5652346A (en)*1990-07-271997-07-29Johnson & Johnson Clinical Diagnostics, Inc.Dicarboxylic acid oxidation products
US5614504A (en)*1990-08-011997-03-25The University Of South FloridaMethod of making inosine monophosphate derivatives and immunopotentiating uses thereof
US5268298A (en)*1991-04-261993-12-07Life Technologies, Inc.System for delivering oxygen to a cell culture medium
US5965379A (en)*1991-07-191999-10-12Cytimmune Sciences Inc.Method for measuring endogenous cytokines
US5587294A (en)*1991-07-191996-12-24Assay Research, Inc.Method and kit for measuring endogenous cytokines
EP0524502A2 (en)1991-07-221993-01-27Bayer CorporationImmunoassay for free analyte
US5939524A (en)*1991-12-091999-08-17The Scripps Research InstitutePlatelet GPIII P1A1 and P1A2 epitopes, their preparation and use
US5683887A (en)*1991-12-201997-11-04The Rockefeller UniversityImmunochemical detection of in vivo advanced glycosylation endproducts
US5702704A (en)*1991-12-201997-12-30The Rockefeller UniversityAntibodies to in vivo advanced glycosylation endproducts
US5712101A (en)*1991-12-201998-01-27The Rockefeller UniversityImmunochemical detection of in vivo advanced glycosylation endproducts
US5629408A (en)*1991-12-201997-05-13The Rockefeller UniversityImmunochemical isolation of in vivo advanced glycosylation endproducts
US5624804A (en)*1991-12-201997-04-29The Rockefeller UniversityImmunochemical detection of In vivo advanced glycosylation end products
US5733546A (en)*1991-12-201998-03-31The Rockefeller UniversityImmunochemical detection of in vivo advanced glycosylation endproducts
US5354692A (en)*1992-09-081994-10-11Pacific Biotech, Inc.Analyte detection device including a hydrophobic barrier for improved fluid flow
US5874423A (en)*1992-09-101999-02-23Yissum Research Development Co. Of The Hebrew University Of JerusalemDigitalis-like compounds
US7988972B2 (en)1992-09-152011-08-02Ortho-Clinical Diagnostics, Inc.Immunoreactive peptides from Epstein-Barr virus
US7060283B1 (en)1992-09-152006-06-13Ortho Diagnostic Systems, Inc.Immunoreactive peptides from Epstein-Barr virus
US5637467A (en)*1992-10-131997-06-10Behringwerke AgHeterogeneous assay using a pendulous drop
US5876712A (en)*1993-03-171999-03-02University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US20040082758A1 (en)*1993-03-172004-04-29University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5801005A (en)*1993-03-171998-09-01University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US6075122A (en)*1993-03-172000-06-13University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US7601697B2 (en)1993-03-172009-10-13University Of WashingtonCompounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US7655239B2 (en)1993-03-172010-02-02University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5846538A (en)*1993-03-171998-12-08University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the her-2/neu oncogene is associated
US8524491B2 (en)1993-03-172013-09-03University Of Washington Through Its Center For CommercializationCompounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US5869445A (en)*1993-03-171999-02-09University Of WashingtonMethods for eliciting or enhancing reactivity to HER-2/neu protein
US6664370B2 (en)1993-03-172003-12-16University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US7247703B2 (en)1993-03-172007-07-24University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US20080076904A1 (en)*1993-03-172008-03-27University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US6953573B1 (en)1993-03-172005-10-11University Of WashingtonCompounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US5726023A (en)*1993-03-171998-03-10University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US20050191285A1 (en)*1993-03-172005-09-01University Of WashingtonCompounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US6482608B1 (en)*1993-06-182002-11-19The Salk Institute For Biological StudiesCloning and recombinant production of CRF receptor(S)
US6495343B1 (en)1993-06-182002-12-17The Salk Institute For Biological StudiesCloning and recombinant production of CRF receptor(s)
US20020055617A1 (en)*1993-06-182002-05-09Marilyn H. PerrinCloning and recombinant production of cfr receptor(s)
US7358225B2 (en)1993-06-182008-04-15The Salk Institute For Biological StudiesCloning and recombinant production of CRF receptor(s)
US6638905B2 (en)1993-06-182003-10-28The Salk Institute For Biological StudiesCloning and recombinant production of CFR receptor(s)
US5516639A (en)*1993-07-221996-05-14Mayo Foundation For Medical Education And ResearchAntibodies specific for human prostate glandular kallkrein
US6103237A (en)*1993-07-222000-08-15Hybritech IncorporatedStable variant hK2 polypeptide
US20040259113A1 (en)*1993-07-222004-12-23Mayo Foundation For Medical Education And Research, Hybritech IncorporatedMethod for detection of metastatic prostate cancer
US5684144A (en)*1993-07-281997-11-04University Of North TexasEscherichia coli csrA gene, protein encoded thereby, and methods of use thereof
US7326535B2 (en)1993-09-152008-02-05Ortho Diagnostic Systems Inc.Immunoreactive peptides from Epstein-Barr virus
US20040013665A1 (en)*1993-09-152004-01-22Ortho Diagnostic Systems, Inc.Immunoreactive peptides from Epstein-Barr virus
EP2364994A1 (en)1994-01-052011-09-14Schering CorporationPurfied primate CTLA-8 antigens and related reagents
US6884590B1 (en)1994-02-112005-04-26Cedars-Sinai Medical CenterMethods of screening for ulcerative colitis and crohn's disease
US6008335A (en)*1994-02-111999-12-28Cedars-Sinai Medical CenterMethods of screening for ulcerative colitis and Crohn's disease
US6613514B2 (en)1994-02-172003-09-02Maxygen, Inc.Methods and compositions for polypeptide engineering
US6406855B1 (en)1994-02-172002-06-18Maxygen, Inc.Methods and compositions for polypeptide engineering
US6319713B1 (en)1994-02-172001-11-20Maxygen, Inc.Methods and compositions for polypeptide engineering
US6355484B1 (en)1994-02-172002-03-12Maxygen, Inc.Methods and compositions for polypeptides engineering
US6013471A (en)*1994-05-102000-01-11Hybritech IncorporatedDNA encoding hK2 variant polypeptides
US6093796A (en)*1994-05-102000-07-25Mayo Foundation For Medical Education And ResearchRecombinant hK2 polypeptide
US5837535A (en)*1994-06-131998-11-17Henry Ford Health SystemNeuronal-neonatal gene: neuronatin
US5589344A (en)*1994-06-151996-12-31Johnson & Johnson Clinical Diagnostics, Inc.Test kit and method for competitive specific binding assay
EP0705903A1 (en)1994-08-121996-04-10Myriad Genetics, Inc.In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene
EP0699754A1 (en)1994-08-121996-03-06Myriad Genetics, Inc.Method for diagnosing a predisposition for breast and ovarian cancer
EP0705902A1 (en)1994-08-121996-04-10Myriad Genetics, Inc.17q-Linked breast and ovarian cancer susceptibility gene
US7994301B2 (en)1994-08-172011-08-09The Rockefeller UniversityModulators of body weight, corresponding nucleic acids and proteins
US6124448A (en)*1994-08-172000-09-26The Rockfeller UniversityNucleic acid primers and probes for the mammalian OB gene
US6001968A (en)*1994-08-171999-12-14The Rockefeller UniversityOB polypeptides, modified forms and compositions
US6350730B1 (en)1994-08-172002-02-26The Rockefeller UniversityOB polypeptides and modified forms as modulators of body weight
US8173793B2 (en)1994-08-172012-05-08The Rockefeller UniversityNucleic acids encoding modulators of body weight
EP2402444A1 (en)1994-08-172012-01-04The Rockefeller UniversityModulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6309853B1 (en)1994-08-172001-10-30The Rockfeller UniversityModulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6048837A (en)*1994-08-172000-04-11The Rockefeller UniversityOB polypeptides as modulators of body weight
US6124439A (en)*1994-08-172000-09-26The Rockefeller UniversityOB polypeptide antibodies and method of making
US6471956B1 (en)1994-08-172002-10-29The Rockefeller UniversityOb polypeptides, modified forms and compositions thereto
US8236493B2 (en)1994-10-212012-08-07Affymetrix, Inc.Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA
US20060292579A1 (en)*1994-10-212006-12-28Affymetrix, Inc.Methods of enzymatic discrimination enhancement and surface bound double-stranded DNA
US5843673A (en)*1994-10-251998-12-01Curators Of The University Of MissouriMethod of screening for endometriosis
US6531277B2 (en)1994-10-252003-03-11The Curators Of The University Of MissouriEndometriosis-specific secretory protein
US20030152909A1 (en)*1994-11-162003-08-14Mitrani Eduardo N.In vitro micro-organs, and uses related thereto
US7708984B2 (en)1994-12-072010-05-04Incyte CorporationMethods of treatment with anitbodies to a chemokine expressed in inflamed adenoid
US20080138346A1 (en)*1994-12-072008-06-12Incyte CorporationAntibodies to a chemokine expressed in inflamed adenoid
US8008027B2 (en)1994-12-072011-08-30Incyte CorporationMethods of screening for compounds that modulate the activity of ADEC, a chemokine expressed in inflamed adenoid
US9090687B2 (en)1995-02-172015-07-28Incyte CorporationMethods of treating pancreatitis
US6335160B1 (en)1995-02-172002-01-01Maxygen, Inc.Methods and compositions for polypeptide engineering
US8617551B2 (en)1995-02-172013-12-31Incyte CorporationMethods of diagnosing pancreatic inflammation by using chemokine PANEC-1 antibodies
US6506553B1 (en)1995-03-302003-01-14Ortho Diagnostics Systems, Inc.Method for diagnosis of Epstein-Barr virus associated disease
US5777093A (en)*1995-05-161998-07-07Ramot-University Authority For Applied Research & Industrial Development Ltd.cDNAs associated with ataxia-telangiectasia
US5728807A (en)*1995-05-161998-03-17Ramot-University Authority For Applied Research And Industrial Development, Ltd.Mutated proteins associated with ataxia-telangiectasia
US5858661A (en)*1995-05-161999-01-12Ramot-University Authority For Applied Research And Industrial DevelopmentAtaxia-telangiectasia gene and its genomic organization
US6200749B1 (en)1995-05-162001-03-13Ramot-University Authority For Applied Research And Industrial Development Ltd.Mutated forms of the ataxia-telangiectasia gene and method to screen for a partial A-T phenotype
EP2258726A1 (en)1995-06-142010-12-08The Regents of the University of CaliforniaHigh affinity human antibodies to c-erbB-2
US6946296B2 (en)1995-11-302005-09-20Maxygen, Inc.Methods and compositions for polypeptide engineering
EP0785216A1 (en)1995-12-181997-07-23Myriad Genetics, Inc.Chomosome 13-linked breast cancer susceptibility gene BRCA2
EP2338913A1 (en)1995-12-182011-06-29The University of Utah Research FoundationChromosome 13-linked breast cancer susceptibility gene
US6858711B2 (en)1996-01-232005-02-22Affymetrix, Inc.Labeling reagents
US6965020B2 (en)1996-01-232005-11-15Affymetrix, Inc.Nucleic acid labeling compounds
US7282327B2 (en)1996-01-232007-10-16Affymetrix, Inc.Nucleic acid labeling compounds
US20030180757A1 (en)*1996-01-232003-09-25Affymetrix, Inc.Nucleic acid labeling compounds
US7291463B2 (en)1996-01-232007-11-06Affymetrix, Inc.Nucleic acid labeling compounds
US20040101892A1 (en)*1996-01-232004-05-27Affymetrix, Inc.Nucleic acid labeling compounds
US7423143B2 (en)1996-01-232008-09-09Affymetrix. Inc.Nucleic acid labeling compounds
US20040210045A1 (en)*1996-01-232004-10-21Mcgall GlennNucleic acid labeling compounds
US20030064364A1 (en)*1996-01-232003-04-03Lockhart David J.Nucleic acid analysis techniques
US20050287563A1 (en)*1996-01-232005-12-29Affymetrix, Inc.Nucleic acid labeling compounds
US6864059B2 (en)1996-01-232005-03-08Affymetrix, Inc.Biotin containing C-glycoside nucleic acid labeling compounds
US7252948B2 (en)1996-02-082007-08-07Affymetrix, Inc.Chip-based speciation and phenotypic characterization of microorganisms
US6228575B1 (en)1996-02-082001-05-08Affymetrix, Inc.Chip-based species identification and phenotypic characterization of microorganisms
US6924094B1 (en)1996-02-082005-08-02Affymetrix, Inc.Chip-based species identification and phenotypic characterization of microorganisms
US20060204970A1 (en)*1996-02-082006-09-14Affymetrix, Inc.Chip-based speciation and phenotypic characterization of microorganisms
EP1728875A2 (en)1996-02-082006-12-06Affymetrix, Inc.Chip-based speciation and phenotypic characterization of microorganisms
US5882644A (en)*1996-03-221999-03-16Protein Design Labs, Inc.Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US6129917A (en)*1996-03-222000-10-10The University Of Georgia Research Foundation, Inc.Immunogenic compositions comprising porphyromonas gingivalis proteins and/or peptides and methods
US20060008479A1 (en)*1996-04-012006-01-12University Of WashingtonMethods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
US7166286B2 (en)1996-05-222007-01-23Viventia Biotech Inc.Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for prophylaxis and detection of cancers
US6207153B1 (en)1996-05-222001-03-27Viventia Biotech, Inc.Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US20040091484A1 (en)*1996-05-222004-05-13Dan Michael D.Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US6342349B1 (en)1996-07-082002-01-29Burstein Technologies, Inc.Optical disk-based assay devices and methods
US20050214827A1 (en)*1996-07-082005-09-29Burstein Technologies, Inc.Assay device and method
US20020106661A1 (en)*1996-07-082002-08-08Burstein Laboratories, Inc.Optical disk-based assay devices and methods
US20050069923A1 (en)*1996-07-082005-03-31Mullis Kary BanksDual bead assays using cleavable spacers and/or ligation to improve specificity and sensitivity including related methods and apparatus
US6331275B1 (en)1996-07-082001-12-18Burstein Technologies, Inc.Spatially addressable, cleavable reflective signal elements, assay device and method
US6312901B2 (en)1996-07-082001-11-06Burstein Technologies, Inc.Spatially addressable, cleavable reflective signal elements, assay device and method
EP1947183A1 (en)1996-08-162008-07-23Schering CorporationMammalian cell surface antigens; related reagents
US7576187B2 (en)1996-09-242009-08-18Genentech, Inc.Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US7045596B2 (en)1996-09-242006-05-16Tanox, Inc.Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US20070299005A1 (en)*1996-09-242007-12-27Tanox, Inc.Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US20040039184A1 (en)*1996-09-242004-02-26Tanox, Inc.Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US20070071751A1 (en)*1996-09-242007-03-29Tanox, Inc.Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US6433155B1 (en)1996-09-242002-08-13Tanox, Inc.Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US20070077574A1 (en)*1996-09-242007-04-05Tanox, Inc. family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US7045604B2 (en)1996-09-242006-05-16Tanox, Inc.Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US20070082371A1 (en)*1996-09-242007-04-12Tanox, Inc.Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US7285639B2 (en)1996-10-012007-10-23Geron CorporationAntibody to telomerase reverse transcriptase
US7005262B2 (en)1996-10-012006-02-28Geron CorporationMethods for detecting nucleic acids encoding human telomerase reverse transcriptase
US8222392B2 (en)1996-10-012012-07-17Geron CorporationKit for detection of telomerase reverse transcriptase nucleic acids
US6808880B2 (en)1996-10-012004-10-26Geron CorporationMethod for detecting polynucleotides encoding telomerase
US6093809A (en)*1996-10-012000-07-25University Technology CorporationTelomerase
US7517971B1 (en)1996-10-012009-04-14Geron CorporationMuteins of human telomerase reverse transcriptase lacking telomerase catalytic activity
US6261836B1 (en)1996-10-012001-07-17Geron CorporationTelomerase
US7056513B2 (en)1996-10-012006-06-06Geron CorporationTelomerase
US20020187471A1 (en)*1996-10-012002-12-12Cech Thomas R.Novel telomerase
EP1333094A2 (en)1996-10-012003-08-06Geron CorporationHuman telomerase catalytic subunit
US20070190561A1 (en)*1996-10-012007-08-16Geron CorporationSegments of the Human Gene for Telomerase Reverse Transcriptase
US6927285B2 (en)1996-10-012005-08-09Geron CorporationGenes for human telomerase reverse transcriptase and telomerase variants
EP2213740A1 (en)1996-10-012010-08-04The Regents of the University of ColoradoHuman telomerase catalytic subunit
US7195911B2 (en)1996-10-012007-03-27Geron CorporationMammalian cells that have increased proliferative capacity
WO1998014593A2 (en)1996-10-011998-04-09Geron CorporationHuman telomerase catalytic subunit
US6921664B2 (en)1996-10-012005-07-26Regents Of The University Of ColoradoTelomerase
US7560437B2 (en)1996-10-012009-07-14Geron CorporationNucleic acid compositions for eliciting an immune response against telomerase reverse transcriptase
US7585622B1 (en)1996-10-012009-09-08Geron CorporationIncreasing the proliferative capacity of cells using telomerase reverse transcriptase
US6617110B1 (en)1996-10-012003-09-09Geron CorporationCells immortalized with telomerase reverse transcriptase for use in drug screening
US6475789B1 (en)1996-10-012002-11-05University Technology CorporationHuman telomerase catalytic subunit: diagnostic and therapeutic methods
US20090269739A1 (en)*1996-10-012009-10-29Geron CorporationKit for detection of telomerase reverse transcriptase nucleic acids
US7879609B2 (en)1996-10-012011-02-01Geron CorporationRegulatory segments of the human gene for telomerase reverse transcriptase
US20030100093A1 (en)*1996-10-012003-05-29Cech Thomas R.Human telomerase catalytic subunit: diagnostic and therapeutic methods
EP1783139A2 (en)1996-10-012007-05-09Geron CorporationHuman telomerase catalytic subunit
US20030096344A1 (en)*1996-10-012003-05-22Cech Thomas R.Human telomerase catalytic subunit: diagnostic and therapeutic methods
US6479263B1 (en)1996-11-142002-11-12Baylor College Of MedicineMethod for detection of micrometastatic prostate cancer
US6294334B1 (en)1996-11-152001-09-25Board Of Regents, The University Of Texas SystemGenetic test for equine severe combined immunodeficiency disease
EP1803816A2 (en)1996-12-132007-07-04Schering CorporationMammalian cell surface antigens; related reagents
EP1995318A1 (en)1996-12-132008-11-26Schering CorporationMammalian cell surface antigens; related reagents
EP1995317A1 (en)1996-12-132008-11-26Schering CorporationMammalian cell surface antigens; related reagents
US20060084091A1 (en)*1996-12-182006-04-20Maxygen, Inc.Methods and compositions for polypeptide engineering
US6579678B1 (en)1996-12-182003-06-17Maxygen, Inc.Methods and compositions for polypeptide engineering
US20060166225A1 (en)*1996-12-182006-07-27Maxygen, Inc.Methods and compositions for polypeptide engineering
US6303344B1 (en)1996-12-182001-10-16Maxygen, Inc.Methods and compositions for polypeptide engineering
US6653072B1 (en)1996-12-182003-11-25Maxygen, Inc.Methods and compositions for polypeptide engineering
US6455253B1 (en)1996-12-182002-09-24Maxygen, Inc.Methods and compositions for polypeptide engineering
US5840322A (en)*1996-12-191998-11-24Ramot-University Authority For Applied Research & Industrial Devel. Ltd.Anti-oral-microbial adhesion fraction derived from vaccinium
EP2172478A2 (en)1997-02-072010-04-07THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICESActivity-dependent neurotrophic factor III (ADNF III)
US6391854B1 (en)1997-04-012002-05-21Calyx Therapeutics, Inc.Orally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes
US20020193310A1 (en)*1997-04-012002-12-19Bishwajit NagOrally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes
US6127338A (en)*1997-04-012000-10-03Calyx Therapeutics, Inc.Orally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes
US6852695B2 (en)1997-04-012005-02-08Theracos, Inc.Orally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes
US20060040307A1 (en)*1997-04-182006-02-23Geron CorporationHuman telomerase catalytic subunit
US8236774B2 (en)1997-04-182012-08-07Geron CorporationHuman telomerase catalytic subunit
US20050013825A1 (en)*1997-04-182005-01-20Geron CorporationVaccine containing the catalytic subunit of telomerase for treating cancer
US20040247613A1 (en)*1997-04-182004-12-09Geron CorporationTreating cancer using a telomerase vaccine
US7750121B2 (en)1997-04-182010-07-06Geron CorporationAntibody to telomerase reverse transcriptive
US20080279871A1 (en)*1997-04-182008-11-13Geron CorporationImmunogenic composition
US20040242529A1 (en)*1997-04-182004-12-02Geron CorporationVector encoding inactivated telomerase for treating cancer
US7413864B2 (en)1997-04-182008-08-19Geron CorporationTreating cancer using a telomerase vaccine
US8709995B2 (en)1997-04-182014-04-29Geron CorporationMethod for eliciting an immune response to human telomerase reverse transcriptase
US7262288B1 (en)1997-04-182007-08-28Geron CorporationNucleic acids encoding human telomerase reverse transcriptase and related homologs
US7622549B2 (en)1997-04-182009-11-24Geron CorporationHuman telomerase reverse transcriptase polypeptides
EP1988166A1 (en)1997-05-072008-11-05Schering CorporationHuman Toll-like receptor proteins, related reagents and methods
US7115722B1 (en)1997-05-222006-10-03Viventia Biotech, Inc.Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US7138240B2 (en)1997-06-052006-11-21Duke UniversityMethods of assaying receptor activity
US7541151B2 (en)1997-06-052009-06-02Duke UniversitySingle-cell biosensor for the measurement of GPCR ligands in a test sample
US20060188944A1 (en)*1997-06-052006-08-24Barak Lawrence SMethods of assaying receptor activity
US6770449B2 (en)1997-06-052004-08-03Duke UniversityMethods of assaying receptor activity and constructs useful in such methods
US7572888B2 (en)1997-06-052009-08-11Duke UniversityMethods of assaying receptor activity and constructs useful in such methods
US20080261256A1 (en)*1997-06-052008-10-23Duke UniversityMethods of assaying receptor activity and constructs useful in such methods
US20040209308A1 (en)*1997-06-052004-10-21Duke UniversityMethods of assaying receptor activity and constructs useful in such methods
US6235486B1 (en)1997-06-202001-05-22Mayo Foundation For Medical Education & ResearchMethod for detection of breast cancer
US20030118593A1 (en)*1997-07-082003-06-26Dan Michael D.Antigen binding fragments, designated 4B5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
EP1980573A2 (en)1997-07-092008-10-15Schering CorporationIsolated dendritic cell membrane protein genes
US20030190752A1 (en)*1997-07-112003-10-09Tony RomeoEscherichia coli csrB gene, RNA encoded thereby, and methods of use thereof
US6537815B2 (en)1997-07-112003-03-25University Of North Texas, Health Science Center At Fort WorthMethod of altering the expression of csrB to modify the properties of a cell
US6228638B1 (en)1997-07-112001-05-08University Of North Texas, Health Science Center At Fort WorthEscherichia coli CSRB gene and RNA encoded thereby
US6833261B2 (en)1997-07-152004-12-21Genencor International, Inc.Proteases from gram-positive organisms
US20050142638A1 (en)*1997-07-152005-06-30Estell David A.Proteases from gram-positive organisms
US20050095683A1 (en)*1997-07-152005-05-05Estell David A.Proteases from gram-positive organisms
US20050101001A1 (en)*1997-07-152005-05-12Estell David A.Proteases from gram-position organisms
US6506579B1 (en)1997-07-152003-01-14Genencor International, Inc.Increasing production of proteins in gram-positive microorganisms using SecG
US20030175892A1 (en)*1997-07-152003-09-18Estell David A.Proteases from gram-positive organisms
US6723550B1 (en)1997-07-152004-04-20Genencor International, Inc.Proteases from gram-positive organisms
US20040137505A1 (en)*1997-07-152004-07-15Estell David A.Gram-positive microorganisms with an inactivated cysteine protease-2
US6911333B2 (en)1997-07-152005-06-28Genencor International, Inc.Proteases from gram-positive organisms
US7316920B2 (en)1997-07-152008-01-08Genencor International, Inc.Serine proteases from gram-positive microorganisms
US6881562B2 (en)1997-07-152005-04-19Genencor International, Inc.Proteases from gram-positive organisms
US20030180932A1 (en)*1997-07-152003-09-25Estell David A.Proteases from gram-positive organisms
US20050214816A1 (en)*1997-07-152005-09-29Estell David AProteases from gram-positive organisms
US7329526B2 (en)1997-07-152008-02-12Genencor International, Inc.Serine proteases from-gram-positive microorganisms
US7329525B2 (en)1997-07-152008-02-12Genencor International, Inc.Serine proteases from gram-positive microorganisms
US6849440B2 (en)1997-07-152005-02-01Genencor International, Inc.Proteases from gram-positive organisms
US20030157642A1 (en)*1997-07-152003-08-21Caldwell Robert M.Increasing production of proteins in gram-positive microorganisms
US20040126868A1 (en)*1997-07-152004-07-01Estell David A.Gram-positive microorganisms with an inactivated cysteine protease-3
US20030166248A1 (en)*1997-07-152003-09-04Estell David A.Proteases from gram-positive organisms
US20030158070A1 (en)*1997-07-152003-08-21Estell David A.Proteases from gram-positive organisms
US7329527B2 (en)1997-07-152008-02-12Genencor International, Inc.Serine proteases from gram-positive microorganisms
US7037714B2 (en)1997-07-162006-05-02Genencor International, Inc.Expression vectors encoding Bacillus subtilis disulfide bond isomerase and methods of secreting proteins in gram-positive microorganisms using the same
US20030124676A1 (en)*1997-07-162003-07-03Quax Wilhelmus J.Increasing production of proteins in gram-positive microorganisms
US6521421B1 (en)1997-07-162003-02-18Genencor International, Inc.Expression vectors encoding Bacillus subtilis disulfide bond isomerase and methods of secreting proteins in gram-positive microorganisms using the same
EP2233574A1 (en)1997-07-252010-09-29Schering CorporationMammalian cytokine: interleukin-B30 and related reagents
EP2100959A2 (en)1997-07-252009-09-16Schering CorporationMammalian cytokine: interleukin-B30 and related reagents
US6180411B1 (en)1997-08-012001-01-30The Regents Of The University Of CaliforniaLight-triggered indicators that memorize analyte concentrations
EP1798287A2 (en)1997-08-012007-06-20Schering CorporationMammalian cell membrane proteins and related reagents
EP1798286A2 (en)1997-08-012007-06-20Schering CorporationMammalian cell membrane proteins and related reagents
US6610839B1 (en)1997-08-142003-08-26Geron CorporationPromoter for telomerase reverse transcriptase
US20030204069A1 (en)*1997-08-142003-10-30Morin Gregg B.Segments of the human gene for telomerase reverse transcriptase
US7199234B2 (en)1997-08-142007-04-03Geron CorporationRegulatory segments of the human gene for telomerase reverse transcriptase
US20080096225A1 (en)*1997-09-042008-04-24The Regents Of The University Of CaliforniaAssays for detecting modulators of cytoskeletal function
US7252950B1 (en)1997-09-042007-08-07The Regents Of The University Of CaliforniaAssays for detecting modulators of cytoskeletal function
US6905868B2 (en)1997-09-152005-06-14Genencor International, Inc.Proteases from gram-positive organisms
US20030113895A1 (en)*1997-09-152003-06-19Estell David A.Proteases from gram-positive organisms
US7189555B2 (en)1997-09-152007-03-13Genecor International, Inc.Proteases from gram-positive organisms
US6521440B1 (en)1997-09-152003-02-18Genencor International, Inc.Proteases from gram-positive organisms
US7220716B2 (en)1997-09-152007-05-22Genencor International, Inc.Proteases from gram-positive organisms
US7241575B2 (en)1997-09-152007-07-10Genecor International, Inc.Proteases from gram-positive organisms
US20050009146A1 (en)*1997-09-152005-01-13Estell David A.Proteases from gram-positive organisms
US20050059112A1 (en)*1997-09-152005-03-17Estell David A.Proteases from gram-positive organisms
US7326531B2 (en)1997-09-152008-02-05Genencor International, Inc.Proteases from gram-positive organisms
US20050106668A1 (en)*1997-09-152005-05-19Estell David A.Proteases from gram-positive organisms
US20050244925A1 (en)*1997-09-152005-11-03Estell David AProteases from gram-positive organisms
US20020127641A1 (en)*1997-09-152002-09-12Estell David A.Proteases from gram-positive organisms
US8101563B2 (en)1997-09-152012-01-24Danisco Us Inc.Proteases from gram-positive organisms
US6833265B2 (en)1997-09-152004-12-21Genencor International, Inc.Proteases from gram-positive organisms
US20060281106A1 (en)*1997-10-012006-12-14Andrews William HTelomerase promoter sequences for screening telomerase modulators
US7378244B2 (en)1997-10-012008-05-27Geron CorporationTelomerase promoters sequences for screening telomerase modulators
US20080220438A1 (en)*1997-10-012008-09-11Geron CorporationTelomerase Promoter Sequences for Screening Telomerase Modulators
US6284496B1 (en)1997-10-032001-09-04University Of South FloridaDNA vector for determining the presence of out-of-reading-frame mutations
US6482389B1 (en)1997-10-172002-11-19University Of South FloridaMethod to diagnose and monitor cellular immune deficiencies
US20050249789A1 (en)*1997-11-202005-11-10Estell David AAlpha/beta hydrolase-fold enzymes
US20020061580A1 (en)*1997-11-202002-05-23Estell David A.Alpha/beta hydrolase-fold enzymes
US6458557B1 (en)1997-11-202002-10-01Genencor International, Inc.Enhancing growth in gram-positive microorganisms using formate supplementation and inactivation of formate-associated transport proteins
US6599731B1 (en)1997-12-302003-07-29Genencor International, Inc.Proteases from gram positive organisms
US20060035367A1 (en)*1997-12-302006-02-16Estell David AProteases from gram positive organisms
US20050019887A1 (en)*1997-12-302005-01-27Estell David A.Proteases from gram positive organisms
US6872807B2 (en)1997-12-302005-03-29Genencor International, Inc.Proteases from gram positive organisms
US20050101504A1 (en)*1997-12-302005-05-12Estell David A.Proteases from gram positive organisms
US20050014227A1 (en)*1997-12-302005-01-20Estell David A.Proteases from gram positive organisms
US20050019888A1 (en)*1997-12-302005-01-27Estell David A.Proteases from gram positive organisms
US6794179B2 (en)1997-12-302004-09-21Genencor International, Inc.Proteases from gram positive organisms
US7078372B2 (en)1997-12-302006-07-18Genencor International, Inc.Proteases from gram positive organisms
US7078216B2 (en)1997-12-302006-07-18Genencor International, Inc.Proteases from gram positive organisms
US7098021B2 (en)1997-12-302006-08-29Genencor International, Inc.Proteases from gram positive organisms
US7070990B2 (en)1997-12-302006-07-04Genencor International, Inc.Proteases from GRAM positive organisms
US7033817B2 (en)1997-12-302006-04-25Genencor International, Inc.Proteases from gram positive organisms
US20050014244A1 (en)*1997-12-302005-01-20Estell David A.Proteases from gram positive organisms
US7070986B2 (en)1997-12-302006-07-04Genencor International, Inc.Proteases from gram positive organisms
US7070819B2 (en)1997-12-302006-07-04Genencor International, Inc.Proteases from gram positive organisms
US20030078177A1 (en)*1997-12-302003-04-24Estell David A.Proteases from gram positive organisms
US20050089963A1 (en)*1997-12-302005-04-28Estell David A.Proteases from gram positive organisms
US20050245417A1 (en)*1997-12-302005-11-03Estell David AProteases from gram positive organisms
US7687057B2 (en)1998-01-092010-03-30Yissum Research Development Company Of The Hebrew University Of JerusalemIn vitro micro-organs, and uses related thereto
US6759243B2 (en)1998-01-202004-07-06Board Of Trustees Of The University Of IllinoisHigh affinity TCR proteins and methods
US7569357B2 (en)1998-01-202009-08-04Board Of Trustees Of The University Of IllinoisHigh affinity TCR proteins and methods
US6673914B1 (en)1998-01-222004-01-06John Wayne Cancer InstituteHuman tumor-associated gene
US7855075B2 (en)1998-02-172010-12-21Gamida Cell Ltd.Methods of controlling proliferation and differentiation of stem and progenitor cells
US8202724B2 (en)1998-02-172012-06-19Gamida Cell Ltd.Methods of controlling proliferation and differentiation of stem and progenitor cells
US6596501B2 (en)1998-02-232003-07-22Fred Hutchinson Cancer Research CenterMethod of diagnosing autoimmune disease
US6060260A (en)*1998-02-272000-05-09Dade Behring Inc.Methods for reducing adsorption in an assay
WO1999045124A2 (en)1998-03-041999-09-10Genencor International, Inc.Modified forms of pullulanase
EP2295978A2 (en)1998-03-202011-03-16The Curators Of The University Of MissouriEarly pregnancy diagnosis using PAGs(Pregnancy-associated Glycoproteins)
US7541194B2 (en)1998-03-302009-06-02Orasure Technologies, Inc.Device for collection and assay of oral fluids
US7192555B2 (en)1998-03-302007-03-20Orasure Technologies, Inc.Device for collection and assay of oral fluids
US20070116597A1 (en)*1998-03-302007-05-24Mink Ronald WDevice for collection and assay of oral fluids
EP1696236A2 (en)1998-03-302006-08-30OraSure Technologies, Inc.Device for assay of antibodies in oral fluids
US20020192839A1 (en)*1998-03-302002-12-19Epitope, Inc.Collection device for single step assay of oral fluids
US8796438B2 (en)1998-03-312014-08-05Geron CorporationNucleic acids encoding inactive variants of human telomerase
US20060275267A1 (en)*1998-03-312006-12-07Morin Gregg BNucleic acids encoding inactive variants of human telomerase
US7846667B2 (en)1998-03-312010-12-07Genzyme CorporationMethods for the diagnosis and treatment of lung cancer
US20110091892A1 (en)*1998-03-312011-04-21Genzyme CorporationMethods for the Diagnosis and Treatment of Lung Cancer
US20070218511A1 (en)*1998-03-312007-09-20Genzyme CorporationMethods for the diagnosis and treatment of lung cancer
US8067240B2 (en)1998-03-312011-11-29Esoterix Genetic Laboratories, LlcMethods for the diagnosis and treatment of lung cancer
US20100062443A1 (en)*1998-03-312010-03-11Genzyme CorporationMethods for the Diagnosis and Treatment of Lung Cancer
US20020187467A1 (en)*1998-04-032002-12-12Thomas GingerasMycobacterial rpob sequences
US7108968B2 (en)1998-04-032006-09-19Affymetrix, Inc.Mycobacterial rpoB sequences
US20060147964A1 (en)*1998-04-032006-07-06Affymetrix, Inc.Mycobacterial rpoB sequences
US6872537B1 (en)1998-04-142005-03-29Regents Of The University Of CaliforniaAssays for the detection of microtubule depolymerization inhibitors
US6410687B1 (en)1998-04-142002-06-25The Regents Of The University Of CaliforniaPolypeptides for the detection of microtubule depolymerization inhibitors
US6429304B1 (en)1998-04-142002-08-06The Regents Of The University Of CaliforniaNucleic acids encoding a katanin p60 subunit
US6699969B1 (en)1998-04-142004-03-02The Regents Of The University Of CaliforniaAssays for the detection of microtubule depolymerization inhibitors
US6344443B1 (en)1998-07-082002-02-05University Of South FloridaPeptide antagonists of tumor necrosis factor alpha
US7605149B1 (en)1998-07-132009-10-20University Of South FloridaModulation of the phospholipase A2 pathway as a therapeutic
US7972638B2 (en)1998-07-212011-07-05Danisco A/SFoodstuff
US8163315B2 (en)1998-07-212012-04-24Danisco A/SFoodstuff
EP2058333A2 (en)1998-07-232009-05-13Millennium Pharmaceuticals, Inc.Anti-CCR2 antibodies and methods of use therefor
US6844433B2 (en)1998-07-312005-01-18Affymetrix, Inc.Nucleic acid labeling compounds
US20050164268A1 (en)*1998-07-312005-07-28Affymetrix, Inc.Nucleic acid labeling compounds
US7179905B2 (en)1998-07-312007-02-20Affymetrix, Inc.Nucleic acid labeling compounds
US20040002595A1 (en)*1998-07-312004-01-01Affymetrix, Inc.Nucleic acid labeling compounds
US20030232979A1 (en)*1998-07-312003-12-18Mcgall GlennNucleic acid labeling compounds
US7491818B2 (en)1998-07-312009-02-17Affymetrix, Inc.Nucleic acid labeling compounds
US6187563B1 (en)1998-08-072001-02-13Yale UniversityβIV-spectrin-polypeptides and nucleic acids encoding same
WO2000015824A1 (en)1998-09-132000-03-23Karolinska Innovations AbTransfer method for specific cellular localisation of nucleic acids
US20100004162A1 (en)*1998-09-182010-01-07Nathaniel HeintzLynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses thereof
US8013118B2 (en)1998-09-182011-09-06The Rockefeller UniversityLynx polypeptides
EP1897949A2 (en)1998-09-212008-03-12Schering CorporationHuman interleukin-B50. Therapeutic uses
EP2314696A1 (en)1998-09-212011-04-27Schering CorporationTherapeutic uses of human Interleukin-B50 antagonist.
EP1983001A2 (en)1998-09-252008-10-22Schering CorporationAntibodies to mammalian Langerhans cell antigen and their uses
EP2341144A1 (en)1999-01-112011-07-06Schering CorporationInterleukin-17 related mammalian cytokines. Polynucleotides encoding them. Uses
US20050176137A1 (en)*1999-02-042005-08-11Technion Research & Development Foundation Ltd.Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
EP2208782A2 (en)1999-02-042010-07-21Pluristem Ltd.Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
EP2311938A1 (en)1999-02-042011-04-20Pluristem Ltd.Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
US7678573B2 (en)1999-02-042010-03-16Pluristem Ltd.Method of preparing a conditioned medium from a confluent stromal cell culture
US7534609B2 (en)1999-02-042009-05-19Pluristem Life Systems Inc.Method of expanding undifferentiated hemopoietic stem cells
US20050176143A1 (en)*1999-02-042005-08-11Technion Research & DevelopmentMethod and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
US20080044416A1 (en)*1999-02-092008-02-21Gang AnNovel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer
US7993830B2 (en)1999-02-092011-08-09Laboratory Corporation Of America HoldingsProstate-specific gene for diagnosis, prognosis and management of prostate cancer
EP1942114A2 (en)1999-03-112008-07-09Schering CorporationMammalian cytokines; related reagents and methods
US8062908B2 (en)1999-03-292011-11-22Orasure Technologies, Inc.Device for collection and assay of oral fluids
US20090170072A1 (en)*1999-03-292009-07-02Orasure Technologies, Inc.Device for collection and assay of oral fluids
EP1762243A1 (en)1999-03-312007-03-14Oxford Biomedica (UK) LtdFactor for regulation of neurite growth
EP2336321A1 (en)1999-05-132011-06-22Medical Research CouncilOx2 receptor homolog
EP2341143A1 (en)1999-05-132011-07-06Medical Research CouncilOX2 receptor homolog
EP2385124A2 (en)1999-05-142011-11-09Arbor Vita CorporationPeptides or peptide analogues for modulating the binding of a PDZ protein and a PL protein
US6440682B1 (en)*1999-05-282002-08-27Detroit R&D Inc.Detection of hypertension using immunoreactive metabolic products
US20050089939A1 (en)*1999-06-012005-04-28Jun TanAssay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
US6787318B1 (en)1999-06-012004-09-07Roskamp Research Institute, LlcAssay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
WO2000073451A1 (en)1999-06-012000-12-07Schering CorporationMammalian receptor proteins; related reagents and methods
EP1950299A1 (en)1999-06-012008-07-30Schering CorporationMammalian receptor proteins; related reagents and methods
EP2258849A1 (en)1999-06-012010-12-08Schering CorporationMammalian receptor proteins; related reagents and methods
US7534605B2 (en)1999-06-082009-05-19Yissum Research Development Company Of The Hebrew University Of JerusalemCD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US20060019340A1 (en)*1999-06-082006-01-26David NaorCD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US8193311B2 (en)1999-06-082012-06-05Yissum Research Development Company Of The Hebrew University Of JerusalemCD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US7053268B1 (en)1999-06-172006-05-30Danisco A/SPromoter
US20060127366A1 (en)*1999-06-252006-06-15Mitrani Eduardo NMethod and device for inducing biological processes by micro-organs
US20030086914A1 (en)*1999-06-252003-05-08Yissum Research Development Company Of The Hebrew University Of JerusalemMethod and device for inducing biological processes by micro-organs
US20020137681A1 (en)*1999-07-062002-09-26Lawrence SteinmanTreatment of demyelinating autoimmune disease with ordered peptides
US6531130B1 (en)1999-07-062003-03-11The Board Of Trustees Of The Leland Stanford UniversityTreatment of demyelinating autoimmune disease with ordered peptides
US7070780B2 (en)1999-07-062006-07-04Board Of Trustees Of The Leland Stanford Junior UniversityTreatment of demyelinating autoimmune disease with ordered peptides
EP2138510A1 (en)1999-07-302009-12-30Schering CorporationMethods of generating antibodies against cytokines
US6875582B1 (en)1999-08-192005-04-05Omniscience Pharmaceuticals, Inc.Methods and targets of antibiotic resistance
US20110008314A1 (en)*1999-08-302011-01-13Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US7101839B1 (en)1999-08-302006-09-05Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US8617867B2 (en)1999-08-302013-12-31Yissum Research Develpment Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US7811981B2 (en)1999-08-302010-10-12Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US8735127B2 (en)1999-08-302014-05-27Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US8236543B2 (en)1999-08-302012-08-07Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US20050113327A1 (en)*1999-08-302005-05-26Levava RoizMethods of and compositions for inhibiting the proliferation of mammalian cells
EP3184637A1 (en)1999-09-092017-06-28Merck Sharp & Dohme Corp.Mammalian interleukin-12 p40 and interleukin b30 complexes, antibodies, uses in pharmaceutical compositions
EP1905832A2 (en)1999-09-092008-04-02Schering CorporationMammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions
EP1903107A1 (en)1999-09-242008-03-26Cybios LLCPluripotent embryonic-like stem cells, compositions, methods and uses thereof
EP2333049A1 (en)1999-09-242011-06-15ABT Holding CompanyPluripotent embryonic-like stem cells, compositions, methods and uses thereof
US6998232B1 (en)1999-09-272006-02-14Quark Biotech, Inc.Methods of diagnosing bladder cancer
US7668658B2 (en)1999-10-132010-02-23Sequenom, Inc.Methods for generating databases and databases for identifying polymorphic genetic markers
US8818735B2 (en)1999-10-132014-08-26Sequenom, Inc.Methods for generating databases and databases for identifying polymorphic genetic markers
US8229677B2 (en)1999-10-132012-07-24Sequenom, Inc.Methods for generating databases and databases for identifying polymorphic genetic markers
US7030228B1 (en)1999-11-152006-04-18Miltenyi Biotec GmbhAntigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
US10407486B2 (en)1999-11-152019-09-10Miltenyi Biotech GmbhLigating BDCA-2 protein with BDCA-2 specific antibody for detecting or modulating dendritic cells
US8183039B2 (en)1999-11-152012-05-22Miltenyi Biotec GmbhMethod for isolating BDCA-4+ dendritic cells
US20060233840A1 (en)*1999-11-152006-10-19Miltenyi Biotech GmbhAntigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
US7223902B1 (en)1999-11-192007-05-29Yissum Research Development Company Of The Hebrew University Of JerusalemMethod of producing recombinant Aspergillus niger β-glucosidase and an aroma spreading plant
US20070292930A1 (en)*1999-11-192007-12-20Yissum Research Development Company Of The Hebrew University Of JerusalemMethod of producing recombinant Aspergillus niger beta-glucosidase and an aroma spreading plant
EP2261256A2 (en)1999-11-242010-12-15Schering CorporationMethods of inhibiting metastasis
EP2275447A1 (en)1999-11-242011-01-19Schering CorporationMethods of inhibiting metastasis
EP2336775A2 (en)1999-12-062011-06-22Board Of Trustees Of The University Of IllinoisHigh affinity TCR proteins and methods
EP2287185A2 (en)1999-12-062011-02-23Board Of Trustees Of The University Of IllinoisHigh affinity TCR proteins and methods
EP2042869A2 (en)1999-12-062009-04-01Board Of Trustees Of The University Of IllinoisHigh affinity TCR proteins and methods
US6544792B1 (en)1999-12-212003-04-08Genencor International, Inc.Production of secreted polypeptides
US20050090644A1 (en)*1999-12-212005-04-28Diaz-Torres Maria R.Production of secreted polypeptides
US6642027B2 (en)1999-12-212003-11-04Genecor International, Inc.Production of secreted polypeptides
US20070264274A1 (en)*2000-01-052007-11-15Yeda Research And Development Co. Ltd.Veto cells effective in preventing graft rejection and devoid of graft versus host potential
US7270810B2 (en)2000-01-052007-09-18Yeda Research And Development Co. Ltd.Veto cells effective in preventing graft rejection and devoid of graft versus host potential
US20030211490A1 (en)*2000-01-242003-11-13Hanan SteinPlants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
US7385106B2 (en)2000-01-242008-06-10Ramot At Tel Aviv University Ltd.Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
US20020154615A1 (en)*2000-01-282002-10-24Martin HansDetection method and device
WO2001062271A1 (en)2000-02-222001-08-30The Board Of Trustees Of The University Of ArkansasCompositions and methods for the early diagnosis of ovarian cancer
US8278098B2 (en)2000-02-252012-10-02Vegenics Pty LimitedMaterials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
US20110207664A1 (en)*2000-02-252011-08-25Vegenics Pty LimitedMaterials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and Proteins
US7829313B2 (en)2000-03-242010-11-09Eppendorf Array TechnologiesIdentification and quantification of a plurality of biological (micro)organisms or their components
US20070037187A1 (en)*2000-03-242007-02-15Isabelle AlexandreIdentification and quantification of a plurality of biological (micro)organisms or their components
US20070099204A1 (en)*2000-03-242007-05-03Isabelle AlexandreIdentification and quantification of a plurality of biological (micro)organisms or their components
US7875442B2 (en)2000-03-242011-01-25Eppendorf Array TechnologiesIdentification and quantification of a plurality of biological (micro)organisms or their components
EP2316950A1 (en)2000-03-272011-05-04Technion Research and Development Foundation, Ltd.Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same
US9095533B2 (en)2000-03-272015-08-04Technion Research & Development Foundation LimitedAntigen-presenting complex-binding compositions and uses thereof
EP2258834A1 (en)2000-03-312010-12-08The Scripps Research InstituteHuman aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis
WO2001075078A1 (en)2000-03-312001-10-11The Scripps Research InstituteHUMAN AMINOACYL-tRNA SYNTHETASE POLYPEPTIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS
US20030108927A1 (en)*2000-04-032003-06-12Kathryn LeishmanCompositions and methods for the prevention, treatment and detection of tuberculosis and other diseases
EP1964921A2 (en)2000-04-052008-09-03Oscient Pharmaceuticals CorporationThe high bone mass gene of 11q13.3
EP2389943A1 (en)2000-04-182011-11-30Schering CorporationUse of IL-174 antagonists for treating Th2-related diseases
EP2020239A1 (en)2000-04-182009-02-04Schering CorporationUse of IL-174 agonists for treating infectious diseases
US20030104491A1 (en)*2000-04-302003-06-05Cabantchik Ioav ZviMolecules and methods using same for measuring non-transferrin bound iron
EP2275548A1 (en)2000-05-102011-01-19Schering CorporationMammalian cytokine receptor subunit proteins, related reagents and methods
EP1918377A1 (en)2000-05-102008-05-07Schering CorporationMammalian cytokine receptor subunit proteins, related reagents and methods
EP1908837A2 (en)2000-05-252008-04-09Schering CorporationHuman receptor proteins, related reagents and methods
US20060003358A1 (en)*2000-07-102006-01-05Sequenom, Inc.Polymorphic kinase anchor proteins and nucleic acids encoding the same
US6958214B2 (en)2000-07-102005-10-25Sequenom, Inc.Polymorphic kinase anchor proteins and nucleic acids encoding the same
US8088160B2 (en)2000-07-202012-01-03Multi-Gene Vascular Systems Ltd. (“MGVS”)Drug-eluting intravascular prostheses and methods of use
EP1810978A2 (en)2000-08-082007-07-25St. Jude Children's Research HospitalGroup B streptococcus polypeptides nucleic acids and therapeutic composition and vaccines thereof
EP2359853A1 (en)2000-08-082011-08-24Technion Research and Development Foundation, Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis
EP2359854A1 (en)2000-08-082011-08-24Technion Research and Development Foundation, Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis
US20030114410A1 (en)*2000-08-082003-06-19Technion Research And Development Foundation Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
EP2202240A1 (en)2000-08-182010-06-30Sterix LimitedCompound
EP1683874A2 (en)2000-08-292006-07-26YEDA RESEARCH AND DEVELOPMENT Co. LTD.Methods of isolating genes encoding proteins of specific function and of screening for pharmaceutically active agents
WO2002020569A2 (en)2000-09-082002-03-14Schering CorporationMammalian genes; related reagents and methods
EP2028187A1 (en)2000-09-082009-02-25Board Of Regents, The University Of Texas SystemHuman and mouse targeting peptides identified by phage display
EP2298789A1 (en)2000-09-082011-03-23Schering CorporationMammalian genes; related reagents and methods
US6673623B1 (en)2000-09-122004-01-06Novocure, Inc.Methods and compositions that control lipid production
US7884191B2 (en)2000-09-182011-02-08Danisco Us Inc.Twin-arginine translocation in Bacillus
US20080248525A1 (en)*2000-09-182008-10-09Sierd BronTwin-Arginine translocation in bacillus
US7884192B2 (en)2000-09-182011-02-08Danisco Us Inc.Twin-arginine translocation in Bacillus
US7316924B2 (en)2000-09-182008-01-08Genencor International, Inc.Twin-arginine translocation in Bacillus
US20020110860A1 (en)*2000-09-182002-08-15Sierd BronTwin-arginine translocation in Bacillus
US20080166757A1 (en)*2000-09-182008-07-10Sierd BronTwin-arginine translocation in Bacillus
US7897742B2 (en)2000-09-182011-03-01Danisco Us Inc.Twin-arginine translocation in Bacillus
US8062660B2 (en)2000-09-282011-11-22Nanocyte Inc.Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US20070160546A1 (en)*2000-09-282007-07-12Tamar LotanUse of stinging cells/capsules for the delivery of active agents to keratinous substances
US7998509B2 (en)2000-09-282011-08-16Nanocyte Inc.Use of stinging cells/capsules for the delivery of active agents to keratinous substances
US20060159769A1 (en)*2000-09-282006-07-20Nanocyte Inc.Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US8486441B2 (en)2000-09-282013-07-16Nanocyte Inc.Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US20110070224A1 (en)*2000-09-282011-03-24Nanocyte Inc.Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US20060099273A1 (en)*2000-09-282006-05-11Nanocyte Inc.Sterile preparations and compositions including stinging capsules and methods of producing and using same
US8287912B2 (en)2000-09-282012-10-16Nanocyte Inc.Use of stinging cells/capsules for the delivery of active agents to keratinous substances
US7632522B2 (en)2000-09-282009-12-15Nanocyte Inc.Use of stinging cells/capsules for the delivery of active agents to keratinous substances
US20070281037A9 (en)*2000-09-282007-12-06Nanocyte Inc.Sterile preparations and compositions including stinging capsules and methods of producing and using same
EP2341346A2 (en)2000-10-182011-07-06The Regents of the University of CaliforniaMethods of high-throughput screening for internalizing antibodies and metal-chelating liposomes
US7163800B2 (en)2000-11-032007-01-16Molecular Devices CorporationMethods of screening compositions for G protein-coupled receptor desensitization inhibitory activity
US20040091946A1 (en)*2000-11-032004-05-13Oakley Robert H.Methods of screening compositions for G protein -coupled receptor desensitization inhibitory activity
US7214496B2 (en)2000-11-032007-05-08Duke UniversityModified G-protein coupled receptors
US20050136431A1 (en)*2000-11-032005-06-23Oakley Robert H.Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity
US20050106623A1 (en)*2000-11-032005-05-19Oakley Robert H.Modified G-protein coupled receptors
US7018812B2 (en)2000-11-032006-03-28Duke UniversityModified G-protein coupled receptors
EP2292760A2 (en)2000-11-102011-03-09Schering CorporationMammalian cytokines, receptors, related reagents and methods
EP2186530A1 (en)2000-11-172010-05-19Vascular Biogenics Ltd.Promoters exhibiting endothelial cell specificity and methods of using same
EP2425841A1 (en)2000-11-242012-03-07Vascular Biogenics Ltd.Methods Employing and Compositions Containing Defined Oxidized Phospholipids for Prevention and Treatment of Atherosclerosis
US20020172980A1 (en)*2000-11-272002-11-21Phan Brigitte ChauMethods for decreasing non-specific binding of beads in dual bead assays including related optical biodiscs and disc drive systems
US20030003464A1 (en)*2000-11-272003-01-02Phan Brigitte C.Dual bead assays including optical biodiscs and methods relating thereto
US20040248093A1 (en)*2000-11-272004-12-09Coombs James HowardMagneto-optical bio-discs and systems including related methods
US20030054446A1 (en)*2000-11-292003-03-20Weber Bernard H. F.Novel retina-specific human proteins C7orf9, C12orf7, MPP4 and F379
WO2002044736A2 (en)2000-11-302002-06-06Molecular Skincare LimitedDiagnosis and treatment of epidermal or skin diseases
US20040052769A1 (en)*2000-11-302004-03-18Yair ReisnerMethods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease
EP2357478A2 (en)2000-11-302011-08-17Crawford Healthcare Holdings LimitedDiagnosis of disease
US20020165149A1 (en)*2000-12-082002-11-07Kranz David M.Mutated class II major histocompatibility proteins
US7087395B1 (en)2001-01-162006-08-08Quest Diagnostics Investments IncorporatedVitamin D assay
US20040132109A1 (en)*2001-01-232004-07-08Masato EnariMethod
US20080108085A1 (en)*2001-01-232008-05-08D-Gen LimitedMethod and Detection of the Presence of Prions Protein
US20050031618A1 (en)*2001-01-312005-02-10Dror MevorachInduction of tolerance by apoptotic and/or necrotic cells
US20050202098A1 (en)*2001-01-312005-09-15TolarenDisease therapy using dying or dead cells
EP2135611A1 (en)2001-03-012009-12-23Hollis-Eden Pharmaceuticals Inc.Pregn-5-en-20-yne-3,7,17-triol derivatives for use in therapy
US8497064B2 (en)2001-03-122013-07-30Affymetrix, Inc.Nucleic acid labelling compounds
US20080287667A1 (en)*2001-03-122008-11-20Affymetrix, Inc.Nucleic Acid Labeling Compounds
US8026057B2 (en)2001-03-122011-09-27Affymetrix, Inc.Nucleic acid labeling compounds
US8076072B2 (en)2001-03-122011-12-13Affymetrix, Inc.Nucleic acid labeling compounds
US20110082289A1 (en)*2001-03-122011-04-07Affymetric, Inc.Nucleic Acid Labeling Compounds
US7468243B2 (en)2001-03-122008-12-23Affymetrix, Inc.2-aminopyrimidin-4-one nucleic acid labeling compounds
US20030104410A1 (en)*2001-03-162003-06-05Affymetrix, Inc.Human microarray
EP2308994A1 (en)2001-03-232011-04-13Yeda Research And Development Co., Ltd.Methods for determining a risk to develop cancer
US20030220475A1 (en)*2001-04-032003-11-27Fields Howard A.Neutralizing immunogenic hev polypepetides
US20040214248A1 (en)*2001-04-062004-10-28Roberts David DUse of semenogelin in the diagnosis, prognosis and treatment of cancer
US7618789B2 (en)2001-04-062009-11-17The United States Of America As Represented By The Secretary Of Department Of Health And Human ServicesUse of semenogelin in the diagnosis, prognosis and treatment of cancer
US20100112626A1 (en)*2001-04-062010-05-06The United States Of America, As Represented By The Secretary, Dept. Of Health & Human ServicesUse of Semenogelin in the Diagnosis, Prognosis and Treatment of Cancer
EP2335728A1 (en)2001-05-112011-06-22Ludwig Institute for Cancer Research Ltd.Specific binding proteins and uses thereof
USRE43135E1 (en)2001-05-182012-01-24Danisco A/SMethod of improving dough and bread quality
US20050281916A1 (en)*2001-05-182005-12-22Kirsten BojsenMethod of improving dough and bread quality
EP1990057A1 (en)2001-05-222008-11-12Merck & Co., Inc.Beta-secretase substrates and uses thereof
US20090324612A1 (en)*2001-06-052009-12-31Kaufman Daniel LModulating neuronal outgrowth via the major histocompatibility complex class i (mhc i) molecule
US20030049254A1 (en)*2001-06-052003-03-13Kaufman Daniel L.Modulating neuronal outgrowth via the major histocompatibility complex Class I (MHC I) molecule
US7553484B2 (en)2001-06-052009-06-30The Regents Of The University Of CaliforniaModulating neuronal outgrowth via the major histocompatibility complex class I (MHC I) molecule
EP2080766A1 (en)2001-06-062009-07-22Bristol-Myers Squibb CompanyB7-related nucleic acids and polypeptides useful for immunomodulation
US6770622B2 (en)2001-06-082004-08-03Gary A. JarvisN-terminally truncated galectin-3 for use in treating cancer
US20070190534A1 (en)*2001-06-112007-08-16Genesis Genomics Inc.Mitochondrial sites and genes associated with prostate cancer
US20050022269A1 (en)*2001-07-192005-01-27Joseph HirschbergPolypeptides having carotenoids isomerase catalytic activity, nucleic acids encoding same and uses thereof
US8722866B2 (en)2001-08-012014-05-13The United States Of America, As Represented By The Department Of Veterans AffairsIsoform-selective inhibitors and activators of PDE3 cyclic nucleotide phosphodiesterases
US20030158133A1 (en)*2001-08-012003-08-21Movsesian Matthew A.Isoform-selective inhibitors and activators of PDE3 cyclic nucleotide phosphodiesterases
US7429652B2 (en)2001-08-012008-09-30Abmaxis, Inc.Compositions and methods for generating chimeric heteromultimers
US20050009139A1 (en)*2001-08-012005-01-13Caili WangCompositions and methods for generating chimeric heteromultimers
US20100267046A1 (en)*2001-08-012010-10-21University Of Utah Research FoundationIsoform-selective inhibitor and activators of pde3 cyclic nucleotide phosphodiesterases
US6833441B2 (en)2001-08-012004-12-21Abmaxis, Inc.Compositions and methods for generating chimeric heteromultimers
US20030082596A1 (en)*2001-08-082003-05-01Michael MittmannMethods of genetic analysis of probes: test3
US20060073530A1 (en)*2001-08-152006-04-06Olaf SchneewindMethods and compositions involving sortase B
US7442781B2 (en)2001-08-162008-10-28Urifer Ltd.Diagnosis, prevention and treatment of cancer
US20030064058A1 (en)*2001-09-072003-04-03Nadir AskenasyMethods of utilizing bone marrow stem cells for inducing immunological tolerance
US7138144B2 (en)2001-09-072006-11-21Nadir AskenasyMethod of inducing immune tolerance via blood/lymph flow-restricted bone marrow transplantation
EP2131198A2 (en)2001-09-202009-12-09Board of Regents, The University of Texas SystemMeasuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
US7687281B2 (en)2001-09-282010-03-30Aspenbio Pharma, Inc.Bovine pregnancy test
US7393696B2 (en)2001-09-282008-07-01Aspenbio Pharma, Inc.Bovine pregnancy test
US20030073248A1 (en)*2001-09-282003-04-17J.W. RothBovine pregnancy test
EP2316845A1 (en)2001-10-112011-05-04Amgen Inc.Specific binding agents of human angiopoietin-2
EP2070944A1 (en)2001-10-112009-06-17Amgen Inc.Specific binding agents of human angiopoietin-2
EP2157097A1 (en)2001-10-112010-02-24Amgen, Inc.Specific binding agents of human angiopoietin-2
EP2272869A2 (en)2001-10-112011-01-12Amgen Inc.Angiopoietin-2 specific binding agents
EP2072059A1 (en)2001-10-122009-06-24Schering CorporationUse of bispecific antibodies to regulate immune responses
WO2003030835A2 (en)2001-10-122003-04-17Schering CorporationUse of bispecific antibodies to regulate immune responses
EP2316485A1 (en)2001-10-122011-05-04Schering CorporationUse of bispecific antibodies to regulate immune responses
US8415318B2 (en)2001-10-192013-04-09Vascular Biogenics Ltd.Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
US20060281181A1 (en)*2001-11-022006-12-14Caili WangAdaptor-directed helper systems
US7175983B2 (en)2001-11-022007-02-13Abmaxis, Inc.Adapter-directed display systems
US7910350B2 (en)2001-11-022011-03-22Abmaxis, Inc.Adaptor-directed helper systems
US20030104355A1 (en)*2001-11-022003-06-05Caili WangAdapter-directed display systems
WO2003043524A2 (en)2001-11-202003-05-30The Curators Of The University Of MissouriCompositions and methods for accurate early pregnancy diagnosis
US20030105770A1 (en)*2001-11-262003-06-05Macleod StewartExtending a directory schema independent of schema modification
US20060051426A1 (en)*2001-12-052006-03-09Gershon GolombNanoparticles containing polymeric nucleic acid homologs pharmaceutical composition and articles of manufacture containing same and methods of use thereof
US8178128B2 (en)2001-12-052012-05-15Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Nanoparticles containing polymeric nucleic acid homologs
US20060100422A1 (en)*2001-12-192006-05-11Goldberg Steven LPichia pastoris formate dehydrogenase and uses therefor
US7087418B2 (en)2001-12-192006-08-08Bristol-Myers Squibb CompanyPichia pastoris formate dehydrogenase and uses therefor
US20040038237A1 (en)*2001-12-192004-02-26Goldberg Steven L.Pichia pastoris formate dehydrogenase and uses therefor
US20050085432A1 (en)*2001-12-262005-04-21Aviva LapidotMethods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections
US20080113394A1 (en)*2002-01-162008-05-15Fatemi S HMethods for Diagnosing Major Depression
US7341844B2 (en)2002-01-162008-03-11Regents Of The University Of MinnesotaMethods for diagnosing autism
US20080113395A1 (en)*2002-01-162008-05-15Fatemi S HMethods for Diagnosing Bi-Polar Disorder
US7682805B2 (en)2002-01-162010-03-23Regents Of The University Of MinnesotaMethods for diagnosing major depression or schizophrenia
US7682806B2 (en)2002-01-162010-03-23Regents Of The University Of MinnesotaMethods for diagnosing bipolar disorder
US20080113393A1 (en)*2002-01-162008-05-15Fatemi S HMethods for Diagnosing Schizophrenia
US20030211556A1 (en)*2002-01-162003-11-13Fatemi S. HosseinMarker for psychiatric conditions
EP1975231A1 (en)2002-01-222008-10-01Corixa CorporationCompositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7955852B2 (en)2002-01-242011-06-07Gamida Cell Ltd.Expansion of renewable stem cell populations
EP2305794A1 (en)2002-01-242011-04-06Gamida Cell Ltd.Expansion of renewable stem cell populations
EP2371861A1 (en)2002-01-252011-10-05G2 Therapies LimitedMonoclonal antibodies against extracellular loops of C5aR
US7655225B2 (en)2002-01-252010-02-02Gamida Cell, Ltd.Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
US8221757B2 (en)2002-01-252012-07-17G2 Therapies LtdMonoclonal antibodies against extracellular loops of C5aR
US8673305B2 (en)2002-01-252014-03-18G2 Therapies LtdMethods of treatment with antibodies against the extracellular loops of C5aR
US8993510B2 (en)2002-01-312015-03-31Tel Aviv University Future Technology Development L.P.Peptides and methods using same for diagnosis and treatment of amyloid-associated disease
US20060234947A1 (en)*2002-01-312006-10-19Tel Aviv University Future Technology Development L.PPeptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US8697634B2 (en)2002-01-312014-04-15Tel Aviv University Future Technology Development L.P.Peptides and methods using same for diagnosis and treatment of amyloid-associated disease
US20100105608A1 (en)*2002-01-312010-04-29Tel Aviv University Future Technology Development L.P.Peptides and methods using same for diagnosis and treatment of amyloid-associated disease
US7781396B2 (en)2002-01-312010-08-24Tel Aviv University Future Technology Development L.P.Peptides directed for diagnosis and treatment of amyloid-associated disease
US8012929B2 (en)2002-01-312011-09-06Tel Aviv University Future Technology Development L.P.Peptides directed for diagnosis and treatment of amyloid-associated diseases
US20100022459A1 (en)*2002-01-312010-01-28Tel Aviv University Future Technology Development L.PPeptides directed for diagnosis and treatment of amyloid-associated diseases
EP2077277A1 (en)2002-02-012009-07-08Schering CorporationUse of mammalian cytokine; related reagents
EP2311869A1 (en)2002-02-012011-04-20Schering CorporationUse of mammalian cytokine; related reagents
EP2072045A2 (en)2002-02-132009-06-24Technion Research and Development Foundation, Ltd.Antibody having a t-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP2329814A1 (en)2002-02-132011-06-08Technion Research and Development Foundation, Ltd.Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer
US6992176B2 (en)2002-02-132006-01-31Technion Research & Development Foundation Ltd.Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20050287141A1 (en)*2002-02-132005-12-29Technion Research & Development Foundation Ltd.Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20050255101A1 (en)*2002-02-132005-11-17Technion Research And Development Foundation Ltd.Antibody having a t-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US7718777B2 (en)2002-02-202010-05-18Technion Research & Development Foundation Ltd.MHC-peptide complex binding ligands
US20070196369A1 (en)*2002-02-202007-08-23Hoogenboom Henricus Renerus JMHC-peptide complex binding ligands
US20100228007A1 (en)*2002-02-202010-09-09Technion Research & Development Foundation Ltd.Mhc-peptide complex binding ligands
WO2003072799A2 (en)2002-02-222003-09-04The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human ServicesBrother of the regulator of imprinted sites (boris)
US7053188B2 (en)2002-02-222006-05-30Purdue Research FoundationMonoclonal antibodies specific for neoplasia-specific NADH:disulfide reductase
US20050220774A1 (en)*2002-03-182005-10-06Tony PeledMethods of inducing differentiation in ex vivo expanded stem cells
US20060026702A1 (en)*2002-03-192006-02-02Duke UniversityPhosphoinositide 3-kinase mediated inhibition of GPCRs
US20030182669A1 (en)*2002-03-192003-09-25Rockman Howard A.Phosphoinositide 3-kinase mediated inhibition of GPCRs
US7611723B2 (en)2002-03-262009-11-03Nanocyte Inc.Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US20100111869A1 (en)*2002-03-262010-05-06Nanocyte Inc.Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US8337868B2 (en)2002-03-262012-12-25Nanocyte Inc.Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US20060039897A1 (en)*2002-03-262006-02-23Tamar LotanStinging cells expressing an exogenous polycleotide encoding a therpeutic, diagnostics or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derive therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US20060029984A1 (en)*2002-05-012006-02-09Jonathan ReevesPSP94 diagnostic reagents and assays
US20040009164A1 (en)*2002-05-012004-01-15Jonathan ReevesPSP94 diagnostic reagents and assays
US7432342B2 (en)2002-05-032008-10-07Sequenom, Inc.Kinase anchor protein muteins, peptides thereof and related documents
US20040121442A1 (en)*2002-05-052004-06-24Ilan ChetFungal chitinase, polynucleotide sequences encoding same, promoters of same, and uses thereof
WO2003101386A2 (en)2002-05-302003-12-11Memorial Sloan-Kettering Cancer CenterKinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis
US7785898B2 (en)2002-05-312010-08-31Genetic Technologies LimitedMaternal antibodies as fetal cell markers to identify and enrich fetal cells from maternal blood
US20050287604A1 (en)*2002-05-312005-12-29Bohmer Ralph MMaternal antibodies as fetal cell markers to identify and enrich fetal cells from maternal blood
US20030222908A1 (en)*2002-06-032003-12-04Microsoft CorporationDynamic wizard interface system and method
EP2281578A2 (en)2002-07-152011-02-09Board of Regents, The University of Texas SystemSelected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in treating viral infections and cancer
EP2266624A2 (en)2002-07-152010-12-29Board of Regents, The University of Texas SystemDuramycin peptide binding to anionic phospholipids and aminophospholipids conjugates and their use in treating viral infections
WO2005019409A2 (en)2002-07-152005-03-03Board Of Regents, The University Of Texas SystemCombinatorial protein library screening by periplasmic expression
US8828386B2 (en)2002-07-252014-09-09Glenveigh Pharmaceuticals, LlcMethod for extending pregnancy by reducing intraventricular hemorrhaging in patients exhibiting at least one symptom of preeclampsia and eclampsia
EP2561889A2 (en)2002-08-012013-02-27Yeda Research and Development Co. Ltd.Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
US8030456B2 (en)2002-08-102011-10-04Yale UniversityNogo receptor antagonists
US20050271655A1 (en)*2002-08-102005-12-08Biogen Idec Ma Inc.Nogo receptor antagonists
US7465705B2 (en)2002-08-102008-12-16Yale UniversityNogo receptor antagonists
EP2298315A1 (en)2002-08-282011-03-23Harbor BioSciences, Inc.Therapeutic treatment methods
EP2298316A1 (en)2002-08-282011-03-23Harbor BioSciences, Inc.Therapeutic treatment methods
US20040052928A1 (en)*2002-09-062004-03-18Ehud GazitPeptides and methods using same for diagnosing and treating amyloid-associated diseases
US20090209041A1 (en)*2002-09-062009-08-20Tel Aviv University Future Technology Development L.P.Peptides and methods for inhibiting amyloid formation
US20070135334A1 (en)*2002-09-062007-06-14Tel Aviv University Future Technology Development L.P.Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US8563273B2 (en)2002-09-062013-10-22Tel Aviv University Future Technology Development L.P.Method of screening for compounds that disaggregate amyloid aggregates
EP2026070A1 (en)2002-09-092009-02-18Arbor Vita CorporationMethods of diagnosing cervical cancer
EP2371955A1 (en)2002-09-262011-10-05K.U. Leuven Research & DevelopmentIntegrase cofactor
EP2182052A1 (en)2002-10-072010-05-05Technion Research and Development Foundation, Ltd.Human foreskin cells suitable for culturing stem cells
WO2004037251A1 (en)2002-10-242004-05-06Sterix LimitedInhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2
US20040146949A1 (en)*2002-10-252004-07-29Jun TanMethods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease
EP2295980A1 (en)2002-10-302011-03-16Yissum Research Development Company, of The Hebrew University of JerusalemMolecules and methods using same for measuring non-transferrin bound iron
US20050054097A1 (en)*2002-11-172005-03-10Tony PeledEX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
US20060198817A1 (en)*2002-11-262006-09-07Alverdy John CMaterials and methods for preventing and treating microbe-mediated epithelial disorders
US9549946B2 (en)2002-11-262017-01-24The University Of ChicagoMaterials and methods for preventing and treating microbe-mediated epithelial disorders
EP2062918A2 (en)2002-11-272009-05-27Technion Research and Development Foundation, Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
EP2062919A2 (en)2002-11-272009-05-27Technion Research and Development Foundation, Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
US8815823B2 (en)2002-11-272014-08-26Technion Research & Development Foundation Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
US20100119515A1 (en)*2002-11-272010-05-13Gera NeufeldPharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
US8163494B2 (en)2002-11-272012-04-24Technion Research & Development Foundation Ltd.Method for assessing metastatic properties of breast cancer
US8168180B2 (en)2002-11-272012-05-01Technion Research & Development Foundation Ltd.Methods and compositions for modulating angiogenesis
US20110027887A1 (en)*2002-11-292011-02-03Technion Research & Development Foundation Ltd.Method of dynamically culturing embryonic stem cells
US7947499B2 (en)2002-11-292011-05-24Technion Research & Development Foundation Ltd.Method of dynamically culturing embryonic stem cells
US20060148078A1 (en)*2002-11-292006-07-06Sharon Gerecht-NirMethod of dynamically culturing embryonic stem cells
WO2004060909A2 (en)2002-12-042004-07-22Genencor International, Inc.Increasing production of proteins in gram-positive microorganisms
EP2031070A1 (en)2002-12-042009-03-04Applera CorporationMultiplex amplification of polynucleotides
EP3000899A1 (en)2002-12-042016-03-30Applied Biosystems, LLCMultiplex amplification of polynucleotides
EP2194147A1 (en)2002-12-042010-06-09Applied Biosystems, LLCMultiplex amplification of polynucleotides
US8053554B2 (en)2002-12-092011-11-08Ramot At Tel-Aviv University Ltd.Peptide nanostructures and methods of generating and using the same
US20090123553A1 (en)*2002-12-092009-05-14Ramot At Tel Aviv University Ltd.Peptide nanostructures and methods of generating and using the same
EP2338896A2 (en)2002-12-122011-06-29R.B.T. (Rakuto Bio Technologies) Ltd.Use of lignin peroxidase in skin and hair lightening
EP2457999A2 (en)2002-12-162012-05-30Technion Research & Development Foundation Ltd.Culture medium for pluropotent stem cells
US20040186280A1 (en)*2002-12-192004-09-23Murdoch UniversityBmpB novel nucleotide and amino acid sequences and diagnostic and therapeutic uses thereof
US20060057151A1 (en)*2002-12-192006-03-16Hampson David JBmpB novel nucleotide and amino acid sequences and diagnostic and therapeutic uses thereof
WO2004060135A2 (en)2003-01-022004-07-22Rappaport Family Institute For Research In The Medical SciencesMethods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients
US20040229245A1 (en)*2003-01-062004-11-18Anton BittnerMethods and algorithms for performing quality control during gene expression profiling on DNA microarray technology
EP2058275A1 (en)2003-01-072009-05-13Ramot at Tel-Aviv University Ltd.Peptide nanostructures encapsulating a foreign material and method of manufacturing same
US8017586B2 (en)2003-01-072011-09-13Ramot At Tel-Aviv University Ltd.Peptide nanostructures encapsulating a foreign material and method of manufacturing same
US20090121709A1 (en)*2003-01-072009-05-14Ramot At Tel Aviv University Ltd.Peptide nanostructures encapsulating A foreign material and method of manufacturing same
US8278062B2 (en)2003-01-142012-10-02Dupont Nutrition Biosciences ApsMethod of using lipid acyltransferase
US7955813B2 (en)2003-01-172011-06-07Danisco, A/SMethod of using lipid acyltransferase
US20070122525A1 (en)*2003-01-172007-05-31Kreij Arno DMethod
EP3323887A2 (en)2003-01-172018-05-23DuPont Nutrition Biosciences ApSMethod for the in situ production of an emulsifier in a foodstuff
EP2290085A2 (en)2003-01-172011-03-02Danisco A/SMethod for the in situ production of an emulsifier in a foodstuff
US7955814B2 (en)2003-01-172011-06-07Danisco A/SMethod
US20070026106A1 (en)*2003-01-172007-02-01Kreij Arno DMethod
US8003095B2 (en)2003-01-172011-08-23Danisco A/SMethod of using lipid acyltransferase
EP2287317A2 (en)2003-01-172011-02-23Danisco A/SMethod of producing a protein ester or a protein subunit ester
EP2278015A1 (en)2003-01-172011-01-26Danisco A/SMethod of producing a carbohydrate ester
US20060263828A1 (en)*2003-01-242006-11-23Sudha ShenoyModified trafficking patterns for arrestin and g-protein-coupled receptors via arrestin-ubiquitin chimera
US7615610B2 (en)2003-01-242009-11-10Duke UniversityModified trafficking patterns for arrestin and G-protein-coupled receptors via arrestin-ubiquitin chimera
US20050032126A1 (en)*2003-03-032005-02-10Coombs James H.Methods and apparatus for use in detection and quantitation of various cell types and use of optical bio-disc for performing same
EP2319857A2 (en)2003-03-042011-05-11Yeda Research And Development Co., Ltd.Pon polypeptides, polynucleotides encoding same and compositions and methods utilizing same
US8394582B2 (en)2003-03-052013-03-12Genetic Technologies, IncIdentification of fetal DNA and fetal cell markers in maternal plasma or serum
US20070134658A1 (en)*2003-03-052007-06-14Genetic Technologies Limited, A.C.N. 009 212 328Identification of fetal dna and fetal cell markers in maternal plasma or serum
EP2216033A2 (en)2003-03-062010-08-11Yeda Research and Development Co. Ltd.Methods of treating disease by transplantation of allogeneic or xenogeneic organs or tissues
US20050054103A1 (en)*2003-03-072005-03-10Tony PeledExpansion of renewable stem cell populations using modulators of PI 3-kinase
WO2004096157A2 (en)2003-03-072004-11-11New England Medical Center Hospitals, Inc.Treatment of igai deposition diseases
US20050152912A1 (en)*2003-03-262005-07-14Technion Research & Development Foundation Ltd.Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20060083735A1 (en)*2003-03-262006-04-20Technion Research & Development Foundation Ltd.Antigen-presenting complex-binding compositions and uses thereof
US7632923B2 (en)2003-03-262009-12-15Technion Research & Development Foundation Ltd.Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20100080805A1 (en)*2003-03-262010-04-01Technion Research & DevelopmentCompositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US9616112B2 (en)2003-03-262017-04-11Technion Research & Development Foundation LimitedCompositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US7638124B2 (en)2003-03-262009-12-29Technion Research & Development Foundation Ltd.Antigen-presenting complex-binding compositions and uses thereof
US9023348B2 (en)2003-03-262015-05-05Technion Research & Development Foundation LimitedCompositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20040197334A1 (en)*2003-04-022004-10-07Technion Research & Development Foundation Ltd.Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
US7294701B2 (en)2003-04-022007-11-13Technion Research & Development Foundation Ltd.Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
EP2330132A1 (en)2003-04-042011-06-08Yeda Research and Development Co. Ltd.Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
US8252588B2 (en)2003-04-082012-08-28Yeda Research And Development Co. Ltd.Stem cells having increased sensitivity to SDF-1 and methods of generating and using same
US8388954B2 (en)2003-04-092013-03-05Laboratoire Francais Du Fractionnement Et Des BiotechnologiesStabilising formulation for immunoglobulin G compositions in liquid form and in lyophilised form
US9463241B2 (en)2003-04-092016-10-11Laboratoire Francais Du Fractionnement Et Des BiotechnologiesMethod for stabilising an immunoglobulin G composition in liquid form
US20040209246A1 (en)*2003-04-152004-10-21Agouron Pharmaceuticals, Inc.Dual reporter/dye reduction methodology for evaluating antiviral and cytotoxicity of hepatitis C virus inhibitors
US20070065429A1 (en)*2003-04-162007-03-22Biogen Idec Ma Inc.Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques
US7355079B2 (en)2003-04-182008-04-08The Regents Of The University Of CaliforniaThyronamine derivatives and analogs and methods of use thereof
US20060035980A1 (en)*2003-04-182006-02-16Scanlan Thomas SThyronamine derivatives and analogs and methods of use thereof
EP2365087A2 (en)2003-05-222011-09-14Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US8481812B2 (en)2003-05-222013-07-09Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants generated thereby
US7554007B2 (en)2003-05-222009-06-30Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants
US10184132B2 (en)2003-05-222019-01-22Evogene Ltd.Methods of increasing abiotic stress tolerance, yield and/or biomass in plants
US9303269B2 (en)2003-05-222016-04-05Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants
US20060123516A1 (en)*2003-05-222006-06-08Gil RonenMethods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US20050020499A1 (en)*2003-05-272005-01-27Bar Ilan UniversityMethods of attenuating cocaine seeking behavior employing glial cell-derived neurotrophic factor (GDNF) and pharmaceutical compositions and articles of manufacture suited for use in practice of the method
US20090036321A1 (en)*2003-06-032009-02-05Chiron CorporationMethods for predicting the course of a malignant disease
US20060260002A1 (en)*2003-06-192006-11-16Gil RonenNucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US8129514B2 (en)2003-06-192012-03-06Evogene Ltd.Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US20090253170A1 (en)*2003-06-192009-10-08Evogene Ltd.Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US7498428B2 (en)2003-06-192009-03-03Evogene Ltd.Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
EP2719394A1 (en)2003-06-302014-04-16Tel Aviv University Future Technology Development L.P.Peptides antibodies directed thereagainst for diagnosing and treating amyloid-associated diseases
EP2526952A1 (en)2003-07-152012-11-28Bar-Ilan UniversityMethods and pharmaceutical compositions for healing wounds
EP2526953A1 (en)2003-07-152012-11-28Bar-Ilan UniversityMethods and pharmaceutical compositions for healing wounds
EP2540301A2 (en)2003-07-152013-01-02Bar-Ilan UniversityMethods and pharmaceutical compositions for healing wounds
EP2540302A1 (en)2003-07-152013-01-02Bar-Ilan UniversityMethods and pharmaceutical compositions for healing wounds
EP2128270A1 (en)2003-08-082009-12-02Genenews Inc.Osteoarthritis biomarkers and uses thereof
US20050064479A1 (en)*2003-08-122005-03-24Affymetrix, Inc.Compounds and methods for post incorporation labeling of nucleic acids
US20050271643A1 (en)*2003-08-142005-12-08Iryna SorokulovaBacterial strains, compositions including same and probiotic use thereof
WO2005016282A2 (en)2003-08-142005-02-24Exelixis, Inc.Prkcs as modifiers of the beta catenin pathway and methods of use
EP2280285A1 (en)2003-09-152011-02-02Oklahoma Medical Research FoundationMethod of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases
EP2280286A1 (en)2003-09-152011-02-02Oklahoma Medical Research FoundationMethod of using cytokine assays to diagnose, treat, and evaluate systemic lupus erythematosus
EP2287616A1 (en)2003-09-152011-02-23Oklahoma Medical Research FoundationMethod of using cytokine assays to diagnose, treat, and evaluate systemic lupus erythematosus
US20070054288A1 (en)*2003-09-242007-03-08Intel CorporationProgrammable molecular barcodes
US20060199216A1 (en)*2003-09-242006-09-07Intel CorporationProgrammable molecular barcodes
US20050064435A1 (en)*2003-09-242005-03-24Xing SuProgrammable molecular barcodes
US7625707B2 (en)2003-10-022009-12-01Ramot At Tel Aviv University Ltd.Antibacterial agents and methods of identifying and utilizing same
WO2005033145A1 (en)2003-10-072005-04-14Yeda Research And Development Co. Ltd.Antibodies to nik, their preparation and use
WO2005033142A2 (en)2003-10-072005-04-14Yeda Research And Development Co. Ltd.Anti-nik antibodies and uses thereof
EP2354164A1 (en)2003-10-072011-08-10Yeda Research And Development Co., Ltd.Anti-NIK antibodies and uses thereof
EP2322561A1 (en)2003-10-072011-05-18Yeda Research And Development Co., Ltd.Anti-NIK antibodies and uses thereof
US9447454B2 (en)2003-10-232016-09-20The Rockefeller UniversityMethod of purifying RNA binding protein-RNA complexes
US20060257429A1 (en)*2003-10-232006-11-16Dreier Kimberly JVaccine for periodontal disease
EP2292661A2 (en)2003-11-102011-03-09Schering CorporationInterleukin-10 antibodies
EP2256203A1 (en)2003-11-212010-12-01Schering CorporationIL-23 and its receptor; related reagents and methods
WO2005051423A2 (en)2003-11-302005-06-09Yeda Research And Development Co. LtdMethods and agents for immune modulation and methods for identifying immune modulators
EP2135619A1 (en)2003-12-102009-12-23Millennium Pharmaceuticals, Inc.Humanized anti-CCR2 antibodies and methods of use therefor
US7790673B2 (en)2003-12-122010-09-07New York UniversityMethods and compositions relating to cystatin C
US20070032421A1 (en)*2003-12-122007-02-08Efrat LevyMethods and compositions relating to cystatin C
US20100221233A1 (en)*2003-12-152010-09-02University Of South FloridaCompositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers
EP2289567A2 (en)2003-12-222011-03-02Regentis Biomaterials Ltd.Matrix comprising naturally-occurring crosslinked protein backbone
US9611315B2 (en)2003-12-232017-04-04Arbor Vita CorporationAntibodies for oncogenic strains of HPV and methods of their use
US8440435B2 (en)2003-12-242013-05-14Dupont Nutrition Biosciences ApsMethod for reducing 1,2-diglyceride content of an edible oil
US20100062501A1 (en)*2003-12-242010-03-11Paul WassellMethod
EP2119771A2 (en)2003-12-242009-11-18Danisco A/SProteins
US8030044B2 (en)2003-12-242011-10-04Danisco A/SLipid acyltransferases
US8007847B2 (en)2004-01-132011-08-30Eytan BidermanFeeding formula appliance
US20050158822A1 (en)*2004-01-202005-07-21Insight Biopharmaceuticals Ltd.High level expression of recombinant human erythropoietin having a modified 5'-UTR
US7893240B2 (en)2004-01-202011-02-22Insight Biopharmaceuticals Ltd.High level expression of recombinant human erythropoietin having a modified 5′-UTR
US20080312179A1 (en)*2004-01-202008-12-18Insight Biopharmaceuticals Ltd.High level expression of recombinant human erythropoietin having a modified 5'-UTR
US7423139B2 (en)2004-01-202008-09-09Insight Biopharmaceuticals Ltd.High level expression of recombinant human erythropoietin having a modified 5′-UTR
US20050186646A1 (en)*2004-01-262005-08-25Cruz Miguel A.Rapid assay to detect ADAMTS-13 activity
US20110091454A1 (en)*2004-01-272011-04-21Alex DiberMethods and systems for annotating biomolecular sequences
US20070178462A1 (en)*2004-02-182007-08-02Uebele Victor NNucleic acid molecules encoding novel murine low-voltage activated calcium channel proteins, designated-alpha1h, encoded proteins and methods of use thereof
EP2514763A1 (en)2004-02-202012-10-24The Ludwig Institute for Cancer ResearchEgf receptor epitope peptides and uses thereof
EP2177503A1 (en)2004-02-202010-04-21UCL Business PLCModulators of cannabinoid receptors
EP2208797A2 (en)2004-03-012010-07-21Applied Biosystems, LLCMethods, compositions and kits for use in polynucleotide amplification
EP3006039A1 (en)2004-03-022016-04-13Acceleron Pharma Inc.Alk7 polypeptides for use in promoting fat loss
US8352031B2 (en)2004-03-102013-01-08Impulse Dynamics NvProtein activity modification
EP2266405A2 (en)2004-03-122010-12-29Danisco A/SFungal lipolytic enzymes
EP2275445A2 (en)2004-03-122011-01-19Vasgene Therapeutics, Inc.Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
US8012732B2 (en)2004-03-122011-09-06Danisco A/SFungal lypolytic and amylase enzyme composition and methods using the same
EP2287194A2 (en)2004-03-122011-02-23Vasgene Therapeutics, Inc.Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
US20080206188A1 (en)*2004-04-202008-08-28Alverdy John CTherapeutic Delivery System Comprising a High Molecular Weight Peg-Like Compound
EP2400030A1 (en)2004-05-182011-12-28The Board Of Trustees Of The University Of the Leland Stanford Junior UniversityDetection of protein translocation by beta-galactosidase reporter fragment complementation
WO2005118864A2 (en)2004-05-282005-12-15Agensys, Inc.Antibodies and related molecules that bind to psca proteins
EP2428522A1 (en)2004-05-282012-03-14Agensys, Inc.Antibodies that bind to PSCA proteins for diagnosis of cancer
EP2583981A2 (en)2004-05-282013-04-24Agensys, Inc.Antibodies and related molecules that bind to PSCA proteins
EP2343373A1 (en)2004-06-142011-07-13Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US9012728B2 (en)2004-06-142015-04-21Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US20090126042A1 (en)*2004-06-142009-05-14Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US8962915B2 (en)2004-06-142015-02-24Evogene Ltd.Isolated polypeptides, polynucleotides encoding same, transgenic plants expressing same and methods of using same
EP2336330A2 (en)2004-06-142011-06-22Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US8034553B2 (en)2004-06-242011-10-11Kimberly-Clark Worldwide, Inc.Biomarkers for wound healing
US20060002135A1 (en)*2004-07-012006-01-05Eurodent S.P.A.Dental lamp particularly for medical and dental surgeries
US8680062B2 (en)2004-07-062014-03-25Deliversir Ltd.System for delivering therapeutic agents into living cells and cells nuclei
US20090156471A1 (en)*2004-07-152009-06-18Ramot At Tel Aviv University Ltd.Use of anti-amyloid agents for treating and typing pathogen infections
US20110014317A1 (en)*2004-07-162011-01-20Andrei MiasnikovLipolytic enzyme uses thereof in the food industry
EP2275522A2 (en)2004-07-162011-01-19Danisco A/SEnzymatic oil-degumming method
US8192782B2 (en)2004-07-162012-06-05Danisco A/SEnzymatic oil-degumming method
EP2267107A2 (en)2004-07-162010-12-29Danisco A/SLipolytic Enzyme. Uses Thereof In The Food Industry
US8535900B2 (en)2004-07-162013-09-17Dupont Nutrition Biosciences ApsLipolytic enzyme uses thereof in the food industry
EP2267108A1 (en)2004-07-162010-12-29Danisco A/SEnzymatic oil-degumming method
US8889371B2 (en)2004-07-162014-11-18Dupont Nutrition Biosciences ApsLipolytic enzyme: uses thereof in the food industry
US20090233986A1 (en)*2004-07-272009-09-17Mount Sinai School Of MedicineMethods and compositions for using sax2
US20090035784A1 (en)*2004-07-302009-02-05Mount Sinai School Of Medicine Of New York UniversityNpc1l1 and npc1l1 inhibitors and methods of use thereof
US20090208533A1 (en)*2004-08-112009-08-20University Of Georgia Research Foundation, Inc.Neisseria meningitidis serogroup a capsular polysaccharide acetyltransferase, methods and compositions
US7883876B2 (en)2004-08-112011-02-08Stephens David SNeisseria meningitidis serogroup A capsular polysaccharide acetyltransferase, methods and compositions
US20110111041A1 (en)*2004-08-262011-05-12EnGenelC Therapy Pty. Ltd.Bacterially derived intact minicells that encompass plasmid free functional nucleic acid for in vivo delivery to mammalian cells
US9730897B2 (en)2004-08-262017-08-15Engeneic Molecular Delivery Pty LtdDelivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
US8735566B2 (en)2004-08-262014-05-27Engeneic Molecular Delivery Pty LtdBacterially derived intact minicells that encompass plasmid free functional nucleic acid for in vivo delivery to mammalian cells
US8691963B2 (en)2004-08-262014-04-08Engeneic Molecular Delivery Pty. Ltd.Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
EP2386640A2 (en)2004-08-262011-11-16EnGeneIC Molecular Delivery Pty LtdDelivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
US9242007B2 (en)2004-08-262016-01-26Engeneic Molecular Delivery Pty. Ltd.Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
US8956864B2 (en)2004-08-262015-02-17Engeneic Molecular Delivery Pty LtdBacterially derived intact minicells that encompass plasmid free functional nucleic acid for in vivo delivery to mammalian cells
US20080299084A1 (en)*2004-08-262008-12-04Engeneic Therapy Pty. Ltd.Bacterially derived intact minicells that encompass plasma free functional nucleic acid for in vivo delivery to mammalian cells
US10441546B2 (en)2004-08-262019-10-15Engenelc Molecular Delivery Pty LtdBacterially derived intact minicells that encompass plasmid free DNA and methods of using the same
US9066982B2 (en)2004-08-262015-06-30Engeneic Molecular Delivery Pty Ltd.Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells
US10383827B2 (en)2004-08-262019-08-20Engeneic Molecular Delivery Pty LtdBacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells
US10098847B2 (en)2004-08-262018-10-16Engeneic Molecular Delivery Pty LtdBacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells
US8669101B2 (en)2004-08-262014-03-11Engeneic Molecular Delivery Pty. Ltd.Bacterially derived intact minicells that encompass plasmid free functional nucleic acid for in vivo delivery to mammalian cells
US10426736B2 (en)2004-08-262019-10-01Engeneic Molecular Delivery Pty. Ltd.Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
WO2006024694A2 (en)2004-09-032006-03-09Licentia OyPeptide inhibitors of hk2 and their use
EP2343311A2 (en)2004-09-032011-07-13Licentia OyPeptide inhibitors of HK2 and their use
EP2246444A1 (en)2004-09-142010-11-03The Regents of the University of Colorado, A Body CorporateMethod for treatment with bucindolol based on genetic targeting
US8080417B2 (en)2004-09-162011-12-20Gamida-Cell Ltd.Methods of ex vivo hematopoietic stem cell expansion by co-culture with mesenchymal cells
EP2359832A2 (en)2004-09-182011-08-24University of Maryland, BaltimoreTherapeutic agents targeting the NCCA-ATP channel and methods of use thereof
WO2006034048A2 (en)2004-09-182006-03-30University Of Maryland, BaltimoreTherapeutic agents targeting the ncca-atp channel and methods of use thereof
EP2382977A1 (en)2004-09-182011-11-02University of Maryland, BaltimoreTherapeutic agents targeting the ncca-atp channel and methods of use thereof
US7645861B2 (en)2004-09-242010-01-12Amgen Inc.Modified Fc molecules
US7442778B2 (en)2004-09-242008-10-28Amgen Inc.Modified Fc molecules
US20060140934A1 (en)*2004-09-242006-06-29Colin GeggModified Fc molecules
US7750128B2 (en)2004-09-242010-07-06Amgen Inc.Modified Fc molecules
US7750127B2 (en)2004-09-242010-07-06Amgen Inc.Modified Fc molecules
US20090022744A1 (en)*2004-09-242009-01-22Amgen Inc.Modified Fc molecules
US7662931B2 (en)2004-09-242010-02-16Amgen Inc.Modified Fc molecules
US20090012272A1 (en)*2004-09-242009-01-08Amgen Inc.Modified Fc molecules
US7655765B2 (en)2004-09-242010-02-02Amgen Inc.Modified Fc molecules
US7655764B2 (en)2004-09-242010-02-02Amgen Inc.Modified Fc molecules
US20080131419A1 (en)*2004-09-292008-06-05Yissum Research Development Company Of The Hebrew University Of JerusalemRecombinant Human T2 Rnase and Uses Thereof
EP3088528A1 (en)2004-09-292016-11-02Collplant Ltd.Collagen producing plants and methods of generating and using same
US8039240B2 (en)2004-09-292011-10-18Yissum Reseach Development Company Of The Hebrew University Of JerusalemRecombinant human T2 RNase and uses thereof
EP2816117A2 (en)2004-09-292014-12-24Collplant Ltd.Collagen producing plants and methods of generating and using same
US9273295B2 (en)2004-10-042016-03-01Dupont Nutrition Biosciences ApsMutant citrobacter freundii phytase polypeptide
US8143045B2 (en)2004-10-042012-03-27Danisco A/SMutant Citrobacter freundii phytase polypeptide
US7390489B2 (en)2004-10-082008-06-24Komed Co., Ltd.Monoclonal antibody selectively recognizing listeria monocytogenes, hybridoma producing the antibody, test kit comprising the antibody and detection method of listeria monocytogenes using the antibody
US20060078951A1 (en)*2004-10-082006-04-13Youn Byung SMonoclonal antibody selectively recognizing listeria monocytogenes, hybridoma producing the antibody, test kit comprising the antibody and detection method of listeria monocytogenes using the antibody
US20110040248A1 (en)*2004-10-122011-02-17Closed Loop Therapies BvMethods and implantable devices for treating supraventricular arrhythmias
US7781402B2 (en)2004-10-122010-08-24Closed Loop Therapies Ltd.Methods and implantable devices for treating supraventricular arrhythmias
US20060079941A1 (en)*2004-10-122006-04-13Eli OvsyshcherMethods and implantable devices for treating supraventricular arrhythmias
WO2006043178A2 (en)2004-10-182006-04-27Danisco A/SEnzymes
EP2264156A1 (en)2004-10-182010-12-22Danisco A/SPhytases
US20070298145A1 (en)*2004-10-182007-12-27Andrei MiasnikovEnzymes
US8053221B2 (en)2004-10-182011-11-08Danisco A/SEnzymes
EP2236601A1 (en)2004-10-182010-10-06Danisco A/SPhytases
EP2236600A1 (en)2004-10-182010-10-06Danisco A/SEnzymes
US20090104170A1 (en)*2004-11-022009-04-23Richard William Wyatt ChildsCompositions and methods for treating hyperproliferative disorders
EP1655381A1 (en)2004-11-042006-05-10Affymetrix, Inc. (A US Entity)Nucleic acid labeling methods
EP2210899A1 (en)2004-11-112010-07-28Danisco A/Spntr transcription factor
EP2174668A2 (en)2004-11-142010-04-14Vascular Biogenics Ltd.Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20060105354A1 (en)*2004-11-182006-05-18Eppendorf Array Technologies S.A.Real-time quantification of multiple targets on a micro-array
EP2302072A1 (en)2004-11-182011-03-30Eppendorf Array Technologies S.A.Real time-PCR of targets on a micro-array
US8288128B2 (en)2004-11-182012-10-16Eppendorf Array Technologies S.A.Real-time quantification of multiple targets on a micro-array
EP2283831A2 (en)2004-12-032011-02-16Schering CorporationBiomakers for pre-selection of patients for anti-IGF1R therapy
EP2281841A2 (en)2004-12-032011-02-09Schering CorporationBiomarkers for pre-selection of patients for anti-IGF1R therapy
US20060134538A1 (en)*2004-12-162006-06-22Radu Nora SAromatic chalcogen compounds and their use
US20060134680A1 (en)*2004-12-222006-06-22Alexander KotlyarHomogeneous populations of nucleic acids, methods of synthesyzing same and uses thereof
US8375327B2 (en)2005-01-162013-02-12Zlango Ltd.Iconic communication
US20080082678A1 (en)*2005-01-162008-04-03Zlango Ltd.Communications Network System and Methods for Using Same
US20090013087A1 (en)*2005-01-182009-01-08Zlango Ltd.Communications Network System and Methods For Using Same
US8019818B2 (en)2005-01-182011-09-13Zlango Ltd.Communications network system and methods for using same
US10335783B2 (en)2005-01-312019-07-02Realbio Technologies, Ltd.Multistep reaction lateral flow capillary device
EP2520669A2 (en)2005-02-072012-11-07GeneNews Inc.Mild osteoathritis biomarkers and uses thereof
EP2316441A1 (en)2005-02-172011-05-04Hadasit Medical Research Services And DevelopmentBisphosphonates for treating endometriosis
US20100047230A1 (en)*2005-02-212010-02-25Hellenic Pasteur InstituteAnti her2/neu antibody
WO2006090388A2 (en)2005-02-252006-08-31The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani CenterFruit cell culture extract for treating inflammation
US7695927B2 (en)2005-03-182010-04-13Detroit R & DDetection of hypertension using glucuronidated metabolic products
US20060211064A1 (en)*2005-03-182006-09-21Hyesook KimDetection of hypertension using glucuronidated metabolic products
EP3300739A2 (en)2005-03-312018-04-04Agensys, Inc.Antibodies and related molecules that bind to 161p2f10b proteins
EP2444099A1 (en)2005-03-312012-04-25Agensys, Inc.Antibodies and related molecules that bind to 161P2F10B proteins
EP3796003A1 (en)2005-04-042021-03-24Biogen MA Inc.Methods for evaluating an immune response to a therapeutic agent
WO2006107962A2 (en)2005-04-042006-10-12Biogen Idec Ma IncMethods and products for evaluating an immune response to a therapeutic protein
US10705095B2 (en)2005-04-042020-07-07Biogen Ma Inc.Methods and products for evaluating an immune response to a therapeutic protein
US11686734B2 (en)2005-04-042023-06-27Biogen Ma Inc.Methods and products for evaluating an immune response to a therapeutic protein
EP3264094A1 (en)2005-04-042018-01-03Biogen MA Inc.Methods for evaluating an immune response to a therapeutic agent
EP2645106A2 (en)2005-04-042013-10-02Biogen Idec MA Inc.Methods and products for evaluating an immune response to a therapeutic agent
US20090068207A1 (en)*2005-04-152009-03-12Vascular Biogenics Ltd.Compositions Containing Beta 2-Glycoprotein I-Derived Peptides for the Prevention and/or Treatment of Vascular Disease
US10308987B2 (en)2005-04-182019-06-04Mdna Life Sciences Inc.3.4 kb mitochondrial DNA deletion for use in the detection of cancer
US9745632B2 (en)2005-04-182017-08-29Mdna Life Sciences Inc.Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
US11111546B2 (en)2005-04-182021-09-07Mdna Life Sciences, Inc.3.4 KB mitochondrial DNA deletion for use in the detection of cancer
US8008008B2 (en)2005-04-182011-08-30Mitomics Inc.Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
EP2339032A1 (en)2005-04-182011-06-29Mitomics Inc.Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
US10907213B2 (en)2005-04-182021-02-02Mdna Life Sciences Inc.Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
US8834862B2 (en)2005-04-192014-09-16Nanocyte Inc.Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
US20060234203A1 (en)*2005-04-192006-10-19Nanocyte Inc.Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
US9567568B2 (en)2005-05-042017-02-14Enlivex Therapeutics Ltd.Method of preparing apoptotic monocytes
EP2224008A2 (en)2005-05-122010-09-01Murdoch UniversityGenes and proteins of brachyspira hyodysenteriae and use of same for diagnosis and therapy
EP2279726A2 (en)2005-05-262011-02-02Biorest Ltd.Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
EP2933265A2 (en)2005-06-032015-10-21Amicus Therapeutics, Inc.Pharmacological chaperones for treating obesity
EP2425850A2 (en)2005-06-152012-03-07The Regents of The University of CaliforniaBispecific single chain FV antibody molecules and methods of use thereof
WO2006134602A2 (en)2005-06-162006-12-21Ramot At Tel Aviv University Ltd.Isolated cells and populations comprising same for the treatment of cns diseases
EP2465924A2 (en)2005-06-162012-06-20Ramot at Tel-Aviv University Ltd.Isolated cells and populations comprising same for the treament of cns diseases
EP2711434A1 (en)2005-06-202014-03-26Advanced Cell Diagnostics, Inc.Multiplex detection of nucleic acids
WO2007001986A2 (en)2005-06-202007-01-04Yuling LuoMethods of detecting nucleic acids in individual cells and of identifying rare cells from large heterogeneous cell populations
EP2460893A1 (en)2005-06-202012-06-06Advanced Cell Diagnostics, Inc.Multiplex detection of nucleic acids
EP2500439A1 (en)2005-06-202012-09-19Advanced Cell Diagnostics, Inc.Methods of detecting nucleic acids in individual cells and of identifying rare cells from large heterogeneous cell populations
US20070225242A1 (en)*2005-06-212007-09-27The Board Of Trustees Of The Leland Stanford Junior UniversityMethod and composition for treating and preventing tumor metastasis in vivo
US8067574B2 (en)2005-07-072011-11-29Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid agents for downregulating H19, and methods of using same
US8067573B2 (en)2005-07-072011-11-29Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid agents for downregulating H19 and methods of using same
EP2487182A2 (en)2005-07-072012-08-15FULCRUM SP Ltd.SP1 polypeptides, modified SP1 polypeptides and uses thereof
US20090143321A1 (en)*2005-07-072009-06-04Avraham HochbergNucleic acid agents for downregulating h19 and methods of using same
EP2441840A1 (en)2005-07-182012-04-18Protalix Ltd.Mucosal or enteral administration of biologically active macromolecules
EP2484768A2 (en)2005-07-182012-08-08Protalix Ltd.Mucosal or enteral administration of biologically active macromolecules
EP2889041A1 (en)2005-07-262015-07-01Rutgers, The State University of New JerseyKit of reagents for tuberculosis assay
US20100068135A1 (en)*2005-08-082010-03-18Onconon, LlcAntibody compositions, methods for treating neoplastic disease and methods for regulating fertility
US8642330B2 (en)2005-08-082014-02-04Onconon, LlcAntibody compositions, methods for treating neoplastic disease and methods for regulating fertility
EP2425860A1 (en)2005-08-122012-03-07Amgen Inc.Modified Fc molecules
US8008453B2 (en)2005-08-122011-08-30Amgen Inc.Modified Fc molecules
US9114175B2 (en)2005-08-122015-08-25Amgen Inc.Modified Fc molecules
US11266744B2 (en)2005-08-122022-03-08Amgen Inc.Modified Fc molecules
US10188740B2 (en)2005-08-122019-01-29Amgen Inc.Modified Fc molecules
EP2995194A1 (en)2005-08-152016-03-16Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
WO2007020638A2 (en)2005-08-152007-02-22Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US7910800B2 (en)2005-08-152011-03-22Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US9487796B2 (en)2005-08-152016-11-08Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US20090089898A1 (en)*2005-08-152009-04-02Hagai KarchiMethods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
EP2514315A2 (en)2005-08-242012-10-24Yeda Research and Development Co. Ltd.Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
WO2007023491A2 (en)2005-08-242007-03-01Yeda Research And Development Co. Ltd.Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
EP3354723A1 (en)2005-08-292018-08-01Technion Research & Development Foundation Ltd.Media for culturing stem cells
EP2354160A1 (en)2005-08-312011-08-10Schering CorporationEngineered anti-IL-23-antibodies
WO2007027714A2 (en)2005-08-312007-03-08Schering CorporationEngineered anti-il-23 antibodies
EP3190125A1 (en)2005-08-312017-07-12Merck Sharp & Dohme Corp.Engineered anti-il-23 antibodies
WO2007031996A1 (en)2005-09-122007-03-22Rappaport Family Institute For Research In The Medical SciencesCompositions and methods for diagnosing and treating an inflammation
US20070059717A1 (en)*2005-09-152007-03-15Baylor Research InstituteSystemic lupus erythematosus diagnostic assay
EP2302079A2 (en)2005-09-152011-03-30Baylor Research InstituteSystemic lupus erythematosus diagnostic assay
US7608395B2 (en)2005-09-152009-10-27Baylor Research InstituteSystemic lupus erythematosus diagnostic assay
US20090221681A1 (en)*2005-09-222009-09-03Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer
WO2007034487A1 (en)2005-09-222007-03-29Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer
US8034914B2 (en)2005-09-222011-10-11Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer
US20080274905A1 (en)*2005-09-302008-11-06The Trustees Of Columbia University In The City Of New YorkMicrofluidic cells with parallel arrays of individual dna molecules
US20070202515A1 (en)*2005-10-122007-08-30Pathologica, Llc.Promac signature application
US20070087437A1 (en)*2005-10-142007-04-19Jifan HuMethods for rejuvenating cells in vitro and in vivo
EP2319941A2 (en)2005-10-212011-05-11GeneNews Inc.Method and apparatus for correlating levels of biomarker products with disease
EP2716654A1 (en)2005-10-242014-04-09Evogene Ltd.Isolated polypeptides, polynucleotides encoding same, transgenic plants expressing same and methods of using same
US20070141658A1 (en)*2005-10-272007-06-21The Regents Of The University Of CaliforniaFluorogenic probes for reactive oxygen species
US7842823B2 (en)2005-10-272010-11-30The Regents Of The University Of CaliforniaFluorogenic probes for reactive oxygen species
EP2395012A2 (en)2005-11-022011-12-14Protiva Biotherapeutics Inc.Modified siRNA molecules and uses thereof
WO2007056352A2 (en)2005-11-072007-05-18The Scripps Research InstituteCompositions and methods for controlling tissue factor signaling specificity
DE212006000071U1 (en)2005-11-182008-07-24Board of Regents, The University of Texas System, Austin Quantification of fusion proteins and their activity as a result of chromosomal translocation
US8846393B2 (en)2005-11-292014-09-30Gamida-Cell Ltd.Methods of improving stem cell homing and engraftment
EP2390312A1 (en)2005-11-292011-11-30Gamida Cell Ltd.Methods of improving stem cell homing and engraftment
EP2546359A1 (en)2005-12-082013-01-16Novartis AGEffects of inhibitors of FGFR3 on gene transcription
US20070134814A1 (en)*2005-12-092007-06-14Kajander E OMethods and compositions for the detection of calcifying nano-particles, identification and quantification of associated proteins thereon, and correlation to disease
EP2674440A2 (en)2005-12-162013-12-18IBC Pharmaceuticals, Inc.Multivalent immunoglobulin-based bioactive assemblies
US20090226387A1 (en)*2005-12-232009-09-10Partnership & Corp. Technology TransferSynthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of cellular relaxation
EP2172210A1 (en)2005-12-232010-04-07Partnership&Corp. Technology TransferSynthetic peptides for use as inhibitors of neurotransmitter secretion
US8318898B2 (en)2005-12-232012-11-27Universite De LausanneSynthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of cellular relaxation
US20070161007A1 (en)*2006-01-112007-07-12Wisconsin Alumni Research FoundationSynthetic cofactor analogs of S-adenosylmethionine as ligatable probes of biological methylation and methods for their use
US7465544B2 (en)2006-01-112008-12-16Wisconsin Alumni Research FoundationSynthetic cofactor analogs of S-adenosylmethionine as ligatable probes of biological methylation and methods for their use
US8775526B2 (en)2006-01-162014-07-08Zlango Ltd.Iconic communication
EP2526968A2 (en)2006-01-272012-11-28Biogen Idec MA Inc.Nogo receptor antagonists
US8669345B2 (en)2006-01-272014-03-11Biogen Idec Ma Inc.Nogo receptor antagonists
US9228015B2 (en)2006-01-272016-01-05Biogen Idec Ma Inc.Nogo receptor antagonists and methods of increasing neurite outgrowth
WO2007088051A2 (en)2006-01-312007-08-09Bayer Schering Pharma AktiengesellschaftModulation of mdl-1 activity for treatment of inflammatory disease
US20070190611A1 (en)*2006-02-032007-08-16Fuad FaresLong-acting polypeptides and methods of producing same
EP2532674A1 (en)2006-02-032012-12-12Modigene IncLong-acting polypeptides and methods of producing and administering same
EP3202779A2 (en)2006-02-032017-08-09OPKO Biologics Ltd.Long-acting hgh polypeptides and uses thereof
US8946155B2 (en)2006-02-032015-02-03Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
US10640758B2 (en)2006-02-032020-05-05Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
WO2007094985A2 (en)2006-02-032007-08-23Modigene IncLong-acting polypeptides and methods of producing and administering same
US10030060B2 (en)2006-02-032018-07-24Opko Biologics Ltd.Long-acting polypeptides and methods of producing same
US10221228B2 (en)2006-02-032019-03-05Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
EP2471807A1 (en)2006-02-032012-07-04Modigene IncLong-acting polypeptides and methods of producing and administering same
EP3663312A1 (en)2006-02-032020-06-10OPKO Biologics Ltd.Long-acting polypeptides and uses thereof
EP2853536A1 (en)2006-02-032015-04-01OPKO Biologics Ltd.Long-acting erythropoietin polypeptides and uses thereof
EP2853541A1 (en)2006-02-032015-04-01OPKO Biologics Ltd.Long-acting polypeptides and uses thereof
US9249407B2 (en)2006-02-032016-02-02Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
US8426166B2 (en)2006-02-032013-04-23Prolor Biotech Inc.Long-acting polypeptides and methods of producing same
US10351615B2 (en)2006-02-032019-07-16Opko Biologics Ltd.Methods of treatment with long-acting growth hormone
US9458444B2 (en)2006-02-032016-10-04Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
US8759292B2 (en)2006-02-032014-06-24Prolor Biotech, LlcLong-acting coagulation factors and methods of producing same
US9908924B2 (en)2006-02-032018-03-06Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
US8999670B2 (en)2006-02-032015-04-07Opko Biologics Ltd.Long-acting polypeptides and methods of producing same
US7553941B2 (en)2006-02-032009-06-30Modigene IncLong-acting polypeptides and methods of producing same
US9896494B2 (en)2006-02-032018-02-20Opko Biologics Ltd.Long-acting polypeptides and methods of producing same
US20070190610A1 (en)*2006-02-032007-08-16Fuad FaresLong-acting EPO polypeptides and derivatives thereof and methods thereof
US10144921B2 (en)2006-02-032018-12-04Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
US7553940B2 (en)2006-02-032009-06-30Modigene IncLong-acting EPO polypeptides and derivatives thereof and methods thereof
US9884901B2 (en)2006-02-032018-02-06Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
US9828417B2 (en)2006-02-032017-11-28Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
EP2532675A1 (en)2006-02-032012-12-12Modigene IncLong-acting polypeptides and methods of producing and administering same
US20070184530A1 (en)*2006-02-032007-08-09Fuad FaresLong-acting veterinary polypeptides and methods of producing and administering same
US8465948B2 (en)2006-02-032013-06-18Prolor Biotech Ltd.Long-acting veterinary polypeptides and methods of producing and administering same
US10119132B2 (en)2006-02-032018-11-06Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
US8450269B2 (en)2006-02-032013-05-28Prolor Biotech Ltd.Long-acting growth hormone and methods of producing same
US8323636B2 (en)2006-02-032012-12-04Prolor Biotech Ltd.Long-acting interferons and derivatives thereof and methods thereof
US11066658B2 (en)2006-02-032021-07-20Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
WO2007091254A1 (en)2006-02-062007-08-16Rappaport Family Institute For Research In The Medical SciencesMethods and kit for diagnosing t1dm
WO2007092563A2 (en)2006-02-082007-08-16Genzyme CorporationGene therapy for niemann-pick disease type a
EP3456331A1 (en)2006-02-082019-03-20Genzyme CorporationGene therapy for niemann-pick disease type a
US11156613B2 (en)2006-02-092021-10-26University Of South FloridaDetection of cancer by elevated levels of bcl-2
US11292845B2 (en)2006-02-282022-04-05Biogen Ma Inc.Methods of treating inflammatory and autoimmune diseases with natalizumab
US11333670B2 (en)2006-03-032022-05-17Biogen Ma Inc.Methods of treating inflammatory and autoimmune diseases with natalizumab
US9057092B2 (en)2006-03-062015-06-16Zetiq Technologies Ltd.Methods and compositions for identifying a cell phenotype
US10018622B2 (en)2006-03-062018-07-10Zetiq Technologies Ltd.Methods and kits for differential staining of abnormal urinary system cells
US8114619B2 (en)2006-03-212012-02-14The Johns Hopkins UniversityMethods for diagnosis and optimizing treatment of multiple sclerosis
EP2366775A1 (en)2006-03-232011-09-21Pluristem Ltd.Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
EP3091071A1 (en)2006-03-232016-11-09Pluristem Ltd.Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
EP2548951A1 (en)2006-03-232013-01-23Pluristem Ltd.Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
EP2626417A1 (en)2006-03-232013-08-14Pluristem Ltd.Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
WO2007110869A2 (en)2006-03-282007-10-04Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods and kits for determining predisposition to warfarin resistance
US20070232556A1 (en)*2006-03-312007-10-04Montine Thomas JMethods and compositions for the treatment of neurological diseases and disorders
US20100055033A1 (en)*2006-04-072010-03-04The Government Of The United States Of America As Represented By The SecretaryAntibody compositions and methods for treatment of neoplastic disease
US8071323B2 (en)2006-04-072011-12-06The United States Of America As Represented By The Secretary Of The Department Of Health And Human ServicesHuman monoclonal antibodies that bind human insulin like growth factors and their use
EP2881468A1 (en)2006-04-212015-06-10Intervet International B.V.Pestivirus species
EP2636743A1 (en)2006-04-212013-09-11Intervet International B.V.Pestivirus species
EP3147365A1 (en)2006-04-212017-03-29Intervet International B.V.Pestivirus species
US9254309B2 (en)2006-04-272016-02-09Centre National De La Recherche Scientifique (Cnrs)Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation
US20110065649A1 (en)*2006-04-272011-03-17Centre National De La Recherche Scientifique (Cnrs)Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation
US8497349B2 (en)2006-04-272013-07-30Centre National De La Recherche Scientifique (Cnrs)Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation
US20090221015A1 (en)*2006-05-092009-09-03Spinale Francis GDetecting Diastolic Heart Failure by Protease and Protease Inhibitor Plasma Profiling
US8790871B2 (en)2006-05-092014-07-29Musc Foundation For Research DevelopmentDetecting diastolic heart failure by protease and protease inhibitor plasma profiling
US20110150874A1 (en)*2006-05-192011-06-23Teva Pharmaceutical Industries Ltd.Fusion proteins, uses thereof and processes for producing same
US8486693B2 (en)2006-05-232013-07-16Bellicum Pharmaceuticals, Inc.Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
US20070281883A1 (en)*2006-06-052007-12-06Hanna RosenfeldDevelopment of follicle stimulating hormone agonists and antagonists in fish
WO2008005429A2 (en)2006-07-032008-01-10Charles David AdairComposition for modulating the expression of cell adhesion molecules
US20100015651A1 (en)*2006-07-112010-01-21Musc Foundation For Research DevelopmentPredicting Heart Failure Following Myocardial Infarction by Protease and Protease Inhibitor Profiling
US20080026394A1 (en)*2006-07-112008-01-31Antara Biosciences Inc.Methods of detecting one or more cancer markers
US8445222B2 (en)2006-07-112013-05-21Musc Foundation For Research DevelopmentPredicting heart failure following myocardial infarction by protease and protease inhibitor profiling
WO2008010934A2 (en)2006-07-142008-01-24Chemocentryx, Inc.Triazolyl phenyl benzenesulfonamides
WO2008010228A2 (en)2006-07-202008-01-24Yeda Research And Development Co. Ltd.Photosyntheticorganisms and compositions and methods of generating same
US20110184747A1 (en)*2006-08-092011-07-28Carmen BozicMethod for distribution of a drug
EP2774987A1 (en)2006-08-172014-09-10Affymetrix, Inc.Nucleic acid quantitation from tissue slides
US8337852B2 (en)2006-08-222012-12-25G2 Inflammation Pty LtdAnti-C5aR antibodies with improved properties
EP2455404A2 (en)2006-08-222012-05-23G2 Inflammation Pty LtdAnti-C5AR antibodies with improved properties
US20100129346A1 (en)*2006-08-222010-05-27G2 Inflammation Pty Ltd.Anti-C5aR Antibodies With Improved Properties
EP2423333A1 (en)2006-08-252012-02-29Oncotherapy Science, Inc.Prognostic markers and therapeutic targets for lung cancer
EP2423332A1 (en)2006-08-252012-02-29Oncotherapy Science, Inc.Prognostic markers and therapeutic targets for lung cancer
WO2008026198A2 (en)2006-08-282008-03-06Yeda Research And Development Co. Ltd.Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the cns
US20090042209A1 (en)*2006-09-012009-02-12Nox Technologies, Inc.Neoplasia-Specific tNOX Isoforms and Methods
US20080064114A1 (en)*2006-09-072008-03-13Institut PasteurGenomic morse code
US20100041036A1 (en)*2006-09-072010-02-18Institut PasteurGenomic morse code
US8586723B2 (en)2006-09-072013-11-19Institut PasteurGenomic morse code
EP3133172A1 (en)2006-09-072017-02-22Institut PasteurGenomic morse code
US7985542B2 (en)2006-09-072011-07-26Institut PasteurGenomic morse code
EP2469282A1 (en)2006-09-082012-06-27University of OxfordClinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers
US9012162B2 (en)2006-09-082015-04-21The Chancellor, Masters And Scholars Of The University Of OxfordClinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers
EP2469283A1 (en)2006-09-082012-06-27University of OxfordClinical diagnosis of hepatic fibrosis using human serum APOL1 as biomarker.
US20080085526A1 (en)*2006-09-082008-04-10United Therapeutics CorporationClinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers
US8600168B2 (en)2006-09-132013-12-03Fluidigm CorporationMethods and systems for image processing of microfluidic devices
US8050516B2 (en)2006-09-132011-11-01Fluidigm CorporationMethods and systems for determining a baseline during image processing
US8055034B2 (en)2006-09-132011-11-08Fluidigm CorporationMethods and systems for image processing of microfluidic devices
US20080075322A1 (en)*2006-09-132008-03-27Fluidigm CorporationMethods and systems for determining a baseline during image processing
US20080075380A1 (en)*2006-09-132008-03-27Fluidigm CorporationMethods and systems for image processing of microfluidic devices
US8849037B2 (en)2006-09-132014-09-30Fluidigm CorporationMethods and systems for image processing of microfluidic devices
WO2008041183A2 (en)2006-10-052008-04-10Technion Research & Development Foundation Ltd.Microtubes and methods of producing same
US20080199895A1 (en)*2006-10-052008-08-21Yeda Research And Development Co. Ltd.Highly purified and stabilized Na,K-ATPase isoforms and methods of producing same
US20100222228A1 (en)*2006-10-112010-09-02Janssen Pharmaceutica N.V.Compositions and methods for treating and diagnosing irritable bowel syndrome
WO2008043566A2 (en)2006-10-112008-04-17Janssen Pharmaceutica N.V.Compositions and methods for treating and diagnosing irritable bowel syndrome
US20080214407A1 (en)*2006-10-122008-09-04Eppendorf Array Technologies S.A.Method and system for quantification of a target compound obtained from a biological sample upon chips
EP2426199A2 (en)2006-10-202012-03-07Danisco US Inc.Polyol oxidases
US8357495B2 (en)2006-10-262013-01-22Abbott LaboratoriesImmunoassay of analytes in samples containing endogenous anti-analyte antibodies
US20100311079A1 (en)*2006-10-262010-12-09Abbott LaboratoriesAssay for cardiac troponin autoantibodies
US20080305512A1 (en)*2006-10-262008-12-11Mattingly Phillip GAssay for cardiac troponin autoantibodies
WO2008051761A2 (en)2006-10-262008-05-02Abbott LaboratoriesAssay for cardiac troponin autoantibodies
US8173382B2 (en)2006-10-262012-05-08Abbott LaboratoriesAssay for cardiac troponin autoantibodies
US20090246800A1 (en)*2006-10-262009-10-01Abbott LaboratoriesImmunoassay of analytes in samples containing endogenous anti-analyte antibodies
EP2407783A1 (en)2006-10-272012-01-18Janssen Pharmaceutica, N.V.A method for pharmacologically profiling compounds
EP2402752A2 (en)2006-10-272012-01-04Janssen Pharmaceutica, N.V.A method for pharmacologically profiling compounds
EP2450456A2 (en)2006-11-022012-05-09Yale UniversityAssessment of oocyte competence
US8293684B2 (en)2006-11-292012-10-23ExiqonLocked nucleic acid reagents for labelling nucleic acids
US20090023594A1 (en)*2006-11-292009-01-22Exiqon A/SReagents for labelling nucleic acids and uses thereof
WO2008067547A2 (en)2006-11-302008-06-05Research Development FoundationImproved immunoglobulin libraries
US20080129736A1 (en)*2006-11-302008-06-05Fluidigm CorporationMethod and apparatus for biological sample analysis
US8473216B2 (en)2006-11-302013-06-25Fluidigm CorporationMethod and program for performing baseline correction of amplification curves in a PCR experiment
EP2628752A1 (en)2006-12-142013-08-21Merck Sharp & Dohme Corp.Engineered anti-TSLP antibody
WO2008076321A1 (en)2006-12-142008-06-26Schering CorporationEngineered anti-tslp antibody
EP2383345A1 (en)2006-12-202011-11-02Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US9631000B2 (en)2006-12-202017-04-25Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US8168857B2 (en)2006-12-202012-05-01Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US20090293146A1 (en)*2006-12-202009-11-26Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US8506499B2 (en)2007-01-042013-08-13Musc Foundation For Research DevelopmentPredicting atrial fibrillation recurrence by protease and protease inhibitor profiling
US20110009861A1 (en)*2007-01-042011-01-13Music Foundation For Research DevelopmentPredicting atrial fibrillation recurrence by protease and protease inhibitor profiling
US8642295B2 (en)2007-01-112014-02-04Erasmus University Medical CenterCircular chromosome conformation capture (4C)
US20100062947A1 (en)*2007-01-112010-03-11Erasmus University Medical CenterCircular chromosome conformation capture (4c)
EP3103451A1 (en)2007-01-122016-12-14University of Maryland, BaltimoreTargetting ncca-atp channel for organ protection following ischemic episode
US7928083B2 (en)2007-01-162011-04-19Yissum Research Development Company Of The Hebrew University Of JerusalemH19 silencing nucleic acid agents for treating rheumatoid arthritis
US20100105759A1 (en)*2007-01-162010-04-29Abraham HochbergH19 silencing nucleic acid agents for treating rheumatoid arthritis
US7960150B2 (en)2007-01-252011-06-14Danisco A/SProduction of a lipid acyltransferase from transformed Bacillus licheniformis cells
EP2405007A1 (en)2007-01-252012-01-11Danisco A/SProduction of a lipid acyltransferase from transformed bacillus cells
WO2008092164A2 (en)2007-01-262008-07-31University Of Louisville Research Foundation, Inc.Methods of detecting autoantibodies for diagnosing and characterizing disorders
EP2450702A2 (en)2007-01-262012-05-09University Of Louisville Research Foundation, Inc.Methods of detecting autoantibodies for diagnosing and characterizing disorders
US20100190662A1 (en)*2007-01-262010-07-29Rebecca SutphenMethods and materials for detection, diagnosis and management of ovarian cancer
US20100196403A1 (en)*2007-01-292010-08-05Jacob HochmanAntibody conjugates for circumventing multi-drug resistance
WO2008093341A2 (en)2007-01-312008-08-07Technion Research & Development Foundation Ltd.Electrospun scaffolds and methods of generating and using same
WO2008093342A2 (en)2007-02-012008-08-07Technion Research & Development Foundation Ltd.Albumin fibers and fabrics and methods of generating and using same
EP2478924A1 (en)2007-02-012012-07-25Technion Research & Development FoundationAlbumin fibers and fabrics and methods of generating and using same
US8629250B2 (en)2007-02-022014-01-14Amgen Inc.Hepcidin, hepcidin antagonists and methods of use
US20090098249A1 (en)*2007-02-072009-04-16Cervin Marguerite AVariant Buttiauxella sp. Phytases having altered properties
US8143046B2 (en)2007-02-072012-03-27Danisco Us Inc., Genencor DivisionVariant Buttiauxella sp. phytases having altered properties
US7641904B2 (en)2007-02-162010-01-05Konkuk University Industrial Cooperation Corp.IL-32 monoclonal antibodies and uses thereof
US20080219995A1 (en)*2007-02-162008-09-11Konkuk University Industrial Cooperation Corp.Il-32 monoclonal antibodies and uses thereof
EP2124055A4 (en)*2007-02-222011-07-27Stella Chemifa CorpKit for immunoassay of bsh, and method for measurement of bsh
JP2008203195A (en)*2007-02-222008-09-04Japan Science & Technology Agency BSH immunoassay kit and method for measuring BSH
EP2426144A1 (en)2007-02-232012-03-07Schering CorporationEngineered anti-IL-23p19 antibodies
EP2426145A1 (en)2007-02-232012-03-07Schering CorporationEngineered anti-IL-23p19 antibodies
US20100105071A1 (en)*2007-02-282010-04-29Children's Medical Center CorporationMethods for predicting the onset of menarche
EP2839839A1 (en)2007-02-282015-02-25Yeda Research And Development Company LimitedNuclear targeting sequences
EP2395025A1 (en)2007-02-282011-12-14Schering CorporationEngineered Anti-IL-23R Antibodies
US20080220498A1 (en)*2007-03-062008-09-11Cervin Marguerite AVariant Buttiauxella sp. phytases having altered properties
US20100015156A1 (en)*2007-03-062010-01-21Cedars-Sinai Medical CenterDiagnosis of inflammatory bowel disease in children
WO2008110006A1 (en)2007-03-122008-09-18Miraculins Inc.Biomarkers of prostate cancer and uses thereof
US8486640B2 (en)2007-03-212013-07-16Cedars-Sinai Medical CenterIleal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
WO2008120202A2 (en)2007-03-292008-10-09Technion Research & Development Foundation Ltd.Antibodies, methods and kits for diagnosing and treating melanoma
EP2514766A2 (en)2007-03-292012-10-24Technion Research & Development Foundation Ltd.Antibodies, methods and kits for diagnosing and treating melanoma
EP2532746A2 (en)2007-03-302012-12-12EnGeneIC Molecular Delivery Pty Ltd.Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells
EP2865755A2 (en)2007-03-302015-04-29EnGeneIC Molecular Delivery Pty LtdBacterially derived, intact minicells encompassing regulatory RNA
EP3205724A1 (en)2007-03-302017-08-16EnGeneIC Molecular Delivery Pty Ltd.Bacterially derived, intact minicells encompassing regulatory rna
EP3564372A1 (en)2007-03-302019-11-06EnGeneIC Molecular Delivery Pty Ltd.Bacterially derived, intact minicells encompassing regulatory rna
WO2008120216A1 (en)2007-04-022008-10-09Ramot At Tel Aviv University Ltd.Methods of detecting cancer cells and use of same for diagnosing and monitoring treatment of the disease
WO2008124670A2 (en)2007-04-062008-10-16Becton, Dickinson And CompanyCompositions and methods for the identification of a carbapenemase gene
US8513488B2 (en)2007-04-092013-08-20Evogene Ltd.Polynucleotides, polypeptides and methods for increasing oil content, growth rate and biomass of plants
US9487793B2 (en)2007-04-092016-11-08Evogene Ltd.Polynucleotides, polypeptides and methods for increasing oil content, growth rate and biomass of plants
US20100255004A1 (en)*2007-04-132010-10-07Dana Farber Cancer InstituteReceptor tyrosine kinase profiling
US11008620B2 (en)2007-04-132021-05-18The General Hospital CorporationMethods for treating cancer resistant to ErbB therapeutics
EP2851091A1 (en)2007-04-132015-03-25Dana-Farber Cancer Institute, Inc.Methods for treating cancer resistant to ERBB therapeutics
US8715665B2 (en)2007-04-132014-05-06The General Hospital CorporationMethods for treating cancer resistant to ErbB therapeutics
US9156865B2 (en)2007-04-232015-10-13Deliversir LtdSystem for delivering therapeutic agents into living cells and cells nuclei
US20100092386A1 (en)*2007-04-232010-04-15David SegevSystem for delivering therapeutic agents into living cells and cells nuclei
US8293209B2 (en)2007-04-232012-10-23Segev Laboratories LimitedSystem for delivering therapeutic agents into living cells and cells nuclei
US9556210B2 (en)2007-04-232017-01-31Sabag-Rfa Ltd.System for delivering therapeutic agents into living cells and cells nuclei
EP3032259A1 (en)2007-05-012016-06-15Tel Hashomer Medical Research Infrastructure and Services Ltd.Methods for detecting trophoblast cells in maternal blood based on cytokeratin-7
WO2008137475A2 (en)2007-05-012008-11-13Research Development FoundationImmunoglobulin fc libraries
WO2008132753A2 (en)2007-05-012008-11-06Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods and kits for detecting fetal cells in the maternal blood
US8795682B2 (en)2007-05-022014-08-05Emory UniversityVirus-like particles comprising chimeric human immunodeficiency virus (HIV)/mouse mammary tumor virus (MMTV) envelopes
US20100196419A1 (en)*2007-05-022010-08-05Compans Richard WEnhancement of glycoprotein incorporation into virus-like particles
EP3360571A1 (en)2007-05-032018-08-15Agency For Science, Technology And Research (A*star)Antibodies binding to an intracellular prl-1 or prl-3 polypeptide
EP2529754A1 (en)2007-05-032012-12-05Agency For Science, Technology And Research (A*star)Antibodies binding to an intracellular PRL-1 or PRL-3 polypeptide
EP3366762A1 (en)2007-05-072018-08-29Protalix Ltd.Large scale disposable bioreactor
US20090081639A1 (en)*2007-05-312009-03-26Phil HillAssay for sensitivity to chemotherapeutic agents
US8198309B2 (en)2007-06-222012-06-12Chemocentryx, Inc.N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl)hetaryl arylsulfonamides
WO2009038847A1 (en)2007-06-222009-03-26Chemocentryx, Inc.N-(2-(hetaryl)aryl)arylsulfonamides and n-(2-(hetaryl)hetaryl)arylsulfonamides
US20090005410A1 (en)*2007-06-222009-01-01Chemocentryx, Inc.N-(2-(hetaryl)aryl) arylsulfonamides and n-(2-(hetaryl) hetaryl arylsulfonamides
US9409909B2 (en)2007-06-222016-08-09Chemocentryx, Inc.N-(2-(hetaryl)aryl)arylsulfonamides and N-(2-(hetaryl)hetaryl)arylsulfonamides
US8835468B2 (en)2007-06-222014-09-16Chemocentryx, Inc.N-(2-(hetaryl)aryl)arylsulfonamides and n-(2-(hetaryl)hetaryl) arylsulfonamides
US7776877B2 (en)2007-06-222010-08-17Chemocentryx, Inc.N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
US20100331302A1 (en)*2007-06-222010-12-30Chemocentryx, Inc.N-(2-(hetaryl)aryl) arylsulfonamides and n-(2-(hetaryl)hetaryl arylsulfonamides
US20100221272A1 (en)*2007-06-282010-09-02University Of SaskatchewanImmunomodulatory compositions and methods for treating disease with modified host defense peptides
US9102754B2 (en)2007-06-282015-08-11University Of SaskatchewanImmunomodulatory compositions and methods for treating disease with modified host defense peptides
US20100184065A1 (en)*2007-07-102010-07-22University Of South FloridaMethod of Predicting Non-Response to First Line Chemotherapy
EP2500428A2 (en)2007-07-112012-09-19Yeda Research and Development Co. Ltd.Nucleic acid construct systems capable of diagnosing or treating a cell state
US10899765B2 (en)2007-07-122021-01-26Chemocentryx, Inc.Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
US9745312B2 (en)2007-07-122017-08-29Chemocentryx, Inc.Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
US9394307B2 (en)2007-07-122016-07-19Chemocentryx, Inc.Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
US20090233946A1 (en)*2007-07-122009-09-17Antoni KrasinskiFused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treatment of inflammation
US8546408B2 (en)2007-07-122013-10-01Chemocentryx, Inc.Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
US7884110B2 (en)2007-07-122011-02-08Chemocentryx, Inc.Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
US10208050B2 (en)2007-07-122019-02-19Chemocentryx, Inc.Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
EP3075854A1 (en)2007-07-152016-10-05Technion Research & Development Foundation Ltd.Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis
WO2009010968A2 (en)2007-07-152009-01-22Yitzchak HillmanDisease treatment via antimicrobial peptides or their inhibitors
EP2527441A2 (en)2007-07-152012-11-28Technion Research & Development FoundationCompositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis
US9518267B2 (en)2007-07-242016-12-13Evogene Ltd.Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same
EP2910638A2 (en)2007-07-242015-08-26Evogene Ltd.Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same
US8686227B2 (en)2007-07-242014-04-01Evogene Ltd.Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same
US10640762B2 (en)2007-07-262020-05-05The Regents Of The University Of CaliforniaMethods for enhancing bacterial cell display of proteins and peptides
US9176139B2 (en)2007-08-022015-11-03Gilead Biologics, Inc.LOX and LOXL2 inhibitors and uses thereof
US8461303B2 (en)2007-08-022013-06-11Gilead Biologics, Inc.LOX and LOXL2 inhibitors and uses thereof
US8658167B2 (en)2007-08-022014-02-25Gilead Biologics, Inc.Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
US8679485B2 (en)2007-08-022014-03-25Gilead Biologics, Inc.Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
US10494443B2 (en)2007-08-022019-12-03Gilead Biologics, Inc.LOX and LOXL2 inhibitors and uses thereof
US20090053224A1 (en)*2007-08-022009-02-26Arresto BiosciencesLox and loxl2 inhibitors and uses thereof
US20090104201A1 (en)*2007-08-022009-04-23Victoria SmithMethods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
EP3293269A1 (en)2007-08-032018-03-14MUSC Foundation For Research DevelopmentHuman monoclonal antibodies and methods for producing the same
EP3018139A2 (en)2007-08-032016-05-11Boehringer Ingelheim Vetmedica GmbHGenes and proteins of brachyspira hyodysenteriae and uses thereof
EP2700723A2 (en)2007-08-062014-02-26Orion Genomics, LLCNovel single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the IGF2 gene
WO2009021054A2 (en)2007-08-062009-02-12Orion Genomics LlcNovel single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the igf2 gene
EP2952588A1 (en)2007-08-062015-12-09Orion Genomics, LLCSingle nucleotide polymorphism in igf2 for determining the allele-specific expression of the igf2 gene
WO2009032477A2 (en)2007-08-082009-03-12The Board Of Regents Of The University Of Texas SystemVegfr-1/nrp-1 targeting peptides
US8067164B2 (en)2007-08-122011-11-29Integrated Dna Technologies, Inc.Microarray system with improved sequence specificity
US8945928B2 (en)2007-08-122015-02-03Kerry B GunningMicroarray system with improved sequence specificity
US20090143243A1 (en)*2007-08-122009-06-04Gunning Kerry BMicroarray system with improved sequence specificity
US20090136916A1 (en)*2007-08-132009-05-28Trustees Of Tufts CollegeMethods and microarrays for detecting enteric viruses
EP2581445A1 (en)2007-08-152013-04-17Yeda Research And Development Co. Ltd.Regulators of MMP-9 and uses thereof
US8652809B2 (en)2007-08-172014-02-18Dupont Nutrition Biosciences ApsMethod for producing ultra-heat treatment milk
US20100215803A1 (en)*2007-08-172010-08-26Niels Erik LarsenProcess
US20090068669A1 (en)*2007-09-122009-03-12Elias GeorgesSlc9a3r1 directed diagnostics for neoplastic disease
WO2009034574A2 (en)2007-09-122009-03-19Yeda Research And Development Co. Ltd.Methods of treating tumors in immune-privileged sites
EP2591789A2 (en)2007-09-192013-05-15Pluristem Ltd.Adherent cells from adipose or placenta tissues and use thereof in therapy
EP3103463A1 (en)2007-09-192016-12-14Pluristem Ltd.Adherent cells from adipose or placenta tissues and use thereof in therapy
EP2511708A1 (en)2007-10-052012-10-17Affymetrix, Inc.Highly multiplexed particle-based assays
EP2781223A1 (en)2007-10-192014-09-24Rappaport Family Institute for Research in the Medical SciencesCompositions comprising semaphorins for the treatment of angiogenesis related diseases
EP2599790A1 (en)2007-11-262013-06-05Yissum Research Development Company of The Hebrew University of JerusalemCompositions comprising fibrous polypeptides and polysachharides
EP2071021A2 (en)2007-12-122009-06-17University of South FloridaBone marrow-derived neuronal cells
US8426682B2 (en)2007-12-272013-04-23Evogene Ltd.Isolated polypeptides, polynucleotides useful for modifying water user efficiency, fertilizer use efficiency, biotic/abiotic stress tolerance, yield and biomass in plants
WO2009083958A2 (en)2007-12-272009-07-09Evogene Ltd.Isolated polypeptides, polynucleotides useful for modifying water user efficiency, fertilizer use efficiency, biotic/abiotic stress tolerance, yield and biomass in plants
WO2009082817A1 (en)2007-12-272009-07-09Protiva Biotherapeutics, Inc.Silencing of polo-like kinase expression using interfering rna
US9670501B2 (en)2007-12-272017-06-06Evogene Ltd.Isolated polypeptides, polynucleotides useful for modifying water user efficiency, fertilizer use efficiency, biotic/abiotic stress tolerance, yield and biomass in plants
EP2944649A1 (en)2008-01-102015-11-18Research Development FoundationVaccines and diagnostics for the ehrlichioses
US9175078B2 (en)2008-01-252015-11-03Amgen Inc.Ferroportin antibodies and methods of use
US9688759B2 (en)2008-01-252017-06-27Amgen, Inc.Ferroportin antibodies and methods of use
EP2574628A1 (en)2008-01-252013-04-03Amgen Inc.Ferroportin antibodies and methods of use
EP2803675A2 (en)2008-01-252014-11-19Amgen, IncFerroportin antibodies and methods of use
WO2009094551A1 (en)2008-01-252009-07-30Amgen Inc.Ferroportin antibodies and methods of use
US20090233295A1 (en)*2008-01-292009-09-17Elias GeorgesTrim59 directed diagnostics for neoplastic disease
US20110052501A1 (en)*2008-01-312011-03-03Liat DassaPolypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
EP2712620A1 (en)2008-02-072014-04-02Cornell UniversityMethods for Preventing or Treating Insulin Resistance
EP3622963A1 (en)2008-02-072020-03-18Cornell UniversityMethods for preventing or treating insulin resistance
EP3103467A1 (en)2008-02-072016-12-14Cornell UniversityMethods for preventing or treating insulin resistance
EP3441079A1 (en)2008-02-072019-02-13Cornell UniversityMethods for preventing or treating insulin resistance
EP3272353A1 (en)2008-02-072018-01-24Cornell UniversityMethods for preventing or treating insulin resistance
EP2902036A1 (en)2008-02-072015-08-05Cornell UniversityMethods for preventing or treating insulin resistance
US8361468B2 (en)2008-02-202013-01-29G2 Inflammation Pty LtdHumanized anti-C5aR antibodies
EP2679599A1 (en)2008-02-202014-01-01Amgen Inc.Antibodies directed to Angiopoietin-1 and Angiopoietin-2 and use thereof
US8808701B2 (en)2008-02-202014-08-19G2 Inflammation Pty LtdMethods of inhibiting the interaction of C5aR with C5a with anti-C5aR antibodies
EP2826791A2 (en)2008-02-202015-01-21G2 Inflammation Pty LtdHumanized anti-C5aR antibodies
US20110190477A1 (en)*2008-02-202011-08-04Peter WhitfeldHumanized Anti-C5aR Antibodies
US8268972B2 (en)2008-02-202012-09-18G2 Inflammation Pty LtdHumanized anti-C5aR antibodies
WO2009104174A2 (en)2008-02-212009-08-27Technion Research & Development Foundation Ltd .A method of attaching a cell-of-interest to a microtube
WO2009105833A1 (en)2008-02-282009-09-03Murdoch UniversityNovel sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof
US20090311695A1 (en)*2008-03-122009-12-17Talat NasimMethod
EP2530087A2 (en)2008-03-272012-12-05Prionics AGSequences of brachyspira, immunogenic composition, methods for preparation and use thereof
WO2009117773A1 (en)2008-03-272009-10-01Murdoch UniversityNovel sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof
US10266899B2 (en)2008-03-282019-04-23Mdna Life Sciences Inc.Aberrant mitochondrial DNA, associated fusion transcripts and hybridization probes therefor
US8715960B2 (en)2008-03-282014-05-06Mitomics Inc.Aberrant mitochondrial DNA, associated fusion transcripts and translation products and hybridization probes therefor
US20110172113A1 (en)*2008-03-282011-07-14Mitomics Inc.Aberrant mitochondrial dna, associated fusion transcripts and hybridization probes therefor
EP2107125A1 (en)2008-03-312009-10-07Eppendorf Array Technologies SA (EAT)Real-time PCR of targets on a micro-array
US20110033473A1 (en)*2008-04-092011-02-10Yoram ReiterAnti influenza antibodies and uses thereof
US8747855B2 (en)2008-04-092014-06-10Technion Research & Development Foundation LimitedAnti human immunodeficiency antibodies and uses thereof
US20110020357A1 (en)*2008-04-092011-01-27Technion Research & Development Foundation Ltd.Anti human immunodeficiency antibodies and uses thereof
US9132587B2 (en)2008-04-102015-09-15Stratasys Ltd.System and method for three dimensional model printing
US20110147993A1 (en)*2008-04-102011-06-23Objet Geometries Ltd.System and method for three dimensional model printing
EP2770057A1 (en)2008-04-152014-08-27Protiva Biotherapeutics Inc.Silencing of CSN5 gene expression using interfering RNA
WO2009129319A2 (en)2008-04-152009-10-22Protiva Biotherapeutics, Inc.Silencing of csn5 gene expression using interfering rna
WO2009127060A1 (en)2008-04-152009-10-22Protiva Biotherapeutics, Inc.Novel lipid formulations for nucleic acid delivery
US20110171346A1 (en)*2008-04-182011-07-14Spaangner Christiansen LivProcess
EP3020410A1 (en)2008-04-182016-05-18Collplant Ltd.Methods of generating and using procollagen
EP2936976A1 (en)2008-04-212015-10-28Danziger Innovations Ltd.Plant viral expression vectors and use of same for generating genotypic variations in plant genomes
US20090269780A1 (en)*2008-04-232009-10-29Luminex CorporationMethod for Creating a Standard for Multiple Analytes Found in a Starting Material of Biological Origin
WO2009132124A2 (en)2008-04-242009-10-29The Trustees Of Columbia University In The City Of New YorkGeometric patterns and lipid bilayers for dna molecule organization and uses thereof
US20110136676A1 (en)*2008-04-242011-06-09Greene Eric CGeometric patterns and lipid bilayers for dna molecule organization and uses thereof
US9255289B2 (en)2008-04-242016-02-09The Trustees Of Columbia University In The City Of New YorkGeometric patterns and lipid bilayers for DNA molecule organization and uses thereof
US8791232B2 (en)2008-04-302014-07-29Dupont Nutrition Biosciences ApsProteins
WO2009139822A1 (en)2008-05-012009-11-19Amgen Inc.Anti-hepcidin antibodies and methods of use
EP2816059A1 (en)2008-05-012014-12-24Amgen, IncAnti-hepcidin antibodies and methods of use
EP2620448A1 (en)2008-05-012013-07-31Amgen Inc.Anti-hepcidin antibodies and methods of use
EP2116618A1 (en)2008-05-092009-11-11Agency for Science, Technology And ResearchDiagnosis and treatment of Kawasaki disease
US20110201559A1 (en)*2008-05-222011-08-18Centre National De La Recherche Scientifique (Cnrs)New Optically Pure Compounds for Improved Therapeutic Efficiency
US9243030B2 (en)2008-05-222016-01-26Centre National De La Recherche Scientifique (Cnrs)Optically pure compounds for improved therapeutic efficiency
US8847008B2 (en)2008-05-222014-09-30Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant utility
EP2641606A1 (en)2008-05-272013-09-25Pluristem Ltd.Methods of treating inflammatory colon diseases
EP2620493A1 (en)2008-05-282013-07-31Ramot at Tel Aviv University Ltd.Mesenchymal stem cells for the treatment of CNS diseases
EP3514229A1 (en)2008-05-282019-07-24Ramot at Tel-Aviv University Ltd.Mesenchymal stem cells for the treatment of cns diseases
US8791258B2 (en)2008-06-102014-07-29The Regents Of The University Of CaliforniaPro-fluorescent probes
US20110130306A1 (en)*2008-06-102011-06-02The Regents Of The University Of CaliforniaPro-fluorescent probes
US11280785B2 (en)2008-06-292022-03-22Realbio Technologies Ltd.Liquid-transfer device particularly useful as a capturing device in a biological assay process
US9952211B2 (en)2008-06-292018-04-24Realbio Technologies Ltd.Liquid-transfer device particularly useful as a capturing device in a biological assay process
EP2657342A1 (en)2008-08-082013-10-30Genisphere Inc.DNA dendrimers protected against nuclease degradation are useful as vectors for the delivery of siRNA
WO2010016806A1 (en)2008-08-082010-02-11Agency For Science, Technology And Research (A*Star)Vhz for diagnosis and treatment of cancers
WO2010017544A2 (en)2008-08-082010-02-11Genisphere, Inc.Long-acting dna dendrimers and methods thereof
EP3616504A2 (en)2008-08-182020-03-04Evogene Ltd.Isolated polypeptides and polynucleotides useful for increasing nitrogen use efficiency, abiotic stress tolerance, yield and biomass in plants
US9018445B2 (en)2008-08-182015-04-28Evogene Ltd.Use of CAD genes to increase nitrogen use efficiency and low nitrogen tolerance to a plant
EP3072972A2 (en)2008-08-182016-09-28Evogene Ltd.Isolated polypeptides and polynucleotides useful for increasing nitrogen use efficiency, abiotic stress tolerance, yield and biomass in plants
EP3115451A1 (en)2008-09-022017-01-11Pluristem Ltd.Adherent cells from placenta tissue and use thereof in therapy
US20100081177A1 (en)*2008-09-052010-04-01TransAlgae LtdDecreasing RUBISCO content of algae and cyanobacteria cultivated in high carbon dioxide
US8367392B2 (en)2008-09-052013-02-05Transalgae Ltd.Genetic transformation of algal and cyanobacteria cells by microporation
WO2010029545A2 (en)2008-09-112010-03-18Ben Gurion University Of The Negev Research And Development AuthorityCompositions and methods for treating s. pneumoniae infection
WO2010031006A1 (en)2008-09-122010-03-18Cryopraxis Criobiologia Ltda.Ischemic tissue cell therapy
EP3670524A1 (en)2008-09-242020-06-24Tel HaShomer Medical Research Infrastructure and Services Ltd.Peptides and compositions for prevention of cell adhesion and methods of using same
EP2789626A2 (en)2008-09-242014-10-15Tel Hashomer Medical Research Infrastructure and Services Ltd.Peptides and compositions for prevention of cell adhesion and methods of using same
US9434985B2 (en)2008-09-252016-09-06University Of MassachusettsMethods of identifying interactions between genomic loci
US12146186B2 (en)2008-09-252024-11-19Presidents And Fellows Of Harvard UniversityHiC: method of identifying regulatory interactions between genomic loci
US10745744B2 (en)2008-09-252020-08-18University Of MassachusettsHiC: method of identifying interactions between genomic loci
US9708648B2 (en)2008-09-252017-07-18University Of MassachusettsHiC: method of identifying interactions between genomic loci
WO2010035261A2 (en)2008-09-292010-04-01Ben Gurion University Of The Negev Research And Development AuthorityAmyloid beta-peptides and methods of use thereof
WO2010040277A1 (en)2008-10-092010-04-15The University Of Hong KongCadherin-17 as diagnostic marker and therapeutic target for liver cancer
WO2010049897A2 (en)2008-10-302010-05-06Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficieny
US8921658B2 (en)2008-10-302014-12-30Evogene Ltd.Isolated polynucleotides encoding a MAP65 polypeptide and methods of using same for increasing plant yield
US20110197315A1 (en)*2008-10-302011-08-11Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield
WO2010054328A2 (en)2008-11-072010-05-14Research Development FoundationCompositions and methods for the inhibition of cripto/grp78 complex formation and signaling
WO2010055525A1 (en)2008-11-172010-05-20Technion Research & Development Foundation Ltd.Method for predicting a patient's responsiveness to anti-folate therapy
WO2010058396A1 (en)2008-11-192010-05-27Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.A cd44vra antibody and diagnostic and therapeutic methods using same
US11236393B2 (en)2008-11-262022-02-01Cedars-Sinai Medical CenterMethods of determining responsiveness to anti-TNFα therapy in inflammatory bowel disease
WO2010061383A1 (en)2008-11-262010-06-03Biodalia Microbiological Technologies Ltd.A method of in-situ enrichment of foods with fructan
US12084722B2 (en)2008-11-262024-09-10Cedars-Sinai Medical CenterMethods of determining responsiveness to anti-TNFα therapy in inflammatory bowel disease
WO2010064231A1 (en)2008-12-022010-06-10Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods of analyzing a-i rna editing and nucleic acid constructs capable of same
WO2010065437A1 (en)2008-12-032010-06-10Research Development FoundationModulation of olfml-3 mediated angiogenesis
WO2010064247A1 (en)2008-12-032010-06-10Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods and kits for determining predisposition to cancer
EP2633854A1 (en)2008-12-052013-09-04Yeda Research And Development Co. Ltd.miRNA-9 or miRNA-9* for use in treating MND
US8809507B2 (en)2008-12-052014-08-19Vuong TrieuSPARC binding ScFvs
US10053504B2 (en)2008-12-052018-08-21Abraxis Bioscience, LlcSPARC binding ScFvs
US8445637B2 (en)2008-12-052013-05-21Abraxis Bioscience, LlcSPARC binding peptides and uses thereof
US9314537B2 (en)2008-12-052016-04-19Abraxis Bioscience, LlcSPARC binding ScFcs
EP3059247A1 (en)2008-12-052016-08-24Abraxis BioScience, LLCSparc binding peptides and uses thereof
US9295733B2 (en)2008-12-052016-03-29Abraxis Bioscience, LlcSPARC binding ScFcs
US9308279B2 (en)2008-12-052016-04-12Abraxis Biosciences, LlcSPARC binding ScFvs
US8821836B2 (en)2008-12-052014-09-02Abraxis Bioscience, LlcSPARC binding peptides and uses thereof
WO2010066252A1 (en)2008-12-092010-06-17Dako Denmark A/SMethod for evaluating pre-treatment
WO2010068757A1 (en)2008-12-122010-06-17The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesCompositions and methods useful for detecting and treating diseases associated with 16p chromosomal disruptions
WO2010071610A1 (en)2008-12-192010-06-24Agency For Science, Technology And Research (A*Star)Severe chikungunya biomarkers
US9580752B2 (en)2008-12-242017-02-28Cedars-Sinai Medical CenterMethods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
EP2808402A2 (en)2008-12-292014-12-03Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Methods of predicting responsiveness to interferon treatment
WO2010076642A1 (en)2008-12-292010-07-08Tel Hashomer Medical Research, Infrastructure And Services LtdPeptides and compositions for prevention of cell adhesion and methods of using same
WO2010076756A2 (en)2008-12-292010-07-08Evogene Ltd.Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance, biomass and/or yield in plants expressing same
WO2010076788A2 (en)2008-12-292010-07-08Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
WO2010076794A1 (en)2008-12-312010-07-08Technion Research & Development Foundation Ltd.Method of denitrifying brine and systems capable of same
US9107935B2 (en)2009-01-062015-08-18Gilead Biologics, Inc.Chemotherapeutic methods and compositions
US9289447B2 (en)2009-01-062016-03-22Gilead Biologics, Inc.Chemotherapeutic methods and compositions
US10093896B2 (en)2009-02-012018-10-09Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of generating tissue using devitalized, acellular scaffold matrices derived from micro-organs
WO2010086856A2 (en)2009-02-012010-08-05Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of generating tissue using devitalized, acellular scaffold matrices derived from micro-organs
US12060574B2 (en)2009-02-012024-08-13Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of generating tissue using devitalized, acellular scaffold matrices derived from micro-organs
WO2010086867A2 (en)2009-02-022010-08-05Ramot At Tel Aviv University Ltd.Peptides, pharmaceutical compositions comprising same and uses thereof
WO2010089707A1 (en)2009-02-042010-08-12Yeda Research And Development Co. Ltd.Methods and kits for determining sensitivity or resistance of prostate cancer to radiation therapy
EP3722810A2 (en)2009-02-112020-10-14Caris MPI, Inc.Molecular profiling of tumors
EP2955234A1 (en)2009-02-112015-12-16Orion Genomics, LLCCombinations of polymorphisms for determining allele-specific expression of igf2
WO2010093450A2 (en)2009-02-112010-08-19Ludwing Institute For Cancer Research Ltd.Pten phosphorylation-driven resistance to cancer treatment and altered patient prognosis
WO2010093820A2 (en)2009-02-112010-08-19Orion Genomics LlcCombinations of polymorphisms for determining allele-specific expression of igf2
EP3301446A1 (en)2009-02-112018-04-04Caris MPI, Inc.Molecular profiling of tumors
EP2913344A1 (en)2009-02-182015-09-02Ludwig Institute for Cancer Research LtdSpecific binding proteins and uses thereof
WO2010096434A2 (en)2009-02-182010-08-26Ludwig Institute For Cancer ResearchSpecific binding proteins and uses thereof
EP3301117A2 (en)2009-02-182018-04-04Ludwig Institute for Cancer Research LtdSpecific binding proteins and uses thereof
WO2010096658A1 (en)2009-02-192010-08-26The Cleveland Clinic FoundationCorin as a marker for heart failure
WO2010097794A1 (en)2009-02-262010-09-02Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods of reprogramming renal cells
EP2465920A2 (en)2009-02-262012-06-20Tel HaShomer Medical Research Infrastructure and Services Ltd.Isolated populations of renal stem cells and methods of isolating and using same
WO2010097793A2 (en)2009-02-262010-09-02Tel Hashomer Medical Research Infrastructure And Services Ltd.Isolated populations of renal stem cells and methods of isolating and using same
EP3000889A2 (en)2009-03-022016-03-30Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
US8937220B2 (en)2009-03-022015-01-20Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield, biomass, vigor and/or growth rate of a plant
WO2010100595A2 (en)2009-03-022010-09-10Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
EP3026057A2 (en)2009-03-092016-06-01Ramot at Tel Aviv University Ltd.Compositions for prevention and treatment of neurodegenerative diseases
WO2010103517A1 (en)2009-03-122010-09-16Rappaport Family Institute For Research In The Medical SciencesSoluble compositions for the treatment of cxcr3-ligand associated diseases
US20100240065A1 (en)*2009-03-182010-09-23Boehringer Ingelheim International GmbhProlyl Hydroxylase Compositions and Methods of Use Thereof
US20100240101A1 (en)*2009-03-192010-09-23Massachusetts Institute Of TechnologyParallel Proximity Ligation Event Analysis
US8481698B2 (en)2009-03-192013-07-09The President And Fellows Of Harvard CollegeParallel proximity ligation event analysis
US20100291100A1 (en)*2009-03-272010-11-18Gojo Industries, Inc.Compositions And Methods For Screening And Using Compounds Antagonizing Spore-Surface Interactions
WO2010126670A2 (en)2009-03-272010-11-04Gojo Industries, Inc.Compositions and methods for screening and using compounds antagonizing spore-surface interactions
WO2010115261A1 (en)2009-03-272010-10-14Genesis Genomics Inc.Aberrant mitochondrial dna, associated fusion transcripts and translation products and hybridization probes therefor
WO2010113096A1 (en)2009-03-302010-10-07Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods of predicting clinical course and treating multiple sclerosis
WO2010113146A1 (en)2009-04-012010-10-07The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical CenterA method of regulating proliferation and differentiation of keratinocyes
WO2010116375A1 (en)2009-04-082010-10-14Yeda Research And Development Co. Ltd.Isolated peptides for regulating apoptosis
US8975016B2 (en)2009-04-162015-03-10Diagnostic Hybrids, Inc.Methods for direct fluorescent antibody virus detection in liquids
US10088481B2 (en)2009-04-162018-10-02Diagnostic Hybrids, Inc.Methods for liquid direct fluorescent antibody intracellular virus detection
US9447467B2 (en)2009-04-212016-09-20Genetic Technologies LimitedMethods for obtaining fetal genetic material
US8940519B2 (en)2009-04-242015-01-27Dupont Nutrition Biosciences ApsMethod of producing a lipolytic enzyme
EP2990421A1 (en)2009-04-302016-03-02Tel HaShomer Medical Research Infrastructure and Services Ltd.Anti ceacam1 antibodies and methods of using same
US9040667B2 (en)2009-05-012015-05-26Dako Denmark A/SAntibody cocktail
US9778262B2 (en)2009-05-012017-10-03Dako Denmark A/SAntibody cocktail
US8889364B2 (en)2009-05-142014-11-18The Chancellor, Masters And Scholars Of The University Of OxfordClinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers
EP2799876A2 (en)2009-05-142014-11-05The Chancellors, Masters and Scholars of the University of OxfordClinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers
US20100291602A1 (en)*2009-05-142010-11-18University Of OxfordClinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers
WO2010134035A1 (en)2009-05-192010-11-25Danisco A/SUse
US9182403B2 (en)2009-05-192015-11-10Zetiq Technologies Ltd.Kits for and methods of differential staining of cervical cancer cells and/or tissues
WO2011019423A2 (en)2009-05-202011-02-17Schering CorporationModulation of pilr receptors to treat microbial infections
WO2010137017A2 (en)2009-05-272010-12-02Yeda Research And Development Co. Ltd.Proteasome inhibitors and uses thereof
WO2010137013A1 (en)2009-05-272010-12-02Ramot At Tel Aviv University Ltd.Crystallized photosystem i units from the pea plant and their use in solid state devices
WO2010137021A2 (en)2009-05-272010-12-02Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of generating connective tissue
WO2010137020A1 (en)2009-05-282010-12-02Yeda Research And Development Co. Ltd.Methods of treating inflammation
WO2010141421A1 (en)2009-06-022010-12-09The Board Of Regents Of The University Of Texas SystemIdentification of small molecules recognized by antibodies in subjects with neurodegenerative diseases
US9096865B2 (en)2009-06-102015-08-04Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance
EP3238534A2 (en)2009-06-102017-11-01Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance
EP3626051A2 (en)2009-06-102020-03-25Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance
WO2010150259A1 (en)2009-06-242010-12-29Fund For Medical Research Development Of Infrastructure And Health Services -Rambam Medical CenterMethods and kits for isolating placental derived microparticles and use of same for diagnosis of fetal disorders
WO2010150213A1 (en)2009-06-252010-12-29Danisco A/SProtein
US9260728B2 (en)2009-06-292016-02-16University Of British ColumbiaTerpene synthases from Santalum
US8569025B2 (en)2009-06-292013-10-29The University Of British ColumbiaTerpene synthases from santalum
US8993284B2 (en)2009-06-292015-03-31The University Of British ColumbiaTerpene synthases from Santalum
WO2011002834A2 (en)2009-07-012011-01-06American Type Culture CollectionCompositions and methods for diagnosis and treatment of type 1 diabetes
WO2011000107A1 (en)2009-07-012011-01-06Protiva Biotherapeutics, Inc.Novel lipid formulations for delivery of therapeutic agents to solid tumors
WO2011004361A2 (en)2009-07-092011-01-13Prolor Biotech Inc.Long-acting coagulation factors and methods of producing same
US10538755B2 (en)2009-07-092020-01-21Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
EP3130346A1 (en)2009-07-092017-02-15OPKO Biologics Ltd.Long-acting factor vii coagulation factors
US12203113B2 (en)2009-07-092025-01-21Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
US9663778B2 (en)2009-07-092017-05-30OPKO Biologies Ltd.Long-acting coagulation factors and methods of producing same
WO2011004379A1 (en)2009-07-102011-01-13Tel Hashomer Medical Research Infrastructure And Services Ltd.Compositions and methods for treating cancer
US11976381B2 (en)2009-07-172024-05-07Bioatla, Inc.Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
EP2907873A1 (en)2009-07-172015-08-19Bioatla LLCSimulataneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
US10920216B2 (en)2009-07-172021-02-16Bioatla, Inc.Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
EP3042957A1 (en)2009-07-172016-07-13Bioatla LLCSimultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
EP3406717A1 (en)2009-07-172018-11-28Bioatla LLCSimultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
US10106788B2 (en)2009-07-172018-10-23Bioatla, LlcSimultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
EP3636759A1 (en)2009-07-172020-04-15BioAtla LLCSimultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
US8859467B2 (en)2009-07-172014-10-14Bioatla, LlcSimultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
US10047357B2 (en)2009-07-172018-08-14Bioatla, LlcSimultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
WO2011011447A1 (en)2009-07-202011-01-27Protiva Biotherapeutics, Inc.Compositions and methods for silencing ebola virus gene expression
WO2011010309A1 (en)2009-07-212011-01-27Tel Hashomer Medical Research Infrastructure And Services Ltd.A method of diagnosing cancer
US9574210B2 (en)2009-07-312017-02-21Ramot At Tel-Aviv University Ltd.Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
US10179113B2 (en)2009-07-312019-01-15Ramot At Tel-Aviv University Ltd.Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
WO2011013130A2 (en)2009-07-312011-02-03Ramot At Tel-Aviv University Ltd.Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
WO2011021194A2 (en)2009-08-172011-02-24Technion Research & Development Foundation Ltd.Pericyte progenitor cells and methods of generating and using same
US8927700B2 (en)2009-08-212015-01-06Gilead Biologics, Inc.Catalytic domains from lysyl oxidase and LOXL2
US8512990B2 (en)2009-08-212013-08-20Gilead Biologics, Inc.Catalytic domains from lysyl oxidase and LOXL2
WO2011021171A1 (en)2009-08-212011-02-24Beeologics, LlcPreventing and curing beneficial insect diseases via plant transcribed molecules
WO2011024172A2 (en)2009-08-272011-03-03Technion Research & Development Foundation Ltd.Liposomal compositions and uses of same
EP3023438A1 (en)2009-09-032016-05-25Merck Sharp & Dohme Corp.Anti-gitr antibodies
WO2011030332A2 (en)2009-09-082011-03-17Yeda Research And Development Co. Ltd.Methods for hematopoietic precursor mobilization
WO2011030336A1 (en)2009-09-082011-03-17Ramot At Tel-Aviv University Ltd.Methods of diagnosing amyotrophic lateral sclerosis (als)
WO2011030329A1 (en)2009-09-102011-03-17Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of treating tumors
WO2011034950A1 (en)2009-09-162011-03-24Vaxart, Inc.Immunization strategy to prevent h1n1 infection
WO2011033511A1 (en)2009-09-172011-03-24Ramot At Tel-Aviv University Ltd.Peptides for the treatment of oxidative stress related disorders
WO2011033506A2 (en)2009-09-172011-03-24Yeda Research And Development Co. Ltd.Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
WO2011038160A2 (en)2009-09-232011-03-31Protiva Biotherapeutics, Inc.Compositions and methods for silencing genes expressed in cancer
WO2011038403A1 (en)2009-09-282011-03-31Yuling LuoMethods of detecting nucleic acid sequences with high specificity
WO2011041319A2 (en)2009-09-292011-04-07Ludwig Institute For Cancer ResearchSpecific binding proteins and uses thereof
US20110081706A1 (en)*2009-10-022011-04-07TransAlgae LtdMethod and system for efficient harvesting of microalgae and cyanobacteria
WO2011040972A1 (en)2009-10-022011-04-07Ludwig Institute For Cancer Research Ltd.Anti-fibroblast activation protein antibodies and methods and uses thereof
WO2011040973A2 (en)2009-10-022011-04-07Ludwig Institute For Cancer Research Ltd.Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
US10464987B2 (en)2009-10-062019-11-05Abbvie Inc.Human single-chain T cell receptors
WO2011044186A1 (en)2009-10-062011-04-14The Board Of Trustees Of The University Of IllinoisHuman single-chain t cell receptors
US9726672B2 (en)2009-10-112017-08-08Biogen Ma Inc.Anti-VLA-4 related assays
WO2011044553A1 (en)2009-10-112011-04-14Biogen Idec Ma Inc.Anti-vla-4 related assays
US11280793B2 (en)2009-10-112022-03-22Biogen Ma Inc.Anti-VLA-4 related assays
US12385925B2 (en)2009-10-112025-08-12Biogen Ma Inc.Anti-VLA-4 related assays
US9377458B2 (en)2009-10-112016-06-28Biogen Ma Inc.Anti-VLA-4 related assays
EP3349010A1 (en)2009-10-112018-07-18Biogen MA Inc.Anti-vla-4 related assays
US10302654B2 (en)2009-10-112019-05-28Biogen Ma Inc.Anti-VLA-4 related assays
WO2011045796A1 (en)2009-10-142011-04-21Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Compositions for controlling varroa mites in bees
EP3272869A1 (en)2009-10-142018-01-24Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.Compositions for controlling varroa mites in bees
US10801028B2 (en)2009-10-142020-10-13Beeologics Inc.Compositions for controlling Varroa mites in bees
WO2011046570A1 (en)2009-10-162011-04-21The University Of Medicine And Dentistry Of New JerseyMethod for treating chronic nerve tissue injury using a cell therapy strategy
WO2011048600A1 (en)2009-10-212011-04-28Danziger Innovations Ltd.Generating genotypic variations in plant genomes by gamete infection
WO2011056688A2 (en)2009-10-272011-05-12Caris Life Sciences, Inc.Molecular profiling for personalized medicine
WO2011055366A1 (en)2009-11-082011-05-12Medical Research & Development Fund For Health Services Bnai Zion Medical Center, The State Of IsraelMo-1 conditional knock-out non-human animal and uses thereof
EP3633025A1 (en)2009-11-122020-04-08Technion Research & Development Foundation Ltd.Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
WO2011058557A1 (en)2009-11-122011-05-19Ramot At Tel-Aviv University Ltd.Compositions comprising pedf and uses of same in the treatment and prevention of ovary-related syndromes
WO2011058555A1 (en)2009-11-122011-05-19Yeda Research And Development Co. Ltd.A method of editing dna in a cell and constructs capable of same
EP4166652A1 (en)2009-11-122023-04-19Technion Research & Development Foundation Ltd.Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
EP3037435A1 (en)2009-11-172016-06-29MUSC Foundation For Research DevelopmentHuman monoclonal antibodies to human nucleolin
US10385128B2 (en)2009-11-172019-08-20Musc Foundation For Research DevelopmentNucleolin antibodies
US20110117560A1 (en)*2009-11-172011-05-19Musc Foundation For Research DevelopmentASSESSING LEFT VENTRICULAR REMODELING VIA TEMPORAL DETECTION AND MEASUREMENT OF microRNA IN BODY FLUIDS
US9260517B2 (en)2009-11-172016-02-16Musc Foundation For Research DevelopmentHuman monoclonal antibodies to human nucleolin
WO2011061657A1 (en)2009-11-172011-05-26Danisco A/SMethod
US8592151B2 (en)2009-11-172013-11-26Musc Foundation For Research DevelopmentAssessing left ventricular remodeling via temporal detection and measurement of microRNA in body fluids
WO2011061736A1 (en)2009-11-172011-05-26Protalix Ltd.Alkaline alpha galactosidase for the treatment of fabry disease
US10900962B2 (en)2009-11-242021-01-26Sienna Cancer Diagnostics Inc.Molecular nets and devices for capturing analytes including exosomes
WO2011064773A1 (en)2009-11-242011-06-03Collplant Ltd.Method of generating collagen fibers
WO2011064669A2 (en)2009-11-302011-06-03Pluristem Ltd.Adherent cells from placenta and use of same in disease treatment
EP2977445A2 (en)2009-11-302016-01-27Pluristem Ltd.Adherent cells from placenta and use of same in disease treatment
EP2806023A2 (en)2009-11-302014-11-26Pluristem Ltd.Adherent cells from placenta and use of same in disease treatment
US20110129818A1 (en)*2009-12-022011-06-02Abbott LaboratoriesASSAY FOR CARDIAC TROPONIN-T (cTnT)
US8835120B2 (en)2009-12-022014-09-16Abbott LaboratoriesAssay for cardiac troponin-T (cTnT)
WO2011068681A1 (en)2009-12-022011-06-09Abbott LaboratoriesASSAY FOR CARDIAC TROPONIN-T (cTnT)
US8652788B2 (en)2009-12-022014-02-18Abbott LaboratoriesAssay for diagnosis of cardiac myocyte damage
US20110129854A1 (en)*2009-12-022011-06-02Abbott LaboratoriesAssay for diagnosis of cardiac myocyte damage
US8183002B2 (en)2009-12-032012-05-22Abbott LaboratoriesAutoantibody enhanced immunoassays and kits
US20110136141A1 (en)*2009-12-032011-06-09Abbott LaboratoriesPeptide reagents and method for inhibiting autoantibody antigen binding
US20110136103A1 (en)*2009-12-032011-06-09Abbott LaboratoriesAutoantibody enhanced immunoassays and kits
US8304201B2 (en)2009-12-032012-11-06Abbott LaboratoriesAutoantibody enhanced immunoassays and kits
WO2011068680A1 (en)2009-12-032011-06-09Abbott LaboratoriesAssay for diagnosis of cardiac myocyte damage
US8574858B2 (en)2009-12-032013-11-05Abbott LaboratoriesAutoantibody enhanced immunoassays and kits
WO2011068676A1 (en)2009-12-032011-06-09Abbott LaboratoriesPeptide reagents and method for inhibiting autoantibody antigen binding
WO2011067745A2 (en)2009-12-062011-06-09Rosetta Green Ltd.Compositions and methods for enhancing plants resistance to abiotic stress
US9562235B2 (en)2009-12-062017-02-07A.B. Seeds Ltd.MicroRNA compositions and methods for enhancing plant resistance to abiotic stress
EP2862929A1 (en)2009-12-092015-04-22Quark Pharmaceuticals, Inc.Compositions and methods for treating diseases, disorders or injury of the CNS
WO2011072091A1 (en)2009-12-092011-06-16Quark Pharmaceuticals, Inc.Methods and compositions for treating diseases, disorders or injury of the cns
WO2011084357A1 (en)2009-12-172011-07-14Schering CorporationModulation of pilr to treat immune disorders
WO2011076881A1 (en)2009-12-222011-06-30Arabian Gulf UniversityMutant ldl receptor gene
WO2011080674A2 (en)2009-12-282011-07-07Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
EP3056569A2 (en)2009-12-282016-08-17Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
US9493785B2 (en)2009-12-282016-11-15Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
EP3785712A1 (en)2009-12-292021-03-03Gamida-Cell Ltd.Methods for enhancing natural killer cell proliferation and activity
WO2011080740A1 (en)2009-12-292011-07-07Gamida-Cell Ltd.Methods for enhancing natural killer cell proliferation and activity
EP3184109A1 (en)2009-12-292017-06-28Gamida-Cell Ltd.Methods for enhancing natural killer cell proliferation and activity
EP3159405A1 (en)2010-01-052017-04-26Vascular Biogenics Ltd.Methods for use of a specific anti-angiogenic adenoviral agent
WO2011084882A2 (en)2010-01-052011-07-14Contrafect CorporationMethods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria
US11287423B2 (en)2010-01-112022-03-29Biogen Ma Inc.Assay for JC virus antibodies
EP4152004A1 (en)2010-01-112023-03-22Biogen MA Inc.Assay for jc virus antibodies
US12345703B2 (en)2010-01-112025-07-01Biogen Ma Inc.Assay for JC virus antibodies
EP3339865A1 (en)2010-01-112018-06-27Biogen MA Inc.Assay for jc virus antibodies
US9316641B2 (en)2010-01-112016-04-19Biogen Ma Inc.Assay for JC virus antibodies
EP4524571A2 (en)2010-01-112025-03-19Biogen MA Inc.Assay for jc virus antibodies
US10444234B2 (en)2010-01-112019-10-15Biogen Ma Inc.Assay for JC virus antibodies
WO2011086509A1 (en)2010-01-122011-07-21Vascular Biogenics Ltd.Methods of producing adenovirus vectors and viral preparations generated thereby
EP3216805A1 (en)2010-01-272017-09-13Yeda Research and Development Co. LtdAntibodies that inhibit metalloproteins
WO2011092700A1 (en)2010-01-272011-08-04Yeda Research And Development Co. Ltd.Antibodies that inhibit metalloproteins
WO2011094669A1 (en)2010-01-292011-08-04Advanced Cell Diagnostics, Inc.Methods of in situ detection of nucleic acids
WO2011096926A1 (en)2010-02-032011-08-11Massachusetts Institute Of TechnologyMethods for preparing sequencing libraries
US20110189677A1 (en)*2010-02-032011-08-04Massachusetts Institute Of TechnologyMethods For Preparing Sequencing Libraries
US8574832B2 (en)2010-02-032013-11-05Massachusetts Institute Of TechnologyMethods for preparing sequencing libraries
US8680246B2 (en)2010-02-042014-03-25Gilead Biologics, Inc.Antibodies that bind to lysyl oxidase-like 2 (LOXL2)
EP3395361A1 (en)2010-02-082018-10-31Agensys, Inc.Antibody drug conjugates (adc) that bind to 161p2f10b proteins
WO2011097627A1 (en)2010-02-082011-08-11Agensys, Inc.Antibody drug conjugates (adc) that bind to 161p2f10b proteins
WO2011099006A2 (en)2010-02-112011-08-18Yeda Research And Development Co. Ltd.Enzymatic systems for carbon fixation and methods of generating same
WO2011104708A2 (en)2010-02-242011-09-01Ben Gurion University Of The Negev Research And Development AuthorityMethods for inhibiting necrosis
WO2011107939A1 (en)2010-03-012011-09-09Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of predicting efficacy of an anti-vegfa treatment for solid tumors
WO2011107994A1 (en)2010-03-042011-09-09Yeda Research And Development Co. Ltd.Methods of measuring protein stability
US9988634B2 (en)2010-03-082018-06-05Monsanto Technology LlcPolynucleotide molecules for gene regulation in plants
US9121022B2 (en)2010-03-082015-09-01Monsanto Technology LlcMethod for controlling herbicide-resistant plants
US11812738B2 (en)2010-03-082023-11-14Monsanto Technology LlcPolynucleotide molecules for gene regulation in plants
WO2011111034A1 (en)2010-03-082011-09-15Yeda Research And Development Co. Ltd.Recombinant protein production in heterologous systems
WO2011111050A2 (en)2010-03-112011-09-15Jacob EdreiMethods of generating hydrogen
WO2011114251A1 (en)2010-03-182011-09-22Danisco A/SFoodstuff
WO2011125015A2 (en)2010-04-052011-10-13Bar-Ilan UniversityProtease-activatable pore-forming polypeptides
WO2011127150A2 (en)2010-04-062011-10-13Massachusetts Institute Of TechnologyGene-expression profiling with reduced numbers of transcript measurements
US9125931B2 (en)2010-04-062015-09-08Massachusetts Institute Of TechnologyPost-transcriptional regulation of RNA-related processes using encoded protein-binding RNA aptamers
US9458438B2 (en)2010-04-122016-10-04Ben Gurion University Of The Negev Research And Development AuthoritySulfotransferase of a red microalga and uses thereof
WO2011128897A1 (en)2010-04-122011-10-20Technion Research & Development Foundation Ltd.Populations of pancreatic progenitor cells and methods of isolating and using same
US9528998B2 (en)2010-04-162016-12-27Abbott LaboratoriesMethods and reagents for diagnosing rheumatoid arthrtis
WO2011132182A1 (en)2010-04-182011-10-27Yeda Research And Development Co. Ltd.MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES
US9328353B2 (en)2010-04-282016-05-03Evogene Ltd.Isolated polynucleotides and polypeptides for increasing plant yield and/or agricultural characteristics
WO2011135527A2 (en)2010-04-282011-11-03Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
WO2011138778A2 (en)2010-05-042011-11-10Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of identifying inhibitors of polypeptides-of-interest
WO2011138785A2 (en)2010-05-052011-11-10Rappaport Family Institute For Research In The Medical SciencesUse of ccl1 in therapy
WO2011138776A2 (en)2010-05-062011-11-10Hervana Ltd.Biologic female contraceptives
WO2011140234A1 (en)2010-05-072011-11-10Abbott LaboratoriesMethods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor
WO2011141914A1 (en)2010-05-132011-11-17Tel Hashomer Medical Research Infrastructure And Services Ltd.Isolated populations of adult renal cells and methods of isolating and using same
WO2011146479A1 (en)2010-05-182011-11-24The Texas A&M University SystemMethod and composition for the diagnosis and monitoring of inflammatory diseases
EP2808344A1 (en)2010-06-012014-12-03Monash UniversityAntibodies directed to the receptor tyrosine kinase c-Met
WO2011151833A1 (en)2010-06-032011-12-08Ramot At Tel-Aviv University Ltd.Methods of treating diabetes and compositions capable of same
WO2011154940A1 (en)2010-06-072011-12-15Osnat Ashur-FabianMethods and kits for diagnosing conditions related to hypoxia
WO2011158242A2 (en)2010-06-162011-12-22Futuragene Israel Ltd.Pest -resistant plants containing a combination of a spider toxin and a chitinase
WO2011158243A2 (en)2010-06-162011-12-22Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of diagnosing and treating cancer
WO2012006056A2 (en)2010-06-292012-01-12Oregon Health & Science UniversityCcr6 as a biomarker of alzheimer's disease
WO2012004759A2 (en)2010-07-082012-01-12Danisco A/SMethod
WO2012007945A2 (en)2010-07-122012-01-19The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani CenterIsolated polynucleotides and methods and plants using same for regulating plant acidity
EP2407242A1 (en)2010-07-132012-01-18Dublin City UniversityDirect clone analysis and selection technology
WO2012007537A1 (en)2010-07-132012-01-19Dublin City UniversityDirect clone analysis and selection technology
WO2012007950A2 (en)2010-07-152012-01-19Technion Research & Development Foundation Ltd.Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides
WO2012007951A1 (en)2010-07-152012-01-19Technion Research & Development Foundation Ltd.Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
WO2012007919A2 (en)2010-07-152012-01-19Technion Research & Development Foundation Ltd.Nucleic acid construct for increasing abiotic stress tolerance in plants
WO2012009627A2 (en)2010-07-162012-01-19Vanderbilt UniversityLow resource processor using surface tension valves for extracting, concentrating and detecting molecular species
EP3435087A1 (en)2010-07-162019-01-30Bioatla LLCNovel methods of protein evolution
WO2012011113A2 (en)2010-07-222012-01-26Shai YarkoniRegulatory immune cells with enhanced targeted cell death effect
WO2012012748A2 (en)2010-07-232012-01-26Luminex CorporationCo-coupling to control reactivity of reagents in immunoassays
KR20130090892A (en)2010-07-232013-08-14루미넥스 코포레이션Co-coupling to control reactivity of reagents in immunoassays
US9120862B2 (en)2010-07-262015-09-01Abbott LaboratoriesAntibodies relating to PIVKA-II and uses thereof
WO2012018476A1 (en)2010-07-262012-02-09Abbott LaboratoriesAntibodies relating to pivka-ii and uses thereof
WO2012014208A2 (en)2010-07-272012-02-02Yeda Research And Development Co. Ltd.Methods and systems for assessing clonality of cell cultures
WO2012014205A1 (en)2010-07-272012-02-02Technion Research & Development Foundation Ltd.Isolated mesenchymal progenitor cells and extracellular matrix produced thereby
WO2012014207A2 (en)2010-07-272012-02-02Technion Research & Development Foundation Ltd.Method for generating induced pluripotent stem cells from keratinocytes derived from plucked hair follicles
WO2012017439A2 (en)2010-08-042012-02-09Ramot At Tel-Aviv University Ltd.Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
US9739773B1 (en)2010-08-132017-08-22David Gordon BermudesCompositions and methods for determining successful immunization by one or more vaccines
WO2012025914A1 (en)2010-08-222012-03-01Ramot At Tel-Aviv University Ltd.Induced pluripotent stem cells derived from human pancreatic beta cells
WO2012025925A1 (en)2010-08-242012-03-01Rappaport Family Institute For Research In The Medical SciencesMethods of improving transplantation using sdf-1alpha
US10457954B2 (en)2010-08-302019-10-29Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance
WO2012032510A1 (en)2010-09-072012-03-15Yeda Research And Development Co. Ltd.Primers for amplifying dna and methods of selecting same
WO2012032521A2 (en)2010-09-072012-03-15Technion Research & Development Foundation Ltd.Novel methods and culture media for culturing pluripotent stem cells
WO2012032519A2 (en)2010-09-072012-03-15Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of diagnosing parkinson's disease
WO2012032520A1 (en)2010-09-072012-03-15Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Readthrough acetylcholinesterase (ache-r) for treating or preventing parkinson's disease
WO2012032526A2 (en)2010-09-082012-03-15Yeda Research And Development Co. Ltd.Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment
WO2012032525A2 (en)2010-09-082012-03-15Yeda Research And Development Co. Ltd.An immunosuppressive drug combination for a stable and long term engraftment
WO2012035539A1 (en)2010-09-152012-03-22Ramot At Tel-Aviv University Ltd.Methods of expanding and redifferentiating islet beta cells
WO2012040168A2 (en)2010-09-202012-03-29Advanced Cell Diagnostics, Inc.Biomarkers for differentiating melanoma from benign nevus in the skin
WO2012038956A1 (en)2010-09-202012-03-29Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of treating neurodegenerative diseases
EP3903812A1 (en)2010-09-292021-11-03Agensys, Inc.Antibody drug conjugates (adc) that bind to 191p4d12 proteins
EP3409287A1 (en)2010-09-292018-12-05Agensys, Inc.Antibody drug conjugates (adc) that bind to 191p4d12 proteins
WO2012047724A1 (en)2010-09-292012-04-12Agensys, Inc.Antibody drug conjugates (adc) that bind to 191p4d12 proteins
US9487559B2 (en)2010-10-042016-11-08Elro Pharma SarlCompositions comprising multivalent synthetic ligands of surface nucleolin and glycosaminoglycans
WO2012049066A2 (en)2010-10-122012-04-19Eppendorf AgReal-time amplification and micro-array based detection of nucleic acid targets in a flow chip assay
EP2441520A1 (en)2010-10-122012-04-18Eppendorf AGReal-time amplification and micro-array based detection of nucleic acid targets in a flow chip assay
WO2012052872A2 (en)2010-10-172012-04-26Yeda Research And Development Co. Ltd.Methods and compositions for the treatment of insulin-associated medical conditions
EP3075396A1 (en)2010-10-172016-10-05Yeda Research and Development Co. Ltd.Methods and compositions for the treatment of insulin-associated medical conditions
WO2012052878A1 (en)2010-10-192012-04-26Vascular Biogenics Ltd.Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells
EP3034625A1 (en)2010-10-212016-06-22Advanced Cell Diagnostics, Inc.An ultra sensitive method for in situ detection of nucleic acids
WO2012054795A1 (en)2010-10-212012-04-26Advanced Cell Diagnostics, Inc.An ultra sensitive method for in situ detection of nucleic acids
WO2012056452A2 (en)2010-10-272012-05-03Nanocyte (Israel) Ltd.Pharmaceutical compositions and delivery devices comprising stinging cells or capsules
WO2012056455A1 (en)2010-10-282012-05-03Yeda Research And Development Co. Ltd.Methods of generating antibodies to metalloenzymes
WO2012059922A2 (en)2010-11-032012-05-10Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Transgenic plants with improved saccharification yields and methods of generating same
WO2012059925A2 (en)2010-11-042012-05-10Ben-Gurion University Of The Negev Research And Development AuthorityAcyl-coa: diacylglycerol acyltransferase 1-like gene (ptdgat1) and uses thereof
US9096645B2 (en)2010-11-152015-08-04Ramot At Tel-Aviv University Ltd.Dipeptide analogs for treating conditions associated with amyloid fibril formation
US9630989B2 (en)2010-11-152017-04-25Ramot At Tel-Aviv University Ltd.Dipeptide analogs for treating conditions associated with amyloid fibril formation
WO2012066495A2 (en)2010-11-172012-05-24Ben Gurion University Of The Negev Research And Development AuthorityT-cell therapy to neurodegenerative diseases
WO2012073238A1 (en)2010-12-022012-06-07Technion Research & Development Foundation Ltd.Methods of generating corneal cells and cell populations comprising same
EP2463382A1 (en)2010-12-072012-06-13Enterologics, Inc.Method for identifying E. Coli M-17
WO2012081029A1 (en)2010-12-152012-06-21Kadimastem Ltd.Insulin producing cells derived from pluripotent stem cells
US9551006B2 (en)2010-12-222017-01-24Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for improving plant properties
US9238843B2 (en)2010-12-272016-01-19Eli Lilly And CompanyCompositions and methods for identifying and differentiating viral components of multivalent shipping fever vaccines
WO2012090205A2 (en)2010-12-282012-07-05Kamedis Ltd.Plant extracts for the treatment and prevention of infections
EP3961214A1 (en)2010-12-312022-03-02BioAtla, Inc.Comprehensive monoclonal antibody generation
WO2012099896A2 (en)2011-01-172012-07-26Life Technologies CorporationWorkflow for detection of ligands using nucleic acids
EP3567121A1 (en)2011-01-172019-11-13Life Technologies CorporationWorkflow for detection of ligands using nucleic acids
EP3216878A1 (en)2011-01-172017-09-13Life Technologies CorporationWorkflow for detection of ligands using nucleic acids
WO2012098537A1 (en)2011-01-202012-07-26Protalix Ltd.Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
WO2012103414A2 (en)2011-01-282012-08-02Advanced Cell Diagnostics, Inc.Rnascope® hpv assay for determining hpv status in head and neck cancers and cervical lesions
WO2012104851A1 (en)2011-01-312012-08-09Yeda Research And Development Co. Ltd.Methods of diagnosing disease using overlap extension pcr
US8658128B2 (en)2011-02-032014-02-25Pop Test Cortisol LlcSystem and method for diagnosis and treatment
US9114147B2 (en)2011-02-032015-08-25Pop Test Oncology Limited Liability CompanySystem and method for diagnosis and treatment
WO2012109133A1 (en)2011-02-072012-08-16Research Development FoundationEngineered immunoglobulin fc polypeptides
WO2012114339A1 (en)2011-02-232012-08-30Rappaport Family Institute For Research In The Medical SciencesHigh affinity molecules capable of binding a type a plexin receptor and uses of same
US9212258B2 (en)2011-02-232015-12-15The Board Of Trustees Of The University Of IllinoisAmphiphilic dendron-coils, micelles thereof and uses
US9770413B2 (en)2011-02-232017-09-26The Board Of Trustees Of The University Of IllinoisAmphiphilic dendron-coils, micelles thereof and uses
WO2012117406A2 (en)2011-03-022012-09-07Futuragene Israel Ltd.Bacterial resistant transgenic plants
WO2012117373A1 (en)2011-03-032012-09-07Ramot At Tel-Aviv University Ltd.Genetically modified muscle cells which express neurotrophic factors
WO2012120500A2 (en)2011-03-062012-09-13Merck Serono S.A.Low fucose cell lines and uses thereof
US9057107B2 (en)2011-03-082015-06-16King Abdullah University Of Science And TechnologyMolecular biomarker set for early detection of ovarian cancer
WO2012120377A2 (en)2011-03-082012-09-13King Abdullah University Of Science And TechnologyMolecular biomarker set for early detection of ovarian cancer
WO2012120518A1 (en)2011-03-082012-09-13Ramot At Tel-Aviv University Ltd.Compositions and methods for diagnosing and treating phenylketonuria (pku)
US9914974B2 (en)2011-03-082018-03-13King Abdullah University Of Science And TechnologyMolecular biomarker set for early detection of ovarian cancer
WO2012125582A1 (en)2011-03-112012-09-20Board Of Regents Of The University Of NebraskaBiomarker for coronary artery disease
WO2012123938A1 (en)2011-03-172012-09-20Tel Hashomer Medical Research Infrastructure And Services Ltd.Quinolone analogs for treating autoimmune diseases
WO2012123949A1 (en)2011-03-172012-09-20Ramot At Tel-Aviv University Ltd.Bi- and monospecific, asymmetric antibodies and methods of generating the same
WO2012127320A1 (en)2011-03-222012-09-27Pluristem Ltd.Methods for treating radiation or chemical injury
WO2012129378A1 (en)2011-03-222012-09-27Keutgen Xavier MDistinguishing benign and malignant indeterminate thyroid lesions
EP3260533A1 (en)2011-03-222017-12-27Pluristem Ltd.Methods for treating radiation or chemical injury
WO2012127475A1 (en)2011-03-242012-09-27Neurim Pharmaceuticals (1991) Ltd.Neuroprotective peptides
WO2012131680A2 (en)2011-03-282012-10-04Yeda Research And Development Co. Ltd.Compositions and methods for treating inflammation
WO2012131594A1 (en)2011-03-282012-10-04Novartis AgMarkers associated with cyclin-dependent kinase inhibitors
EP3318273A1 (en)2011-04-012018-05-09ImmunoGen, Inc.Methods for increasing efficacy of folr1 cancer therapy
EP3636279A1 (en)2011-04-012020-04-15ImmunoGen, Inc.Methods for increasing efficacy of folr1 cancer therapy
WO2012135360A1 (en)2011-04-012012-10-04Ludwig Institute For Cancer Research Ltd.Binding proteins specific for egfr expressed on tumor and uses thereof
EP4309671A2 (en)2011-04-012024-01-24ImmunoGen, Inc.Methods for increasing efficacy of folr1 cancer therapy
WO2012138941A1 (en)2011-04-052012-10-11Longevity Biotech, Inc.Compositions comprising glucagon analogs and methods of making and using the same
WO2012137202A1 (en)2011-04-052012-10-11Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Composition comprising an iron indicator attached to a microparticle and uses of same for quantifying non-transferrin bound iron (ntbi) and cellular labile iron (lci)
US9790262B2 (en)2011-04-052017-10-17Longevity Biotech, Inc.Compositions comprising glucagon analogs and methods of making and using the same
WO2012137207A1 (en)2011-04-062012-10-11Ramot At Tel-Aviv University Ltd.Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same
WO2012137147A1 (en)2011-04-082012-10-11Danisco Us, Inc.Compositions
US9676846B2 (en)2011-04-122017-06-13The United States Of America As Represented By The Secretary, Department Of Health And Human ServicesHuman monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US9150644B2 (en)2011-04-122015-10-06The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesHuman monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
WO2012140519A2 (en)2011-04-152012-10-18Pluristem Ltd.Methods and systems for harvesting cells
EP3252155A1 (en)2011-04-212017-12-06The Rockefeller UniversityStreptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
US10760088B2 (en)2011-05-032020-09-01Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
WO2012150600A2 (en)2011-05-042012-11-08Ramot At Tel-Aviv University Ltd.Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease
WO2012150959A1 (en)2011-05-042012-11-08Abbott LaboratoriesMethods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor
WO2012153333A1 (en)2011-05-092012-11-15Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Regeneration and repair of mesenchymal tissue using amelogenin
WO2012153336A2 (en)2011-05-122012-11-15Rakuto Bio Technologies Ltd.Methods and device for lightening skin complexion
WO2012156976A1 (en)2011-05-162012-11-22Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of producing artemisinin in non-host plants and vectors for use in same
US10107826B2 (en)2011-05-202018-10-23Abbott Japan Co. Ltd.Immunoassay methods and reagents for decreasing nonspecific binding
WO2012162179A1 (en)2011-05-202012-11-29Oligomerix, Inc.Tau protease compositions and methods of use
WO2012160526A2 (en)2011-05-232012-11-29Ofir MenasheFormulations of microorganism comprising particles and uses of same
EP3263127A1 (en)2011-05-232018-01-03Yeda Research and Development Co. LtdUse of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
US12105090B2 (en)2011-05-312024-10-01Biogen Ma Inc.Methods of treating a multiple sclerosis patient with anti-VLA-4 therapy
US12066442B2 (en)2011-05-312024-08-20Biogen Ma Inc.Method of assessing risk of PML
WO2012164380A2 (en)2011-05-312012-12-06Hutchison Biofilm Medical Solutions LimitedDispersion and detachment of cell aggregates
EP3527581A2 (en)2011-05-312019-08-21Hutchison Biofilm Medical Solutions LimitedDispersion and detachment of cell aggregates
EP4187248A1 (en)2011-05-312023-05-31Biogen MA Inc.Method of assessing risk of pml
EP3575792A1 (en)2011-05-312019-12-04Biogen MA Inc.Method of assessing risk of pml
WO2012164565A1 (en)2011-06-012012-12-06Yeda Research And Development Co. Ltd.Compositions and methods for downregulating prokaryotic genes
US10166295B2 (en)2011-06-022019-01-01Opko Biologics Ltd.Pegylated OXM variants
US10323097B2 (en)2011-06-062019-06-18Novo Nordisk A/SAnti-C5a receptor antibodies
US10882916B2 (en)2011-06-062021-01-05Novo Nordisk A/SAnti-C5a receptor antibodies
US8846045B2 (en)2011-06-062014-09-30Novo Nordisk A/SAnti-C5a receptor antibodies
US8613926B2 (en)2011-06-062013-12-24Novo Nordisk A/SAnti-C5a receptor antibodies
WO2012172555A1 (en)2011-06-142012-12-20Yeda Research And Development Co. Ltd.Combination therapy to prevent dcis formation and progression to breast cancer
WO2012176203A1 (en)2011-06-232012-12-27Kaiima Bio Agritech Ltd.Common wheat, plants or parts thereof having partially or fully multiplied genome, hybrids and products thereof and methods of generating and using same
US11013773B2 (en)2011-07-142021-05-254D Pharma Research LimitedLactic acid bacterial strains
WO2013010170A1 (en)2011-07-142013-01-17Lovell Mark AProcess for detection of alzheimer's disease from a serum sample
EP3081937A1 (en)2011-07-182016-10-19President and Fellows of Harvard CollegeEngineered microbe-targeting molecules and uses thereof
WO2013012924A2 (en)2011-07-182013-01-24President And Fellows Of Harvard CollegeEngineered microbe-targeting molecules and uses thereof
WO2013011507A1 (en)2011-07-202013-01-24Kaiima Bio Agritech Ltd.Maize plants having a partially or fully multiplied genome and uses thereof
EP2550982A1 (en)2011-07-272013-01-30Technion Research & Development Foundation Ltd.Devices for surgical applications
WO2013018098A2 (en)2011-08-022013-02-07Prolor Biotech Ltd.Long-acting growth hormone and methods of producing same
EP3482765A1 (en)2011-08-022019-05-15OPKO Biologics Ltd.Long-acting growth hormone and methods of producing same
EP3208338A1 (en)2011-08-042017-08-23Yeda Research and Development Co., Ltd.Micro-rna mir-15 and compositions comprising same for the treatment of corticotropin-releasing hormone- associated medical conditions
EP3524679A1 (en)2011-08-042019-08-14Yeda Research and Development Co., Ltd.Micro-rna mir-19 and compositions comprising same for the treatment of medical conditions in which low adrenaline or noradrenaline level is therapeutically beneficial
WO2013018060A2 (en)2011-08-042013-02-07Yeda Research And Development Co. Ltd.Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
WO2013022599A1 (en)2011-08-052013-02-14Research Development FoundationImproved methods and compositions for modulation of olfml3 mediated angiogenesis
WO2013021389A2 (en)2011-08-092013-02-14Yeda Research And Development Co.Ltd.Downregulation of mir-7 for promotion of beta cell differentiation and insulin production
WO2013024481A1 (en)2011-08-142013-02-21Kaiima Bio Agritech Ltd.Durum wheat plants having a partially or fully multiplied genome and uses thereof
WO2013025834A2 (en)2011-08-152013-02-21The University Of ChicagoCompositions and methods related to antibodies to staphylococcal protein a
EP3348575A1 (en)2011-08-162018-07-18Emory UniversityJaml specific binding agents, antibodies, and uses related thereto
WO2013035070A1 (en)2011-09-072013-03-14Yeda Research And Development Co. Ltd.Olfactory signature and odorant mixture having the same
WO2013035099A1 (en)2011-09-082013-03-14Yeda Research And Development Co. Ltd.Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
WO2013035071A1 (en)2011-09-082013-03-14Yeda Research And Development Co. Ltd.Novel risk biomarkers for lung cancer
US9422558B2 (en)2011-09-132016-08-23Monsanto Technology LlcMethods and compositions for weed control
US9422557B2 (en)2011-09-132016-08-23Monsanto Technology LlcMethods and compositions for weed control
US9840715B1 (en)2011-09-132017-12-12Monsanto Technology LlcMethods and compositions for delaying senescence and improving disease tolerance and yield in plants
US10435702B2 (en)2011-09-132019-10-08Monsanto Technology LlcMethods and compositions for delaying senescence and improving disease tolerance and yield in plants
US10760086B2 (en)2011-09-132020-09-01Monsanto Technology LlcMethods and compositions for weed control
US10806146B2 (en)2011-09-132020-10-20Monsanto Technology LlcMethods and compositions for weed control
US10808249B2 (en)2011-09-132020-10-20Monsanto Technology LlcMethods and compositions for weed control
US9416363B2 (en)2011-09-132016-08-16Monsanto Technology LlcMethods and compositions for weed control
US10829828B2 (en)2011-09-132020-11-10Monsanto Technology LlcMethods and compositions for weed control
US9920326B1 (en)2011-09-142018-03-20Monsanto Technology LlcMethods and compositions for increasing invertase activity in plants
US10428338B2 (en)2011-09-142019-10-01Monsanto Technology LlcMethods and compositions for increasing invertase activity in plants
WO2014042763A1 (en)2011-09-162014-03-20Steve GoodisonBladder cancer detection composition kit, and associated methods
EP3369742A1 (en)2011-10-052018-09-05The Rockefeller UniversityDimeric bacteriophage lysins
WO2013052643A1 (en)2011-10-052013-04-11The Rockefeller UniversityDimeric bacteriophage lysins
US9937211B2 (en)2011-10-072018-04-104D Pharma Research LimitedComposition of Roseburia hominis
US11266698B2 (en)2011-10-072022-03-084D Pharma Research LimitedBacterium for use as a probiotic for nutritional and medical applications
US11891453B2 (en)2011-10-112024-02-06Famewave Ltd.Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM)
US9771431B2 (en)2011-10-112017-09-26Ccam Biotherapeutics Ltd.Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM)
EP3360899A1 (en)2011-10-112018-08-15Tel HaShomer Medical Research Infrastructure and Services Ltd.Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
WO2013054331A1 (en)2011-10-112013-04-18Tel Hashomer Medical Research Infrastructure And Services Ltd.Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
WO2013056377A1 (en)2011-10-212013-04-25Augurex Life Sciences CorporationAntigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis
WO2013061328A2 (en)2011-10-272013-05-02Yeda Research And Development Co. Ltd.Method of treating cancer
WO2013064163A1 (en)2011-11-012013-05-10Academisch Medisch CentrumMethylation markers for colorectal cancer
WO2013067076A2 (en)2011-11-032013-05-10Quark Pharmaceuticals, Inc.Methods and compositions for neuroprotection
WO2013070821A1 (en)2011-11-082013-05-16Quark Pharmaceuticals, Inc.Methods and compositions for treating diseases, disorders or injury of the nervous system
WO2013076729A1 (en)2011-11-232013-05-30Danziger Dan Flower FarmOtomeria plants
WO2013076730A1 (en)2011-11-272013-05-30Yeda Research And Development Co. Ltd.Methods of regulating angiogenesis and compositions capable of same
WO2013084190A1 (en)2011-12-082013-06-13Yeda Research And Development Co. Ltd.Mammalian fetal pulmonary cells and therapeutic use of same
EP3034087A1 (en)2011-12-082016-06-22Yeda Research and Development Co. Ltd.Mammalian fetal pulmonary cells and therapeutic use of same
US10444158B2 (en)2011-12-122019-10-15Step Ahead Innovations, Inc.Error monitoring and correction systems and methods in aquatic environment monitoring
US9494526B2 (en)2011-12-122016-11-15Step Ahead Innovations, Inc.Combined illuminator/light collectors for optical readers
US9494527B2 (en)2011-12-122016-11-15Step Ahead Innovations, Inc.Optical reader optic cleaning systems having motion deployed cleaning elements
US9261462B2 (en)2011-12-122016-02-16Step Ahead Innovations, Inc.Monitoring of photo-aging of light-based chemical indicators using illumination-brightness differential scheme
WO2013093921A1 (en)2011-12-202013-06-27Collplant Ltd.Collagen coated synthetic polymer fibers
US10598572B2 (en)2011-12-222020-03-24Realbio Technologies, Ltd.Sequential lateral capillary flow device for analyte determination
US9726581B2 (en)2011-12-222017-08-08Realbio Technologies Ltd.Sequential lateral flow capillary device for analyte determination
WO2013093920A2 (en)2011-12-222013-06-27Yeda Research And Development Co. Ltd.A combination therapy for a stable and long term engraftment
US9035039B2 (en)2011-12-222015-05-19Protiva Biotherapeutics, Inc.Compositions and methods for silencing SMAD4
WO2013098820A1 (en)2011-12-282013-07-04Kaiima Bio Agritech Ltd.Cultivated sorghum plant having a partially or fully multiplied genome and uses of same
WO2013101758A1 (en)2011-12-292013-07-04Baylor Research InstituteBiomarkers for kawasaki disease
WO2013098813A1 (en)2012-01-012013-07-04Qbi Enterprises Ltd.Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
EP3418397A1 (en)2012-01-242018-12-26CD Diagnostics, Inc.System for detecting infection in synovial fluid
WO2013114363A2 (en)2012-01-302013-08-08Yeda Research And Development Co.Ltd.Antimicrobial agents
WO2013114371A1 (en)2012-02-012013-08-08Protalix Ltd.Dry powder formulations of dnase i
WO2013114374A1 (en)2012-02-012013-08-08Protalix Ltd.Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
WO2013114373A1 (en)2012-02-012013-08-08Protalix Ltd.Inhalable liquid formulations of dnase i
US10184131B2 (en)2012-02-062019-01-22A.B. Seeds Ltd.Isolated polynucleotides expressing or modulating microRNAs or targets of same, transgenic plants comprising same and uses thereof
WO2013121427A1 (en)2012-02-132013-08-22Gamida-Cell Ltd.Mesenchymal stem cells conditioned medium and methods of generating and using the same
US10047345B2 (en)2012-02-132018-08-14Gamida-Cell Ltd.Culturing of mesenchymal stem cells with FGF4 and nicotinamide
WO2013121426A1 (en)2012-02-132013-08-22Gamida-Cell Ltd.Culturing of mesenchymal stem cells
EP3326642A1 (en)2012-02-142018-05-30OPKO Biologics Ltd.Long-acting coagulation factors and uses thereof
EP3791890A1 (en)2012-02-142021-03-17OPKO Biologics Ltd.Long-acting coagulation factors and uses thereof
WO2013121416A1 (en)2012-02-142013-08-22Prolor Biotech Inc.Long-acting coagulation factors and methods of producing same
EP4488289A2 (en)2012-02-142025-01-08OPKO Biologics Ltd.Long-acting coagulation factors and uses thereof
WO2013121405A1 (en)2012-02-192013-08-22Protalix Ltd.Oral unit dosage forms and uses of same for the treatment of gaucher disease
EP3401393A1 (en)2012-02-222018-11-14Exostem Biotec LtdMicrornas for the generation of astrocytes
WO2013124817A2 (en)2012-02-222013-08-29Brainstem Biotec Ltd.MicroRNAS FOR THE GENERATION OF ASTROCYTES
EP3401394A1 (en)2012-02-222018-11-14Exostem Biotec LtdGeneration of neural stem cells
WO2013124816A2 (en)2012-02-222013-08-29Brainstem Biotec Ltd.Generation of neural stem cells and motor neurons
WO2013126803A1 (en)2012-02-242013-08-29Protiva Biotherapeutics Inc.Trialkyl cationic lipids and methods of use thereof
EP3988104A1 (en)2012-02-242022-04-27Arbutus Biopharma CorporationTrialkyl cationic lipids and methods of use thereof
EP3473611A1 (en)2012-02-242019-04-24Arbutus Biopharma CorporationTrialkyl cationic lipids and methods of use thereof
EP3263564A1 (en)2012-02-292018-01-03ChemoCentryx, Inc.Aza-aryl 1h-pyrazol-1-yl benzene sulfonamides as ccr(9) antagonists
WO2013130811A1 (en)2012-02-292013-09-06Chemocentryx, Inc.Pyrazol-1-yl benzene sulfonamides as ccr9 antagonists
EP3738958A1 (en)2012-02-292020-11-18ChemoCentryx, Inc.Aza-aryl 1h-pyrazol-1-yl benzene sulfonamides as ccr(9) antagonists
WO2013128454A1 (en)2012-03-012013-09-06The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani CenterMale sterile garlic plants, hybrid offspring of same and methods of generating and using same
EP3483184A1 (en)2012-03-072019-05-15Yeda Research and Development Co. LtdCompositions for inhibition of quiescinsulfhydryl oxidase (qsox1) and uses of same
WO2013132495A1 (en)2012-03-072013-09-12Yeda Research And Development Co. Ltd.Compositions for inhibition of quiescin sulfhydryl oxidase (qsox1) and uses of same
WO2013136335A1 (en)2012-03-152013-09-19Yeda Research And Development Co. Ltd.Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
EP3575311A1 (en)2012-03-202019-12-04Biogen MA Inc.Jcv neutralizing antibodies
WO2013140389A1 (en)2012-03-222013-09-26Ramot At Tel-Aviv University Ltd.Plif multimeric peptides and uses thereof
WO2013149219A2 (en)2012-03-302013-10-03Sorrento Therapeutics Inc.Fully human antibodies that bind to vegfr2
EP3312296A1 (en)2012-04-052018-04-25Advanced Cell Diagnostics, Inc.Detection of immunoglobulin light chain restrication by rna in situ hybridization
WO2013152295A1 (en)2012-04-052013-10-10Advanced Cell Diagnostics, Inc.Detection of immunoglobulin light chain restrication by rna in situ hybridization
EP3591072A1 (en)2012-04-052020-01-08Advanced Cell Diagnostics, Inc.Detection of immunoglobulin light chain restrication by rna in situ hybridization
WO2013153553A2 (en)2012-04-132013-10-17Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Compositions for controlling varroa mites in bees
US9925143B2 (en)2012-04-182018-03-27Ramot At Tel-Aviv University Ltd.Lipidated glycosaminoglycan particles for the delivery of nucleic acids
US9522945B2 (en)2012-04-192016-12-20Opko Biologics Ltd.Long-acting oxyntomodulin variants and methods of producing same
WO2013163035A1 (en)2012-04-232013-10-31Uhl Ii, LlcDevices and methods for detecting analyte in bodily fluid
WO2013160895A1 (en)2012-04-242013-10-31Biokine Therapeutics Ltd.Peptides and use thereof in the treatment of large cell lung cancer
WO2013162751A1 (en)2012-04-262013-10-31University Of ChicagoCompositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
WO2013168164A1 (en)2012-05-092013-11-14Yeda Research And Development Co. Ltd.Variants of tace pro-domain as tnf-a inhibitor and their medical use
WO2013170168A1 (en)2012-05-102013-11-14Bioatla LlcMulti-specific monoclonal antibodies
EP3553089A1 (en)2012-05-102019-10-16Bioatla, LLCMulti-specific monoclonal antibodies
US8865158B2 (en)2012-05-222014-10-21Ramot At Tel-Aviv University Ltd.Bacteriophages for reducing toxicity of bacteria
US10240162B2 (en)2012-05-242019-03-26A.B. Seeds Ltd.Compositions and methods for silencing gene expression
US10934555B2 (en)2012-05-242021-03-02Monsanto Technology LlcCompositions and methods for silencing gene expression
US9290564B2 (en)2012-05-242016-03-22Mountgate Group LimitedCompositions and methods related to the prevention and treatment of rabies infection
US10240161B2 (en)2012-05-242019-03-26A.B. Seeds Ltd.Compositions and methods for silencing gene expression
WO2013174003A1 (en)2012-05-242013-11-28Mountgate Group LimitedCompositions and methods related to prevention and treatment of rabies infection
WO2013175480A1 (en)2012-05-242013-11-28A.B. Seeds Ltd.Compositions and methods for silencing gene expression
EP3508497A1 (en)2012-05-242019-07-10Mountgate Group LimitedCompositions and methods related to prevention and treatment of rabies infection
EP3553086A1 (en)2012-05-312019-10-16Sorrento Therapeutics Inc.Antigen binding proteins that bind pd-l1
WO2013181530A1 (en)2012-06-012013-12-05Icahn School Of Medicine At Mount SinaiCeramide levels in the treatment and prevention of infections
EP3679923A1 (en)2012-06-012020-07-15Icahn School of Medicine at Mount SinaiCeramide levels in the treatment and prevention of infections
WO2013183048A1 (en)2012-06-032013-12-12Ben-Gurion University Of The Negev Research And Development AuthorityFunctionalized titanium binding peptides and implants coated with same
US9821070B2 (en)2012-06-042017-11-21Opko Biologics Ltd.Pegylated OXM variants
US10537646B2 (en)2012-06-042020-01-21Opko Biologics Ltd.Pegylated OXM variants
WO2013183052A1 (en)2012-06-042013-12-12Prolor Biotech Inc.Pegylated oxm variants
WO2013192594A2 (en)2012-06-212013-12-27Sorrento Therapeutics Inc.Antigen binding proteins that bind c-met
WO2013192596A2 (en)2012-06-222013-12-27Sorrento Therapeutics Inc.Antigen binding proteins that bind ccr2
WO2013192616A1 (en)2012-06-222013-12-27Htg Molecular Diagnostics, Inc.Molecular malignancy in melanocytic lesions
WO2014006621A1 (en)2012-07-032014-01-09Nanospun Technologies Ltd.Methods and devices for adsorption and biodegradation of petroleum
EP3309263A1 (en)2012-07-092018-04-18Novartis AGBiomarkers associated with cdk inhibitors
WO2014011398A1 (en)2012-07-092014-01-16Novartis AgBiomarkers associated with cdk inhibitors
US9910040B2 (en)2012-07-092018-03-06Sevident, Inc.Molecular nets comprising capture agents and linking agents
WO2014011881A2 (en)2012-07-112014-01-16Imstem Biotechnology, Inc.Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
WO2014014788A2 (en)2012-07-182014-01-23President And Fellows Of Harvard CollegeModification of surfaces for simulataneous repellency and targeted binding of desired moieties
EP3327090A1 (en)2012-07-182018-05-30President and Fellows of Harvard CollegeModification of surfaces for simulataneous repellency and targeted binding of desired moieties
US9175266B2 (en)2012-07-232015-11-03Gamida Cell Ltd.Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en)2012-07-232017-02-14Gamida Cell Ltd.Methods of culturing and expanding mesenchymal stem cells
WO2014018375A1 (en)2012-07-232014-01-30Xenon Pharmaceuticals Inc.Cyp8b1 and uses thereof in therapeutic and diagnostic methods
EP3636664A1 (en)2012-07-272020-04-15The Board of Trustees of the University of IllinoisEngineering t-cell receptors
EP3594331A1 (en)2012-07-292020-01-15Yeda Research and Development Co. Ltd.Use of the reductive glycine pathway for generating formatotrophic and autotrophic microorganisms
WO2014020599A1 (en)2012-07-292014-02-06Yeda Research And Development Co. Ltd.Use of the reductive glycine pathway for generating formatotrophic and autotrophic microorganisms
WO2014020502A2 (en)2012-07-312014-02-06Novartis AgMarkers associated with human double minute 2 inhibitors
WO2014020608A1 (en)2012-07-312014-02-06Yeda Research And Development Co. Ltd.Methods of diagnosing and treating motor neuron diseases
WO2014024183A1 (en)2012-08-062014-02-13Brainstorm Cell Therapeutics Ltd.Methods of generating mesenchymal stem cells which secrete neurotrophic factors
EP3494996A1 (en)2012-08-232019-06-12Agensys, Inc.Antibody drug conjugates (adc) that bind to 158p1d7 proteins
WO2014033723A1 (en)2012-09-032014-03-06A.B. Seeds Ltd.Method of improving abiotic stress tolerance of plants and plants generated thereby
WO2014041544A1 (en)2012-09-122014-03-20Ramot At Tel-Aviv University Ltd.Immunoparticles and methods of generating and using same
US9733242B2 (en)2012-10-072017-08-15Sevident, Inc.Devices for capturing analyte
WO2014058915A2 (en)2012-10-082014-04-17St. Jude Children's Research HospitalTherapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
EP3677310A1 (en)2012-10-082020-07-08St. Jude Children's Research HospitalTherapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
WO2014057490A1 (en)2012-10-092014-04-17Ramot At Tel-Aviv University Ltd.Methods and kits for predicting prognosis of cancer using soluble mortalin in blood
EP4356927A2 (en)2012-10-122024-04-24Arizona Board of Regents on behalf of Arizona State UniversityAntibody based reagents that specifically recognize toxic oligomeric forms of tau
US9915668B2 (en)2012-10-122018-03-13Arizona Board Of Regents On Behalf Of Arizona State UniversityAntibody based reagents that specifically recognize toxic oligomeric forms of tau
US11046755B2 (en)2012-10-122021-06-29Arizona Board Of Regents On Behalf Of Arizona State UniversityAntibody based reagents that specifically recognize toxic oligomeric forms of tau
WO2014059442A2 (en)2012-10-122014-04-17Arizona Board Agents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State UniversityAntibody based reagents that specifically recognize toxic oligomeric forms of tau
US9650436B2 (en)2012-10-122017-05-16Arizona Board Of Regents On Behalf Of Arizona State UniversityAntibody based reagents that specifically recognize toxic oligomeric forms of tau
US10844398B2 (en)2012-10-182020-11-24Monsanto Technology LlcMethods and compositions for plant pest control
US10077451B2 (en)2012-10-182018-09-18Monsanto Technology LlcMethods and compositions for plant pest control
US9395369B2 (en)2012-10-192016-07-19Regents Of The University Of MinnesotaGuinea pig cytomegalovirus (CIDMTR strain)
WO2014063097A1 (en)2012-10-192014-04-24Danisco Us Inc.Stabilization of biomimetic membranes
WO2014062635A1 (en)2012-10-192014-04-24Novartis AgMarkers for acute lymphoblastic leukemia
US9822134B2 (en)2012-10-222017-11-21Sabag-Rfa Ltd.System for delivering therapeutic agents into living cells and cells nuclei
WO2014064682A1 (en)2012-10-242014-05-01Yeda Research And Development Co. Ltd.Combinations of epidermal growth factor receptor targeting antibodies for treating cancer
WO2014066590A1 (en)2012-10-242014-05-01Research Development FoundationJam-c antibodies and methods for treatment of cancer
EP3584259A1 (en)2012-10-242019-12-25Yeda Research and Development Co., Ltd.Combinations of epidermal growth factor receptor targeting antibodies for treating cancer
WO2014068553A1 (en)2012-10-292014-05-08Yeda Research And Development Co. Ltd.Aptamers, multimeric aptamers and uses thereof
US9808534B2 (en)2012-11-202017-11-07Opko Biologics Ltd.Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
WO2014083567A2 (en)2012-11-292014-06-05Yeda Research And Development Co. Ltd.Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitors
WO2014106837A2 (en)2013-01-012014-07-10A. B. Seeds Ltd.ISOLATED dsRNA MOLECULES AND METHODS OF USING SAME FOR SILENCING TARGET MOLECULES OF INTEREST
US10683505B2 (en)2013-01-012020-06-16Monsanto Technology LlcMethods of introducing dsRNA to plant seeds for modulating gene expression
WO2014106838A2 (en)2013-01-012014-07-10A.B. Seeds Ltd.Methods of introducing dsrna to plant seeds for modulating gene expression
US10041068B2 (en)2013-01-012018-08-07A. B. Seeds Ltd.Isolated dsRNA molecules and methods of using same for silencing target molecules of interest
US11041212B2 (en)2013-01-072021-06-22The Cleveland Clinic FoundationABCA1 downregulation in prostate cancer
US10047399B2 (en)2013-01-072018-08-14The Cleveland Clinic FoundationABCA1 downregulation in prostate cancer
WO2014108850A2 (en)2013-01-092014-07-17Yeda Research And Development Co. Ltd.High throughput transcriptome analysis
WO2014108854A1 (en)2013-01-092014-07-17Fusimab Ltd.Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
WO2014111936A1 (en)2013-01-172014-07-24Novellusdx Ltd.Methods and systems for identifying patient specific driver mutations
US10815477B2 (en)2013-01-172020-10-27Novellusdx Ltd.Methods and systems for identifying patient specific driver mutations
US10047356B2 (en)2013-01-172018-08-14Novellusdx Ltd.Methods and systems for identifying patient specific driver mutations
EP3431985A1 (en)2013-01-172019-01-23Novellusdx Ltd.Methods and systems for identifying patient specific driver mutations
US10125373B2 (en)2013-01-222018-11-13Arizona Board Of Regents On Behalf Of Arizona State UniversityGeminiviral vector for expression of rituximab
US10000767B2 (en)2013-01-282018-06-19Monsanto Technology LlcMethods and compositions for plant pest control
WO2014121077A2 (en)2013-02-012014-08-07The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesMETHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs)
US10089437B2 (en)2013-02-012018-10-02The Regents Of The University Of CaliforniaMethods for genome assembly and haplotype phasing
US11081209B2 (en)2013-02-012021-08-03The Regents Of The University Of CaliforniaMethods for genome assembly and haplotype phasing
US9411930B2 (en)2013-02-012016-08-09The Regents Of The University Of CaliforniaMethods for genome assembly and haplotype phasing
US9910955B2 (en)2013-02-012018-03-06The Regents Of The University Of CaliforniaMethods for genome assembly and haplotype phasing
US11935626B2 (en)2013-02-012024-03-19The Regents Of The University Of CaliforniaMethods for genome assembly and haplotype phasing
US10825553B2 (en)2013-02-012020-11-03The Regents Of The University Of CaliforniaMethods for genome assembly and haplotype phasing
EP3323884A1 (en)2013-02-012018-05-23The United States Of America as Represented by the Secretary, Department of Health an Human ServiceMethod for generating retinal pigment epithelium (rpe) cells from induced pluripotent stem cells (ipscs)
US10529443B2 (en)2013-02-012020-01-07The Regents Of The University Of CaliforniaMethods for genome assembly and haplotype phasing
EP3885446A1 (en)2013-02-012021-09-29The Regents of The University of CaliforniaMethods for genome assembly and haplotype phasing
WO2014118785A1 (en)2013-02-042014-08-07Ramot At Tel-Aviv University Ltd.Generation of cytotoxic tumor specific cell lines and uses thereof
US10543171B2 (en)2013-02-222020-01-28The Board Of Trustees Of The University Of IllinoisDermal drug delivery using amphiphilic dendron-coil micelles
WO2014136117A1 (en)2013-03-062014-09-12Protalix Ltd.USE OF PLANT CELLS EXPRESSING A TNFalpha POLYPEPTIDE INHIBITOR IN THERAPY
WO2014136114A1 (en)2013-03-062014-09-12Protalix Ltd.TNF alpha INHIBITOR POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAME
WO2014136113A1 (en)2013-03-062014-09-12Protalix Ltd.Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same
WO2014141038A2 (en)2013-03-112014-09-18Irm LlcMarkers associated with wnt inhibitors
US10612019B2 (en)2013-03-132020-04-07Monsanto Technology LlcMethods and compositions for weed control
US10609930B2 (en)2013-03-132020-04-07Monsanto Technology LlcMethods and compositions for weed control
WO2014159242A1 (en)2013-03-142014-10-02Novartis AgNotch 3 mutants and uses thereof
WO2014159239A2 (en)2013-03-142014-10-02Novartis AgAntibodies against notch 3
WO2014153056A2 (en)2013-03-142014-09-25Parkash GillCancer treatment using antibodies that bing cell surface grp78
US10435701B2 (en)2013-03-142019-10-08Monsanto Technology LlcMethods and compositions for plant pest control
US9273349B2 (en)2013-03-142016-03-01Affymetrix, Inc.Detection of nucleic acids
EP3611189A1 (en)2013-03-142020-02-19Novartis AGAntibodies against notch 3
US10266879B2 (en)2013-03-142019-04-23Affymetrix, Inc.Detection of nucleic acids
WO2014151683A1 (en)2013-03-152014-09-25Bayer Healthcare LlcGla domains as targeting agents
WO2014145718A2 (en)2013-03-152014-09-18Longevity Biotech, Inc.Peptides comprising non-natural amino acids and methods of making and using the same
EP3404116A1 (en)2013-03-152018-11-21The University of ChicagoMethods and compositions related to t-cell activity
US10568328B2 (en)2013-03-152020-02-25Monsanto Technology LlcMethods and compositions for weed control
WO2014151535A1 (en)2013-03-152014-09-25Bayer Healthcare LlcGla domains as targeting agents
EP4163387A1 (en)2013-03-152023-04-12The University of ChicagoMethods and compositions related to t-cell activity
WO2014144170A1 (en)2013-03-152014-09-18The Cleveland Clinic FoundationIn-vitro method for monoclonal antibody production using non-human act1 -deficient mice
US12195531B2 (en)2013-03-212025-01-14Code Biotherapeutics, Inc.Cellular delivery of DNA intercalating agents
WO2014147622A1 (en)2013-03-212014-09-25Collplant Ltd.Compositions comprising collagen and prp for tissue regeneration
WO2014155376A1 (en)2013-03-242014-10-02Biokine Therapeutics Ltd.Methods of treating myeloid leukemia
US10633449B2 (en)2013-03-272020-04-28Cedars-Sinai Medical CenterTreatment and reversal of fibrosis and inflammation by inhibition of the TL1A-DR3 signaling pathway
US9796762B2 (en)2013-04-102017-10-244D Pharma Research LimitedPolypeptide and immune modulation
US11414463B2 (en)2013-04-102022-08-164D Pharma Research LimitedPolypeptide and immune modulation
US10851137B2 (en)2013-04-102020-12-014D Pharma Research LimitedPolypeptide and immune modulation
WO2014174511A1 (en)2013-04-212014-10-30Yeda Research And Development Co. Ltd.Agents for downregulation of the activity and/or amount of bcl-xl and/or bcl-w
WO2014174470A1 (en)2013-04-232014-10-30Yeda Research And Development Co. Ltd.Isolated naive pluripotent stem cells and methods of generating same
WO2014174520A1 (en)2013-04-252014-10-30Yeda Research And Development Co. Ltd.Use of inhibitory peptides for the treatment of inflammatory diseases
WO2014176047A1 (en)2013-04-252014-10-30Novartis AgMarkers for ezh2 inhibitors
EP3848044A1 (en)2013-05-212021-07-14President and Fellows of Harvard CollegeEngineered heme-binding compositions and uses thereof
EP3848045A1 (en)2013-05-212021-07-14President and Fellows of Harvard CollegeEngineered heme-binding compositions and uses thereof
WO2014188423A1 (en)2013-05-212014-11-27Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Treatment of mast cell related pathologies
WO2014190040A1 (en)2013-05-212014-11-27President And Fellows Of Harvard CollegeEngineered heme-binding compositions and uses thereof
EP3626310A1 (en)2013-05-272020-03-25Rakuto Bio Technologies Ltd.Enzymatic system containing cosmetic compositions
WO2014191995A2 (en)2013-05-272014-12-04Rakuto Bio Technologies Ltd.Enzymatic system-containing cosmetic compositions
US12031990B2 (en)2013-05-282024-07-09Biogen Ma Inc.Method of assessing risk of PML
US12392784B2 (en)2013-05-282025-08-19Biogen Ma Inc.Method of assessing risk of PML
US10119976B2 (en)2013-05-282018-11-06Biogen Ma Inc.Method of assessing risk of PML
US10677803B2 (en)2013-05-282020-06-09Biogen Ma Inc.Method of assessing risk of PML
US11280794B2 (en)2013-05-282022-03-22Biogen Ma Inc.Method of assessing risk of PML
WO2014200767A1 (en)2013-06-122014-12-18The General Hospital CorporationMethods, kits, and systems for multiplexed detection of target molecules and uses thereof
EP3587585A1 (en)2013-06-122020-01-01The General Hospital CorporationMethods, kits, and systems for multiplexed detection of target molecules and uses thereof
WO2014204814A1 (en)2013-06-182014-12-24Dnatrix, Inc.Treatment of brain cancer with oncolytic adenovirus
US10203287B2 (en)2013-06-192019-02-12Step Ahead Innovations, Inc.Aquatic environment water parameter testing systems
US9797844B2 (en)2013-06-192017-10-24Step Ahead Innovations, Inc.Chemical indicator element systems for aquatic environment water parameter testing
US9784686B2 (en)2013-06-192017-10-10Step Ahead Innovations, Inc.Aquatic environment water parameter testing systems and methods
WO2014207744A1 (en)2013-06-242014-12-31Ramot At Tel-Aviv University Ltd.Omentum based scaffold and delivery system
WO2014210540A1 (en)2013-06-282014-12-31Baylor Research InstituteDendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
US9856495B2 (en)2013-07-192018-01-02Monsanto Technology LlcCompositions and methods for controlling Leptinotarsa
US11377667B2 (en)2013-07-192022-07-05Monsanto Technology LlcCompositions and methods for controlling Leptinotarsa
US10316083B2 (en)2013-07-192019-06-11Cedars-Sinai Medical CenterSignature of TL1A (TNFSF15) signaling pathway
US9850496B2 (en)2013-07-192017-12-26Monsanto Technology LlcCompositions and methods for controlling Leptinotarsa
US12269873B2 (en)2013-07-192025-04-08Cedars-Sinai Medical CenterSignature of TL1A (TNFSF15) signaling pathway
US11312768B2 (en)2013-07-192022-04-26Cedars-Sinai Medical CenterSignature of TL1A (TNFSF15) signaling pathway
US9777288B2 (en)2013-07-192017-10-03Monsanto Technology LlcCompositions and methods for controlling leptinotarsa
US10597676B2 (en)2013-07-192020-03-24Monsanto Technology LlcCompositions and methods for controlling Leptinotarsa
WO2015015489A1 (en)2013-07-302015-02-05Biolinerx Ltd.Antibody for treating diabetes and autoimmune diseases
US11633500B2 (en)2013-08-012023-04-25Agensys, Inc.Antibody drug conjugates (ADC) that bind to CD37 proteins
US10646583B2 (en)2013-08-012020-05-12Agensys, Inc.Antibody drug conjugates (ADC) that bind to CD37 proteins
WO2015017552A1 (en)2013-08-012015-02-05Agensys, Inc.Antibody drug conjugates (adc) that bind to cd37 proteins
US9925273B2 (en)2013-08-012018-03-27Agensys, Inc.Antibody drug conjugates (ADC) that bind to CD37 proteins
US11208479B2 (en)2013-08-212021-12-28Board Of Regents, The University Of Texas SystemCX43 hemichannel antibodies and methods of use
US11912762B2 (en)2013-08-212024-02-27Board Of Regents Of The University Of Texas SystemMethod of treating osteoarthritis by administering an anti-connexin 43 antibody
US10633442B2 (en)2013-08-212020-04-28Board Of Regents Of The University Of Texas SystemAntibodies to connexin 43 (Cx43) hemichannels and methods of use thereof to inhibit Cx43 hemichannel opening
US12162937B2 (en)2013-08-212024-12-10Board Of Regents Of The University Of Texas SystemMethods of treating an inflammatory disorder by administering an antibody which binds to a connexin CX43 hemichannel
US9938316B2 (en)2013-08-292018-04-10Yeda Research And Development Co. Ltd.Selective inhibitors of α2 isoform of Na,K-ATPase and use thereof for reduction of intra-ocular pressure and as cardiotonic agents
EP3925980A1 (en)2013-08-302021-12-22ImmunoGen, Inc.Antibodies and assays for detection of folate receptor 1
WO2015033337A1 (en)2013-09-032015-03-12Technion Research & Development Foundation Limited.A flap for de-novo tissue regeneration
WO2015033343A1 (en)2013-09-032015-03-12Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Compositions and methods for expressing recombinant polypeptides
WO2015033344A1 (en)2013-09-052015-03-12Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs)
WO2015037009A1 (en)2013-09-162015-03-19Plexicure Ltd.Isolated proteins capable of binding plexin-a4 and methods of producing and using same
WO2015040609A1 (en)2013-09-172015-03-26Yeda Research And Development Co. Ltd.Erk-derived peptides and uses thereof
WO2015049677A1 (en)2013-10-012015-04-09Kadimastem Ltd.Directed differentiation of astrocytes from human pluripotent stem cells for use in drug screening and the treatment of amyotrophic lateral sclerosis (als)
US10393739B2 (en)2013-10-032019-08-27Oklahoma Medical Research FoundationBiomarkers for systemic lupus erythematosus disease activity, and intensity and flare
US11585810B2 (en)2013-10-032023-02-21Oklahoma Medical Research FoundationBiomarkers for systemic lupus erythematosus disease activity, and intensity and flare
US9476884B2 (en)2013-10-042016-10-25University Of MassachusettsHybridization- independent labeling of repetitive DNA sequence in human chromosomes
EP3763733A1 (en)2013-10-212021-01-13OPKO Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
US11197915B2 (en)2013-10-212021-12-14Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
WO2015059695A1 (en)2013-10-212015-04-30Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
US12029780B2 (en)2013-10-212024-07-09Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
US10767156B2 (en)2013-10-242020-09-08Yeda Research And Development Co., Ltd.Polynucleotides encoding BREX system polypeptides and methods of using same
WO2015059690A1 (en)2013-10-242015-04-30Yeda Research And Development Co. Ltd.Polynucleotides encoding brex system polypeptides and methods of using s ame
WO2015063768A1 (en)2013-10-312015-05-07Biokine Therapeutics Ltd.Methods of treating acute myeloid leukemia with a flt3 mutation
US10927374B2 (en)2013-11-042021-02-23Monsanto Technology LlcCompositions and methods for controlling arthropod parasite and pest infestations
US10100306B2 (en)2013-11-042018-10-16Monsanto Technology LlcCompositions and methods for controlling arthropod parasite and pest infestations
US9540642B2 (en)2013-11-042017-01-10The United States Of America, As Represented By The Secretary Of AgricultureCompositions and methods for controlling arthropod parasite and pest infestations
WO2015070009A2 (en)2013-11-082015-05-14The Board Of Regents Of The University Of Texas SystemVh4 antibodies against gray matter neuron and astrocyte
US10172916B2 (en)2013-11-152019-01-08The Board Of Trustees Of The Leland Stanford Junior UniversityMethods of treating heart failure with agonists of hypocretin receptor 2
WO2015077473A1 (en)2013-11-202015-05-28University Of Iowa Research FoundationMethods and compositions for treating amyloid deposits
WO2015077607A1 (en)2013-11-222015-05-28The Board Of Trustees Of The University Of IllinoisEngineered high-affinity human t cell receptors
WO2015079411A1 (en)2013-11-282015-06-04Tel Hashomer Medical Research Infrastructure And Services Ltd.Rna polymerase i inhibitors and uses thereof
WO2015079413A2 (en)2013-11-282015-06-04Yeda Research And Development Co. Ltd.Synaptojanin-2 inhibitors and uses thereof
US10557138B2 (en)2013-12-102020-02-11Beeologics, Inc.Compositions and methods for virus control in Varroa mite and bees
WO2015087327A1 (en)2013-12-102015-06-18Yeda Research And Development Co. Ltd.Use of enzymes which catalyze pyruvate synthesis from formate and acetyl-coa and bacteria expressing same
US12098381B2 (en)2013-12-172024-09-24University Of MassachusettsCompositions and methods for differential Cas9 gene labeling and/or editing
EP3546474A2 (en)2013-12-182019-10-02President and Fellows of Harvard CollegeCrp capture/detection of gram positive bacteria
WO2015094527A1 (en)2013-12-192015-06-25Danisco Us Inc.Use of hydrophobins to increase gas transferin aerobic fermentation processes
US11293929B2 (en)2014-01-072022-04-05Bioatla, Inc.Proteins targeting orthologs
EP3447493A1 (en)2014-01-072019-02-27Bioatla, LLCProteins targeting orthologs
WO2015105888A1 (en)2014-01-072015-07-16Bioatla, LlcProteins targeting orthologs
EP3992210A1 (en)2014-01-132022-05-04Baylor Research InstituteNovel vaccines against hpv and hpv-related diseases
US10334848B2 (en)2014-01-152019-07-02Monsanto Technology LlcMethods and compositions for weed control using EPSPS polynucleotides
WO2015116753A1 (en)2014-01-292015-08-06Dana-Farber Cancer Institute, Inc.Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)
WO2015114633A1 (en)2014-01-302015-08-06Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd.Actin binding peptides and compositions comprising same for inhibiting angiogenes is and treating medical conditions associated with same
WO2015114638A2 (en)2014-02-032015-08-06Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of eliminating stem cells
WO2015118537A2 (en)2014-02-052015-08-13Yeda Research And Development Co. Ltd.Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
WO2015118538A1 (en)2014-02-062015-08-13Yeda Research And Development Co. Ltd.Anti cd84 antibodies, compositions comprising same and uses thereof
WO2015120273A1 (en)2014-02-072015-08-13The General Hospital CorporationDifferential diagnosis of hepatic neoplasms
WO2015118547A1 (en)2014-02-102015-08-13Protalix Ltd.Method of maintaining disease stability in a subject having gaucher's disease
WO2015121859A1 (en)2014-02-112015-08-20Brainstorm Cell Therapeutics Ltd.Method of qualifying cells
WO2015123565A1 (en)2014-02-142015-08-20The General Hospital CorporationMethods for diagnosing igg4-related disease
WO2015131099A1 (en)2014-02-282015-09-03The General Hospital CorporationDiagnosis of multiple myeloma and lymphoma
WO2015132784A1 (en)2014-03-032015-09-11Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method and device for detection of pseudomonas aeruginosa
WO2015144874A1 (en)2014-03-282015-10-01Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Multi-component-multistage malaria vaccines
US10183066B2 (en)2014-03-282019-01-22Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.VMulti-component-multistage malaria vaccines
EP2923709A1 (en)2014-03-282015-09-30Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Multi-component-multistage malaria vaccine
US11091770B2 (en)2014-04-012021-08-17Monsanto Technology LlcCompositions and methods for controlling insect pests
US11433163B2 (en)2014-04-102022-09-06Bonus Therapeutics Ltd.Bone repair compositions
EP4306659A2 (en)2014-04-142024-01-17Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd.A method and kit for determining the tissue or cell origin of dna
EP3643795A1 (en)2014-04-142020-04-29Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd.A method for determining the death of cells or tissue by dna methylation analysis
EP4026917A1 (en)2014-04-142022-07-13Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd.A method and kit for determining the death of cells or tissue or the tissue or cell origin of dna by dna methylation analysis
WO2015159292A2 (en)2014-04-142015-10-22Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.A method and kit for determining the tissue or cell origin of dna
WO2015159293A2 (en)2014-04-142015-10-22Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.A method and kit for determining the tissue or cell origin of dna
WO2015159295A1 (en)2014-04-172015-10-22Yeda Research And Development Co. Ltd.Methods and kits for analyzing dna binding moieties attached to dna
US10550196B2 (en)2014-04-272020-02-04Famewave Ltd.Humanized antibodies against CEACAM1
US11866509B2 (en)2014-04-272024-01-09Famewave Ltd.Humanized antibodies against CEACAM1
US11427647B2 (en)2014-04-272022-08-30Famewave Ltd.Polynucleotides encoding humanized antibodies against CEACAM1
WO2015166492A2 (en)2014-04-282015-11-05Yeda Research And Development Co. Ltd.Microbiome response to agents
WO2015170323A2 (en)2014-05-042015-11-12Forrest Innovations Ltd.Compositions and methods of using same for reducing resistance to mosquito larvicides
WO2015170324A2 (en)2014-05-042015-11-12Forrest Innovations Ltd.Compositions for mosquito control and uses of same
WO2015170320A2 (en)2014-05-042015-11-12Forrest Innovations Ltd.Compositions and methods of using same for controlling pathogenically infected mosquitoes
WO2015170325A2 (en)2014-05-042015-11-12Forrest Innovations Ltd.Compositions and methods for reducing pathogen-induced citrus greening
WO2015170322A2 (en)2014-05-042015-11-12Forrest Innovations Ltd.Compositions and methods of using same for increasing resistance of infected mosquitoes
EP2942627A1 (en)2014-05-052015-11-11MicroBPlex, Inc.Media elaborated with newly synthesized antibodies (mensa) from recently proliferated antibody secreting cells (asc) and uses thereof
EP3502698A1 (en)2014-05-052019-06-26MicroBPlex, Inc.Media elaborated with newly synthesized antibodies and uses thereof
WO2015171938A1 (en)2014-05-082015-11-12Novodiax, Inc.Direct immunohistochemistry assay
US11474101B2 (en)2014-05-082022-10-18Novodiax, Inc.Direct immunohistochemistry assay
WO2015179435A1 (en)2014-05-192015-11-26Bayer Healthcare LlcOptimized humanized monoclonal antibodies against activated protein c and uses thereof
WO2015177800A2 (en)2014-05-222015-11-26Yeda Research And Development Co. Ltd.Recombinant microorganisms capable of carbon fixation
WO2015186128A1 (en)2014-06-022015-12-10Kadimastem Ltd.Methods of inducing myelination and maturation of oligodendrocytes
WO2015186129A1 (en)2014-06-022015-12-10Technion Research & Development Foundation Limited.Compositions and methods of selectively inhibiting irp1 and treating inflammation
US10988764B2 (en)2014-06-232021-04-27Monsanto Technology LlcCompositions and methods for regulating gene expression via RNA interference
WO2015198320A1 (en)2014-06-242015-12-30Insight Biopharmaceuticals Ltd.Methods of purifying antibodies
WO2015198334A2 (en)2014-06-252015-12-30Tel Hashomer Medical Research Infrastructure And Services Ltd.Identification of cancer stem cells and use of same for diagnosis and treatment
US11807857B2 (en)2014-06-252023-11-07Monsanto Technology LlcMethods and compositions for delivering nucleic acids to plant cells and regulating gene expression
US10583084B2 (en)2014-06-262020-03-10Ramot At Tel-Aviv University Ltd.Liposomal formulations for delivery of nucleic acids
WO2016005985A2 (en)2014-07-092016-01-14Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method for reprogramming cells
US10611819B2 (en)2014-07-152020-04-07Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Isolated polypeptides of CD44 and uses thereof
US11560417B2 (en)2014-07-152023-01-24Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Isolated polypeptides of CD44 and uses thereof
WO2016009436A1 (en)2014-07-152016-01-21Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Isolated polypeptides of cd44 and uses thereof
US10550439B2 (en)2014-07-212020-02-04Novellusdx Ltd.Methods for determining drug response of patient specific mutations
US11015229B2 (en)2014-07-212021-05-25Novellusdx Ltd.Methods and systems for determining oncogenic index of patient specific mutations
US10378012B2 (en)2014-07-292019-08-13Monsanto Technology LlcCompositions and methods for controlling insect pests
US11124792B2 (en)2014-07-292021-09-21Monsanto Technology LlcCompositions and methods for controlling insect pests
WO2016016894A1 (en)2014-07-302016-02-04Yeda Research And Development Co. Ltd.Media for culturing pluripotent stem cells
US12180535B2 (en)2014-08-012024-12-31Dovetail Genomics, LlcTagging nucleic acids for sequence assembly
US10526641B2 (en)2014-08-012020-01-07Dovetail Genomics, LlcTagging nucleic acids for sequence assembly
EP4219710A2 (en)2014-08-012023-08-02Dovetail Genomics, LLCTagging nucleic acids for sequence assembly
EP3699930A2 (en)2014-08-142020-08-26MeMed Diagnostics Ltd.Computational analysis of biological data using manifold and a hyperplane
WO2016024278A1 (en)2014-08-142016-02-18Memed Diagnostics Ltd.Computational analysis of biological data using manifold and a hyperplane
EP3485910A2 (en)2014-08-222019-05-22Sorrento Therapeutics, Inc.Antigen binding proteins that bind cxcr3
WO2016030899A1 (en)2014-08-282016-03-03Yeda Research And Development Co. Ltd.Methods of treating amyotrophic lateral scleroses
US10213501B2 (en)2014-09-082019-02-26Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V.Three-component-multistage malaria vaccine
WO2016038609A1 (en)2014-09-082016-03-17Yeda Research And Development Co. Ltd.Anti-her3 antibodies and uses of same
WO2016038610A1 (en)2014-09-082016-03-17Yeda Research And Development Co. Ltd.Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
EP2992895A1 (en)2014-09-082016-03-09Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Three-component-multistage malaria vaccine
WO2016038550A1 (en)2014-09-112016-03-17Novartis AgInhibition of prmt5 to treat mtap-deficiency-related diseases
WO2016038617A1 (en)2014-09-112016-03-17The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Methods of producing mogrosides and compositions comprising same and uses thereof
WO2016038616A1 (en)2014-09-142016-03-17Yeda Research And Development Co. Ltd.Nmda receptor antagonists for treating gaucher disease
WO2016044234A1 (en)2014-09-162016-03-24Eric TsaoAnti-egfr antibody and uses of same
WO2016042561A2 (en)2014-09-212016-03-24Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Downregulating mir-132 for the treatment of lipid related disorders
EP4268820A2 (en)2014-10-062023-11-01ChemoCentryx, Inc.Combination therapy of c-c chemokine receptor-9 (ccr9) inhibitors and anti-alpha4beta7 integrin blocking antibodies for the treatment of inflammatory bowel disease
WO2016057424A1 (en)2014-10-062016-04-14Chemocentryx, Inc.Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies
WO2016061111A1 (en)2014-10-132016-04-21Life Technologies CorporationMethods, kits & compositions for determining gene copy numbers
DE102015220401A1 (en)2014-10-202016-05-19Gen-Probe Incorporated Erythrocyte lysis solution
WO2016064887A1 (en)2014-10-202016-04-28Gen-Probe IncorporatedRed blood cell lysis solution
EP3739062A1 (en)2014-10-202020-11-18Gen-Probe IncorporatedRed blood cell lysis solution
WO2016065238A1 (en)2014-10-242016-04-28Danisco Us Inc.Method for producing alcohol by use of a tripeptidyl peptidase
WO2016062857A1 (en)2014-10-242016-04-28Dupont Nutrition Biosciences ApsUse of proline tolerant tripeptidyl peptidases in feed additive compositions
WO2016062855A1 (en)2014-10-242016-04-28Dupont Nutrition Biosciences ApsProline tolerant tripeptidyl peptidases and uses thereof
WO2016075697A1 (en)2014-11-132016-05-19Enzootic Holdings Ltd.Functional sex-reversal of decapod crustacean females
US11624052B2 (en)2014-11-132023-04-11Enzootic Holdings Ltd.Functional sex-reversal of decapod crustacean females
WO2016079731A2 (en)2014-11-172016-05-26Yeda Research And Development Co. Ltd.Method of analyzing microbiome
WO2016079736A2 (en)2014-11-172016-05-26Yeda Research And Development Co. Ltd.Methods of treating diseases related to mitochondrial function
US11270782B2 (en)2014-11-192022-03-08Koninklijke Philips N.V.Diagnostic method employing HNL
WO2016079739A2 (en)2014-11-202016-05-26Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Compositions and methods for producing polypeptides with a modified glycosylation pattern in plant cells
US11697819B2 (en)2014-11-202023-07-11Yissum Research Development Company Of The Hebrew University Of Jerusalem LtdCompositions and methods for producing polypeptides with a modified glycosylation pattern in plant cells
WO2016084088A1 (en)2014-11-262016-06-02Ramot At Tel-Aviv University Ltd.Targeted elimination of bacterial genes
WO2016084084A1 (en)2014-11-272016-06-02Danziger Innovations Ltd.Nucleic acid constructs for genome editing
US11279974B2 (en)2014-12-012022-03-22The Broad Institute, Inc.Method for in situ determination of nucleic acid proximity
WO2016089883A1 (en)2014-12-012016-06-09Novartis AgCompositions and methods for diagnosis and treatment of prostate cancer
EP3754027A1 (en)2014-12-012020-12-23The Broad Institute, Inc.Methods for altering or modulating spatial proximity between nucleic acids inside of a cell
EP4242329A2 (en)2014-12-082023-09-13Berg LLCUse of markers including filamin a in the diagnosis and treatment of prostate cancer
WO2016092555A2 (en)2014-12-112016-06-16Yeda Research And Development Co. Ltd.Isolated phosphotriesterase polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
WO2016092554A1 (en)2014-12-112016-06-16Memed Diagnostics Ltd.Marker combinations for diagnosing infections and methods of use thereof
WO2016103269A1 (en)2014-12-232016-06-30Ramot At Tel-Aviv University Ltd.Populations of neural progenitor cells and methods of producing and using same
US10973872B2 (en)2014-12-232021-04-134D Pharma Research LimitedPirin polypeptide and immune modulation
US10456444B2 (en)2014-12-232019-10-294D Pharma Research LimitedPirin polypeptide and immune modulation
US11723933B2 (en)2014-12-232023-08-15Cj Bioscience, Inc.Composition of bacteroides thetaiotaomicron for immune modulation
WO2016108240A1 (en)2014-12-302016-07-07Cell Cure Neurosciences Ltd.Assessing retinal pigment epithelial cell populations
US11987810B2 (en)2014-12-302024-05-21Cell Cure Neurosciences Ltd.RPE cell populations and methods of generating same
EP3916085A1 (en)2014-12-302021-12-01Cell Cure Neurosciences Ltd.Assessing retinal pigment epithelial cell populations
WO2016108239A1 (en)2014-12-302016-07-07Cell Cure Neurosciences Ltd.Rpe cell populations and methods of generating same
EP3674397A1 (en)2014-12-302020-07-01Cell Cure Neurosciences Ltd.Rpe cell populations and methods of generating same
WO2016108219A1 (en)2014-12-302016-07-07Cell Cure Neurosciences Ltd.Methods of treating retinal diseases
US11891622B2 (en)2014-12-302024-02-06Cell Cure Neurosciences Ltd.RPE cell populations and methods of generating same
WO2016108244A1 (en)2015-01-042016-07-07Protalix Ltd.Modified dnase and uses thereof
WO2016116935A1 (en)2015-01-212016-07-28Yeda Research And Development Co. Ltd.Use of rasa2 as a prognostic and therapeutic marker for melanoma
US10968449B2 (en)2015-01-222021-04-06Monsanto Technology LlcCompositions and methods for controlling Leptinotarsa
WO2016130516A1 (en)2015-02-092016-08-18Research Development FoundationEngineered immunoglobulin fc polypeptides displaying improved complement activation
WO2016130898A2 (en)2015-02-132016-08-18Sorrento Therapeutics, Inc.Antibody therapeutics that bind ctla4
EP4151231A1 (en)2015-02-132023-03-22Sorrento Therapeutics, Inc.Antibody therapeutics that bind ctla4
EP3949984A1 (en)2015-02-132022-02-09Sorrento Therapeutics, Inc.Antibody therapeutics that bind ctla4
US10318706B2 (en)2015-02-172019-06-11Dovetail Genomics, LlcNucleic acid sequence assembly
US11600361B2 (en)2015-02-172023-03-07Dovetail Genomics, LlcNucleic acid sequence assembly
US9715573B2 (en)2015-02-172017-07-25Dovetail Genomics, LlcNucleic acid sequence assembly
WO2016138312A2 (en)2015-02-252016-09-01Vanderbilt UniversityAntibody-mediated neutralization of marburg virus
WO2016135732A1 (en)2015-02-262016-09-01Yeda Research And Development Co. Ltd.Method of promoting hair growth
WO2016145099A1 (en)2015-03-092016-09-15Agensys, Inc.Antibody drug conjugates (adc) that bind to flt3 proteins
WO2016142948A1 (en)2015-03-112016-09-15Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Decoy oligonucleotides for the treatment of diseases
WO2016145409A1 (en)2015-03-112016-09-15The Broad Institute, Inc.Genotype and phenotype coupling
US11873483B2 (en)2015-03-112024-01-16The Broad Institute, Inc.Proteomic analysis with nucleic acid identifiers
WO2016147194A1 (en)2015-03-192016-09-22Yeda Research And Development Co. Ltd.Anti amphiregulin antibodies, compositions comprising same and uses thereof
US11807896B2 (en)2015-03-262023-11-07Dovetail Genomics, LlcPhysical linkage preservation in DNA storage
WO2016160618A2 (en)2015-03-272016-10-06University Of Southern CaliforniaCar t-cell therapy directed to lhr for the treatment of solid tumors
EP4218771A1 (en)2015-03-272023-08-02Yeda Research and Development Co. LtdMethods of treating motor neuron diseases
WO2016157190A1 (en)2015-03-312016-10-06Yeda Research And Development Co. Ltd.Glutamate oxaloacetate transaminase 1 (got1), preparations and methods of generating same and uses thereof
US11175584B2 (en)2015-03-312021-11-16Arizona Board Of Regents On Behalf Of Arizona State UniversityMethods for detecting traumatic brain injury
WO2016157192A1 (en)2015-04-012016-10-06The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Erodium crassifolium l'her plant extracts and uses thereof
WO2016162870A1 (en)2015-04-072016-10-13Ilana NathanCompositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto
EP4005569A2 (en)2015-04-072022-06-01ELA Pharma LtdCompositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto
EP4180058A1 (en)2015-04-082023-05-17Sorrento Therapeutics, Inc.Antibody therapeutics that bind cd38
US10577412B2 (en)2015-04-122020-03-03Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V.Anti-plasmodium parasite antibodies
WO2016174674A1 (en)2015-04-272016-11-03The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterEgr1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions
US10674732B2 (en)2015-04-292020-06-09The State Of Israel, Ministry Of Agriculture & Rural Development Agricultural Research OrganizationAnti-phytopathogenic compositions
WO2016174673A1 (en)2015-04-292016-11-03The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Anti-phytopathogenic compositions
WO2016174652A1 (en)2015-04-302016-11-03Technion Research & Development Foundation LimitedChimeric antigen receptors and methods of their use
WO2016178207A1 (en)2015-05-042016-11-10Ramot At Tel-Aviv University Ltd.Methods and kits for fragmenting dna
EP3091026A1 (en)2015-05-082016-11-09Centrillion Technology Holdings CorporationDisulfide-linked reversible terminators
US11180522B2 (en)2015-05-082021-11-23Centrillion Technology Holdings CorporationDisulfide-linked reversible terminators
WO2016181393A1 (en)2015-05-112016-11-17Yeda Research And Development Co. Ltd.Citrin inhibitors for the treatment of cancer
WO2016185471A1 (en)2015-05-172016-11-24The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterCompositions and methods for treating cancer
WO2016187354A1 (en)2015-05-182016-11-24Agensys, Inc.Antibodies that bind to axl proteins
WO2016187356A1 (en)2015-05-182016-11-24Agensys, Inc.Antibodies that bind to axl proteins
WO2016185457A1 (en)2015-05-192016-11-24Yeda Research And Development Co. Ltd.Methods of promoting lymphangiogenesis
WO2016185481A2 (en)2015-05-202016-11-24Yeda Research And Development Co. Ltd.Method of targeting senescent cells
WO2016185469A1 (en)2015-05-212016-11-24Yeda Research And Development Co. Ltd.Bacterial populations for promoting health
WO2016193969A2 (en)2015-05-292016-12-08Opko Biologics Ltd.Pegylated oxyntomodulin variants
US10883103B2 (en)2015-06-022021-01-05Monsanto Technology LlcCompositions and methods for delivery of a polynucleotide into a plant
US10655136B2 (en)2015-06-032020-05-19Monsanto Technology LlcMethods and compositions for introducing nucleic acids into plants
WO2016197064A1 (en)2015-06-042016-12-08Epstein Alan LLym-1 and lym-2 targeted car cell immunotherapy
EP4039270A1 (en)2015-06-082022-08-10Adicet Bio Inc.Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
WO2016199140A1 (en)2015-06-082016-12-15Adicet Bio Inc.T cell receptor like antibodies having fine specificity
WO2016199141A2 (en)2015-06-082016-12-15Adicet Bio Inc.Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
EP4488293A2 (en)2015-06-082025-01-08Adicet Therapeutics, Inc.Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
US11433106B2 (en)2015-06-152022-09-064D Pharma Research LimitedCompositions comprising bacterial strains
US10500237B2 (en)2015-06-152019-12-104D Pharma Research LimitedCompositions comprising bacterial strains
US10744167B2 (en)2015-06-152020-08-184D Pharma Research LimitedCompositions comprising bacterial strains
US10864236B2 (en)2015-06-152020-12-154D Pharma Research LimitedCompositions comprising bacterial strains
US11389493B2 (en)2015-06-152022-07-194D Pharma Research LimitedCompositions comprising bacterial strains
US10493112B2 (en)2015-06-152019-12-034D Pharma Research LimitedCompositions comprising bacterial strains
US11273185B2 (en)2015-06-152022-03-154D Pharma Research LimitedCompositions comprising bacterial strains
US11331352B2 (en)2015-06-152022-05-174D Pharma Research LimitedCompositions comprising bacterial strains
US10322151B2 (en)2015-06-152019-06-184D Pharma Research LimitedCompositions comprising bacterial strains
US11040075B2 (en)2015-06-152021-06-224D Pharma Research LimitedCompositions comprising bacterial strains
US10736926B2 (en)2015-06-152020-08-114D Pharma Research LimitedCompositions comprising bacterial strains
US10780134B2 (en)2015-06-152020-09-224D Pharma Research LimitedCompositions comprising bacterial strains
US10391130B2 (en)2015-06-152019-08-274D Pharma Research LimitedCompositions comprising bacterial strains
WO2016203476A1 (en)2015-06-182016-12-22Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods and compositions for diagnosing and treating urothelial cancer
WO2016203477A1 (en)2015-06-182016-12-22Yeda Research And Development Co. Ltd.Conditioning protocols and use of same for tissue regeneration
EP4026563A1 (en)2015-06-182022-07-13Yeda Research and Development Co. LtdConditioning protocols and use of same for tissue regeneration
EP3988113A1 (en)2015-06-192022-04-27OPKO Biologics Ltd.Long-acting coagulation factors and methods of producing same
US10960058B2 (en)2015-06-192021-03-30Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
WO2016203482A2 (en)2015-06-192016-12-22Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
WO2016210395A1 (en)2015-06-262016-12-29Dupont Nutrition Biosciences ApsAminopeptidases for protein hydrlyzates
WO2017011329A1 (en)2015-07-102017-01-19West Virginia UniversityMarkers of stroke and stroke severity
EP3744340A2 (en)2015-07-162020-12-02Biokine Therapeutics Ltd.Compositions and methods for treating cancer
EP3943098A2 (en)2015-07-162022-01-26Biokine Therapeutics Ltd.Compositions and methods for treating cancer
WO2017009842A2 (en)2015-07-162017-01-19Biokine Therapeutics Ltd.Compositions and methods for treating cancer
WO2017009852A1 (en)2015-07-162017-01-19Yeda Research And Development Co. Ltd.Use of anti third party central memory t cells
WO2017009853A1 (en)2015-07-162017-01-19Yeda Research And Development Co. Ltd.Genetically modified anti-third party central memory t cells and use of same in immunotherapy
US10668094B2 (en)2015-07-192020-06-02Yeda Research And Development Co. Ltd.Selective inhibitors of Alpha2-containing isoforms of Na,K-ATPase and use thereof for reduction of intraocular pressure
US11077128B2 (en)2015-07-192021-08-03Yeda Research And Development Co. Ltd.Selective inhibitors of Alpha2-containing isoforms of Na,K-ATPase and use thereof for reduction of intraocular pressure
US10877045B2 (en)2015-07-212020-12-29Saint Louis UniversityCompositions and methods for diagnosing and treating endometriosis-related infertility
WO2017013661A1 (en)2015-07-222017-01-26Phytopharma International Ltd.Bee-ingestible compositions, methods of using same for producing honey and honey produced thereby
EP3862425A1 (en)2015-07-292021-08-11Hadasit Medical Research Services and Development Ltd.Large scale production of retinal pigment epithelial cells
WO2017017686A1 (en)2015-07-292017-02-02Hadasit Medical Research Services And Development Ltd.Large scale production of retinal pigment epithelial cells
US11230696B2 (en)2015-07-292022-01-25Hadasit Medical Research Services And Development Ltd.Large scale production of retinal pigment epithelial cells
WO2017021963A1 (en)2015-08-032017-02-09Biokine Therapeutics Ltd.Cxcr4 binding agents for treatment of diseases
WO2017023929A1 (en)2015-08-042017-02-09Cd Diagnostics, Inc.Methods for detecting adverse local tissue reaction (altr) necrosis
WO2017021961A1 (en)2015-08-042017-02-09Yeda Research And Development Co. Ltd.Methods of screening for riboswitches and attenuators
EP4155391A1 (en)2015-08-052023-03-29Cell Cure Neurosciences Ltd.Preparation of retinal pigment epithelium cells
US11066642B2 (en)2015-08-052021-07-20Cell Cure Neurosciences LtdPreparation of retinal pigment epithelium cells
US12203097B2 (en)2015-08-052025-01-21Cell Cure Neurosciences Ltd.Preparation of retinal pigment epithelium cells
US11090337B2 (en)2015-08-052021-08-17Cell Cure Neurosciences LtdPreparation of photoreceptors for the treatment of retinal diseases
WO2017021973A1 (en)2015-08-052017-02-09Cell Cure Neurosciences Ltd.Preparation of retinal pigment epithelium cells
WO2017021972A1 (en)2015-08-052017-02-09Cell Cure Neurosciences Ltd.Preparation of photoreceptors for the treatment of retinal diseases
EP3763378A1 (en)2015-08-062021-01-13President and Fellows of Harvard CollegeImproved microbe-binding molecules and uses thereof
WO2017024114A1 (en)2015-08-062017-02-09President And Fellows Of Harvard CollegeImproved microbe-binding molecules and uses thereof
WO2017025963A1 (en)2015-08-102017-02-16The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterMethods and pharmaceutical compositions for improving wound healing using cd24
WO2017025967A1 (en)2015-08-132017-02-16Forrest Innovations Ltd.Formulations and compositions for delivery of nucleic acids to plant cells
US11214800B2 (en)2015-08-182022-01-04The Broad Institute, Inc.Methods and compositions for altering function and structure of chromatin loops and/or domains
WO2017033188A1 (en)2015-08-242017-03-02Yeda Research And Development Co. Ltd.Algal oil and biofuel and methods of producing same
WO2017033152A1 (en)2015-08-252017-03-02Prothena Biosciences LimitedMethods for detecting phosphorylated alpha-synuclein
WO2017040380A2 (en)2015-08-282017-03-09Research Development FoundationEngineered antibody fc variants
WO2017040813A2 (en)2015-09-022017-03-09University Of MassachusettsDetection of gene loci with crispr arrayed repeats and/or polychromatic single guide ribonucleic acids
US11390908B2 (en)2015-09-022022-07-19University Of MassachusettsDetection of gene loci with CRISPR arrayed repeats and/or polychromatic single guide ribonucleic acids
US10765706B2 (en)2015-09-032020-09-08University Of South FloridaMethod of stem cell delivery into the brain during chronic disease using blood brain barrier permeabilizers
US12104183B2 (en)2015-09-082024-10-01University Of MassachusettsDNase H activity of Neisseria meningitidis Cas9
WO2017044419A1 (en)2015-09-082017-03-16University Of MassachusettsDnase h activity of neisseria meningitidis cas9
US11453864B2 (en)2015-09-082022-09-27University Of MassachusettsDNase H activity of Neisseria meningitidis Cas9
WO2017042814A1 (en)2015-09-102017-03-16Yeda Research And Development Co. Ltd.Use of perforin positive immature dendritic cells in disease treatment
US11001872B2 (en)2015-09-222021-05-11Shawn ClarkDesigning customized protein-specific buffer system
WO2017059108A1 (en)2015-09-292017-04-06Htg Molecular Diagnostics, Inc.Methods for subtyping diffuse b-cell lymphoma (dlbcl)
WO2017062953A1 (en)2015-10-102017-04-13Intrexon CorporationImproved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
EP3913068A1 (en)2015-10-122021-11-24Advanced Cell Diagnostics, Inc.In situ detection of nucleotide variants in high noise samples, and compositions and methods related thereto
US11078528B2 (en)2015-10-122021-08-03Advanced Cell Diagnostics, Inc.In situ detection of nucleotide variants in high noise samples, and compositions and methods related thereto
US10457934B2 (en)2015-10-192019-10-29Dovetail Genomics, LlcMethods for genome assembly, haplotype phasing, and target independent nucleic acid detection
WO2017072757A1 (en)2015-10-252017-05-04Yeda Research And Development Co. Ltd.Antibodies targeting quiescin sulfhydryl oxidase (qsox1) and uses of same
EP4545633A2 (en)2015-10-262025-04-30Cell Cure Neurosciences Ltd. PREPARATION OF RETINAL PIGMENT EPITHELIUM CELLS
US12188047B2 (en)2015-10-262025-01-07Hadasit Medical Research Services And Development Ltd.Preparation of retinal pigment epithelium cells
WO2017072763A1 (en)2015-10-262017-05-04Cell Cure Neurosciences Ltd.Preparation of retinal pigment epithelium cells
WO2017072773A1 (en)2015-10-272017-05-04Ilana NathanCompositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
WO2017072772A1 (en)2015-10-292017-05-04Yeda Research And Development Co. Ltd.A method of inducing cardiomyocytes proliferation and treating heart diseases
EP4400164A2 (en)2015-10-292024-07-17Yeda Research and Development Co. LtdA method of inducing cardiomyocytes proliferation and treating heart diseases
WO2017077539A1 (en)2015-11-032017-05-11Ariel-University Research And Development Company Ltd.Compositions for regeneration and repair of neural tissue
WO2017083296A1 (en)2015-11-092017-05-18The Children's Hospital Of PhiladelphiaGlypican 2 as a cancer marker and therapeutic target
EP4382127A2 (en)2015-11-092024-06-12The Children's Hospital of PhiladelphiaGlypican 2 as a cancer marker and therapeutic target
WO2017081689A1 (en)2015-11-112017-05-18Ramot At Tel-Aviv University Ltd.Methods of detecting 5-hydroxymethylcytosine and diagnosing of cancer
US10471108B2 (en)2015-11-202019-11-124D Pharma Research LimitedCompositions comprising bacterial strains
US10610550B2 (en)2015-11-202020-04-074D Pharma Research LimitedCompositions comprising bacterial strains
US11058732B2 (en)2015-11-202021-07-134D Pharma Research LimitedCompositions comprising bacterial strains
US10744166B2 (en)2015-11-232020-08-184D Pharma Research LimitedCompositions comprising bacterial strains
US10391128B2 (en)2015-11-232019-08-274D Pharma Research LimitedCompositions comprising bacterial strains
WO2017094001A1 (en)2015-11-302017-06-08Kadimastem LtdMethods for differentiating and purifying pancreatic endocrine cells
EP4231015A1 (en)2015-11-302023-08-23Kadimastem Ltd.Methods for differentiating and purifying pancreatic endocrine cells
EP3176183A1 (en)2015-12-022017-06-07Yeda Research and Development Co. LtdCompositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
US11253590B2 (en)2015-12-022022-02-22Stsciences, Inc.Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
EP3909983A1 (en)2015-12-022021-11-17STCube & Co. Inc.Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
WO2017096304A1 (en)2015-12-042017-06-08Board Of Regents, The University Of Texas SystemSlc45a2 peptides for immunotherapy
EP4059507A1 (en)2015-12-162022-09-21Ramot at Tel-Aviv University Ltd.Particles comprising decellularized omentum
WO2017109679A1 (en)2015-12-212017-06-29Novartis AgCompositions and methods for decreasing tau expression
EP4406541A2 (en)2015-12-212024-07-31Novartis AGCompositions and methods for decreasing tau expression
WO2017112492A2 (en)2015-12-222017-06-29The Regents Of The University Of Colorado, A Body CorporateProtecting rnas from degradation using engineered viral rnas
US10561706B2 (en)2015-12-282020-02-18B. G. Negev Technologies And ApplicationsIsolated polypeptide and compositions comprising same
WO2017118985A1 (en)2016-01-062017-07-13Yeda Research And Development Co. Ltd.Compositions and methods for treating malignant, autoimmune and inflammatory diseases
WO2017122203A1 (en)2016-01-112017-07-20Technion Research & Development Foundation LimitedMethods of determining prognosis of sepsis and treating same
WO2017125931A1 (en)2016-01-212017-07-27The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Parthenocarpic plants and methods of producing same
US10954313B2 (en)2016-01-282021-03-23Sp Nano Ltd.Composition comprising SP1 and carbon based nanoparticles and uses thereof
US10964443B2 (en)2016-01-282021-03-30Sp Nano Ltd.Conductive yarn
WO2017132562A1 (en)2016-01-292017-08-03Heyue ZhouAntigen binding proteins that bind pd-l1
WO2017130205A1 (en)2016-01-312017-08-03Hadasit Medical Research Services And Development Ltd.Autosomal-identical pluripotent stem cell populations having non-identical sex chromosomal composition and uses thereof
US11230578B2 (en)2016-02-042022-01-25Yeda Research And Development Co. Ltd.Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant P53
WO2017134671A1 (en)2016-02-042017-08-10Yeda Research And Development Co. Ltd.Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53
US10036011B2 (en)2016-02-112018-07-31Qiagen Waltham, Inc.Scavenger compounds for improved sequencing-by-synthesis
US10337050B2 (en)2016-02-112019-07-02Qiagen Sciences, LlcPolyphenolic additives in sequencing by synthesis
US11078526B2 (en)2016-02-112021-08-03IsoPlexis CorporationPolyphenolic additives in sequencing by synthesis
WO2017138007A1 (en)2016-02-142017-08-17Yeda Research And Development Co. Ltd. At The Weizmann Institute Of ScienceMicrobiome-based diagnosis, prediction and treatment of relapsing obesity
WO2017138008A2 (en)2016-02-142017-08-17Yeda Research And Development Co. Ltd.Methods of modulating protein exocytosis and uses of same in therapy
EP3708675A1 (en)2016-02-142020-09-16Yeda Research and Development Co. Ltd.Microbiome-based diagnosis, prediction and treatment of relapsing obesity
WO2017141253A1 (en)2016-02-162017-08-24Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Non-protein phenylalanine analogues for inhibiting cyanobacteria and plant growth
US12338435B2 (en)2016-02-192025-06-24Code Biotherapeutics, Inc.Nucleic acid carriers and therapeutic methods of use
WO2017147186A1 (en)2016-02-222017-08-31Ursure, Inc.System and method for detecting therapeutic agents to monitor adherence to a treatment regimen
US10975417B2 (en)2016-02-232021-04-13Dovetail Genomics, LlcGeneration of phased read-sets for genome assembly and haplotype phasing
US12404537B2 (en)2016-02-232025-09-02Dovetail Genomics, LlcGeneration of phased read-sets for genome assembly and haplotype phasing
WO2017145162A1 (en)2016-02-232017-08-31Chaya BrodieGeneration of cancer stem cells and use thereof
WO2017147060A1 (en)2016-02-252017-08-31Dupont Nutrition Biosciences ApsMethod for producing a protein hydrolysate employing an aspergillus fumigatus tripeptidyl peptidase
US10889637B2 (en)2016-02-262021-01-12The Board Of Regents Of The University Of Texas SystemMethods of treating an osteolytic tumor and spinal cord injury by administering connexin (Cx) 43 hemichannel-binding antibodies
US11912758B2 (en)2016-02-262024-02-27The Board Of Regents Of The University Of Texas SystemMethods of treating metastasis, including inhibiting bone cancer metastasis, by administering an antibody which binds connexin 43 (Cx43) hemichannel
US10906987B2 (en)2016-03-012021-02-02Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Antibodies specific to human poliovirus receptor (PVR)
EP3907292A1 (en)2016-03-032021-11-10Memed Diagnostics Ltd.Analyzing rna for diagnosing infection type
WO2017149547A1 (en)2016-03-032017-09-08Memed Diagnostics Ltd.Analyzing rna for diagnosing infection type
US10583158B2 (en)2016-03-042020-03-104D Pharma PlcCompositions comprising bacterial strains
WO2017153982A1 (en)2016-03-062017-09-14Yeda Research And Development Co. Ltd.Method for modulating myelination
WO2017158610A1 (en)2016-03-172017-09-21Yeda Research And Development Co. Ltd.Methods of isolating barrel-like proteases and identifying peptides processed thereby
US11186872B2 (en)2016-03-172021-11-30Cedars-Sinai Medical CenterMethods of diagnosing inflammatory bowel disease through RNASET2
US10458995B2 (en)2016-03-252019-10-29Muralidhar Reddy MoolaCombinatorial synthesis and biomarker development
WO2017165438A1 (en)2016-03-252017-09-28Muralidhar Reddy MoolaCombinatorial synthesis and biomarker development
EP3943508A1 (en)2016-03-292022-01-26Board Of Regents, The University Of Texas SystemDual function antibodies specific to glycosylated pd-l1 and methods of use thereof
WO2017172518A1 (en)2016-03-292017-10-05Stcube, Inc.Dual function antibodies specific to glycosylated pd-l1 and methods of use thereof
WO2017173091A1 (en)2016-03-302017-10-05Musc Foundation For Research DevelopmentMethods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
WO2017175228A1 (en)2016-04-062017-10-12Technion Research & Development Foundation LimitedInfiltrating immune cell proportions predict anti-tnf response in colon biopsies
DE202017007130U1 (en)2016-04-272019-08-29Gen-Probe Inc. Lysis reagent for blood cells
EP3736332A1 (en)2016-04-272020-11-11Gen-Probe IncorporatedBlood cell lysis reagent
WO2017189746A1 (en)2016-04-272017-11-02Gen-Probe IncorporatedBlood cell lysis reagent
DE202017007129U1 (en)2016-04-272019-08-29Gen-Probe Incorporated Lysis reagent for blood cells
WO2017194589A1 (en)2016-05-102017-11-16Vib VzwInhibition of tau-mediated early synaptic dysfunction
US12065691B2 (en)2016-05-132024-08-20Dovetail Genomics, LlcRecovering long-range linkage information from preserved samples
US10947579B2 (en)2016-05-132021-03-16Dovetail Genomics, LlcRecovering long-range linkage information from preserved samples
WO2017201064A1 (en)2016-05-162017-11-23President And Fellows Of Harvard CollegeAqueous biomolecule coupling on co2-plasma-activated surfaces
WO2017203520A1 (en)2016-05-222017-11-30Yeda Research And Development Co. Ltd.Methods of using pulmonary cells for transplantation and induction of tolerance
WO2017203532A1 (en)2016-05-252017-11-30Yeda Research And Development Co. Ltd. At The Weizmann Institute Of ScienceAgents for use treating drug resistant tumors and triple negative breast cancer
WO2017208247A1 (en)2016-06-022017-12-07Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Assay for the removal of methyl-cytosine residues from dna
WO2017212476A1 (en)2016-06-052017-12-14Tel Hashomer Medical Research Infrastructure And Services Ltd.Novel molecules for the treatment of inflammation
WO2017214068A1 (en)2016-06-052017-12-14Berg LlcSystems and methods for patient stratification and identification of potential biomarkers
WO2017212494A1 (en)2016-06-092017-12-14Opko Biologics Ltd.Long-acting oxyntomodulin formulation and methods of producing and administering same
WO2017221225A1 (en)2016-06-192017-12-28Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Screening for chemotherapy resistance in human haploid cells
US11859232B2 (en)2016-06-192024-01-02Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Screening for chemotherapy resistance in human haploid cells
EP3472193A1 (en)2016-06-202019-04-24The Board of Trustees of the Leland Stanford Junior UniversityCircular rnas and their use in immunomodulation
WO2018002924A1 (en)2016-06-272018-01-04Yeda Research And Development Co. Ltd.Veto cells generated from memory t cells
WO2018001932A1 (en)2016-06-302018-01-04Koninklijke Philips N.V.Device, system and method for detecting an analyte in a body fluid sample containing a plurality of cells
US11125744B2 (en)2016-06-302021-09-21Siemens Healthineers Nederland B.V.Device, system and method for detecting an analyte in a body fluid sample containing a plurality of cells
EP4141448A1 (en)2016-07-102023-03-01MeMed Diagnostics Ltd.Protein signatures for distinguishing between bacterial and viral infections
WO2018011796A1 (en)2016-07-102018-01-18Memed Diagnostics Ltd.Early diagnosis of infections
EP4184167A1 (en)2016-07-102023-05-24MeMed Diagnostics Ltd.Early diagnosis of infections
WO2018011795A1 (en)2016-07-102018-01-18Memed Diagnostics Ltd.Protein signatures for distinguishing between bacterial and viral infections
US12325866B2 (en)2016-07-112025-06-10Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Systems and methods for growing cells in vitro
WO2018011799A1 (en)2016-07-112018-01-18Opko Biologics Ltd.Long-acting coagulation factor vii and methods of producing same
WO2018011805A2 (en)2016-07-112018-01-18Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Systems and methods for growing cells in vitro
WO2018011804A1 (en)2016-07-112018-01-18Bonus Therapeutics Ltd.Cell compositions for tissue regeneration
EP4303228A2 (en)2016-07-112024-01-10OPKO Biologics Ltd.Long-acting coagulation factor vii and methods of producing same
US11976106B2 (en)2016-07-112024-05-07Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
WO2018011806A1 (en)2016-07-112018-01-18Yeda Research And Development Co. Ltd.Combination therapy to increase endogenous nitric oxide (no) synthesis
US10610549B2 (en)2016-07-132020-04-074D Pharma PlcComposition comprising bacterial strains
US11224620B2 (en)2016-07-132022-01-184D Pharma PlcCompositions comprising bacterial strains
US10967010B2 (en)2016-07-132021-04-064D Pharma PlcCompositions comprising bacterial strains
US10960031B2 (en)2016-07-132021-03-304D Pharma PlcCompositions comprising bacterial strains
US10610548B2 (en)2016-07-132020-04-074D Pharma PlcCompositions comprising bacterial strains
WO2018015881A1 (en)2016-07-182018-01-25Ramot At Tel-Aviv University Ltd.Modular platform for targeted therapeutics
EP4434516A2 (en)2016-07-182024-09-25Ramot at Tel-Aviv University Ltd.Modular platform for targeted therapeutics
WO2018015296A1 (en)2016-07-202018-01-25Vib VzwTherapeutic agents for neurological and psychiatric disorders
WO2018017673A1 (en)2016-07-202018-01-25Stcube, Inc.Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
WO2018020489A1 (en)2016-07-242018-02-01Yeda Research And Development Co. Ltd.Methods and kits for analyzing dna binding moieties attached to dna
WO2018029682A1 (en)2016-08-082018-02-15Ramot At Tel-Aviv University Ltd.Bacterial systems for analyzing ubiquitylated polypeptides
WO2018029690A1 (en)2016-08-102018-02-15Memed Diagnostics Ltd.System and method for analysis of biological data
WO2018029693A1 (en)2016-08-102018-02-15Ramot At Tel-Aviv University Ltd.Analysis of methylation status and copy number
EP4033248A1 (en)2016-08-102022-07-27MeMed Diagnostics Ltd.System and method for analysis of biological data
US11129852B2 (en)2016-08-142021-09-28Ramot At Tel Aviv University Ltd.Mesenchymal cell-derived exosomes to treat neurological disorders
WO2018033911A1 (en)2016-08-142018-02-22Ramot At Tel-Aviv University Ltd.Mesenchymal cell-derived exosomes to treat neurological disorders
WO2018033929A1 (en)2016-08-182018-02-22Yeda Research And Development Co. Ltd.Diagnostic and therapeutic uses of exosomes
WO2018037416A1 (en)2016-08-252018-03-01Yeda Research And Development Co. Ltd.Methods and compositions for treating autoimmune diseases
EP3503729A1 (en)2016-08-282019-07-03The State of Isreal, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO)Method of controlling fungal infections in plants
US10716864B2 (en)2016-09-072020-07-21Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Anti-NKP46 antibodies, toxin conjugates, and therapeutic use of same
WO2018047154A1 (en)2016-09-072018-03-15Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Anti-nkp46 antibodies and therapeutic use of same
WO2018051347A1 (en)2016-09-142018-03-22Yeda Research And Development Co. Ltd.Crisp-seq, an integrated method for massively parallel single cell rna-seq and crispr pooled screens
WO2018060998A1 (en)2016-09-292018-04-05Memed Diagnostics Ltd.Methods of prognosis and treatment
WO2018069885A1 (en)2016-10-132018-04-19Technion Research & Development Foundation LimitedUse of caspase-3 inhibitors and caspase-3 activators in the manufacture of medicament for treating cancer and wound healing
WO2018073823A2 (en)2016-10-182018-04-26Yeda Research And Development Co. Ltd.Treatment of a circadian rhythm disorder
WO2018085400A1 (en)2016-11-022018-05-11Vanderbilt UniversityHuman zika virus antibodies and methods of use therefor
WO2018085679A1 (en)2016-11-042018-05-11Stave James WDirect detection of microorganisms in patient samples by immunoassay
WO2018089231A1 (en)2016-11-092018-05-17Qiagen Sciences LlcPhotoprotective mixtures as imaging reagents in sequencing-by-synthesis
US11162129B2 (en)2016-11-092021-11-02IsoPlexis CorporationPhotoprotective mixtures as imaging reagents in sequencing-by-synthesis
WO2018087759A1 (en)2016-11-102018-05-17Yeda Research And Development Co. Ltd.Phosphotriesterases for treating or preventing organophosphate exposure associated damage
US11324736B2 (en)2016-11-232022-05-10Chemocentryx, Inc.Method of Treating Focal Segmental Glomerulosclerosis
US12194032B2 (en)2016-11-232025-01-14Chemocentryx, Inc.Method of treating focal segmental glomerulosclerosis
US10973809B2 (en)2016-11-232021-04-13Chemocentryx, Inc.Method of treating focal segmental glomerulosclerosis
WO2018096547A1 (en)2016-11-282018-05-31Yeda Research And Development Co. Ltd.Isolated polynucleotides and polypeptides and methods of using same for expressing an expression product of interest
WO2018100431A1 (en)2016-11-292018-06-07Genomic VisionMethod for designing a set of polynucleotide sequences for analysis of specific events in a genetic region of interest
WO2018100574A1 (en)2016-11-302018-06-07Yeda Research And Development Co. Ltd.Methods of treating liver toxicity and disorders
WO2018100511A1 (en)2016-12-012018-06-07Ramot At Tel-Aviv University Ltd.Combined treatment for nerve injuries
WO2018104346A1 (en)2016-12-052018-06-14Nuritas LimitedCompositions comprising peptide wkdeagkplvk
EP3329930A1 (en)2016-12-052018-06-06Nuritas LimitedPharmaceuctical compositions
EP3329905A1 (en)2016-12-052018-06-06Nuritas LimitedTopical cosmetic compositions comprising an oligopeptide against anti-aging of the skin
EP4129321A1 (en)2016-12-052023-02-08Nuritas LimitedCompositions comprising peptide wkdeagkplvk
US10485830B2 (en)2016-12-122019-11-264D Pharma PlcCompositions comprising bacterial strains
WO2018134824A1 (en)2017-01-182018-07-26Yeda Research And Development Co. Ltd.Genetically modified veto cells and use of same in immunotherapy
WO2018138668A1 (en)2017-01-252018-08-02Mor Research Applications Ltd.Methods of diagnosing malignant diseases
US11267885B2 (en)2017-01-262022-03-08Zlip Holding LimitedCD47 antigen binding unit and uses thereof
WO2018140606A1 (en)2017-01-262018-08-02Oklahoma Medical Research FoundationBiomarkers for systemic lupus erythematosus disease activity, and intensity and flare
WO2018144425A1 (en)2017-01-312018-08-09Vanderbilt UniversityGeneration of human allergen-and helminth-specific ige monoclonal antibodies for diagnostic and therapeutic use
WO2018142416A1 (en)2017-02-062018-08-09Yeda Research And Development Co. Ltd.Isolated cells genetically modified to express a disarm system having an anti-phage activity and methods of producing same
WO2018146162A1 (en)2017-02-072018-08-16Academisch Medisch CentrumMolecular biomarker for prognosis of sepsis patients
US12281328B2 (en)2017-02-082025-04-22Hadasit Medical Research Services And Development Ltd.Photoreceptor cells for the treatment of retinal diseases
WO2018158775A1 (en)2017-03-022018-09-07Yeda Research And Development Co. Ltd.Methods of culturing t cells and uses of same
WO2018163051A1 (en)2017-03-062018-09-13Novartis AgMethods of treatment of cancer with reduced ubb expression
WO2018167778A1 (en)2017-03-122018-09-20Yeda Research And Development Co. Ltd.Methods of diagnosing and prognosing cancer
WO2018167780A1 (en)2017-03-122018-09-20Yeda Research And Development Co. Ltd.Methods of prognosing and treating cancer
WO2018170494A1 (en)2017-03-162018-09-20Bio Time, Inc.Methods for measuring therapeutic effects of retinal disease therapies
WO2018185760A1 (en)2017-04-052018-10-11Yeda Research And Development Co. Ltd.Ex-vivo culture system and methods of using same
EP4317971A2 (en)2017-04-052024-02-07Yeda Research and Development Co. LtdEx-vivo culture system and methods of using same
WO2018207178A1 (en)2017-05-072018-11-15Yeda Research And Development Co. Ltd.Methods of treating psychiatric stress disorders
EP3821888A1 (en)2017-05-072021-05-19Yeda Research and Development Co. LtdLxr agonists for treating psychiatric stress disorders
WO2018207184A2 (en)2017-05-102018-11-15Ariel Scientific Innovations Ltd.Methods of purifying antibodies
US12174187B2 (en)2017-05-102024-12-24Rowan UniversityMethods for detecting multiple sclerosis (MS) diagnostic autoantibodies
WO2018216006A1 (en)2017-05-212018-11-29The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterCombination of markers for diagnosing cancer
US11382936B2 (en)2017-05-222022-07-124D Pharma Research LimitedCompositions comprising bacterial strains
US11376284B2 (en)2017-05-222022-07-054D Pharma Research LimitedCompositions comprising bacterial strains
US11123378B2 (en)2017-05-222021-09-214D Pharma Research LimitedCompositions comprising bacterial strains
WO2018216011A1 (en)2017-05-232018-11-29Technion Research & Development Foundation LimitedAgents which inhibit gads dimerization and methods of use thereof
US10987387B2 (en)2017-05-242021-04-274D Pharma Research LimitedCompositions comprising bacterial strain
WO2018222685A1 (en)2017-05-312018-12-06Stcube & Co., Inc.Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
WO2018220581A1 (en)2017-05-312018-12-06Tropic Biosciences UK LimitedCompositions and methods for increasing shelf-life of banana
US12215151B2 (en)2017-05-312025-02-04Stcube & Co., Inc.Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
WO2018220579A1 (en)2017-05-312018-12-06Tropic Biosciences UK LimitedCompositions and methods for increasing extractability of solids from coffee beans
WO2018222689A1 (en)2017-05-312018-12-06Stcube & Co., Inc.Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
WO2018220582A1 (en)2017-05-312018-12-06Tropic Biosciences UK LimitedMethods of selecting cells comprising genome editing events
EP4461813A2 (en)2017-05-312024-11-13Tropic Biosciences UK LimitedCompositions and methods for increasing shelf-life of banana
WO2018226671A1 (en)2017-06-062018-12-13Stcube & Co., Inc.Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
US11542331B2 (en)2017-06-062023-01-03Stcube & Co., Inc.Methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands
WO2018229764A1 (en)2017-06-132018-12-20Yeda Research And Development Co. Ltd.Treatment of advanced or progressive multiple sclerosis
US11779613B2 (en)2017-06-142023-10-10Cj Bioscience, Inc.Compositions comprising a bacterial strain of the genus Megasphera and uses thereof
US11660319B2 (en)2017-06-142023-05-304D Pharma Research LimitedCompositions comprising bacterial strains
US11123379B2 (en)2017-06-142021-09-214D Pharma Research LimitedCompositions comprising bacterial strains
US11007233B2 (en)2017-06-142021-05-184D Pharma Research LimitedCompositions comprising a bacterial strain of the genus Megasphera and uses thereof
US12048720B2 (en)2017-06-142024-07-30Cj Bioscience, Inc.Compositions comprising bacterial strains
US12140592B2 (en)2017-06-162024-11-12Oklahoma Medical Research FoundationBiomarkers for assessing risk of transitioning to systemic lupus erythematosus classification and disease pathogenesis
WO2019012543A1 (en)2017-07-132019-01-17Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Dna targets as tissue-specific methylation markers
EP4403646A2 (en)2017-07-132024-07-24Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd.Dna targets as tissue-specific methylation markers
WO2019012542A1 (en)2017-07-132019-01-17Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Detecting tissue-specific dna
WO2019012544A1 (en)2017-07-132019-01-17Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Dual-probe digital droplet pcr strategy for specific detection of tissue-specific circulating dna molecules
US10768185B2 (en)2017-07-202020-09-08Trustees Of Boston UniversityTenofovir detection assay
WO2019016772A2 (en)2017-07-212019-01-24Novartis AgCompositions and methods to treat cancer
EP4085919A2 (en)2017-07-212022-11-09Novartis AGCompositions and methods to treat cancer
WO2019021284A1 (en)2017-07-242019-01-31Yeda Research And Development Co. Ltd.Combination therapy for the treatment of cancer
US12428637B2 (en)2017-08-082025-09-30Technology Innovation Momentum Fund (Israel) Limited PartnershipChloramphenicol resistant split protein and uses thereof
WO2019035128A1 (en)2017-08-142019-02-21Yeda Research And Development Co. Ltd.Immunotherapy against transferrin receptor 1 (tfr1)-tropic arenaviruses
WO2019038761A1 (en)2017-08-212019-02-28Savicell Diagnostic Ltd.Methods of diagnosing and treating lung cancer
WO2019038771A1 (en)2017-08-232019-02-28Technion Research & Development Foundation LimitedCompositions and methods for improving alcohol tolerance in yeast
US11306144B2 (en)2017-08-252022-04-19Five Prime Therapeutics, Inc.B7-H4 antibodies and methods of use thereof
US11814431B2 (en)2017-08-252023-11-14Five Prime Therapeutics, Inc.B7-H4 antibodies and methods of use thereof
WO2019042153A1 (en)2017-09-012019-03-07四川科伦博泰生物医药股份有限公司 Recombinant bispecific antibody
WO2019051002A1 (en)2017-09-052019-03-14GLAdiator Biosciences, Inc.A method of intracellular delivery
WO2019050997A1 (en)2017-09-052019-03-14GLAdiator Biosciences, Inc.Delivery of payloads to stem cells
WO2019050998A1 (en)2017-09-052019-03-14GLAdiator Biosciences, Inc.Method of targeting exosomes
US11464784B2 (en)2017-09-152022-10-11The Regents Of The University Of CaliforniaInhibition of aminocylase 3 (AA3) in the treatment of cancer
DE112018005145T5 (en)2017-09-152020-07-23The Regents Of The University Of California INHIBITION OF AMINOACYLASE 3 (AA3) IN TREATMENT OF CANCER
WO2019058376A1 (en)2017-09-192019-03-28The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Genome-edited birds
US12275939B2 (en)2017-09-192025-04-15Tropic Biosciences UK LimitedModifying the specificity of plant non-coding RNA molecules for silencing gene expression
US12331295B2 (en)2017-09-192025-06-17Tropic Biosciences UK LimitedModifying the specificity of plant non-coding RNA molecules for silencing gene expression
US11555199B2 (en)2017-09-192023-01-17Tropic Biosciences UK LimitedModifying the specificity of plant non-coding RNA molecules for silencing gene expression
EP4170029A2 (en)2017-09-192023-04-26Tropic Biosciences UK LimitedModifying the specifity of plant non-coding rna molecules for silencing gene expression
WO2019067543A1 (en)2017-09-262019-04-04The Regents Of The University Of CaliforniaCompositions and methods for treating cancer
WO2019071054A1 (en)2017-10-042019-04-11The Broad Institute, Inc.Methods and compositions for altering function and structure of chromatin loops and/or domains
EP4116327A1 (en)2017-10-112023-01-11Board Of Regents, The University Of Texas SystemHuman pd-l1 antibodies and methods of use therefor
US11382915B2 (en)2017-10-112022-07-12Chemocentryx, Inc.Treatment of focal segmental glomerulosclerosis with CCR2 antagonists
US10758540B2 (en)2017-10-112020-09-01Chemocentryx, Inc.Treatment of focal segmental glomerulosclerosis with CCR2 antagonists
EP3694872A1 (en)2017-10-122020-08-19Board Of Regents, The University Of Texas SystemT cell receptors for immunotherapy
EP4461356A2 (en)2017-10-242024-11-13Elani, DaliaMethods of treating an ischemic disease
WO2019094595A2 (en)2017-11-092019-05-16Pinteon Therapeutics Inc.Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
WO2019097514A1 (en)2017-11-142019-05-23Yeda Research And Development Co. Ltd.Hematopoietic stem cells with improved properties
WO2019106671A1 (en)2017-11-292019-06-06Ramot At Tel-Aviv University Ltd.Methods of preventing or treating neurogenic shock
WO2019106667A1 (en)2017-11-292019-06-06Weedout Ltd.Compositions, kits and methods for controlling weed of the amaranthus genus
WO2019106680A1 (en)2017-12-032019-06-06Yeda Research And Development Co. Ltd.Treatment of an ischemic heart disease
WO2019109864A1 (en)2017-12-042019-06-13厦门万泰凯瑞生物技术有限公司Kit and method for quantitative detecting hbsag
WO2019118721A2 (en)2017-12-152019-06-20Syngenta Participations AgNon-antibody ligands for detecting target proteins
WO2019116376A1 (en)2017-12-172019-06-20Yeda Research And Development Co. Ltd.Cop9 signalosome (csn) complex modulators and uses thereof
WO2019130313A1 (en)2017-12-282019-07-04Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method to reproduce circadian rhythms on a microfluidic chip
WO2019156758A2 (en)2018-01-052019-08-15Vanderbilt UniversityAntibody-mediated neutralization of chikungunya virus
WO2019145964A1 (en)2018-01-292019-08-01Yeda Research And Development Co. Ltd.Combination of a mek inhibitor and a cdk4/6 inhibitor for the treatment of sarcoma
EP4610372A2 (en)2018-01-292025-09-03Lavie Bio Ltd.Plant microbial preparations, compositions and formulations comprising same and uses thereof
WO2019150373A1 (en)2018-01-312019-08-08Yeda Research And Development Co. Ltd.Endoplasmic reticulum targeting signal
US12378592B2 (en)2018-01-312025-08-05Dovetail Genomics, Llc.Sample prep for DNA linkage recovery
WO2019155459A1 (en)2018-02-082019-08-15Yeda Research And Development Co. Ltd.Inhibitors of the 20s proteasome
WO2019155465A1 (en)2018-02-082019-08-15Yeda Research And Development Co. Ltd.Methods of identifying and using agents for treating diseases associated with intestinal barrier dysfunction
WO2019155041A1 (en)2018-02-122019-08-15Vib VzwGβγ COMPLEX ANTIBODIES AND USES THEREOF
US12435145B2 (en)2018-02-212025-10-07Five Prime Therapeutics, Inc.B7-H4 antibody formulations
WO2019165217A1 (en)2018-02-222019-08-29The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesCd153 and/or cd30 in infection
US11571433B2 (en)2018-02-232023-02-07Carmel Haifa University Economic Corporation Ltd.Methods for treating memory impairment and cognitive dysfunction
WO2019167047A1 (en)2018-02-282019-09-06The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterMethods of diagnosing and treating bladder cancer
WO2019169212A1 (en)2018-03-022019-09-06Five Prime Therapeutics, Inc.B7-h4 antibodies and methods of use thereof
US11939383B2 (en)2018-03-022024-03-26Five Prime Therapeutics, Inc.B7-H4 antibodies and methods and use thereof
WO2019175869A1 (en)2018-03-122019-09-19Yeda Research And Development Co. LtdTreatment of a heart disease
WO2019182896A1 (en)2018-03-232019-09-26Board Of Regents, The University Of Texas SystemDual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
EP4501355A2 (en)2018-03-232025-02-05Board Of Regents, The University Of Texas SystemDual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
WO2019182867A1 (en)2018-03-232019-09-26Board Of Regents, The University Of Texas SystemDual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
WO2019186570A1 (en)2018-03-292019-10-03Yeda Research And Development Co. Ltd.Methods of disrupting a biofilm and/or preventing formation of same
US11648260B2 (en)2018-03-292023-05-16Technion Research And Development Foundation LimittedVesicles comprising a PTEN inhibitor and uses of same
WO2019186569A1 (en)2018-03-292019-10-03Yeda Research And Development Co. Ltd.Use of electric field gradients to control gene expression
EP4063519A1 (en)2018-04-092022-09-28Advanced Cell Diagnostics, Inc.Methods to further enhance signal amplification for the in situ detection of nucleic acids
WO2019199643A1 (en)2018-04-092019-10-17Bio-Techne CorporationMethods to further enhance signal amplification for the in situ detection of nucleic acids
US11788124B2 (en)2018-04-092023-10-17Advanced Cell Diagnostics, Inc.Methods to further enhance signal amplification for the in situ detection of nucleic acids
WO2019206095A1 (en)2018-04-242019-10-31安源医药科技(上海)有限公司Antibody against tim-3 and application thereof
US11884725B2 (en)2018-04-242024-01-30Ampsource Biopharma Shanghai Inc.Antibody against TIM-3 and application thereof
WO2019211750A1 (en)2018-05-012019-11-07Tropic Biosciences UK LimitedCompositions and methods for reducing caffeine content in coffee beans
WO2019213276A1 (en)2018-05-022019-11-07Novartis AgRegulators of human pluripotent stem cells and uses thereof
WO2019220437A1 (en)2018-05-152019-11-21Yeda Research And Development Co. Ltd.Vaccination with cancer neoantigens
WO2019220441A1 (en)2018-05-152019-11-21Hadasit Medical Research Services And Development Ltd.Compositions and methods for treating cancer resistant to an anti-cancer agent
WO2019222618A1 (en)2018-05-172019-11-21The Trustees Of Columbia University In The City Of New YorkMethods for treating, preventing and detecting the prognosis of colorectal cancer
WO2019229745A1 (en)2018-05-272019-12-05Biolinerx Ltd.Agi-134 combined with a checkpoint inhibitor for the treatment of solid tumors
WO2019234754A1 (en)2018-06-072019-12-12The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Nucleic acid constructs and methods of using same
WO2019234750A1 (en)2018-06-072019-12-12The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Methods of regenerating and transforming cannabis
WO2019238962A1 (en)2018-06-142019-12-19University College Cork - National University Of Ireland, CorkPeptide for disease treatment
WO2019244107A1 (en)2018-06-212019-12-26Daiichi Sankyo Company, LimitedCompositions including cd3 antigen binding fragments and uses thereof
WO2020003311A1 (en)2018-06-252020-01-02Yeda Research And Development Co. Ltd.Systems and methods for increasing efficiency of genome editing
WO2020008412A1 (en)2018-07-042020-01-09Ukko Inc.Methods of de-epitoping wheat proteins and use of same for the treatment of celiac disease
WO2020012467A2 (en)2018-07-082020-01-16Yeda Research And Development Co. Ltd.Person-specific assessment of probiotics responsiveness
WO2020012478A2 (en)2018-07-112020-01-16Immunity Pharma Ltd.Peptide compounds and therapeutic uses of same
EP4566617A2 (en)2018-07-112025-06-11Immunity Pharma Ltd.Peptide compounds and therapeutic uses of same
WO2020012486A1 (en)2018-07-112020-01-16Kahr Medical Ltd.SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
WO2020026241A1 (en)2018-07-312020-02-06Collplant Ltd.Tobacco transgenic event and methods for detection and use thereof
WO2020035863A1 (en)2018-08-142020-02-20Yeda Research And Development Co. Ltd.Chimeric quiescin sulfhydryl oxidase (qsox1) antibodies and uses of same
WO2020039440A1 (en)2018-08-242020-02-27Yeda Research And Development Co. Ltd.Methods of modulating m2 macrophage polarization and use of same in therapy
WO2020056077A1 (en)2018-09-132020-03-19The Board Of Regents Of The University Of Texas SystemNovel lilrb4 antibodies and uses thereof
WO2020058979A2 (en)2018-09-202020-03-26Yeda Research And Development Co. Ltd.Methods of treating amyotrophic lateral sclerosis
WO2020065647A1 (en)2018-09-252020-04-02Biolinerx Ltd.Methods of selecting treatment for cxcr4-associated cancer
WO2020069424A1 (en)2018-09-282020-04-02Centrillion Technologies, Inc.Disulfide-linked reversible terminators
WO2020081568A1 (en)2018-10-152020-04-23University Of MassachusettsProgrammable dna base editing by nme2cas9-deaminase fusion proteins
WO2020081204A1 (en)2018-10-182020-04-23Oklahoma Medical Research FoundationBiomarkers for a systemic lupus erythematosus (sle) disease activity immune index that characterizes disease activity
WO2020082209A1 (en)2018-10-222020-04-30上海吉倍生物技术有限公司Anti-cldn128.2 antibody and uses thereof
WO2020083979A1 (en)2018-10-232020-04-30Glycardial Diagnostics, S.L.Antibodies specific for glycosylated apoj and uses thereof
WO2020089892A1 (en)2018-10-282020-05-07Yeda Research And Development Co. Ltd.Prevention of age related clonal hematopoiesis and diseases associated therewith
WO2020103691A1 (en)2018-11-202020-05-28厦门万泰凯瑞生物技术有限公司Specific antibody for amh, and uses thereof
WO2020105050A2 (en)2018-11-212020-05-28Yeda Research And Development Co. Ltd.Method of treating cancer and compositions for same
WO2020113084A1 (en)2018-11-282020-06-04Oregon Health & Science UniversityTherapeutic factor xii antibody
US12165759B2 (en)2018-11-302024-12-10Caris Mpi, Inc.Classifying an entity for FOLFOX treatment
EP4369356A2 (en)2018-11-302024-05-15Caris MPI, Inc.Next-generation molecular profiling
WO2020113237A1 (en)2018-11-302020-06-04Caris Mpi, Inc.Next-generation molecular profiling
US11315673B2 (en)2018-11-302022-04-26Caris Mpi, Inc.Next-generation molecular profiling
WO2020135201A1 (en)2018-12-282020-07-02四川科伦博泰生物医药股份有限公司Antibody and use thereof
WO2020152686A1 (en)2019-01-232020-07-30Yeda Research And Development Co. Ltd.Culture media for pluripotent stem cells
WO2020185312A2 (en)2019-01-252020-09-17President And Fellows Of Harvard CollegeCompositions and method for synthesizing nucleic acids
WO2020161724A1 (en)2019-02-102020-08-13Yeda Research And Development Co. Ltd.Anti-matrix metalloproteinase 7 (mmp-7) inhibitory antibody and uses thereof
WO2020165907A1 (en)2019-02-142020-08-20Yeda Research And Development Co. Ltd.Spt5 inhibitors and uses thereof
WO2020168162A1 (en)2019-02-152020-08-20Bio-Techne CorporationMethods for multiplex detection of nucleic acids by in situ hybridization
WO2020170239A1 (en)2019-02-212020-08-27Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of generating organoids for high throughput screening of drugs
WO2020170240A1 (en)2019-02-212020-08-27Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method for reduction drug-induced nephrotoxicity
WO2020178822A1 (en)2019-03-052020-09-10The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Genome-edited birds
WO2020185763A1 (en)2019-03-112020-09-17Memorial Sloan Kettering Cancer CenterCd22 antibodies and methods of using the same
WO2020183419A1 (en)2019-03-142020-09-17Tropic Biosciences UK LimitedIntroducing silencing activity to dysfunctional rna molecules and modifying their specificity against a gene of interest
WO2020183416A1 (en)2019-03-142020-09-17Tropic Biosciences UK LimitedPRODUCTION OF dsRNA IN PLANT CELLS FOR PEST PROTECTION VIA GENE SILENCING
WO2020183414A2 (en)2019-03-142020-09-17Tropic Biosciences UK LimitedModifying the specificity of non-coding rna molecules for silencing genes in eukaryotic cells
WO2020188572A1 (en)2019-03-192020-09-24Yeda Research And Development Co. Ltd.Bistable type ii opsins and uses thereof
WO2020194317A1 (en)2019-03-282020-10-01Yeda Research And Development Co. Ltd.Method of treating lipid-related disorders
US12419902B2 (en)2019-03-312025-09-23Yeda Research And Development Co. Ltd.Anti-viral and anti-tumoral compounds
WO2020202142A2 (en)2019-03-312020-10-08Yeda Research And Development Co. Ltd.Anti-viral and anti-tumoral compounds
US12258419B2 (en)2019-04-162025-03-25Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Anti-FXI/FXIa antibody and use thereof
WO2020211674A1 (en)2019-04-162020-10-22四川科伦博泰生物医药股份有限公司Anti-fxi/fxia antibody and use thereof
WO2020223576A1 (en)2019-04-302020-11-05Chondrial Therapeutics, Inc.Frataxin-sensitive markers for determining effectiveness of frataxin replacement therapy
WO2020222241A1 (en)2019-05-022020-11-05Yeda Research And Development Co. Ltd.Compositions comprising the propeptide of lysyl oxidase and uses thereof
WO2020230133A1 (en)2019-05-132020-11-19Yeda Research And Development Co. Ltd.Cell-free mirna biomarkers for prognosis and diagnosis of neurodegenerative diseases
WO2020234875A2 (en)2019-05-192020-11-26Yeda Research And Development Co. Ltd.Identification of recurrent mutated neopeptides
WO2020234888A1 (en)2019-05-222020-11-26Hadasit Medical Research Services And Development Ltd.Methods of culturing human pluripotent cells
IT201900007222A1 (en)2019-05-242020-11-24Univ Degli Studi Di Torino COMPOSITION OF LIPOSOMES AND METHOD OF DOSAGE BASED ON THE USE OF THE SAME
WO2020237491A1 (en)2019-05-282020-12-03Shanghaitech UniversityComposition and methods to treat ectodermal dysplasia 2, clouston type
WO2020250232A1 (en)2019-06-122020-12-17Hadasit Medical Research Services And Development Ltd.Methods of generating oligodendrocytes
WO2020255124A1 (en)2019-06-162020-12-24Yeda Research And Development Co. Ltd.Method for stabilizing intracellular rna
WO2020264185A1 (en)2019-06-272020-12-30Dovetail Genomics, LlcMethods and compositions for proximity ligation
EP4545965A2 (en)2019-06-272025-04-30Dovetail Genomics, LLCMethods and compositions for proximity ligation
WO2020261281A1 (en)2019-06-272020-12-30Ramot At Tel-Aviv University Ltd.Semaphorin 3a antibodies and uses thereof
WO2021001784A1 (en)2019-07-042021-01-07Ukko Inc.De-epitoped alpha gliadin and use of same for the management of celiac disease and gluten sensitivity
WO2021005599A1 (en)2019-07-112021-01-14Kahr Medical Ltd.Heterodimers and methods of use thereof
WO2021009763A1 (en)2019-07-162021-01-21Yeda Research And Development Co. Ltd.Methods of treating pain
WO2021009740A1 (en)2019-07-162021-01-21Ramot At Tel-Aviv University Ltd.Compositions and methods for the treatment of tuberculosis
WO2021016062A1 (en)2019-07-192021-01-28The Children's Hospital Of PhiladelphiaChimeric antigen receptors containing glypican 2 binding domains
WO2021021605A1 (en)2019-07-262021-02-04Vanderbilt UniversityHuman monoclonal antibodies to enterovirus d68
WO2021019526A1 (en)2019-07-292021-02-04Yeda Research And Development Co. Ltd.Methods of treating and diagnosing lung cancer
WO2021019536A1 (en)2019-07-302021-02-04The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Methods of controlling cannabinoid synthesis in plants or cells and plants and cells produced thereby
WO2021028909A1 (en)2019-08-122021-02-18Yeda Research And Development Co. Ltd.Dna repair blood test for predicting response of lung cancer patients to immunotherapy
EP3783012A1 (en)2019-08-202021-02-24Nuritas LimitedAn antimicrobial peptide
EP4218787A2 (en)2019-08-202023-08-02Nuritas LimitedPeptides for treating muscle atrophy
WO2021032650A1 (en)2019-08-202021-02-25Nuritas LimitedPeptides for treating muscle atrophy
WO2021033176A1 (en)2019-08-222021-02-25Ariel Scientific Innovations Ltd.Scaled-up methods for purifying antibodies
WO2021038569A1 (en)2019-08-272021-03-04Yeda Research And Development Co. Ltd.Treatment of bacterial vaginosis
WO2021048852A1 (en)2019-09-112021-03-18Yeda Research And Development Co. Ltd.Methods of treating breast cancer
WO2021055489A1 (en)2019-09-162021-03-25Grohar Patrick JCompositions and methods for the treatment of swi-snf mutant tumors
WO2021051390A1 (en)2019-09-202021-03-25上海吉倍生物技术有限公司Bcma-targeted antibody and chimeric antigen receptor
WO2021059269A1 (en)2019-09-252021-04-01Yeda Research And Development Co. Ltd.Assembly of protein complexes on a chip
WO2021062323A1 (en)2019-09-262021-04-01Stcube & Co.Antibodies specific to glycosylated ctla-4 and methods of use thereof
WO2021063201A1 (en)2019-09-302021-04-08四川科伦博泰生物医药股份有限公司Anti-pd-1 antibody and use thereof
WO2021072277A1 (en)2019-10-092021-04-15Stcube & Co.Antibodies specific to glycosylated lag3 and methods of use thereof
WO2021078912A1 (en)2019-10-222021-04-29Nuritas LimitedTreatment of non-alcoholic fatty liver disease
WO2021084540A1 (en)2019-10-302021-05-06Yeda Research And Development Co. Ltd.Inhibitors of mmej pathway for prevention and treatment of pre-myeloid and myeloid malignancies
WO2021084526A1 (en)2019-10-312021-05-06Yeda Research And Development Co. Ltd.Engineered autotrophic bacteria for co2 conversion to organic materials
WO2021095031A2 (en)2019-11-112021-05-20Ibi-Ag Innovative Bio Insecticides Ltd.Insect control nanobodies and uses thereof
WO2021100034A1 (en)2019-11-192021-05-27Protalix Ltd.Removal of constructs from transformed cells
WO2021100041A1 (en)2019-11-202021-05-27Yeda Research And Development Co. Ltd.Treating alzheimer's disease
US10792360B1 (en)2019-11-212020-10-06Chemocentryx, Inc.Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
US12441776B2 (en)2019-11-272025-10-14Eirgen Pharma Ltd.Oxyntomodulin peptide analog formulations
US11842805B2 (en)2019-12-022023-12-12Caris Mpi, Inc.Pan-cancer platinum response predictor
WO2021119402A1 (en)2019-12-122021-06-17President And Fellows Of Harvard CollegeCompositions and methods for light-directed biomolecular barcoding
WO2021115240A1 (en)2019-12-132021-06-17四川科伦博泰生物医药股份有限公司Anti-tslp antibody and uses thereof
WO2021126435A1 (en)2019-12-202021-06-24Novarock Biotherapeutics, Ltd.Anti-interleukin-23 p19 antibodies and methods of use thereof
WO2021130753A1 (en)2019-12-222021-07-01Yeda Research And Development Co. Ltd.Diagnosis of frontotemporal dementia
WO2021130752A1 (en)2019-12-222021-07-01Yeda Research And Development Co. Ltd.Systems and methods for identifying cells that have undergone genome editing
WO2021130390A1 (en)2019-12-262021-07-01Universitat Autònoma De BarcelonaScaffold proteins and therapeutic nanoconjugates based on nidogen
EP3842452A1 (en)2019-12-262021-06-30Universitat Autònoma de BarcelonaScaffold proteins and therapeutic nanoconjugates based on nidogen
WO2021137230A1 (en)2019-12-312021-07-08Kahr Medical Ltd.Methods of culturing t cells and uses of same
WO2021137222A1 (en)2019-12-312021-07-08Ichilov Tech Ltd.Methods of treating atopic dermatitis
WO2021137231A1 (en)2019-12-312021-07-08Kahr Medical Ltd.Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same
WO2021136082A1 (en)2020-01-022021-07-08厦门大学Polypeptide encoded by bnlf2b gene in eb virus and detection use thereof
WO2021144798A1 (en)2020-01-152021-07-22Immunity Pharma Ltd.Peptide compounds and methods of treating diseases using same
WO2021149053A1 (en)2020-01-222021-07-29Yeda Research And Development Co. Ltd.Multispecific antibodies for use in treating diseases
WO2021152584A1 (en)2020-01-282021-08-05Ariel Scientific Innovations Ltd.Methods of analyzing cell membranes
EP4484956A2 (en)2020-01-292025-01-01MeMed Diagnostics Ltd.Methods of diagnosing and classifying viral infections
WO2021152590A1 (en)2020-01-302021-08-05Yeda Research And Development Co. Ltd.Articles of manufacture comprising anti pd-l1 antibodies and their use in therapy
WO2021152592A1 (en)2020-01-302021-08-05Yeda Research And Development Co. Ltd.Methods of treating cancer
WO2021152586A1 (en)2020-01-302021-08-05Yeda Research And Development Co. Ltd.Methods of analyzing microbiome, immunoglobulin profile and physiological state
WO2021152587A1 (en)2020-01-302021-08-05Yeda Research And Development Co. Ltd.Treating acute liver disease with tlr-mik inhibitors
WO2021151180A2 (en)2020-01-312021-08-05Fundação Oswaldo CruzAntibody, related use, pharmaceutical composition including method for diagnosing fungal infections, fungal infection diagnosis kit and method for treating fungal infections
WO2021156490A2 (en)2020-02-062021-08-12Vib VzwCorona virus binders
WO2021156504A1 (en)2020-02-072021-08-12Nuritas LimitedTreatment of panx1 associates diseases
EP3862014A1 (en)2020-02-072021-08-11Nuritas LimitedTreatment of panx1 associated diseases
WO2021156878A2 (en)2020-02-092021-08-12Nlc Pharma LtdRapid detection test for sars-cov-2
WO2021161310A1 (en)2020-02-102021-08-19Yeda Research And Development Co. Ltd.Method for analyzing cell clusters
WO2021163265A1 (en)2020-02-112021-08-19Vanderbilt UniversityHuman monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov- 2)
WO2021167908A1 (en)2020-02-172021-08-26Board Of Regents, The University Of Texas SystemMethods for expansion of tumor infiltrating lymphocytes and use thereof
WO2021170540A1 (en)2020-02-252021-09-02Vib VzwLeucine-rich repeat kinase 2 allosteric modulators
WO2021173674A1 (en)2020-02-262021-09-02A2 Biotherapeutics, Inc.Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
WO2021186431A1 (en)2020-03-162021-09-23Yeda Research And Development Co. Ltd.Peptide analogs and use of same in treating diseases, disorders or conditions associated with a mutant p53 protein
WO2021188389A2 (en)2020-03-172021-09-23Genevant Sciences GmbhCationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
WO2021195385A1 (en)2020-03-262021-09-30Vanderbilt UniversityHUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
WO2021195418A1 (en)2020-03-262021-09-30Vanderbilt UniversityHuman monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
EP4356924A2 (en)2020-03-262024-04-24Vanderbilt UniversityHuman monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
WO2021199039A1 (en)2020-03-292021-10-07Yeda Research And Development Co. Ltd.Variants of beta-glucocerebrosidase for use in treating gaucher disease
US11883391B2 (en)2020-03-312024-01-30Chemocentryx, Inc.Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-IL-23 blocking antibodies
WO2021199047A1 (en)2020-03-312021-10-07Biomuse Ltd.Bacteria for the prevention and treatment of smoke-induced lung damage
WO2021205444A1 (en)2020-04-062021-10-14Yeda Research And Development Co. Ltd.Methods of diagnosing cancer and predicting responsiveness to therapy
WO2021205459A1 (en)2020-04-072021-10-14Ramot At Tel-Aviv University Ltd.Cannabidiol-containing compositions and uses thereof
WO2021209995A1 (en)2020-04-132021-10-21Exoprother Medical Ltd.Cell-derived vesicles comprising wild-type p53 protein for antiviral therapy
EP3895697A1 (en)2020-04-162021-10-20Ichilov Tech Ltd.Cell-derived particles presenting heterologous cd24 and use thereof in therapy
WO2021210002A1 (en)2020-04-162021-10-21Ichilov Tech Ltd.Cell-derived particles presenting heterologous cd24 and use thereof in therapy
WO2021216728A1 (en)2020-04-222021-10-28President And Fellows Of Harvard CollegeIsothermal methods, compositions, kits, and systems for detecting nucleic acids
WO2021229577A1 (en)2020-05-122021-11-18Collplant Ltd.Collagen as a delivery tool for metal-based anti-viral agents
WO2021228141A1 (en)2020-05-152021-11-18四川科伦博泰生物医药股份有限公司Antibody drug conjugate, preparation method therefor and use thereof
WO2021234698A1 (en)2020-05-202021-11-25Yeda Research And Development Co. Ltd.Indexing spatial information for a single-cell downstream applications
WO2021247908A1 (en)2020-06-032021-12-09Bionecure Therapeutics, Inc.Trophoblast cell-surface antigen-2 (trop-2) antibodies
EP4521115A2 (en)2020-06-102025-03-12Ramot at Tel-Aviv University Ltd.Methods of detecting methylated cpg
US12077569B2 (en)2020-06-222024-09-03Ramot At Tel-Aviv University Ltd.Multi subunit protein modules, cells expressing same and uses thereof
WO2021260675A1 (en)2020-06-242021-12-30Yeda Research And Development Co. Ltd.Agents for sensitizing solid tumors to treatment
WO2022013300A1 (en)2020-07-142022-01-20Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO)Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof
EP3939999A1 (en)2020-07-142022-01-19Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO)Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof
WO2022034575A1 (en)2020-08-092022-02-17Yeda Research And Development Co. Ltd.Mage-a1 specific t cell receptor and uses thereof
WO2022034588A1 (en)2020-08-102022-02-17Yeda Research And Development Co. Ltd.Compositions for diagnosis and treatment of coronavirus infections
WO2022038536A1 (en)2020-08-182022-02-24International Rice Research InstituteMethods of increasing outcrossing rates in gramineae
WO2022040455A1 (en)2020-08-212022-02-24Advanced Cell Diagnostics, Inc.Compositions and methods for determining t cell clonality
WO2022047359A1 (en)2020-08-312022-03-03Berg LlcProtein biomarkers for pancreatic cancer
WO2022051591A2 (en)2020-09-042022-03-10Novarock Biotherapeutics, Ltd.Nectin-4 antibodies and uses thereof
WO2022059015A1 (en)2020-09-212022-03-24Yeda Research And Development Co. Ltd.Method for modulating weight
WO2022064494A2 (en)2020-09-232022-03-31Yeda Research And Development Co. Ltd.Methods and compositions for treating coronaviral infections
WO2022070194A1 (en)2020-10-012022-04-07Yeda Research And Development Co. Ltd.Method of diagnosing breast cancer
WO2022074646A1 (en)2020-10-052022-04-14Protalix Ltd.Dicer-like knock-out plant cells
WO2022074656A1 (en)2020-10-072022-04-14Protalix Ltd.Long-acting dnase
EP4225364A1 (en)2020-10-092023-08-16Board of Regents, The University of Texas SystemPrefusion-stabilized hmpv f proteins
WO2022079719A1 (en)2020-10-152022-04-21Yeda Research And Development Co. Ltd.Method of treating myeloid malignancies
WO2022091100A1 (en)2020-10-292022-05-05Yeda Research And Development Co. Ltd.Polynucleotides for rna editing and methods of using same
WO2022097157A2 (en)2020-11-092022-05-121E Therapeutics, Ltd.Catalytic sequence based methods of treating or preventing bacterial infections
WO2022108897A1 (en)2020-11-202022-05-27Vanderbilt UniversityUse of microvirin in the identification of mycobacterium tuberculosis mannose-capped lipoarabinomannan
WO2022115498A1 (en)2020-11-262022-06-02Ukko Inc.Modified high molecular weight glutenin subunit and uses thereof
EP4623930A2 (en)2020-12-032025-10-01The Board Of Regents Of The University Of Texas SystemMethods for identifying lilrb-blocking antibodies
WO2022120378A1 (en)2020-12-042022-06-09University Of Tennessee Research FoundationMethod for diagnosing amyloid diseases
WO2022130384A1 (en)2020-12-172022-06-23Yeda Research And Development Co. Ltd.Controlling ubiquitination of mlkl for treatment of disease
EP4617367A2 (en)2020-12-182025-09-17Genevant Sciences GmbhPeg lipids and lipid nanoparticles
WO2022133344A1 (en)2020-12-182022-06-23Genevant Sciences GmbhPeg lipids and lipid nanoparticles
WO2022144883A2 (en)2020-12-282022-07-071E Therapeutics, Ltd.P21 mrna targeting dnazymes
US11879140B2 (en)2020-12-282024-01-231E Therapeutics Ltd.P21 mRNA targeting DNAzymes
WO2022144882A2 (en)2020-12-282022-07-071E Therapeutics, Ltd.P21 mrna target areas for silencing
US11981896B2 (en)2020-12-282024-05-141E Therapeutics Ltd.p21 mRNA target areas for silencing
WO2022143743A1 (en)2020-12-312022-07-07和铂医药(苏州)有限公司Human lifr antigen binding protein, preparation method therefor, and application thereof
WO2022149142A2 (en)2021-01-102022-07-14Supermeat The Essence Of Meat Ltd.Pluripotent stem cell aggregates and microtissues obtained therefrom for the cultured meat industry
WO2022153286A1 (en)2021-01-142022-07-21Yeda Research And Development Co. Ltd.Methods of producing vitamin d
WO2022157774A1 (en)2021-01-212022-07-28Yeda Research And Development Co. Ltd.Antibodies, peptides and combinations of same for the treatment or prevention of coronavirus infection
WO2022159984A1 (en)2021-01-222022-07-28Bionecure Therapeutics, Inc.Anti-her-2/trop-2 constructs and uses thereof
WO2022162192A2 (en)2021-01-292022-08-04Thelper AsTherapeutic and diagnostic agents and uses thereof
WO2022170971A1 (en)2021-02-092022-08-18苏州宜联生物医药有限公司Bioactive substance conjugate, preparation method therefor and use thereof
WO2022175951A1 (en)2021-02-182022-08-25Yeda Research And Development Co. Ltd.Genetically modified bacteria for generating vaccines
WO2022175952A1 (en)2021-02-182022-08-25Yeda Research And Development Co. Ltd.Method of generating vaccines
WO2022175532A1 (en)2021-02-192022-08-25Vib VzwCation-independent mannose-6-phosphate receptor binders
WO2022183502A1 (en)2021-03-052022-09-09上海吉倍生物技术有限公司Anti-cldn6 antibody and use thereof
WO2022192134A1 (en)2021-03-082022-09-15Immunogen, Inc.Methods for increasing efficacy of immunoconjugates targeting adam9 for the treatment of cancer
WO2022188652A1 (en)2021-03-092022-09-15四川科伦博泰生物医药股份有限公司Ror1 binding protein and use thereof
WO2022195589A2 (en)2021-03-162022-09-22Yeda Research And Development Co. Ltd.Methods and devices for ex-utero mouse embryonic development
WO2022208369A1 (en)2021-03-302022-10-06Biomx Ltd.Pseudomonas bacteriophage and uses thereof
WO2022216798A1 (en)2021-04-062022-10-13Berg LlcProtein markers for the prognosis of breast cancer progression
WO2022216846A1 (en)2021-04-062022-10-13Berg LlcProtein markers for estrogen receptor (er)-positive-like and estrogen receptor (er)-negative-like breast cancer
WO2022216841A1 (en)2021-04-062022-10-13Berg LlcProtein markers for estrogen receptor (er)-positive luminal a(la)-like and luminal b1 (lb1)-like breast cancer
WO2022215080A1 (en)2021-04-082022-10-13Yeda Research And Development Co. Ltd.A combined use of ketamine and retigabine (ezogabine) for the treatment of psychiatric disorders
WO2022219008A1 (en)2021-04-142022-10-20University College Cork - National University Of Ireland, CorkTreatment of cerebrovascular events and neurological disorders
WO2022219168A1 (en)2021-04-142022-10-20University College Cork - National University Of Ireland, CorkPsg1 for use in the treatment of osteoarthritis
EP4322837A1 (en)2021-04-162024-02-21Advanced Cell Diagnostics, Inc.Materials and methods related to image processing
WO2022224137A1 (en)2021-04-192022-10-27Temple Therapeutics BVMethods for detecting or treating endometrial and ovarian hyperproliferative disorders
WO2022238947A1 (en)2021-05-122022-11-17Biomx Ltd.Staphylococcus bacteriophage and uses thereof
WO2022254430A1 (en)2021-05-302022-12-08Yeda Research And Development Co. Ltd.Anti-microbial peptide (amp) signatures for diagnostics, stratification, and treatment of microbiome-associated disease
WO2022259242A1 (en)2021-06-062022-12-15Yeda Research And Development Co. Ltd.Combined treatment for cancer
WO2022264132A1 (en)2021-06-132022-12-22Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method for reprogramming human cells
NL2028466B1 (en)2021-06-162022-12-21Sakata Holland B VMethods of sorting matthiola seeds
WO2022264076A1 (en)2021-06-162022-12-22Seedx Technologies Inc.Methods of sorting matthiola seeds
WO2023275255A1 (en)2021-07-022023-01-05Tropic Biosciences UK LimitedDelay or prevention of browning in banana fruit
WO2023288046A1 (en)2021-07-152023-01-19President And Fellows Of Harvard CollegeCompositions and methods relating to cells with adhered particles
WO2023003809A1 (en)2021-07-182023-01-26Gamida-Cell Ltd.Therapeutic nk cell populations
WO2023002492A1 (en)2021-07-222023-01-26Yeda Research And Development Co. Ltd.Codon optimization of nucleic acids
WO2023016828A2 (en)2021-07-302023-02-16Vib VzwCation-independent mannose-6-phosphate receptor binders for targeted protein degradation
WO2023012798A2 (en)2021-08-022023-02-09Yeda Research And Development Co. Ltd.Antibodies for the treatment of cancer
WO2023012584A2 (en)2021-08-032023-02-09Genicity LimitedEngineered tcr complex and methods of using same
EP4130028A1 (en)2021-08-032023-02-08Rhazes Therapeutics LtdEngineered tcr complex and methods of using same
WO2023018621A1 (en)2021-08-102023-02-16Gamida-Cell Ltd.Engineered nk cells, methods of their production and uses thereof
GB202112866D0 (en)2021-09-092021-10-27Tropic Biosciences Uk LtdResistance to fusarium wilt in a banana
GB202112865D0 (en)2021-09-092021-10-27Tropic Biosciences Uk LtdResistance to black sigatoka disease in banana
WO2023042202A1 (en)2021-09-142023-03-23Yeda Research And Development Co. Ltd.Multispecific antibodies for use in treating diseases
WO2023081070A1 (en)2021-11-022023-05-11University Of MassachusettsNme2Cas9 INLAID DOMAIN FUSION PROTEINS
WO2023089377A2 (en)2021-11-192023-05-25Mirobio LimitedEngineered pd-1 antibodies and uses thereof
US12343723B2 (en)2021-12-072025-07-01Insilixa, Inc.Methods and compositions for surface functionalization of optical semiconductor-integrated biochips
WO2023105526A1 (en)2021-12-082023-06-15Yeda Research And Development Co. Ltd.Multipotent lung progenitor cells for lung regeneration
WO2023143263A1 (en)2022-01-252023-08-03苏州宜联生物医药有限公司Antibody against her3, conjugate and use thereof
WO2023144392A1 (en)2022-01-282023-08-03Thelper AsTherapeutic and diagnostic agents and uses thereof
WO2023144798A1 (en)2022-01-312023-08-03Genevant Sciences GmbhIonizable cationic lipids for lipid nanoparticles
EP4574172A2 (en)2022-01-312025-06-25Genevant Sciences GmbhIonizable cationic lipids for lipid nanoparticles
EP4238988A1 (en)2022-03-012023-09-06Consejo Superior De Investigaciones CientíficasAntibodies against sars-cov-2 and uses thereof
WO2023174029A1 (en)2022-03-162023-09-21沈阳三生制药有限责任公司Prlr antigen-binding protein, preparation method therefor and use thereof
WO2023187407A1 (en)2022-04-012023-10-05Bradcode LimitedHuman monoclonal antibodies binding to sars-cov-2 and methods of use thereof
WO2023192976A1 (en)2022-04-012023-10-05Board Of Regents, The University Of Texas SystemDual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
WO2023196866A1 (en)2022-04-062023-10-12Mirobio LimitedEngineered cd200r antibodies and uses thereof
WO2023196937A1 (en)2022-04-062023-10-12Larimar Therapeutics, Inc.Frataxin-sensitive markers for monitoring frataxin replacement therapy
WO2023209708A1 (en)2022-04-252023-11-02Yeda Research And Development Co. Ltd.Compositions for altering cyclic adp-ribose secondary messenger signalling
WO2023240201A1 (en)2022-06-082023-12-14Larimar Therapeutics, Inc.Frataxin-sensitive markers for monitoring progression and treatment of leigh syndrome
WO2023239710A1 (en)2022-06-082023-12-14Onkure, Inc.Benzopyrimidin-4(3h)-ones as pi3k inhibitors
WO2023239940A1 (en)2022-06-102023-12-14Research Development FoundationEngineered fcriib selective igg1 fc variants and uses thereof
WO2023246701A1 (en)2022-06-202023-12-28四川汇宇制药股份有限公司Antibody and use thereof
WO2024012523A1 (en)2022-07-142024-01-18苏州宜联生物医药有限公司Antibody-drug conjugate, and preparation method therefor and use thereof
WO2024012524A1 (en)2022-07-142024-01-18苏州宜联生物医药有限公司Antibody-drug conjugate, and preparation method therefor and use thereof
WO2024028794A1 (en)2022-08-022024-02-08Temple Therapeutics BVMethods for treating endometrial and ovarian hyperproliferative disorders
WO2024040020A1 (en)2022-08-152024-02-22Absci CorporationQuantitative affinity activity specific cell enrichment
WO2024038160A1 (en)2022-08-182024-02-22Vib VzwMeans and methods to modulate neuron excitability
WO2024054469A1 (en)2022-09-082024-03-14Onkure, Inc.Isoquinolones as pi3k inhibitors
WO2024064024A1 (en)2022-09-192024-03-28Onkure, Inc.((4-oxo-3,4-dihydroquinazolin-8-yl)methyl)amine derivatives as p13k inhibitors for the treatment of cancer
WO2024064002A1 (en)2022-09-202024-03-28Onkure, Inc.Hdac inhibitor oki-179 for the treatment of cancers resulting from a mapk pathway mutation
WO2024068744A1 (en)2022-09-272024-04-04Vib VzwAntivirals against human parainfluenza virus
WO2024078729A1 (en)2022-10-142024-04-18University College Cork - National University Of Ireland, CorkPlacenta expressed proteins for use in the treatment of tendon injury
WO2024081345A1 (en)2022-10-142024-04-18Onkure, Inc.Benzopyrimidin-4(3h)-ones as pi3k inhibitors
WO2024102466A2 (en)2022-11-112024-05-16Igan BiosciencesIga protease polypeptide agents
WO2024124041A1 (en)2022-12-072024-06-13Advanced Cell Diagnostics, Inc.Multiplexed detection of nucleic acid targets
WO2024178172A1 (en)2023-02-232024-08-29University Of RochesterAgents and methods for making closed-end dna thread molecules
WO2024213648A1 (en)2023-04-112024-10-17Sterling Ip Pte. Ltd.Treatment of haematological cancer
WO2024213640A1 (en)2023-04-112024-10-17Sterling Ip Pte. Ltd.Inhibition of: stroma/cancer cell cross-talk &/or stroma generated resistance to treatment
WO2024258743A1 (en)2023-06-132024-12-19Adcentrx Therapeutics, Inc.Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
WO2024261344A1 (en)2023-06-232024-12-26Vib VzwNovel binders targeting the multi-drug resistant pathogen acinetobacter baumannii
WO2025038395A1 (en)2023-08-112025-02-20Onkure, Inc.Benzopyridinones and benzopyrimidinones as pi3k inhibitors
WO2025052278A1 (en)2023-09-052025-03-13Genevant Sciences GmbhPyrrolidine based cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
WO2025054524A1 (en)2023-09-072025-03-13University Of Tennessee Research FoundationMethod for diagnosing amyloid diseases
WO2025125577A1 (en)2023-12-142025-06-19Vib VzwAntibodies against influenza b virus
WO2025133951A1 (en)2023-12-212025-06-26Genevant Sciences GmbhIonizable lipids suitable for lipid nanoparticles
WO2025150045A1 (en)2024-01-122025-07-17Gabriel NussbaumBacterial targets, therapeutics, compositions, kits and methods of use in treating and/or preventing cancer
WO2025155991A2 (en)2024-01-192025-07-24Bpgbio, Inc.Predictive biomarkers for response to coenzyme q10 treatment in pancreatic cancer
US12444480B2 (en)2024-02-082025-10-14The Regents Of The University Of CaliforniaMethods for genome assembly and haplotype phasing
WO2025202871A1 (en)2024-03-272025-10-02Pfizer Inc.Methods for identifying biomarkers of treatment response and use thereof with a cdk4 inhibitor
WO2025207755A1 (en)2024-03-292025-10-02Onkure, Inc.Quinolizinones as pi3k inhibitors

Also Published As

Publication numberPublication date
BE775187A (en)1972-03-01
IT986829B (en)1975-01-30
DK140268C (en)1979-12-10
NL154598B (en)1977-09-15
DK140268B (en)1979-07-16
GB1348935A (en)1974-03-27
DE2155658A1 (en)1972-05-18
ES396741A1 (en)1975-05-16
FI54033C (en)1978-09-11
NL7016396A (en)1972-05-15
SE451162B (en)1987-09-07
DE2155658B2 (en)1976-08-05
ZA717192B (en)1972-08-30
BR7107459D0 (en)1973-06-21
DE2155658C3 (en)1978-09-14
FR2113733A5 (en)1972-06-23
FI54033B (en)1978-05-31
CH617774A5 (en)1980-06-13
CA967464A (en)1975-05-13
AU468060B2 (en)1975-12-18
AU3508271A (en)1973-05-03

Similar Documents

PublicationPublication DateTitle
US3850752A (en)Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically
US3791932A (en)Process for the demonstration and determination of reaction components having specific binding affinity for each other
US3839153A (en)Process for the detection and determination of specific binding proteins and their corresponding bindable substances
USRE31006E (en)Process for the demonstration and determination of reaction components having specific binding affinity for each other
USRE29169E (en)Process for the demonstration and determination of reaction components having specific binding affinity for each other
US4343896A (en)Method and test pack for the demonstration and determination of an antigen or antibody
US3879262A (en)Detection and determination of haptens
US4228237A (en)Methods for the detection and determination of ligands
US4840895A (en)Monoclonal antibodies reactive with immune complexes
US4828985A (en)Antibodies against the complex of a small molecule and its binding protein, their preparation and their use in diagnostic methods
US4427781A (en)Particle agglutination immunoassay with agglutinator for determining haptens; PACIA
EP0064318B1 (en)A method and a kit for the assay of antibodies to soluble antigens
US4230683A (en)Hapten conjugated antibody for antibody or antigen detection
US4621048A (en)Reagents containing an anti-ligand bound to an anti-enzyme and methods for employing said reagents in an immunoassy
US4410634A (en)Method of passively adsorbing immuno-reactive haptens to solid phases
EP0124366B1 (en)Method of measuring biological ligands
US4323647A (en)Steric hindrance enzyme immunoassay
EP0028132A2 (en)Method of passively adsorbing immuno-reactive haptens to solid phases
US4180556A (en)Pretreatment method for carcinoembryonic antigen assay
Bodley et al.A highly specific radioimmunoassay for progesterone using antibodies covalently linked to arylamine-glass particles
US5196349A (en)Immunoassays for thyroid hormones using thyroglobulin
HOSODA et al.A direct enzyme immunoassay of 6β-hydroxycortisol in human urine
JP3154724B2 (en) Methods for detecting monoclonal antibodies, hybridomas and diarrheal shellfish poisons specific to diarrheal shellfish toxins
EP0184701B1 (en)A method for determining a ligand
CA1071535A (en)Method for enzyme immunoassay of progesterone

Legal Events

DateCodeTitleDescription
CCCertificate of correction

[8]ページ先頭

©2009-2025 Movatter.jp